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Oesophageal adenocarcinoma (OAC) is a leading cause of cancer death in the UK 
and current systemic therapies are ineffective for the majority of patients.   The 
central aim of this work was to explore strategies to identify novel therapeutic 
targets.  
Research has failed, thus far, to identify a dominant oncogene in OAC, although the 
tumour suppressor p53 is frequently mutated.  Inhibiting the mitotic kinase, polo-like 
kinase 1 (PLK-1), was proposed as a synthetic lethal strategy.  PLK-1 was 
demonstrated to be overexpressed in both verified OAC cell lines and human OAC 
tissue compared to non-transformed cells and epithelium.  Mutation of p53 was 
associated with over-expression of PLK-1 in both OAC and ovarian cancer tissue.  
Using a carefully validated viability assay, both an established and novel PLK-1 
inhibitor were demonstrated to induce a G2/M arrest and reduce OAC cell 
proliferation.  Relative selectivity was demonstrated for OAC compared to non-
transformed cells.  This therapeutic window could be enhanced with the induction of 
cancer cell cytotoxicity by pulsed administration of a short half-life inhibitor.   
Immunotherapeutics offer potential tumour-selectivity but no OAC-specific proteins 
have been defined.  A comparative proteomic approach was employed to identify 
OAC-specific proteins as potential therapeutic targets.  A tissue resource was 
established and methods to lyse fresh frozen biopsies optimised. An isobaric 
quantitative proteomic workflow was applied to OAC and matched normal biopsies 
and quantitative accuracy confirmed for 6 candidate proteins by 
immunohistochemistry.  Proteome coverage and quantitative dynamic range were 
compared between isobaric and label-free systematic sequencing proteomic 
strategies applied to further patients’ tissues.  The challenges of combining 
incomplete datasets were approached with a Bayesian framework to estimate the 
probability that a protein was missed during an experiment compared to not being 
present in the sample.  This method was applied to generate a complete set of protein 




To gain insight into the dysregulated cellular processes in human OAC tissue, a 
network analysis was applied to the quantitative proteomic data.  Enriched functional 
clusters were identified suggesting deranged glucose metabolism, potentially due to 
the Warburg effect.  These findings were duplicated and candidate tumour-specific 
proteins identified in a further set of biopsies using the optimised quantitative 
proteomic method.  The combined quantitative oesophageal proteomic dataset 
represents the largest in OAC to date.    
This thesis demonstrates a hypothesis-driven, synthetic lethal approach can yield 
cancer-selective therapeutic effects.  Novel candidate therapeutic targets are also 
revealed through the development of quantitative proteomic methods and the 
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1.1 Oesophageal Cancer 
1.1.1 Changes in the incidence of oesophageal cancer and 
histological subtypes 
Oesophageal cancer is the fifth leading cause of cancer death in Scotland and the 
sixth leading cause worldwide.  Globally over 400,000 people die of the disease 
annually and the incidence continues to increase1,2.  Oesophageal squamous cell 
carcinoma (OSCC) is the predominant histological subtype worldwide although there 
are marked geographical variations in the pattern of disease.   Between 1970 and 
2000 there was a six-fold increase in the incidence of oesophageal adenocarcinoma 
(OAC) in the USA and this is now the most common subtype3.   This marked 
increase has been mirrored in the UK4, Europe5,6 and Australia7.  Other histological 
subtypes of oesophageal cancer include neuroendocrine carcinoma, melanoma, 
lymphoma and leiomyosarcoma but together these contribute less than 5% of all 
cancer diagnoses.  Adenocarcinoma is now the predominant subtype in the UK and 
this disease will form the focus for this thesis.  
Central and east Asia, by contrast, have a higher incidence of OSCC.  Discrete 
geographical areas including northern Iran, northern and central China, southern and 
eastern Africa have very high incidences of OSCC and this may reflect a 
combination of genetic predisposition and environmental factors8. 
1.1.2 Effect of Age and Gender on Risk of Oesophageal Cancer 
In all countries there is an increasing incidence with age and over 95% of diagnoses 
are made in people over 45 (Figure 1-1)1,2.  In Scotland in 2010, oesophageal cancer 
was diagnosed in 554 men (62%) and 336 women (38%) with deaths from 
oesophageal cancer in 533 men and 278 women respectively1.  This male 
predominance is observed across the UK and across age groups (Figure 1-1).  The 
higher incidence of oesophageal cancer in men is largely due to a marked male 
predominance for OAC with a male to female incidence ratio of between 4:1 and 
5:11,9.  The factors responsible for this have not yet been fully elucidated.  A greater 
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prevalence of known risk factors does not appear to completely explain the risk and a 
protective role for oestrogen and breast-feeding has been proposed10,11.    
Figure 1-1 The Incidence of Oesophageal Cancer in the UK by Age and Gender (2010 data).  Figure 
adapted from reference12 .  
1.1.3 Aetiology and Pathogenesis of OSCC 
The oesophagus is lined with squamous epithelium which is directly vulnerable to 
toxins and viral infection.  The role of direct injury in the process of OSCC 
development is supported by the higher incidence of OSCC in the proximal 
oesophagus compared to the distal oesophagus.  Indeed proximal OSCC shares many 
risk factors with lung carcinoma including cigarette smoking and excessive alcohol 
consumption13,14.   
The oesophageal squamous epithelium is also exposed to viruses implicated in 
oncogenesis.  The human papilloma virus (HPV) has been widely implicated in 
cervical squamous carcinogenesis and evidence of HPV serotype 16 infection has 
been demonstrated in up to 50% of OSCCs15; although there is significant 
geographic variability in the reported prevalence16,17.   
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Further evidence of direct damage in the pathogenesis of OSCC is provided by a case 
control study from Iran.  In the province studied, followers of the custom of drinking 
scalding hot tea had a significantly higher risk of developing OSCC.  This was 
presumably due to the chronic effects of the direct thermal injury on the upper 
oesophageal epithelium8. 
The role of alcohol on the development of OSCC appears to be related to the 
carcinogenic effect of the ethanol metabolite, acetaldehyde18.  Polymorphisms in the 
enzymes responsible for ethanol metabolism including ALDH1B and ALDH2 are 
associated with a four-fold increased risk of OSCC in alcohol drinkers compared to 
non-drinkers and may explain some of the geographic variation in OSCC 
incidence19,20.   
Other rarer genetic conditions associated with a high lifetime risk of OSCC include 
the tylosis oesophageal cancer syndrome which is due to a missense mutation in the 
RHBDF2 gene leading to altered squamous maturation and potentially altered 
epidermal growth factor signalling21,22.     
1.1.4 Aetiology and Pathogenesis of OAC 
In contrast to OSCC, adenocarcinoma of the oesophagus is most common in the 
distal oesophagus and at the gastro-oesophageal junction (GOJ).  This is likely to be 
a consequence of one of the major risk factors for OAC; gastro-oesophageal reflux 
disease (GORD)23,24.  In one population-based study, patients with recurrent reflux 
symptoms had a 5-10% increased risk of developing OAC, rising to a >40% 
increased risk if symptoms were severe and prolonged23.  Unfortunately, in over 40% 
of people, significant gastro-oesophageal reflux is asymptomatic23.  Reflux 
symptoms are a relatively poor arbiter of risk, however, as most people experiencing 
reflux do not go on to develop OAC and severe reflux can be asymptomatic in over 
40% of people.  
Obesity is also associated with an increased risk of OAC25.  This reflects both the 
confounding tendency of central obesity to promote GORD26 but also a potentially 
pro-inflammatory and carcinogenic effect of visceral adipose tissue27,28.  This effect 
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Introduction   23 
may in part contribute to the gender bias in OAC incidence as men are more likely to 
accumulate visceral fat than women29.  Further contributors in obese patients include 
a low dietary intake of fruit and other anti-oxidants and higher intake of saturated fat, 
both of which are associated with OAC24,30.        
There is a growing body of evidence suggesting that the combination of refluxed 
gastric acid and bile creates a distal oesophageal luminal environment most likely to 
result in the accumulation of genetic mutations and eventually epithelial 
transformation31-35.  This same noxious stimulus can, however, lead to epithelial 
damage and effective mucosal repair, chronic oesophagitis or even loss of the normal 
stratified squamous epithelium and replacement with a columnar epithelium36.  The 
factors governing the oesophageal mucosal response are still poorly understood and 
likely reflect a combination of host genetic and environmental factors.         
Interestingly the development of oesophagitis in response to reflux has not been 
associated with an increased risk of OAC37.  It is the appearance of metaplastic 
columnar epithelium in the distal oesophagus which appears to be associated with the 
development of OAC38.  This change was first described over a century ago by the 
pathologist Wilder Tileston39 but it was a report in 1957 by the Australian thoracic 
surgeon, Norman Barrett, that gained recognition and led to the eponym for 
columnar metaplasia of the oesophagus; “Barrett’s oesophagus”40.  
1.1.5 Contemporary Definition of Barrett’s Oesophagus. 
Three types of columnar epithelium have been described lining the distal 
oesophagus; a junctional (gastric cardia) type comprised of mucus secreting cells, an 
acid-secreting gastric type containing parietal and chief cells and intestinal-type 
metaplasia with prominent goblet cells41.  These cell types can exist as a mosaic, 
further complicating diagnosis.  In several reports the increased risk of OAC 
development has been exclusively associated with intestinal-type metaplasia42,43.  
One clinical utility for diagnosing Barrett’s oesophagus is to define a group of 
patients with a higher risk of adenocarcinoma development.  Therefore it has been 
proposed that Barrett’s oesophagus should only be diagnosed in patients with 
intestinal type-metaplasia44.      
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This definition has been challenged recently by reports of adenocarcinoma associated 
with gastric cardia type metaplasia  and DNA aneuploidy similar to intestinal 
metaplasia in cardia-type epithelium45,46.  Sampling bias can also lead to the under-
diagnosis of intestinal-type metaplasia in patients with the characteristic endoscopic 
salmon-pink mucosal changes of columnar metaplasia47. 
With this background, the British Society for Gastroenterology now defines Barrett’s 
oesophagus as histologically-confirmed replacement of the normal stratified 
squamous epithelium of the distal oesophagus with metaplastic columnar epithelium 
of any type, visible endoscopically ≥1 cm above the GOJ48.  This remains a 
controversial area and in contrast the most recent American Gastroenterology 
Association guidelines suggest the presence of goblet cells and therefore intestinal 
metaplasia are required for a diagnosis of Barrett’s oesophagus49.   
1.1.6 Risk of OAC development in Barrett’s Oesophagus 
Longitudinal studies with serial endoscopic biopsies have identified a pathological 
sequence of events that are widely regarded to precede the development of OAC.  
The normal stratified squamous epithelium of the oesophagus undergoes Barrett’s 
metaplasia as previously described.  Over time and in the face of further carcinogenic 
stimuli, foci of dysplasia arise in this metaplastic epithelium.  These progress through 
pathologically distinct low and high grade stages before adenocarcinoma, with the 
potential for invasion and metastasis, finally develops.       
Although Barrett’s oesophagus can be considered a premalignant stage of OAC, 
most patients with Barrett’s will not develop adenocarcinoma.  Predicting those 
patients who will progress through the metaplasia-dysplasia-adenocarcinoma 
sequence has been the subject of intense study for over three decades.  
Historical cohort studies have reported the risk of developing OAC with non-
dysplastic Barrett’s as 30-100 fold increased50.  However, as endoscopic techniques 
have improved, the sensitivity to detect dysplasia has increased and the risk for OAC 
development with a truly non-dysplastic Barrett’s segment appears lower51.  In a 
Northern Irish cohort with over 8,500 cases, the annual risk of development of high-
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grade dysplasia or OAC was 0.38% per year for patients with intestinal metaplasia at 
index endoscopy43.  A recent meta-analysis of over 50 studies included 11,434 
patients with 58,547 years of follow-up and calculated the risk as 0.33% per year52.   
Although this risk is relatively low, the potential to identify OAC at an earlier, 
potentially curable, stage has driven the development of Barrett’s surveillance 
programmes.  In these, patients with Barrett’s oesophagus undergo an upper 
gastrointestinal endoscopy with targeted biopsy of any mucosal lesions and random 
mucosal sampling by oesophageal biopsy every three years48.  The end point of 
surveillance is normally the identification of high grade dysplasia or adenocarcinoma 
at which point treatment is instigated.          
The risk of progression to adenocarcinoma is significantly higher once dysplasia has 
developed43,51.  Unfortunately the classification of low (LGD) and high grade 
dysplasia (HGD) is based on morphological criteria and is highly subjective.  Studies 
comparing expert upper GI pathologists have determined the kappa value for inter-
observer agreement for a diagnosis of LGD can be as low as 0.1853.  High grade 
dysplasia (HGD) is associated with a risk of progression to OAC of 20-60% per 
year54-56.  Diagnostic concordance is greater for HGD, however, in some series of 
patients undergoing oesophagectomy for high grade dysplasia, occult 
adenocarcinoma was identified in up to 40% of cases limiting the application of 
HGD as a progression biomarker57,58.  Reproducible biomarkers, evident at earlier 
pathological stages are clearly required.         
 
1.1.7 Molecular Pathogenesis of Barrett’s Carcinogenesis 
Oesophageal biopsies obtained from patients undergoing Barrett’s surveillance 
endoscopy and resection for OAC have enabled some of the genetic events present at 
each stage in the metaplasia-dysplasia-adenocarcinoma sequence to be determined.  
Although the key features have yet to be determined conclusively, a number features 
are common to most studies.  A selection of these are summarised in Figure 1-2.    
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Columnar metaplasia is currently believed to arise as an adaptive response to bile and 
acid reflux in the distal oesophagus.  Gene expression studies have identified a key 
role for the transcription factors Cdx1, Cdx2, BMP-4 and NF-κB in this process59-61. 
This likely reflects the pro-inflammatory effect of bile acid-induced epithelial 
damage and the subsequent activation of a developmental pathway responsible for 





Figure 1-2 Commonly Observed Molecular Changes during Barrett's Carcinogenesis.  Adapted from 
references 65-67.  Gastro-oesophageal reflux disease (GORD) is thought to be a key driver of the 
adenocarcinoma development.  The genes or genetic changes implicated during the progression from 
Barrett’s metaplasia to adenocarcinoma are highlighted at the corresponding stage in the sequence.   
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During the progression from non-dysplastic Barrett’s through LGD and HGD, p16 
gene silencing, predominantly by promoter methylation68-70, and loss of the 
chromosomal region 17p containing the TP53 gene71 are key steps.  In one series, 
loss of p16 expression was observed in 85% of patients with non-dysplastic 
Barrett’s72.   A study reporting the genetic status of individual crypts from Barrett’s 
mucosal biopsies and oesophagectomy specimens confirmed these changes but also 
unveiled a tapestry of competing clones with heterogeneous p53 mutations within a 
single Barrett’s segment.  This highlights the magnitude of the genotoxic 
oesophageal environment in these patients and the importance of loss of p53 in the 
progression sequence73.  The loss of p53 also marks a key step in the development of 
genomic instability.  Aneuploidy together with mutation of p53 have been proposed 
as biomarkers signifying a higher risk of adenocarcinoma development in patients 
with non-dysplastic Barrett’s74-76. 
  
In addition to the loss of p53 function, the constitutive activation of Cyclin proteins 
leads to inhibition of cell-cycle checkpoint mechanisms and clonal proliferation 
ensues68,72,77-81.   Ongoing genotoxic stimuli leads to the accumulation of further 
mutations in these proliferating clones with activation of growth factor pathways 
including FGF, MAPK, EGFR, TGF-β and Wnt signalling resulting in invasive 
adenocarcinoma82-84.  
 
1.1.8 Cell lines as Models of Barrett’s and OAC 
As the steps during Barrett’s carcinogenesis are gradually revealed with more detail, 
attempts to model the process in vitro and in animal systems have intensified.  The 
development of an accurate model would allow the steps of carcinogenesis to be 
manipulated with potential therapeutic and preventative applications.    
After the misidentification of several oesophageal cell lines, a recent study has 
provided a verified list of OAC lines 85,86. Ninety percent of these were able to  
generate tumour xenografts in nude mice and all the xenografts demonstrated the 
histological features of human adenocarcinoma.  These cell lines have been widely 
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used to assess the effect of chemotherapeutic drugs in vitro and to unravel cell 
signalling mechanisms including the development of treatment resistance87.   
Cancer cell lines are usually grown in monolayers, on plastic plates, with high 
nutrient growth medium and at a supra-physiological oxygen tension.  This has the 
potential to induce significant changes in phenotype compared to tumour cells in 
their native microenvironment.  This has led some commentators to question the 
relevance of cell line-based research88.  Despite these concerns a panel of 51 breast 
cancer cell lines was found to model the genomic and transcriptomic features of 145 
primary breast tumours, including their biological heterogeneity89.  Importantly, the 
cell line panel could be used to predict molecular features conferring sensitivity or 
resistance to a targeted therapy.  In a further study using gene expression profiles 
from 37 gastric cancer cell lines, 2 intrinsic subtypes were predicted.  In human 
gastric tumour samples classified using these molecular subtypes, the groups differed 
in both prognosis and chemotherapy sensitivity providing direct translational 
application90.          
 
As a comparator to cancer cell lines, a series of non-transformed immortalised 
epithelial cell lines have become available by the stable expression of the catalytic 
sub-unit of the human telomerase gene (hTERT).  These include a Barrett’s cell line 
derived from non-dysplastic intestinal metaplasia91.  This cell line is already deficient 
in p16, in keeping with the origin from Barrett’s oesophagus.  Discrete genetic 
manipulations, including p53 inhibition and transfection of the oncogenic form of H-
Ras, successfully transformed this cell line to allow contact-independent growth, and 
xenograft development92.  This highlights some of the key steps required during 
Barrett’s carcinogenesis and this model system may provide a useful tool in 
therapeutic development.    
The parallel use of normal squamous cells allows further comparisons with both 
transformed cancer cells and Barrett’s cells representing an intermediate stage in 
oesophageal carcinogenesis.  Immortalised normal oesophageal squamous cells have 
been used as a representative model.  A widely used squamous cell line, Het-1A, has 
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been immortalised using the oncogenic virus; SV-40.  Unfortunately this 
immortalises cells by inhibiting p53 and other tumour suppressor proteins93 and 
results in a dysplastic growth pattern with a  loss of epithelial marker expression 
when Het-1A cells are cultured in organotypic conditions94.   For this reason, the 
Het-1A cell line should not be used as a model of normal squamous oesophagus.  A 
telomerase-immortalised squamous cell line; EPC-hTERT has been described that 
demonstrates stratified squamous growth in organotypic conditions,  or alternatively 
primary oesophageal squamous cells provide a possible alternative95.          
1.1.9 Animal Models of Barrett’s and OAC 
Animal models of oesophageal cancer offer the opportunity to closer recapitulate the 
conditions of human cancer cells in vivo and the experimental findings from these 
models offer potentially greater relevance.  One approach is to use nude (immuno-
deficient) mice to establish xenografts of human cancer cell lines or fresh explants of 
human tumour tissue, usually as subcutaneous tumour growths.   This approach has 
the advantage of allowing a tumour mass to grow under similar stresses to human 
cancer cells in vivo but the lack of a competent immune system severely limits the 
conclusions that can be drawn96.  This model system is therefore usually reserved to 
test the effect of a treatment on tumour growth rather than to elaborate the 
mechanisms of tumour invasion or development.   
The majority of animal models trying to recapitulate the development of OAC de 
novo have induced duodeno-gastro-oesophageal reflux through surgical means.  A 
surgical reflux model was first described in dogs but is currently predominantly 
performed in rodents due to the shorter generation time97.   
The most successful procedure reported is an oesophago-jejunostomy as the presence 
of both gastric acid and duodenal content in the refluxate is critical for cancer 
development98.  Although oesophagitis and columnar metaplasia can usually be 
generated by this procedure, cancers developing can either be OSCC or OAC.  
Various dietary supplements and genetic backgrounds have been added to the reflux 
procedure to address this limitation without consistent success.  A further significant 
limitation of the rodent as a model organism is that the squamocolumnar junction is 
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in the stomach rather than at the GOJ as in the human99.  Furthermore both the mouse 
and rat oesophagus are lined by a keratinized squamous epithelium which does not 
contain submucosal glands in contrast to the non-keratinized epithelium in 
humans100.  
This last limitation may be particularly significant as the cell of origin of human 
Barrett’s metaplasia has been proposed as arising in the submucosal ducts of the 
squamous epithelium73.  Other possibilities have however, recently been proposed.   
A study using p63 -/- mouse embryos revealed the development of a Barrett’s-like 
metaplasia in the distal oesophagus101.  This epithelium demonstrated similar gene 
expression and immunohistochemical markers as human Barrett’s epithelium.  
Strikingly, lineage tracing suggested this epithelium developed from a small 
population of embryonic cells present at the squamo-columnar junction.  This 
population was observed in both mouse and human oesophagi.  Unfortunately, 
widespread epithelial defects in the p63 -/- mice preclude their use as models of 
Barrett’s carcinogenesis.                                  
A transgenic mouse model of Barrett’s carcinogenesis has, however, recently been 
proposed.  In this model, the Epstein-Barr viral promoter (ED-L2) was used to 
specifically target the constitutive expression of the inflammatory mediator IL1β to 
the squamous forestomach, oesophagus and oral cavity102.  This established chronic 
oesophagitis which over the course of 20 months progressed through columnar 
metaplasia to high grade dysplasia and adenocarcinoma in 20% of mice.  The process 
of tumour development could be accelerated by the addition of bile-acids to the 
drinking water of the mice.  Importantly, no squamous cell carcinomas were 
observed, underscoring the accuracy of the model.   As new therapies for OAC 
develop, this mouse model provides the potential for pre-clinical testing in a 
representative system.     
1.1.10 Diagnosis and Staging of Oesophageal Cancer  
Despite increased attempts to identify and survey patients with Barrett’s oesophagus, 
the majority of patients with OAC still present at a symptomatic stage.  The 
oesophagus is a flexible muscular tube and therefore symptoms do not manifest until 
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the tumour achieves a large enough size to cause obstruction or the tumour invades 
surrounding structures causing pain, airway compromise or bleeding103.   
Patients are most commonly diagnosed by upper-gastrointestinal endoscopy.  This 
has several advantages over a Barium contrast oesophagogram as biopsies can be 
taken for confirmation of the histological subtype, the length of the tumour and its 
relation to the anatomic GOJ can be determined and ionising radiation is avoided104.  
With advances in endoscopy technology, the sensitivity for detection of small 
cancers has greatly improved and is now superior to contrast radiology. 
Controversy exists as to the origin and most appropriate treatment for tumours 
arising around the GOJ.  A subjective clinical classification proposed by Siewert and 
Stein, has been widely adopted105.  In this system all tumours centred within 5cm of 
the GOJ are regarded as junctional.  Tumours centred in the distal oesophagus 1-5cm 
proximal to the GOJ are classified as Type I, Type II tumours are those centred at the 
anatomical junction, defined as the most proximal extent of the gastric rugal folds 
and tumours centred 2-5cm distal to the junction are classified as Type III. 
Once the diagnosis of oesophageal cancer is made, and if a patient is fit enough to 
receive further treatment, staging is undertaken.  This involves a combination of 
computed tomography (CT), 18Fluorodeoxyglucose positron-emission tomography 
(PET), endoscopic ultrasound (EUS) and laparoscopy with peritoneal lavage106.  The 
information from these investigations is combined to derive a clinical stage under the 
International Union against Cancer Tumour Node Metastasis (UICC TNM) 
classification107. This incorporates a prediction of the depth of tumour invasion into 
the oesophageal wall (T-stage), the extent of regional lymphatic metastasis (N-Stage) 
and the presence of any distant metastasis (M-Stage) (Figure 1-3).  The same 
classification is used to provide prognostic information on the basis of definitive 
pathological findings from surgical resections.  
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Figure 1-3 Summary of TNM classification for Oesophageal Cancer (7th Edition).  From reference108   
1.1.11 Treatment options for OAC  
If staging investigations reveal any evidence of distant metastasis or local invasion 
rendering the tumour irresectable the patient is considered incurable.  Due to the 
aggressive nature and late presentation of OAC, 70% of patients in the UK have 
advanced disease at presentation and can only be palliated1.  For the remainder, 
attempted curative therapy can be offered and this is tailored to the tumour stage.  
 
1.1.12 Treatment for Early Stage OAC 
Patients diagnosed with high-grade dysplasia within Barrett’s were historically 
offered oesophagectomy.  This was due to surgical series reporting a combined 
incidence of occult intramucosal adenocarcinoma of 35% (total n=430)106.  Although 
subject to publication bias, only 4 mortalities were reported across these series with 
excellent oncological results.  There is still a significant morbidity associated with 
oesophagectomy, however, and technological advances including high-resolution 
white light endoscopy and narrow band imaging have improved the sensitivity for 
adenocarcinoma detection during endoscopy to greater than 95%109.  Endoscopic 
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therapies such as radio-frequency ablation can now be safely applied for HGD, 
avoiding the need for oesophageal resection although extensive follow-up is still 
required as the development of metachronous lesions is common110,111.    
Once OAC is diagnosed and metastasis excluded on staging, it is important to 
determine the T-stage.  This is most accurately performed with EUS, although the 
discrimination between T1 tumours that are entirely intramucosal (T1a) and those 
that breach the muscularis mucosae to enter the submucosa (T1b) is still poor (see 
Figure 1-3)112.  For these early tumours, endoscopic mucosal resection (EMR) is 
recommended which allows deep biopsies down to the submucosa to permit accurate 
pathological T-staging112,113.   
The assessment of depth of invasion and delineation between T1a and T1b cancers is 
critical as the incidence of lymph node metastasis with T1a cancers is less than 2% in 
published series114,115.  As tumours invade the submucosa the prevalence of 
lymphatic metastasis increases from 20% with invasion limited to the superficial 
submucosal to 50% with deeper invasion116.  It currently recommended that patients 
with a T1b or deeper adenocarcinoma are considered for oesophagectomy and 
lymphadenectomy.  In contrast those patients with an intramucosal adenocarcinoma 
can be potentially cured by EMR if the tumour can be completely excised as the risk 
of tumour cell dissemination is very low. 
1.1.13 Treatment for Locally Advanced OAC         
For all attempted curative cancer resections the aim of surgery is to completely 
remove the primary tumour and the corresponding lymphatic basin117.  For junctional 
tumours the lymphatic drainage appears to differ according to the Siewert junctional 
type.  Type II and III tumours predominantly spread to intra-abdominal lymph nodes 
with only 10% exhibiting lower mediastinal metastasis118,119.  In contrast, Type I 
tumours commonly spread to both intra-thoracic and intra-abdominal nodes120.  The 
common surgical approaches to these tumours reflect this with a combined thoracic 
and upper-abdominal lymphadenectomy performed for Type I tumours121.                    
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Introduction   34 
Previously, Type I tumours were staged as oesophageal and Type III as gastric with 
Type II cancers classified according to discretion of the reporting pathologist.   The 
most recent TNM classification has revised this with all junctional tumours involving 
the oesophagus staged as oesophageal tumours107.  This classification has been 
demonstrated to be superior to previous versions in predicting prognosis, most likely 
due to the revised nodal staging algorithm which incorporates the number of positive 
lymph nodes122.     
Patients with OAC and regional nodal metastasis undergoing surgical resection alone 
have a high risk of both local and distant recurrent disease and 5 year survivals 
remain <20%122.  In contrast, over 60% of those undergoing surgery alone for OAC 
with no lymphatic metastasis can expect to survive 5 years122.  On this basis 
neoadjuvant therapy is currently recommended for those patients likely to have 
lymphatic metastasis.  From a clinical staging perspective this includes all patients 
with evidence of lymph node involvement or T3/T4 disease.  The management of 
patients staged as T2N0 remains controversial as clinical staging is inaccurate for 
three quarters with half of all cases being subsequently upstaged.  In many centres 
these patients are consequently recommended for neoadjuvant therapy123.        
1.1.14 Neoadjuvant therapy for OAC 
The MRC OE02 trial randomized 802 patients to receive either neoadjuvant 
chemotherapy, given as 2 cycles of cisplatin and 5-fluorouracil (2xCF), followed by 
oesophagectomy or oesophagectomy alone. The 2 year survival rate was 43% in the 
group receiving chemotherapy compared to 34% in the group undergoing surgery 
alone (p=0.004).  On this basis, neo-adjuvant chemotherapy is recommended in the 
UK for patients with locally advanced oesophageal cancer undergoing attempted 
curative therapy.  A long-term survival analysis of this trial has recently confirmed 
the absolute survival advantage of 5% at 5 years although sub-group analysis 
suggests this is lower in patients with OAC124.         
There are a number of limitations in this trial which reflect the period (1992-1998) 
during which it was conducted.  The post-operative mortality rate was 10% in each 
group and macroscopically incomplete resections (R2) were performed in 13% of the 
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Introduction   35 
surgery only group and 9% of the chemotherapy group125.  Current data suggest a 
post-operative mortality rate of <3% should be expected for oesophagectomy in most 
large-volume centres126.  Improvements in staging have also reduced the number of 
R2 resections to <1% of cases117.  These improvements in surgical care are expected 
to change outcome and interestingly recent audit data from England and Wales 
suggests a 2 year survival rate of 56% for patients with OAC and 51% for patients 
with OSCC, a significant improvement over the OE02 cohort127.  
The OE02 trial findings also contradict the results of the smaller North American 
Intergroup 113 trial (INT 113)128.  This trial randomized 440 patients to 3 
preoperative and 2 postoperative cycles of cisplatin and 5-FU or surgery alone.  This 
trial had a higher proportion of OSCC (46% compared to 31%) and fewer patients 
completed the preoperative regime (70% compared to 90% for OE02).  Only 40% of 
eligible patients completed both post-operative cycles perhaps reflecting the 
challenges of post-operative chemotherapy administration in this patient group.  
Similar to OE02, 15% of patients underwent an R2 resection in the surgery alone 
group with 10% in the chemotherapy group.  Post-operative mortality rate was 6% in 
both groups.  There was no difference in median survival between groups and 2 year 
survivals rates were 37% for the surgery only group and 35% for the chemotherapy 
group.  Reasons for this could include the longer delay to surgery for patients not 
responding to preoperative chemotherapy (12 weeks versus 6 weeks in OE02) and a 
greater proportion of OSCC masking differences in the OAC groups.  
A trial initially powered for patients with gastric cancer (MAGIC) has provided some 
further evidence of the benefit of pre-operative chemotherapy for patients with GOJ 
and oesophageal adenocarcinoma129.  A total of 503 patients were randomized to 3 
pre-operative and 3 post-operative cycles of Epirubicin, Cisplatin and 5-FU or 
surgery alone.  Although only 26% of the patients included had GOJ or oesophageal 
tumours, a trend favouring chemotherapy was noted for both oesophageal and 
junctional tumours.  Pre-operative epirubicin, cisplatin and 5-FU will be compared to 
cisplatin and 5-FU for patients with OAC or GOJ adenocarcinoma in the OE05 
trial130.     
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Of note the MAGIC trial again highlighted the challenge of post-operative 
chemotherapy administration in patients undergoing gastric or oesophageal resection.  
Although 86% of patients completed pre-operative chemotherapy only 42% 
completed both all preoperative and post-operative cycles129.  This reflects the 
significant morbidity of major upper-gastrointestinal resection and the extended 
recovery period required.        
The use of neoadjuvant radiotherapy alone for oesophageal cancer is not supported 
by a meta-analysis of randomized trials131.  Early trials of neoadjuvant 
chemoradiotherapy were associated with significantly increased perioperative 
mortality and this approach has not yet been adopted in the UK132,133.  A recent meta-
analysis of trials of neoadjuvant chemoradiotherapy including a total 1,854 patients 
has, however, identified a 22% reduction in mortality compared to surgery alone (HR 
0.78; 95% confidence interval 0.70-0.88, p<0.0001)134.  This strategy has become the 
predominant treatment for locally advanced oesophageal cancer in Europe, Australia, 
and North America.  A prospective randomised comparison of neoadjuvant 
chemotherapy and neoadjuvant chemoradiotherapy has yet to be undertaken but 
would help inform future UK practice135.  Despite neoadjuvant treatment and 
surgical resection, over 75% will still succumb to systemic disease and therefore 
effective therapeutics are urgently required136.        
A complete pathological response (pCR), defined as no viable tumour cells in the 
resection specimen, has been observed in 25% of neoadjuvant chemoradiotherapy 
treated patients137.  Patients experiencing a pCR after chemoradiotherapy have a 
significant survival benefit over those experiencing no response with 5 year survival 
rates reported between 34 and 70%138.  In contrast the pCR rate is <5% across trials 
of neoadjuvant chemotherapy139.  Long-term follow-up from the INT 113 trial also 
suggests a significant disparity in survival between those patients experiencing a 
response to neoadjuvant chemotherapy and those experiencing no response140.  
Indeed those patients showing no response had a trend for poorer survival than 
patients undergoing surgery alone.  Identifying patients who will go on to respond to 
neoadjuvant therapy is an active area of research but no biomarkers have yet been 
validated.   
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1.1.15 Effect of Immunosuppression during Cancer Therapy 
Most chemotherapies in current use act on dividing cells. The toxicity of these drugs 
can be considerable with treatment related mortality even in the neoadjuvant 
setting141.  If these therapies are not effective against the tumour there may be 
negative consequences to their use.   
Surgical resection for OAC carries a risk of major morbidity and the systemic 
sequelae of surgical stress, particularly catecholamine release may enhance disease 
dissemination.  In a study in rats the use of a β-blocker and a non-steroidal anti-
inflammatory drug to mitigate the stress of surgery significantly reduced the 
development of pulmonary metastasis from intravenous inoculation of a highly 
metastatic cancer cell line142.  This effect could be further enhanced by the addition 
of an immune stimulant; CpG-C.  The extension of these observations is that 
immunosuppression from systemic chemotherapy and surgical stress during tumour 
resection may allow more effective dissemination of cancer cells. 
In OAC, tumour cell invasion and metastasis occur early in the disease process.  In a 
study including 20 patients with the most superficial stage of submucosal 
oesophageal adenocarcinoma, micrometastasis and isolated tumour cells could be 
identified by cytokeratin immunohistochemistry in the resected lymph nodes in 20% 
of cases143.  Isolated tumour cells could even be identified in the lymph nodes in 8% 
of patients with intramucosal adenocarcinoma.  OAC is also liable to haematogenous 
spread.  Disseminated tumour cells can be demonstrated in iliac crest bone marrow 
aspirates in a quarter of patients with T1 stage adenocarcinoma undergoing 
oesophagectomy144.  The demonstration of disseminated tumour cells is also 
associated with a significantly poorer survival144. 
The early metastasis of isolated tumour cells in OAC suggests the host immune 
response to this cancer may be critical in determining if the disease will be indolent 
or progressive with the development of multiple macroscopic metastases.  In breast 
cancer, circulating tumour cells can also be identified at the time of surgical 
resection145.  Although 5 year survival rates of > 90% are expected in stage I and II 
disease, in up to 20% of these patients, multiple metastases appear over 5 years after 
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the original treatment146.  This phenotype has been rationalized with the model of 
immunosurveillance and tumour cell dormancy.   
The immunosurveillance hypothesis states that micrometastases and isolated tumour 
cells may be maintained in a senescent state by interaction with immune cells.  These 
dormant tumour cells are still viable and can exhibit slow rates of proliferation and 
cell death.  If the balance between immune cell and cancer cell is altered in favour of 
the latter then rapid proliferation ensues and macroscopic metastases appear147.  This 
phenotype has been demonstrated in a mouse breast cancer model148.  A fatal case of 
donor transmission of malignant melanoma to a lung transplant recipient despite the 
donor surviving 32 years after the original melanoma treatment provides additional 
clinical evidence for this149.  The powerful immunosuppressive regime required 
following transplantation presumably allowed tumour cells to rapidly escape their 
dormant state.   
Genetic heterogeneity within solid tumours predicts a small resistant percentage of 
cells will be clonally selected after most targeted therapies150.  Tumour selective 
treatments should however allow tumouricidal doses without the attendant morbidity 
associated with current therapies.  This will also prevent immune compromise, 
crucially allowing immune-mediated clearance of the residual intrinsically-resistant 
tumour cells or at least the maintenance of disseminated tumour cells in a dormant 
state151.  Identifying tumour-specific therapies and minimising immunosuppression 







Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Introduction   39 
1.2 Oncogene Targeted therapy for cancer   
The discovery that normal cells could be transformed by oncogenes spawned the 
targeted-therapy paradigm.  This strategy has achieved most success in examples 
where cells are dependent on the function of one oncogene product.  This 
phenomenon has been coined oncogene-addiction152.  Notable clinical examples of 
oncogene addiction have been successfully treated with targeted therapies.   
The first successful targeted therapy was imatinib153, directed against the product of 
the BCR-ABL fusion gene known to drive the development of chronic myeloid 
leukaemia154.  In a landmark randomised controlled trial, Imatinib produced a 
reduction in BCR-ABL transcript levels of greater than 1000 fold in 39% of cases 
compared to 2% in the best medical therapy group ( interferon + cytarabine)155.  This 
resulted in a complete cytogenic remission at 12 months in 68% of patients treated 
with imatinib compared to 7% of patients treated with interferon + cytarabine.             
A subset of non-small cell lung cancers have been found to exhibit oncogene 
addiction to the epidermal growth factor receptor (EGFR) due to activating mutations 
within the kinase domain156.  This has been successfully exploited using EGFR 
inhibitors such as Gefitinib157 and Erlotinib158.  Similarly an activating mutation in 
another kinase; BRAF has also been identified in over half of all patients with 
malignant melanoma159.  This has also been successfully targeted using a specific 
inhibitor, Vemurafenib which dramatically increased response rates in metastatic 
disease160,161.   
1.2.1 Targeted therapies for OAC 
Following the successes of these targeted agents, researchers have tried to identify 
similar activated oncogenic kinases in other cancer types.  The human epidermal 
growth factor receptor 2 (HER2) tyrosine kinase is part of the EGF superfamily and 
is amplified in 20-30% of breast cancers.  Trastuzumab is a humanized monoclonal 
antibody directed against the extracellular domain of HER2 and has been shown to 
improve disease-free survival in HER2 positive breast cancer162.  HER2 has also 
been shown to be amplified in up to 30% of oesophageal and gastric 
adenocarcinomas163,164.                
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A randomized trial of Trastuzumab in combination with chemotherapy versus 
chemotherapy alone (ToGA) recruited 584 patients with inoperable locally advanced, 
recurrent or metastatic adenocarcinoma of the stomach (80%) or GOJ (20%)165.  
Trastuzumab significantly improved survival from a median of 11.1 months to 13.8 
months (p=0.0046).  Consistent with an active effect on HER2, those patients with 
higher HER2 positivity on IHC demonstrated the greatest improvement in survival.  
Importantly, there was minimal additional toxicity observed with the addition of 
Trastuzumab.   Following this work, Trastuzumab and a further HER2 targeted 
agent, Lapatinib, have entered clinical studies in OAC in both the metastatic and 
perioperative setting and may represent a valuable therapy for HER2 positive 
tumours166,167. 
Multiple other kinase inhibitors are currently under investigation in clinical trials in 
OAC either as adjuvants to standard chemotherapy regimens or as monotherapies in 
patients with metastatic disease.  Results, especially for EGFR inhibitors, have been 
mixed to date168.  One promising lead is the vascular endothelial growth factor 
receptor (VEGF) inhibitor bevacizumab.  This is currently being evaluated in a phase 
II/III trial in adenocarcinoma of the stomach and GOJ (National Clinical Trials 
number 00450203) and also in the neo-adjuvant setting in localised gastric or GOJ 
adenocarcinoma (National Clinical Trials number 00737438).  
Unfortunately gene expression and kinase profiling studies have failed to identify an 
oncogene or kinase over-expressed in the majority of OACs60,82,169-171.  Oncogene or 
kinase-targeted therapies are therefore likely to only be applicable to selected 
subgroups selected by relevant response biomarkers.  An alternative approach that 
may be relevant to a greater proportion of patients is to target vulnerabilities 
generated by the loss of a tumour suppressor.  This approach, termed synthetic 
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1.3 Exploiting TP53 Mutation for Cancer Therapy. 
1.3.1 The discovery of p53 
The human p53 protein was named due to the apparent mass of 53kDa on denaturing 
polyacrylamide gel electrophoresis (PAGE)173.  This 393 amino acid protein is 
encoded by an 11 exon gene located on the short arm of chromosome 17 
(17p13.1)174.  The major functions of p53 appear to be mediated through its role as a 
transcription factor175.  The observation of p53 over-expression in transformed cells 
and binding to viral oncoproteins initially led to its classification as an 
oncogene176,177.  A decade after the original identification, the true wild-type TP53 
gene was cloned rather than the original sequence which contained a missense 
mutation.  This allowed the true role of p53 as a tumour suppressor to be revealed178.   
1.3.2 The function of p53 
The activation of p53 in response to DNA damage leads to expression of genes with 
important functions in cell cycle arrest, senescence and apoptosis175.  The relative 
expression of the genes mediating each function and the subsequent final cellular 
response is dependent on the mutational and transcriptional state of the cell.  The fine 
details of the regulatory mechanisms are still being uncovered and as the ability to 
identify transcriptional targets improves, the number of p53-responsive elements, and 
potential p53-mediated functions, has expanded considerably179.  Despite this 
increased complexity, the central role of p53 in the response to DNA damage and 
designation as “guardian of the genome” underpins the likely reason this gene is 
frequently mutated in cancer180,181.         
1.3.3 The Domain Structure of p53 
Five functional domains within the protein have been described (Figure 1-4).   The 
transactivation domain, immediately adjacent to the proline-rich domain in the 
amino-terminus of the mature protein contains a sequence that allows efficient 
activation of transcriptional targets182.   The proline rich domain is thought to 
contribute to the p53-mediated apoptotic response and the transcriptional response to 
gamma irradiation183.  Post-translational modification of p53 can augment or inhibit 
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its interactions with down-stream targets and the transactivation and proline-rich 
domains are key sites for reversible phosphorylation184.   
The DNA-binding domain is the most frequent site of TP53 mutation in cancer.  
Some mutations have been identified at a far higher frequency than others; so-called 
“hot-spot” mutations.  These have been subsequently demonstrated to coincide with 
key residues responsible for DNA-binding, consistent with the role of p53 as a 
transcription factor185.  For example, Arginine 248 is critical for binding to the minor 
groove of the DNA double helix and mutation of this residue is the most commonly 
observed p53 mutation in cancer186.   The function of p53 has also been demonstrated 
to be dependent on the assembly of a p53 tetramer via the tetramerisation domain, 
and this domain is also a site of mutation in cancer187,188. 
The c-terminal regulatory domain is thought to modulate the function of p53 in 
response to external factors and can switch p53 from a latent to an active DNA-
binding conformation.  This may occur via an allosteric mechanism where the DNA-
binding domain availability is decreased within the tetramer by regulatory domain 
binding189,190.               
Figure 1-4 The domain structure of human p53 protein.  The amino acid positions are detailed below.  
TAD – Transactivation domain, PRD – Proline rich domain, TET – Tetramerisation domain, REG – 
regulatory domain.  
 
1.3.4 MDM2 and p53 
One of the transcriptional targets of p53 is the E3 ubiquitin ligase MDM2 which 
inhibits the function of p53.  This occurs by both direct binding and inhibition of 
transactivation, and through enhanced p53 degradation at the proteasome via 
MDM2-mediated polyubiquitylation191,192.  This negative feedback loop ensures 
expression of p53 protein is transient to prevent deleterious activation of apoptotic 
machinery.  Conversely, stable expression of p53 is often observed in cancers due to 
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the loss of MDM2 transactivation, and subsequent p53 degradation.  Overexpression 
of p53 protein has therefore been used as a surrogate marker of loss of p53 
function193.      
1.3.5 TP53 is commonly mutated in cancer 
The combined evasion of growth suppression and inhibition of apoptotic signalling 
confers a significant survival advantage on cells with loss of p53 transcriptional 
activity186.  In the process of oncogenesis, clones with mutant p53 may be selected 
due to evolutionary pressure and therefore p53 is frequently observed as a mutated 
gene in cancer186.   
Large scale sequencing efforts have now confirmed a high frequency of p53 
mutation in several cancer types including head and neck squamous cell carcinomas 
(SCC), endometrial cancers and high grade serous ovarian cancers194-197.  In head and 
neck SCCs, mutations in TP53 were identified in 50 – 80% of the tumours with 
evidence of human papilloma virus 16 infection in wild-type tumours196,197.  This 
confirms the loss of p53 function as critical in SCC development as the E6 viral 
protein induced by HPV infection has transforming potential through the inactivation 
of wild-type p53 protein198. 
A further striking example of the selective pressure for mutation of p53 in the 
development of cancer comes from a laser capture microdissection study on Barrett’s 
epithelium199.  This revealed multiple clones with differing p16 and p53 mutations 
arising from the same Barrett’s field confirming the mutagenic environment of the 
distal oesophagus in these patients.  In some cases, a single p53 mutation was 
observed over a wide epithelial area suggesting rapid expansion of this clone due to a 
competitive advantage.          
1.3.6 Mutant p53 gain of function 
Some p53 mutations are associated with oncogenic functions including the ability to 
complex and inactivate other p53-related proteins integral to the tumour suppressor 
mechanism including p63 and p73200.  Disruption of the mutant p53-p73 interaction 
inhibits cell growth in vitro and the ability to form tumour xenografts in vivo201.  
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Mutation of one allele of p53 can also lead to a loss of p53 function due to 
inactivation of the wild-type protein via a dominant negative effect202.      
Selective knockdown of overexpressed mutant isoforms by RNA interference 
increases chemo- and radiosensitivity, induces  apoptosis and reduces tumour cell 
growth and capacity to metastasise in vivo suggesting mutant p53 may be a potential 
therapeutic target in cancer203,204.  Small molecules have been also been developed to 
target mutant p53 proteins205 although targeting the thousands of discrete mutant 
isoforms directly may prove difficult with a single drug206. 
Different p53 mutations may confer different phenotypes including variable  
chemotherapy sensitivities207.  Mutant p53 has been associated with poor survival in 
oesophageal adenocarcinoma208 and mutations in part of the DNA binding domain of 
the protein are associated with poor prognosis in colon cancers209.  Targeted 
mutagenesis has been used to catalogue the phenotype of the heterogeneous p53 
mutations210.       
1.3.7 TP53 is Commonly Mutated in OAC 
Multiple studies have assessed the mutation frequency of p53 in oesophageal 
adenocarcinoma.  Historically this was achieved by identifying coding variants 
within exons 4-9 by sequencing of restriction fragment length polymorphisms206,211.  
Reported frequencies using this method include 15/17 cases (88%)212, 18/37 cases 
(49%)213 , 67/142 cases (47%)208, 8/9 cases (89%)214, 17/30 cases (57%)215 and 30/40 
cases (75%)216 producing a total of 155/254 cases (61%).  This method will miss 
mutations outside the sequenced exons and will also miss a functionally inactivated 
pathway with a wild-type p53 allele.  Notably these studies also report p53 over-
expression in supposedly wild-type tumours.  This supports the presence of occult 
mutations or pathway inactivation by some other mechanism217.  Studies examining 
p53 protein over-expression (a surrogate marker of pathway inactivation) report 
frequencies of ~80%217. 
One recent study has sequenced the exomes of 149 OACs and patient-matched 
normal tissues at over 80-fold coverage, providing a very high sensitivity for 
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identification of TP53 genetic variants218.  Somatic p53 mutations were detected in 
108 tumours (72%) confirming the high frequency reported in previous smaller 
studies.   
1.3.8 Loss of tumour suppressors provides a synthetic lethal 
opportunity 
Loss of tumour suppressor activity can generate unique dependencies on targetable 
pathways.  The synthetic lethal hypothesis states that inhibiting these pathways can 
yield cancer-specific cytotoxic effects.  This approach is effective in cancers 
deficient in Breast Cancer proteins (BRCA)1 and 2 where sensitivity to poly(ADP-
ribose) polymerase-1 (PARP-1) inhibitors has been described219.  A similar approach 
may be feasible in tumours with mutant p53.  
A study on the effect of p53 loss on gene expression used isogenic HCT116 cell lines 
with either wild type p53, heterozygous (p53 +/-) or homozygous (p53 -/-) loss of 
expression of the endogenous protein220.  Using gene expression profiling, the 
HCT116 p53 -/- cell line was found to express higher levels of genes associated with 
the G2/M checkpoint, in particular Polokinase-1 (PLK-1)220.  This prompts the 
suggestion that loss of p53 may be associated with unique dependency on genes 
involved in this checkpoint. 
This hypothesis is supported by a large-scale transcriptomic and genomic study of 
high-grade serous ovarian adenocarcinomas195.  This cancer was characterised by a 
TP53 mutation frequency of 96% suggesting this is a critical step in the development 
of this cancer.  Using gene expression data, copy number analysis and a 
computational pathway activity inference method221 a significantly dysregulated 
network of genes centred on the transcription factor FOXM1 was identified.  This 
network is responsible for the control of various phases of the cell cycle including 
G2/M exit and may represent a therapeutic target222.   
These data, both from in vitro and in vivo studies support a model where loss of p53 
function creates upregulation of genes related to the G2/M checkpoint.  Targeting the 
cell cycle may therefore represent a therapeutic strategy in tumours with mutant p53.           
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1.3.9 The Cell Cycle  
All dividing cells possess sophisticated cell cycle machinery to allow the perfect 
replication and propagation of the genome.  A carefully orchestrated, kinase-
mediated sequence of events is responsible for driving cell cycle progression.  The 
core features of this cycle are conserved across prokaryotes, yeast and diverse animal 
phyla.  An uncorrected error at any stage of this process could allow the transmission 
of a corrupt genetic code to daughter cells with dire consequences.  Checkpoints 
have evolved within the cell cycle to allow error- correction or, in the case of 
irreparable damage, for the cell to enter a state of senescence or undergo apoptosis223.  
The task of faultless DNA replication is further complicated by mutagens including 
UV light, ionising radiation, reactive oxygen species and chemical carcinogens 
inducing DNA damage.   
The cell cycle has been conceptually subdivided into four phases based on two 
processes, DNA synthesis (S phase) and mitosis (M Phase) separated by two gaps 
(G1 and G2).  The principle checkpoints exist at the G1/S phase transition, intra-S 
phase, G2/M phase transition and at the spindle assembly stage of mitosis.  A major 
checkpoint trigger is DNA damage and although checkpoint activation is the final 
endpoint, different forms of DNA damage appear to induce different signalling 
pathways.   
The double-stranded DNA breaks produced by ionising radiation predominantly 
induce the Mutated in Ataxia Telangiectasia (ATM) pathway and the interstrand 
cross-links and single-strand DNA breaks produced by UV light (and Cisplatin) 
predominantly induce the ATM and Rad3 related protein (ATR) pathway224.  These 
pathways both comprise of a canonical series of phosphorylation events that finally 
inactivate the cyclin dependent kinases (CDK) and arrest the cell cycle.   
Part of the ATM and ATR-dependent DNA damage response leads to 
phosphorylation and activation of the tumour suppressor p53 with subsequent 
expression of the CDK inhibitor p21 and G1-S phase checkpoint activation.  The 
presence of a functional p53 pathway appears to be critical for initiation and 
maintenance of G1-S phase arrest after DNA damage220,224.   One of the key roles of 
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p53 is to trigger the cell cycle checkpoints at the G1/S and G2/M transitions.  These 
checkpoints allow DNA repair and without them cells rapidly accumulate lethal 
genetic mutations and undergo cell death225.  With the loss of p53 function, cancer 
cells become dependent on other mechanisms for checkpoint activation and these 
mechanisms may represent key targets for synthetic lethality 226.  The G2/M 
checkpoint can, for example, be activated independent of p53 and may become the 
critical point of DNA repair in cells without wild-type p53.  This is supported by the 
finding that while p53 is the most commonly mutated gene in human cancer, genes 
involved in the G2/M checkpoint are rarely mutated227.   
1.3.10 The G2/M checkpoint  
The Chk1 and Chk2 kinases are key mediators of the G2/M checkpoint and are 
activated by ATM/ATR in response to DNA damage223.  These kinases inactivate 
cdc25A-C preventing the activation of the cyclin B/CDK1 complex and delaying the 
onset of mitosis.  An essential component in triggering the G2/M checkpoint is the 
inhibition of the mitotic kinases; Polo-like kinase 1 (PLK-1) and Aurora kinase A 
(AURKA). 
1.4 Polo-like Kinase 1: A Mitotic Kinase 
1.4.1 The Polo-like Kinase Family.  
A search for mitotic mutants in Drosophila larval neuroblasts identified the polo 
gene228,229.  The human ortholog of polo, Pololike kinase 1 (PLK-1), was cloned 
three years later230.  A further 4 human polo-like kinase genes have now been 
described.  PLK-1 to 4 share structural homology with an N-terminal 
serine/threonine kinase domain and one (PLK-4) or two c-terminal polo-box domains 
(PLK-1 to 3)231.  While the kinase domain is responsible for the catalytic function of 
these proteins, it is structurally similar to many other kinases and substrate specificity 
appears to be controlled by the polo-box domain (PBD)232.  A fifth PLK family 
member (PLK-5) has been identified with a homologous PBD but it does not contain 
a kinase domain and appears to control neuron differentiation rather than function in 
the cell cycle233. 
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1.4.2 A Mitotic Role for PLK-1 
PLK-1 functions as a master switch controlling entry to mitosis and recovery from 
the G2/M checkpoint234-236.  In unstressed conditions, cells can proceed to mitosis in 
the absence of PLK-1.   After DNA damage, however, active PLK-1 becomes 
essential for initiation of mitosis and therefore PLK-1 is critical for cell cycle re-start 
following G2/M arrest 236-238.  PLK-1 appears to be integral in centrosome 
maturation, spindle assembly, chromosome segregation and cytokinesis239-244.  The 
role of PLK-1 in mitosis has recently been comprehensively reviewed245.  PLK-1 has 
also been implicated in the AMP-activated protein kinase pathway and preliminary 
studies propose links to cell motility through changes in γ-tubulin localisation246.       
1.4.3 Regulation of PLK-1 expression 
PLK-1 expression is tightly controlled to provide appropriate expression given the 
cell cycle context.  In normal cycling human cells, expression rises through s-phase 
to peak at the G2/M transition247.  The major positive regulators of transcription are 
the forkhead transcription factors - in particular FOXM1248.  These transcription 
factors act in a positive feedback loop with both PLK-1 and FOXM1 further 
enhancing FOXM1 transcription249,250.   Levels are maintained through mitosis and 
then, between late M phase and early G1, PLK-1 is ubiquitylated, potentially by the 
anaphase promoting complex (APC), and degraded at the proteasome251.  PLK-1 
expression is suppressed during G1 phase by the cell-cycle-dependent element/cell 
cycle gene homology region protein (CDE/CHR) allowing the cycle to reset247.   
1.4.4 Regulation of PLK-1 activity 
The kinase activity of PLK-1 is itself regulated by reversible phosphorylation.  In the 
inactive conformation, the C-terminal PBD associates with the kinase domain 
preventing ATP-binding231.  Phosphorylation of threonine 210 in the T-loop of the 
PLK-1 kinase domain is associated with a conformational change which allows the 
polobox and kinase domains to dissociate and dock with their respective ligands 252.  
The activation of PLK-1 in this fashion is controlled by Aurora kinase A and the co-
factor hBora236,238.  Activation of PLK-1 allows substrate recognition and reversible 
phosphorylation of the key PLK-1 cell cycle targets Wee-1 and cdc25A236.  The 
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combined inactivation and activation of these targets drives dephosphorylation and 
activation of the Cyclin B/CDK1 complex, restarting the cell cycle machinery.  The 
reciprocal dephosphorylation and deactivation of PLK-1 is controlled by protein 
phosphatase 1 (PP1) and the co-factor myosin phosphatase-targeting subunit 1 
(MYPT1)253 (summarised in Figure 1-5).   
1.4.5 Checkpoint Adaptation. 
Cells sustaining DNA damage during G2 can trigger the G2/M checkpoint and 
engage DNA repair mechanisms.  If the damage is corrected then cells can proceed 
onto mitosis.  If the damage cannot be corrected the cells can trigger apoptosis or 
remain at the checkpoint.  Adaptation to the checkpoint has been described in vitro. 
In this process, cells enter mitosis after a prolonged G2 arrest such as that induced by 
irradiation and demonstrate persistent DNA double-stranded breaks.  This adaptation 
can be enhanced by depletion of Chk1 and inhibited by depletion of PLK-1254.  It is 
possible that dysregulation of this pathway due to hyperactive PLK-1 could promote 
early mitotic onset in the presence of damaged DNA leading to genomic instability.  
Aneuploidy is a general feature of oesophageal adenocarcinomas and is also 
observed in Barrett’s, predicting a high risk of progression to adenocarcinoma68,255.  
Checkpoint adaptation may allow gradual progression of carcinogenesis due to 
tolerated genomic instability.  This may be exploited in cells with mutant p53 where 
only the G2/M checkpoint is functional.   Complete inhibition of this checkpoint 
sensitises cancer cells to DNA damage and can induce massive apoptosis when 
combined with a genotoxic treatment.  This has been demonstrated with selective 
Chk1 inhibitors in a cervical, lung and colon cancer cell lines256.  A role for a Wee-1 
inhibitor as a radiosensitising agent has also been proposed in glioblastoma226. 
In glioblastoma cells with wt p53, induction of DNA damage with Temozolomide 
induced a G2/M arrest which was preserved for over 7 days.  Subsequent to this, 
cells became senescent.  When p53 function was inhibited in the same cells, the 
G2/M arrest was followed by apoptosis and a loss of colony formation capacity257.  
This provides evidence that the fate of cells after prolonged G2/M arrest may depend 
on p53 function.  Inhibiting the drivers of G2/M exit, the mitotic kinases, may 
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therefore allow a therapeutic window to be achieved between cells differing in their 
p53 status.  The key mitotic kinase responsible for the G2/M exit is PLK-1. 
 
Figure 1-5 Key Components in the G2/M Transition. Adapted from Reference237.  Damaged DNA is 
recognised by the DNA damage sensor mechanism consisting of a complex of proteins, specific to the type of DNA 
damage including double and single stranded DNA breaks and replication stalls.  A phosphorylation cascade is 
triggered inducing the activation of ATM/ATR and Chk1 and Chk2.  This leads to stabilisation and activation of p53 
via phosphorylation.  In cells with functional p53, p21 is upregulated and leads to G2 arrest by direct inhibition of 
the Cyclin B/CDK1 complex258. A p53-independent checkpoint mechanism can also be triggered by the Chk1/Chk2-
mediated inhibition of PLK-1 activation.  This prevents the phosphorylation-dependent recognition of Wee-1 by the 
E3 ubiquitin ligase SCF-βTRCP1/2 and subsequent proteasomal degradation.  The abundant Wee-1 can then 
phosphorylate and inactivate the CDK1-CyclinB complex leading to G2 arrest259.    
After DNA repair, a still elusive signal triggers checkpoint exit.  Aurora A becomes activated and together with the 
co-factor hBora phosphorylates PLK-1 on threonine 210238.  Phosphorylated PLK-1 then phosphorylates and 
activates the phosphatase Cdc25260 and targets wee1 for ubiquitylation and degradation.  The cyclin B/CDK1 
complex is activated and triggers mitotic entry.  Active PLK-1 creates a phosphodegron on hBora which allows 
recognition by the SCF- βTRCP1/2 complex, polyubiquitylation and degradation261.  Aurora kinase A is then released 
from the hBora-PLK-1 complex and together with the co-factor TPX2 becomes critical for the initiation of bipolar 
spindles.  Ste20-like kinase (SLK) may play a role in the AURKA-independent maintenance of phosphothreonine 210 
Plk-1 in mitosis. With mitosis complete, phosphothreonine 210 Plk-1 is degraded by interaction with protein 
phosphatase 1(PP1)-Myosin phosphatase-targeting subunit 1 (MYPTY1) and the cycle resets. 
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1.5 The role of Polokinase -1 in Cancer 
1.5.1 PLK-1 Expression in Cancer 
PLK-1 overexpression has now been demonstrated in a large number of cancer types 
and it appears PLK-1 mRNA levels are elevated in the vast majority of rapidly 
dividing cells262,263.    Expression has been correlated with poor prognosis in breast 
cancer264, lung cancer265, head and neck cancer266 among others.  PLK-1 also appears 
to be independently oncogenic as over-expression can transform the spontaneously 
immortalised mouse fibroblast cell line NIH 3T3267. 
1.5.2 PLK-1 Expression in Oesophageal Squamous Cell Carcinoma 
PLK-1 mRNA has been shown to be overexpressed in OSCC tissue compared to 
normal squamous epithelium by several authors and has been independently 
associated with a poorer prognosis262,268-270.  When multiple OSCC cell lines and the 
OAC lines OE33 and FLO-1 were subjected to limited gene expression profiling 
using a custom cDNA array, PLK-1 was significantly overexpressed compared to a 
mixture of human normal tissues271.  This overexpression was confirmed by 
quantitative real-time polymerase chain reaction (qRT-PCR) in OSCC and OAC 
tissues compared to a wide range of normal tissues with the exception of testis which 
expressed higher levels of PLK-1 than either cancer type.  The PLK-1 promoter was 
also confirmed to be more active in OSCC cells compared to normal human 
bronchial and renal cortical epithelial cells although cell proliferation rate may be the 
explanation for this271.   
PLK-1 has also been shown to be overexpressed in OSCC compared to adjacent 
normal tissues by IHC using a tissue microarray with material from 150 patients269.  
These findings were reproduced in a further study of 79 patients272. In both studies, 
PLK-1 expression was restricted to a few cells within the proliferating basal zone in 
oesophageal squamous epithelium but was more widely expressed in OSCC.  High 
PLK-1 protein expression was also correlated with lymph node metastasis, and 
independently predictive of survival269.  Using fluorescence in situ hybridisation to 
assess PLK-1 copy number, the same authors reported amplification in 6 out of 16 
cases269.  This is the only report to suggest PLK-1 amplification as a mechanism of 
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overexpression in cancer and no data were presented for control probes against other 
genomic loci.  Therefore this can only be interpreted with caution since aneuploidy, a 
common finding in this cancer, rather than PLK-1 locus amplification, may explain 
the findings273.   
Rodent reflux models have also been used to generate oesophageal tumours bearing a 
mixture or adenocarcinoma and squamous cell carcinoma histologies.  When three 
cell lines derived from these reflux-induced tumours were xenografted into nude 
mice, well differentiated squamous cell carcinomas were produced.  PLK-1 was 
found to be highly expressed in these cell lines further underlining its prominent role 
in either the development or maintenance of OSCC274. 
1.5.3 PLK-1 Expression in OAC 
A study of gene expression in oesophageal and OGJ adenocarcinomas identified 
PLK-1 mRNA expression as strongly correlated with the number of lymph node 
metastasis, the most significant determinant of prognosis in these patients275.  PLK-1 
mRNA overexpression has also been demonstrated in OAC tissue compared to 
Barrett’s and normal squamous oesophageal tissue although the results were not 
confirmed by IHC276.  Overexpression of PLK-1 in OAC is closely correlated with 
FOXM1, cyclin B1, Aurora kinase B and ki-67.  These genes form part of a 
transcriptional network closely linked to mitotic progression and their overexpression 
was associated with a poorer prognosis in OAC276,277.   
1.5.4 Inhibiting PLK-1 
The evidence for PLK-1 as a potential driver of cancer cell proliferation prompted 
research into the effects of PLK-1 inhibition.  This was initially accomplished by 
genetic means, including antisense oligonucleotides, transfection of a dominant 
negative mutant and RNA interference260,278-286.   Interest from the pharmaceutical 
industry in PLK-1 as an anticancer target prompted the development of selective 
inhibitors of the PLK-1 kinase domain.  The high level of sequence and structural 
similarity between the kinase domains of pololike kinase family members presents a 
significant challenge for the development of isoform specific inhibitors287-289.  The 
first potent PLK-1 inhibitor developed, for example, inhibits pololike kinases with 
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over 1,000-fold greater potency compared to a panel of over 60 other human kinases, 
but only inhibited PLK-1with 4 fold greater potency than PLK-2 and 11 fold greater 
potency than PLK-3290.  This may have a significant impact on the in vivo effect of 
this compound as PLK-2 and PLK-3 have potentially antagonistic effects to PLK-1.  
In contrast to the tight regulation of PLK-1 expression, both PLK-2 and PLK-3 are 
rapidly and transiently expressed after a diverse range of external stimuli including 
growth factor or hormone exposure and cellular stress as part of a group of 
immediate early response genes291,292.  PLK-2 is predominantly expressed during G1 
and exhibits tumour suppressor properties293.  PLK-3 is activated in response to DNA 
damage and is reported to activate and stabilise p53 by phosphorylation at serine-
20294.   With this in mind, PLK-1 inhibitors that have been optimised to enhance the 
specificity for PLK-1 may possess greater in vivo activity (Table 1-1). 
1.5.5 Enhancing Specificity for PLK-1 
Several approaches have been attempted to enhance drug specificity for PLK-1.  
Non-ATP competitive inhibitors thought to inhibit PLK-1 kinase activity include 
ON01910a295 and Cyclapolin 1296.  ON01910a is reported to produce a G2/M 
accumulation and multipolar spindles and appears to be relatively selective in vitro 
for PLK-1 over other pololike kinases295.  This inhibitor is, however, active against a 
range of other kinases and the mitotic phenotype differed from cells treated with 
PLK-1 RNAi prompting the suggestion this inhibitor does not act via PLK-1 
inhibition297.  Cyclapolin 1 was identified through structure-guided drug design and 
inhibits the kinase activity of PLK-1 in a non-ATP competitive mechanism which 
may involve covalent modification of a residue in the ATP binding cleft296.   It is 
unknown if this mechanism of inhibition confers greater specificity as the activity 
against PLK2 and PLK3 has not been reported for this compound.          
A novel strategy to inhibit PLK function in vivo is to target the ligand-binding 
interface of the PBD to prevent localisation of the kinase domain with biological 
substrates.  This structure is unique to pololike kinases and therefore off-target 
effects across the kinome can potentially be avoided.  The first in class non-peptide 
PBD inhibitor, poloxin, exhibited specific activity against pololike kinases298.  The 
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Introduction   54 
phosphopeptide binding groove of the PBD differs between PLK-1,2 and 3 and 
therefore the potential for isoform specific inhibitors appears greater.  This inhibitor, 
however, only showed a 4 fold relative specificity for PLK-1 over PLK-2. Treatment 
with this inhibitor induced mislocalisation of PLK-1, mitotic arrest, and apoptosis in 
Hela cells consistent with a specific effect on PLK-1.  Similar effects were also 
observed with the naturally occurring compound Purpurogallin, and the non-selective 
PBD inhibitor Poloxipan299,300.  These phenotypes were reproduced in a further study 
through overexpression of the PBD domain or expression of a kinase-domain only 
PLK-1 mutant301.  This confirms the subcellular localisation of PLK-1, mediated via 
PBD interactions, is critical for PLK-1 function. 
1.5.6 Early Clinical Trials of PLK-1 Inhibitors 
Encouraging preclinical data has propelled several PLK-1 inhibitors into clinical 
trials (Table 1-2).   The observed major toxicities appear to be related to the activity 
of the inhibitors on haematopoietic cells with dose limiting neutropaenia and 
leucopaenia in the majority of phase I trials.  This haematological toxicity can be a 
significant source of morbidity and even mortality but can be controlled in the 
clinical setting of advanced malignancy if therapeutic efficacy is observed.  
Unfortunately the strong preclinical anti-tumour activity of the PLK-1 inhibitors has 
not been replicated in Phase II studies of solid cancers to date.   Partial response 
rates, commonly determined by cross-sectional imaging of tumour deposit size, of 
<5% of treated cases have been reported with BI2536 (Table 1-2).  The relatively 
limited anticancer efficacy in the early clinical studies of PLK-1 inhibitors highlights 
the need to identify predictors of sensitivity and methods to enhance the therapeutic 
index between cancer and normal tissues.
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Table 1-1 Published PLK-1 Inhibitors.  Adapted in part from reference302. 
Compound Mechanism of Action IC50 for PLK-1 IC50 for other PLKs. Activity on Other Kinases 
Clinical 
Development Stage 
(Clinical Trials ID) 
BI2536290 ATP-competitive inhibitor 0.83 nM PLK-2 =3.5nM 
PLK-3 = 9.0nM 
IC50 >10μM for 63 kinases  Phase II 
BI6727 (Volasertib)303 ATP-competitive inhibitor 0.87nM PLK-2 = 5nM 
PLK-3 = 56nM 
IC50 >10μM for over 50 kinases. Phase III 
POLO-AML-2 
(NCT01721876) 
Compound 36304 Not determined 9.8nM PLK-2 = 21nM 
PLK-3 = 178nM 
High selectivity for PLKs over other kinases. Preclinical 
Cyclapolin 1296 
 
Non-ATP competitive.  ~20nM Not determined Src  IC50 = ~100μM  Preclinical 
DAP-81297 Predicted activity against the PLK-1 
ATP-binding domain   
0.9μM Not determined Not determined Preclinical 




Some activity against KDR, FLT4, CSF1R and 
PDGFRB 
Phase I306
HMN-176307 Disrupts PLK-1 cytoskeletal 
localisation 
118nM Not determined Not determined Phase I308 
LFM-A13309 
 
Kinase domain inhibitor 32.5μM PLK-3= 61μM BTK IC50 = 17.2μM Preclinical 
NMS-P937310 ATP-competitive inhibitor  2nM PLK-2 = 10μM 
PLK-3 = 10μM 
FLT3  IC50 = 510nM,  MELK IC50 = 744nM 
CSNK2A1 IC50 = 826nM.  60 other kinases >10μM 




Affects microtubule dynamics.  
Phenotype may not be mediated via 
PLK1297.   
9nM but limited 
effect in vitro up 
to 30μM 
PLK-2 = 260nM 
PLK-3 = >10μM 
Multikinase activity - IC50s;  PDGFR  = 18nm, Abl = 
32nM, FLT = 42nM, Src = 155nM, Fyn = 182nM, 




Poloxin298 Inhibitor of PLK-1 PBD. PBD = 4.8μM PLK-2 PBD = 18.7μM  
PLK-2 PBD = 53.9μM 
No reported non-PBD activity Preclinical 
Poloxipan300 Panspecific PBD inhibitor. PBD = 3.2μM PLK-2 PBD = 1.7μM  
PLK-2 PBD = 3.0μM 
Weak activity against other phosphopeptide 
binding domains . 
Preclinical 
Purpurogallin299 PBD inhibitor PBD = ~0.3μM Some activity against PLK-
2 PBD but not PLK-3 
None reported Preclinical 
SBE13311 Blocks PLK-1 in an inactive state Inactive PLK-1 = 
0.2nM 
PLK-2 = 66 μM 
PLK-3 = 875nM 
Not Evaluated Preclinical 
ZK-thiazolidinone 
(TAL)312 
ATP-competitive inhibitor 19nM PLK-2 <100nM 
PLK-3 <100nM 
High selectivity across a panel of 93 kinases. Preclinical 
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Table 1-2 Published Clinical Trials of PLK-1 Inhibitors. Continued Overleaf 
Compound Phase Trial Protocol Number of 
Subjects 




Treatment Related Toxicities 
(Most Frequent) or Deaths 
BI2536 I313 Open label, dose escalation 40 patients 
Advanced disease, 











BI2536 I314 Open label, dose escalation 70 patients 
Advanced disease, 








BI2536 I315 Open label, dose escalation 21 patients 
Advanced disease, 










BI 2536 I316 
Open label, dose escalation in 
combination with pemetrexed. 
41 patients 
Advanced or metastatic 










BI 2536 II317 
Open label, Day 1 (200mg 





Stage IIIB/IV non-small 







PFS 8 weeks. 
Grade 4 neutropaenia (37%) 
Fatigue (31%) 
Nausea (27%) 
Deaths 1 patient. 
BI2536 II318 
Open label, single protocol 
multiple tumour types 
71 patients 
Head and Neck (n=14), 












Febrile neutropaenia (20%) 
Deaths 1 patient. 
BI2536 II319 
Open label, Day 1 (200mg 


















Open label, Day 1 (200mg 
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Treatment Related Toxicities 
(Most Frequent) or Deaths 
ON01910.Na I321 
Open label, dose escalation.  
Twice-weekly 2-hour i.v. 
infusion for three weeks. 
20 patients 
Advanced disease, 









Open label, dose escalation.  




multiple cancer types 
DLT 33% stable disease Fatigue (48%) 
ON01910.Na I323 
Open label, dose escalation. 
One 72 hour i.v. infusion. 
27 patients 
Advanced disease, 
multiple cancer types 





Open label, dose escalation. 
Twice-weekly 2-hour i.v. 
infusion for three weeks in 
combination with once weekly 
infusion of Gemcitabine 
40 patients 
Advanced solid tumours 
(n = 19) and 21 further 




Solid tumours; 10% 
partial response, 
5% stable disease 








ON01910.Na I325 Open label, dose escalation. 14 patients 
High risk myelodysplastic 







Upper respiratory tract infection (28%) 
Haematuria (14%) 
Atrial fibrillation (14%) 
ON01910.Na II326 
Randomised comparison of oral 
intermittent (2 out of three 





 Response & PFS 
47% transfusion 
independent for >8 
weeks 
Urinary symptoms higher (60%) in 
continuous dosing arm vs intermittent 
(20%). 
HMN-214 I308 
Open label, dose escalation days 
1-21 out of 28 
33 
Advanced disease, 










Open label, dose escalation days 
1-5 out of 28 
32 
Advanced disease, 








BI6727 I328 Open label, dose escalation 65 patients 
Advanced disease, 








GSK461364 I306 Open label, dose escalation 40 patients 
Advanced disease, 
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1.5.7 The Effect PLK-1 suppression on non-transformed cells. 
Crosses between PLK-1 heterozygous mice do not yield viable homozygous 
knockouts329.  Subsequent investigations reveal PLK-1 -/- embryos show spindle 
abnormalities and cannot develop beyond the 8-cell stage, confirming the essential 
role of PLK-1 in mammalian embryonic cell proliferation329.  PLK-1 also appears to 
be ubiquitously expressed in proliferating human tissues262,263.    
It is surprising, therefore, that a divergent mitotic phenotype has been observed 
between HeLa cells and non-immortalised human foreskin fibroblasts in an early 
study of PLK-1 inhibition by antibody microinjection239.  This prompted several 
studies comparing cancer cell lines and non-transformed cells.  Viability was 
significantly reduced at 48 hours after PLK-1 expression was inhibited by siRNA in 
MiaPaCa and Hela cancer cell lines but not in human fibroblasts281.  A small 
reduction in fibroblast viability was noted in PLK-1 siRNA treated cells at 96 hours 
post transfection suggesting the effects of PLK-1 inhibition may be evident in non-
transformed cells in longer term assays.  This was supported by a clonogenic assay 
which confirmed significantly reduced colony formation at 14 days after 
transfection281.  Treatment of rat primary cardiac fibroblasts and Human umbilical 
Vein Endothelial Cells (HUVECs) with BI2536 also results in apoptosis330.        
In a further study, PLK-1 was suppressed by lenti-viral transduction of shRNA in 
cancer cell lines, the hTERT-immortalised retinal pigment epithelial cell line 
hTERT-RPE1, and the spontaneously immortalised breast epithelial cell line 
MCF10A.  PLK-1 shRNA produced an accumulation of 4N cells and reduced viable 
cancer cell number but had no significant effect on cell cycle profile nor cell number 
in the non-transformed line, although the viability method used was not reported in 
this study331.  Subsequent studies have confirmed hTERT-RPE1 cells can proliferate 
after reduction of PLK-1 expression by >90% using RNA interference methods but 
complete loss of the PLK-1 gene locus is associated with mitotic abnormalities242.   
Supporting this gene dosage effect, divergent cell cycle phenotypes have been 
observed with variable levels of PLK-1 suppression.  In Drosophila, a partially 
active,  weakly hypomorphic polo mutant results in persisting cell cycle progression 
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in contrast to inactivating strongly hypomorphic mutants which completely arrest 
proliferation332.  In human cancer cell lines, partial PLK-1 knockdown leads to 
mitotic arrest and complete PLK-1 depletion leads to G2 arrest and failure to activate 
Cdc25c333. 
Raab and colleagues interrogated the role of PLK-1in normal adult mammalian 
tissues in vivo using a mouse model with doxycycline-inducible expression of PLK-
1-targeting shRNA334.  The non-transformed mouse fibroblast cell line NIH3T3 
expressed 10-fold higher levels of PLK-1 than adult mouse GI-tract tissues, and other 
organs with low basal levels of cell proliferation but similar levels to mouse 
embryonic tissues, and adult mouse thymus and testis.  After PLK-1 was suppressed 
for 6 weeks by doxycycline-treatment of adult mice, a comprehensive tissue analysis 
was performed.  Spermatogenesis was found to be unperturbed by PLK-1 
suppression, in contrast to findings in Drosophila after abrogation of the fly homolog 
polo335.  Surprisingly, no evidence of marrow suppression was observed and control 
mice exhibited similar white cell and granulocyte counts to PLK-1 suppressed mice.  
This may be due to the residual 10-20% expression of PLK-1 being sufficient to 
maintain normal cell function.  This could also be secondary to artificial dependence 
on PLK-1 in rapid proliferating cultured cells.  
To test this, the authors used the same inducible expression system in primary mouse 
embryonic fibroblasts (MEFs) in vitro and found suppression of PLK-1 did not 
significantly reduce proliferation at 96 hours.  In contrast a range of human cancer 
cell lines were found to be more sensitive to PLK-1 siRNA compared to HUVECS, 
human fibroblasts and keratinocytes.                     
The widespread observation of haematological toxicity in Phase I human clinical 
trials of PLK-1 inhibitors despite the apparent cancer-cell selectivity from preclinical 
studies suggests there may be important flaws in preclinical models.  In particular the 
lack of marrow suppression in the conditional PLK-1 shRNA mouse model is 
concerning for future toxicity prediction and translation of preclinical therapeutic 
leads from rodent to man.  Importantly, MEFs treated with BI2536 showed 
significantly reduced proliferation and induction of apoptosis at doses >100 nM334.  
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This suggests PLK-1 suppression by RNA interference may not be a suitable method 
to model the phenotype of PLK-1 inhibition using kinase-inhibitors.     
1.5.8 Enhancing specificity through synthetic interactions. 
Identifying the features of cancer cells which confer sensitivity to PLK-1 inhibitors 
may allow the therapeutic window between malignant and non-transformed cells to 
be widened.  Somatic mutations are commonplace in cancers and may disrupt 
signalling networks to induce the transformed phenotype.  The same mutations may 
also create a unique dependency on a signalling pathway that is not present in normal 
cells.  Inhibiting this pathway would therefore only produce significant effects in 
cells with the appropriate mutations.   One commonly mutated oncogene in solid 
tumours is the inhibitory GTPase KRAS.  Mutations commonly lead to a loss of 
GTPase activity either directly, or by preventing the binding of GTPase-Activating 
Proteins, leading to constitutively active KRAS signalling336.      
A search for synthetic lethal interactions with the oncogenic KRAS G13D allele has 
been conducted using a genome-wide RNA interference strategy.  For this study, two 
isogenic colorectal adenocarcinoma cell lines bearing either KRAS wt/G13D alleles 
or KRAS wt/- were transfected with pools of shRNA sequences337.  Sequences that 
were significantly depleted in KRAS wt/G13D cells over subsequent population 
doublings were identified and a subset subsequently validated on a candidate basis.  
A number of genes involved in mitosis were proposed as synthetic lethal candidates, 
with PLK-1 identified as the only kinase in this study.  PLK-1 suppression using 
shRNA significantly depleted cells with KRAS wt/G13D compared to KRAS wt/- 
and KRAS wt/G13D cells were also sensitive to BI2536 in vitro and in a nude mouse 
xenograft assay337.  The possibility to preferentially target cells with activating 
KRAS mutations provides a compelling rationale for further development of the 
PLK-1 inhibitor class and highlights the importance of identifying predictors of 
sensitivity.           
1.5.9 Cross regulation between PLK-1 and p53 
The high frequency of TP53 mutation in cancer also makes this gene a compelling 
target for a synthetic lethal strategy.  The interaction of p53 and PLK-1 is complex.  
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When p53 was co-suppressed with PLK-1 using a lentiviral shRNA vector, 
proliferation was inhibited in MCF10A cells suggesting wild-type p53 protects cells 
from the effects of PLK-1 depletion331.  Depletion of PLK-1 produced a greater 
reduction in viable cell number in  cell lines with wild-type p53 inhibited by the E6 
oncoprotein198 or SV40 large T antigen173 compared to identical cells with 
uninhibited p53281.  Furthermore, inhibition of the DNA damage sensor ATM has 
also been reported to enhance the lethality of PLK-1 depletion, potentially by 
blunting p53 activation283.  These data suggest short-term inhibition of PLK-1 may 
preferentially target cancer cell lines and loss of p53 function may potentiate this 
effect.   
Hela cells depleted of PLK-1 or treated with PLK-1 inhibitors show stabilisation of 
p53282,338.  Temporary loss of p53 expression mediated by siRNA does not appear to 
potentiate the PLK-1 effect suggesting a more prolonged inhibition is required281.   
The activity of the PLK-1 promoter can also be indirectly supressed by p53.  In 
response to genotoxic stress, p53 regulates expression through transcriptional 
repression rather than promoter site binding to mediate the apoptotic cascade339. 
Wild-type p53 represses PLK-1 expression and regulates PLK-1 expression during 
the G2/M transition340,341.  This has been proposed to be mediated by p21-
dependent342 and independent mechanisms340.   
PLK-1 can also directly bind p53 within the DNA-binding domain resulting in 
reduced p53-mediated transcriptional activity in response to DNA damage343. It 
remains to be conclusively determined whether PLK-1 phosphorylates a specific 
residue on p53 to mediate this effect344.  PLK-1 can also indirectly regulate p53 
protein levels via phosphorylation and activation of  the p53-regulating E3 ubiquitin 
ligases, MDM2345 and Topors344.  
This reciprocal negative regulation suggests a model where loss of p53 function by 
mutation in many cancers allows PLK-1 over-expression and inhibition of PLK-1 
induces wild-type p53 expression.  This is supported by one study in breast cancer 
tissue where mutation of p53 was significantly correlated with high expression of 
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PLK-1.  Notably, the combination of p53 mutation and PLK-1 overexpression 
defined a group with significantly poorer prognosis than either p53 mutation or PLK-
1 overexpression alone264.        
 
1.5.10 The status of p53 as a determinant of PLK-1 inhibitor 
sensitivity 
In a study using isogenic HCT116 cells the dose- responses to BI2536 under basal 
growth conditions were independent of p53 status.  A follow-up study from a 
different group used the same cell lines and concluded that p53 function does not 
determine response to PLK-1 inhibition.  A similar induction of apoptosis and 
reduction of proliferation was noted on transfection of siRNA to PLK-1 in both wt 
and p53 null cells338.  Very similar results were also noted with transfection of 
scrambled siRNA suggesting that the cytotoxicity during transfection may mask the 
results of PLK-1 suppression338.   
In the same study, the responses to the PLK-1 inhibitors BI2536, BI6727 and Poloxin 
were examined and minimal differences in proliferation rates noted between cells 
isogenic for p53.  Unfortunately IC50 values were not calculated to allow comparison 
with other studies.  The inhibitors also appeared to produce similar mitotic 
phenotypes in the isogenic cells338.  Retention of p21 induction after DNA damage 
has been observed in the p53 null HCT116 cells, potentially through a p65-mediated 
mechanism346,347.  This does not appear to explain the cell cycle effects since p21 
was not induced in HCT116 p53 -/- cells after PLK-1 inhibitor treatment338.  MCF7 
and A549 cells both exhibited unchanged responses to PLK-1 inhibitors when wild-
type p53 was suppressed by siRNA338.  The lack of an augmented phenotype from 
PLK-1 inhibition when p53 expression is temporarily reduced has been previously 
observed281.  Low levels of residual p53 may be sufficient to mediate the effect in 
this case. 
The aneuploid human embryonic kidney cell line HEK 293 exhibits G2/M blockade 
after PLK-1 suppression despite wild-type p53 function suggesting p53 status is not 
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the only determinant of susceptibility to PLK-1 inhibitors281.  The cross inhibition of 
other polo-like kinases by BI2536 may also confound comparisons with RNA 
interference approaches and other compounds with greater specificity for PLK-1 
over other pololike kinases. 
Colony outgrowth was evaluated after a 72 hour treatment with the PLK-1 inhibitor 
GSK461364A across a panel of 43 cell lines representing various cancer types.  Gene 
expression, copy number variation and p53 genotype were correlated with 
sensitivity.  Mutation of p53 was 88% sensitive and 67% specific for the prediction 
of sensitivity to this compound348.  Those sensitive cell lines with wt p53 were also 
found to express higher levels of MDM2 compared to resistant cells with the wild-
type allele or sensitive cells with p53 mutations348.  Interestingly, neither PLK-1 
mRNA expression, nor KRAS or BRAF mutation status correlated with sensitivity to 
the inhibitor used in this study348.   
The apparent therapeutic index observed between wild-type and p53 mutant cell lines 
may be a consequence of the assay used.  Studies with GSK461364A in a standard 
72 hours proliferation assay identified differences between cell lines that correlated 
with proliferative rate rather than p53 genotype349.  The effect of p53 on colony 
outgrowth after PLK-1 inhibitor treatment has not yet been assessed using isogenic 
cells. This would help to clarify the effect of p53 genotype on response to these 
compounds. 
1.5.11 Strategies to augmenting sensitivity to PLK-1 
inhibitors 
The rationale for the use of PLK-1 inhibitors in cancer is that they target rapidly 
proliferating cells.  If normal cells can be induced to underdo temporary cell cycle 
arrest, they may be spared from the toxic effects of PLK-1 inhibition.  Activation of 
wild-type p53 by inhibition of MDM2 has been reported to lead to cell cycle arrest 
but not cell death in non-transformed cells through activation of the G1/S and G2/M 
checkpoints350-352.  Tumour cells with mutant p53 have been reported to be 
insensitive to this treatment and continue to progress through the cell cycle.   
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Combining an activator of wild-type (wt) p53 with a cytotoxic cell cycle inhibitor, 
referred to as “cyclotherapy”, represents a potential strategy to enhance the 
therapeutic window between cancer and normal cells.   
A reportedly specific inhibitor of the MDM2-p53 interaction, Nutlin-3A has been 
employed for this purpose.  When p53 was activated by gamma irradiation or Nutlin-
3A treatment, HCT116 cells with wt p53 were resistant to the effects of BI2536 in a 
short term viability assay relative to HCT 116 cells without p53220.  Interestingly, in 
the same study, Nutlin-3A significantly reduced viability in all cell lines at 10 µM 
regardless of p53 genotype and p53 null cells were only ten to fifty-fold more 
sensitive than cells with wt p53.  Treatment with BI2536 eradicated established 
HCT116 p53 -/- xenografts in nude mice and Nutlin-3A treatment did not affect 
tumour sensitivity to BI2536 but did reduce the BI2536-induced neutropaenia220.  
Nutlin-3A treatment alone also appeared to reduce HCT116 p53 -/- tumour growth 
rates compared to control and Nutlin-3A treatment could not protect HCT116 wt p53 
cells from the cytotoxic effect of BI2536. 
This suggests that Nutlin-3A may have undesirable off-target effects and p53 
activation using this compound may not be sufficient to protect against the effects of 
PLK-1 inhibitor treatment.  Cyclotherapy relies on non-genotoxic activation of p53 
in normal cells to induce G1/S arrest.  A recent report has highlighted a further 
undesirable toxicity of Nutlin-3A treatment with the observation of de novo p53 
mutations arising in cells with previously wt p53 treated with Nutlin-3A353.         
To identify synthetic lethal interactions with the PLK-1 inhibitor GSK461364, an 
RNAi screening approach was employed using a barcoded library of 4603 shRNAs 
directed against 1657 genes.  A group of differentially enriched shRNAs 
corresponding to 97 genes was identified354.  Retinoic acid receptor inhibition was 
found to induce resistance to the inhibitor.  Conversely a combination of retinoic acid 
receptor agonists was found to enhance sensitivity by an average of 10 fold354.  
Further studies are awaited to confirm if this is a drug specific effect or applicable to 
all PLK-1 inhibitors.   
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In a phase I study of the PLK-1 inhibitor GSK461364, 4 out of the 6 patients 
exhibiting stable disease had oesophageal cancer and one patient with metastatic 
OAC exhibited stable disease for over 1 year306. Although very preliminary data, this 
apparent relative sensitivity may reflect a disease-specific vulnerability to this class 
of inhibitor.  This may be a consequence of a high natural frequency of TP53 
mutation in this cancer type, or other undetermined genetic susceptibility.  
1.5.12 Targeting PLK-1 in Oesophageal Cancer 
Therapeutic targeting of PLK-1 has only been reported to date in squamous cell 
carcinomas of the oesophagus.  In one study, partial PLK-1 suppression by shRNA 
transfection reduced, but did not abolish, proliferation of OSCC cells and induced 
caspase-3 activation and apoptosis269.  A further study in OSCC cell lines confirmed 
reduction of proliferation and viability with induction of apoptosis 48-72 hours after 
transfection of siRNA to PLK-1355.  Colony formation and xenograft formation has 
also been shown to be reduced after transient transfection of siRNA to PLK-1 in 
OSCC cells271,272.  
PLK-1 inhibitors have also been investigated and complete regression of established 
xenografts of the OSCC cell line KYSE510 was observed when twice weekly tail 
vein injections of 50 mg/kg BI2536 were administered356.  This more robust assay 
confirms a tumour cell killing effect rather than a cytostatic phenomenon in vivo.   
A study into the regulation of PLK-1 in oesophageal cancer cell lines identified hsa-
miR-539-5p as a potential endogenous regulator of PLK-1 expression270.  A 
complementation site in the PLK-1 3’-UTR was identified and, importantly, 
transfection of hsa-miR-539-5p reduced both PLK-1 expression and proliferation in 
cell lines270.  The activity of this mechanism was not assessed in non-transformed 
cells and the relevance of this mechanism in vivo is unknown.  Small molecule drug-
like mimetics of this microRNA may however be useful as alternative strategies to 
target PLK-1. 
PLK-1 has also been shown to enhance the growth of OSCC cells in suspension, a 
key property of metastasising cells in vivo357.  This was dependent on an active PLK-
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1 kinase domain which prevented the proteasomal degradation of β-catenin.  The 
transcription factor RelA, a component of the NF-κB complex, was subsequently 
proposed as an upstream regulator of PLK-1 expression in detached OSCC cells.  
This transcription factor complex is widely implicated in the link between 
inflammation and cancer and may represent a therapeutic target in its own right358. 
A follow-up study by the same group confirmed STAT3 was frequently 
constitutively active in OSCC cells and tissue, compared to normal squamous tissue.  
They also identified STAT3 positively regulates PLK-1 expression, potentially via a 
STAT3 consensus sequence in the PLK-1 promoter, and that PLK-1 could augment 
STAT3 expression356.  This reciprocal activation enhanced cell survival in vitro and 
when cells were treated with BI2536, relative levels of active STAT3 decreased. 
Interestingly, constitutively active STAT3 expression partially protected KYSE510 
cells from the apoptosis induced by BI2536356.  Although most of the data was 
produced in one OSCC cell line, this study provides a clear rationale for the 
assessment of combination therapy with STAT3 and PLK-1 inhibitors.  
1.6 Immunotherapy – an alternative therapeutic 
strategy. 
The human immune system has evolved over millions of years to cope with a huge 
diversity of pathogens.  The remarkable sensitivity of antigen recognition 
mechanisms allows both non-human tissues to be recognised from diverse 
evolutionary kingdoms but also allows the clearance of host cells that have 
developed mutations359.  A hallmark of established cancers is that they manage to 
evade recognition by the immune system360.  Reactivation or augmentation of the 
immune response to cancer therefore provides a compelling therapeutic strategy. 
1.6.1 Mechanisms of immunotherapeutic activity 
The most commonly method of cancer immunotherapy uses antibodies directed 
against cell-surface antigens expressed on tumour cells.  Rituximab, trastuzumab, 
cetuximab have all reached clinical practice as targeted agents direct against CD20, 
HER2 and EGFR respectively359.   
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The mechanisms of action for therapeutic antibodies are diverse and context 
dependent for each agent.  Anti-tumour activity can be achieved directly by blocking 
growth promoting ligand-receptor interactions as in the case of EGFR-family 
directed antibodies.  Much research has been focussed on expanding this paradigm to 
other cancer types but the mechanistic specificity is vulnerable to the development of 
downstream resistance361,362.   
The presentation of the crystallisable fragment (Fc) portion of IgG on the surface of 
cancer cells can also play an important role in engaging innate immune effector 
mechanisms via Fc receptors.  This important mechanism of activity can lead to 
immune cell activation and cell-mediated cytotoxicity (antibody-dependent cellular 
cytotoxicity; ADCC)363.  The specific mechanisms of ADCC in vivo remain an area 
of intense investigation but appear to include both direct phagocytosis by stimulated 
macrophages, neutrophils and other phagocytes and the development of acquired 
immunity via the induction of tumour-directed cytotoxic T-cells and host-derived 
anti-tumour antibodies364.      
1.6.2 T-cell Meditated Therapies 
Improvements in the understanding of the microenvironment of the cancer niche has 
led to interest in T-cell based therapies.  Modulating the cytotoxic T-cell response to 
cancer has been attempted using several strategies.  CD4 positive T-helper cells 
regulate cytotoxic CD8 positive T-cells through combination of humoral and direct 
mechanisms including competition for CD80 and CD86 binding on antigen-
presenting cells, preventing cytotoxic T cell activation365.  Cytotoxic lymphocyte-
related antigen-4 (CTLA-4) is present on CD4 positive cells and a monoclonal 
antibody to this immunosuppressive molecule, Ipilimumab, enhances cytotoxic T-
cell activation366.  Crucially, this antibody enhances cancer-specific survival in 
metastatic melanoma and is being investigated in several other cancer types367.  
Significant side-effects of this therapy, however, include various autoimmune effects 
including skin rash, colitis and hepatotoxicity.   
A further approach includes the isolation of tumour-associated T cells directly from 
cancer biopsies, expansion and activation of these cells in vitro and then reinfusion 
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after systemic immunosuppression by lympho-depletion with cytotoxic 
chemotherapy with or without radiotherapy.  This method has been shown to produce 
response rates of up to 70% of patients with metastatic melanoma368.   
In a variation of this method, cytotoxic T-cells are engineered to express T-cell 
receptors with high affinity to putative tumour cell specific antigens.  This adoptive 
cell transfer method has been attempted for the melanocyte differentiation antigens 
gp100 and melanoma antigen recognised by T-cells1; (MART1) and clinical trials 
resulted in mild to moderate melanoma regression but also toxicity to normal 
melanocytes in the skin and eye.   
In a further study using T-cells engineered to express a high affinity receptor to the 
melanoma antigen family A protein 3; (MAGEA3), five out of nine patients 
experienced objective tumour responses369.  Unexpectedly, four patients developed 
severe neurological toxicity and subsequent investigations determined T-cell receptor 
cross-reactivity with MAGEA12 and MAGEA9, both of which were expressed at 
low levels in the brain.  A further trial with engineered T-cells expressing a different 
receptor targeting MAGEA3 resulted in fatal cardiac toxicity due to cross-reactivity 
with the myocardial protein titin370. Serious toxicities from off-target effects have 
also been observed with T-cells directed against the carcinoembryonic antigen 
(CEA) expressed in colon cancer and HER2371,372.                       
These studies confirm the significant in vivo efficacy of cytotoxic T-cell therapies 
but highlight the formidable potential toxicities associated with infusing activated T-
cells with high-affinity towards epitopes not exclusively expressed on cancer cells.  
Indeed the success of most immunotherapeutic strategies relies on targeting a cancer 
specific antigen.  Identifying these antigens is therefore a critical step in the 
development of these therapies. 
1.6.3 Cancer-cell Antigens 
Strategies directed toward identifying candidate cell-specific antigens for antibody-
based therapeutics have previously emphasised the selection of cell-surface or 
secreted proteins.  This follows the dogma that immunoglobulins are too large to 
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access intracellular epitopes.  An intriguing recent study has demonstrated antibodies 
directed against intracellular proteins can arrest the development of spontaneous 
tumours and xenografts in immune-competent mice373.  One possible explanation for 
the efficacy of antibodies directed to putatively intracellular targets is that proteins 
are actually available on the cell surface.  This phenomenon has been observed with 
chaperones normally confined to the endoplasmic reticulum and cytoplasm in non-
transformed cells identified on the cell membrane in cancer cells374.  Nevertheless, if 
this paradigm holds true in humans, the range of candidate cell-specific targets would 
be significantly broadened373. 
Tissue specific proteins can also be used as targets for novel antibody-based imaging 
agents to assist in clinical staging375 or, in the case of secreted proteins, for blood 
biomarker assays.  Each of these applications could have clear clinical impact in 
OAC but no specific markers have yet been identified.  To identify these candidate 
proteins de novo, expression must be measured using unbiased proteomic methods.  
1.7 Proteomics  
1.7.1 The Challenge of Measuring the Proteome  
The study of the entire protein content of an organism, tissue or cell was first 
described as proteomics nearly twenty years ago376.  In that time frame, the goal of 
measuring an entire eukaryotic proteome has been achieved377.  Despite significant 
methodological advances, however, the human proteome remains to be measured in 
toto almost a decade after the publication of the complete human genome378.  Several 
reasons can be proposed for this disparity.   
The polymerase chain reaction (PCR), allows template nucleotide sequences to be 
copied with an increase in number of many orders of magnitude with very low error 
rates379.  Complementary-base pairing also allows cryptic nucleotide sequences to be 
rapidly deciphered380.  The combination of these methods and advances in 
computational assembly of short sequence reads allows nucleotide sequencing to 
proceed in massively parallel configurations to produce entire genomes within 
hours381.                
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In contrast, the de novo identification of protein sequences contains greater intrinsic 
challenges.   No method exists to amplify protein or peptide sequences and therefore 
proteomic methods are always restricted by the input mass.  Similarly amino acids do 
not exhibit complementation and identification relies on mass measurement or, 
historically, chromatography or electrophoresis382.  The proteome is also 
significantly larger than the genome with alternative splicing and alternative 
transcription start sites contributing to transcriptome and ultimately proteome 
diversity383.   
A further challenge is posed by greater combinatorial possibilities with up to 21 
amino acids used interchangeably to generate peptides.  This complexity is further 
increased by post-translational modifications (PTMs) including the addition of 
biochemical groups such as a phosphate (phosphorylation), a carbohydrate 
(glycosylation), and at least 25 other distinct moieties or modifications382.   
A final compounding difficulty is the dynamic nature of the proteome.  The germline 
genome sequence of an organism is constant across all cells in that organism and is 
relatively stable in the face of DNA extraction methods even allowing DNA 
sequences to be obtained from ancient specimens384.  In contrast the proteome varies 
from cell to cell and is highly context dependent with the post-translational state of a 
single protein varying across subcellular localisations.  Extracting the proteome for 
quantification is also confounded by the rapid alterations in the PTM state induced 
by hypoxia and changes in intracellular pH with some phosphorylations reported to 
be lost within 60 minutes of tissue biopsy385.  Many of these challenges have been 
addressed with recent technological advances, the most significant of which is the 
use of high accuracy mass spectrometry386. 
1.7.2 Mass Spectrometry for Proteomics 
Mass spectrometry (MS) has become the definitive method to identify and quantify 
proteins de novo from complex mixtures.  In essence, a mass spectrometer consists of 
a detector coupled to a mass analyser that measures both the number and the mass to 
charge ratio (m/z) of ions generated into the gas phase from an ionisation source.  
Variations on the instrumentation abound however, each with their own strengths 
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and weaknesses.    A significant technological advance was made with the 
development of the Orbitrap mass spectrometer387.  These instruments combine high 
sensitivity, high mass accuracy and cover wide m/z ranges to finally bring the 
measurement of whole proteomes within reach.   
Electrospray ionisation  (ESI) sources take a liquid, commonly a polar volatile 
solvent eluted from  a chromatography column, and ionise the analytes directly into 
the gas phase388.  These sources are most commonly used for the analysis of complex 
mixtures including cell lysates.  Alternatives include matrix-assisted laser desorption 
ionisation (MALDI) sources which use a laser to ionise analytes directly into the gas 
phase out of a solid matrix389.  These sources are limited in the number of ions that 
can be generated and have previously been reserved for relatively homogenous 
analytes.        
1.7.3 Protein Identification using MS – Bottom-up Approach 
The de novo identification of proteins from a complex mixture can be achieved by 
several means.  The most common method, termed “shotgun” or “bottom-up” 
proteomics relies on the identification of peptides generated by proteolytic digestion 
of the protein mixture.  The presence of a protein in the original mixture is then 
inferred by interrogation of a protein sequence database with the identified peptide 
sequences.  Matching a peptide sequence unique to a particular protein provides 
evidence of the protein in the original mixture386.  An example workflow is 
illustrated in Figure 1-6.   
Shotgun proteomics relies on tandem mass spectrometry (MS/MS) where peptides 
are ionised to generate precursor ions, analysed and separated according to their m/z 
in the primary mass spectrometry run (MS1).  Precursor ions are then selected for 
fragmentation, usually by collision ion dissociation, and the fragment ions are 
separated and analysed in the second MS run (MS2)390.  Multiple fragment species 
are generated from the same peptide and, with high quality spectra and sufficient 
fragment ions, species differing by each individual amino acid in the peptide will be 
discernible as discrete ion peaks separated by a measured mass difference.  As amino 
acids all have a fixed, defined mass, the measured difference can be used to identify 
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the amino acid.  Thus the sequence of the peptide can be determined directly; defined 
as de novo peptide sequencing391.  In practice, with complex peptide mixtures it is 
rarely possible to sequence all peptides directly and this labour intensive approach is 
reserved for organisms with limited genome sequence information and therefore 
limited or absent potential protein databases.     
More commonly, database searching is performed to generate peptide-spectrum 
matches.  A number of algorithms have been described but in general the measured 
precursor mass is used to filter a database of peptides generated by in silico digestion 
of a list of potentially identifiable proteins.  Theoretical fragment ion mass 
differences are generated for all the candidate peptides with a matching precursor 
mass.  These are compared with the identified fragment ion spectra and candidates 
ranked using a scoring algorithm, specific to the database search method392.   
These methods identify peptides without the requirement for prior mass 
spectrometry.  Recently, organism-specific spectral libraries generated using 
stringent identification thresholds and evaluation of millions of published 
experimentally-derived peptide spectra have become available393.  An alternative, or 
complementary, approach is to search identified spectra against these libraries, 
incorporating other spectral features such as relative ion intensity.  This has been 
reported to enhance the number of peptide identifications compared to standard 
database search strategies393,394.  These algorithms may become more widespread in 
the future as spectral libraries become more complete but this approach has not yet 
been widely adopted.           
Peptide sequences are then used to identify proteins from the original search 
database.  A variety of statistical approaches are included in commonly used 
software packages to deal with protein inference problems such as repeated peptide 
sequencing events, peptides shared between multiple proteins and estimating the 
false-discovery rate395.                     
A significant limitation of mass spectrometry is the throughput of ions that can be 
analysed.  Although this has improved with the current generation of Orbitrap 
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instruments396, the number of analytes that can be studied simultaneously without 
loss of data is still restricted.  Tissue lysates contain highly diverse mixtures of 
proteins.  This diversity is further compounded by proteolytic digestion, presenting 
significant challenges for peptide spectrum matching.  To reduce the complexity of 
the original sample, fractionation approaches are often employed.  These can include 
strong cation exchange397, subcellular fractionation398, isoelectric focusing 
electrophoresis399, and other chromatography methods400.  By delivering fractions 
with reduced numbers of unique peptides into the mass spectrometer, homogenous 
m/z fractions can be produced during the MS1 phase which can be accurately 
sequenced during the MS2 phase401,402. 
1.7.4 Data-Dependent and Independent Shotgun Proteomics 
A key feature of the shotgun proteomic method as described previously is the 
selection of precursor ions for fragmentation in the MS2 phase.  This is usually 
performed on the basis of precursor ion intensity and is referred to as a data-
dependent approach403. This method has the limitation that a precursor ion must be 
detected to allow peptide sequencing and places an intrinsic bias towards abundant 
precursor species.  An alternative strategy, exemplified by the Precursor-acquisition 
Count Independent from Ion Count (PAcIFIC) method, is to fragment all precursor 
ions within defined m/z windows regardless of whether a precursor ion was detected 
or not404.  The precursor mass used for peptide spectrum matching is assigned as the 
centre of the MS1 m/z window.  When this method is applied, fragment ions yielding 
high-confidence peptide spectrum matches can be detected in up to 10% of cases in 
the absence of a precursor ion404,405.  Applied systematically across a wide range of 
precursor m/z windows, this approach can enhance the depth of proteome coverage 
by identifying low abundance peptides.  A disadvantage is the long data acquisition 
times required to obtain spectra across all m/z windows.  With optimised liquid 
chromatography gradients, however, the mass spectrometry time can be reduced by 
over 50%406.     
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Figure 1-6 An Overview of Protein Identification by Shotgun Proteomics.  A complex protein mixture, in this example a tissue sample containing proteins A-D, is 
proteolytically digested to yield peptides.  Each peptide is schematically represented as a coloured box. To reduce the mixture complexity, peptides are fractionated by 
a common property.  In this illustration the property is colour but in practice this is a biochemical property such as isoelectric point.  Peptide fractions are subjected to 
tandem mass spectrometry to yield fragment ion spectra.  Peptide-spectrum matches (IDs) are made using a protein database, the peptide (precursor) ion masses and 
a database search tool407.  Not all fragment ion spectra result in a peptide match and some peptide matches are of low confidence (e.g. light green peptide).  Using 
further statistical tools395, proteins are identified with unique peptide matches confirming the presence of a protein in the original mixture.  Each shotgun experiment 
only identifies a subset of the proteome from complex mixtures such as tissue lysate so in this example protein “D” has not been identified. 
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1.7.5 Protein Identification using MS – Top-Down Approach 
An exciting recent development has been the enhancement of techniques to identify 
intact proteins by mass-spectrometry; a so-called “top-down” approach.  In a recent 
report, over 1000 distinct protein isoforms could be identified using cultured 
mammalian cells and extensive orthogonal fractionation in the liquid-phase408.  An 
advantage of this method is the direct identification of proteins, rather than inference 
from peptide identifications using the shotgun approach.  This provides the potential 
to characterize the entire population of isoforms generated from a single gene and 
identify dynamic changes in protein-processing, alternative-splicing or post-
translational modification often not possible from peptide-level data alone.  Although 
not currently capable of proteome-scale analysis, with further developments in 
automated fractionation, instrumentation and data-analysis methods, this may 
become feasible in the future409.  Measuring dynamic changes in cellular states, the 
ultimate goal of most biological proteomic experiments, however, requires 
quantitation in addition to protein identification and methods to undertake this using 
a hypothesis-free top-down approach remain to be described.  
1.7.6 Gel-based Methods for Quantitative Proteomics 
A typical proteomics experimental design would be to compare a cell line under two 
or more conditions and attempt to identify differentially expressed proteins.  
Historically, 2D gel electrophoresis would be used to separate the cell lysates from 
each condition according to protein mass and isoelectric point410.  Gels could then be 
stained using a silver-based or other similar methods and differentially expressed 
proteins could be identified as spots of differing intensities411.   
A variation of this method minimised the gel to gel variability by labelling all the 
proteins in each sample with a different fluorophore and running all the samples 
together on the same gel412.  By quantifying the relative emission from each 
fluorophore across the spots, the relative expression could be determined.   
In both examples, protein spots were excised from the gels, digested to peptides 
using proteolytic enzymes and subjected to mass spectrometry for peptide and 
subsequent protein identification using similar strategies to shotgun proteomics.  This 
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method has the advantage of limiting the protein identifications to a small number of 
differentially expressed proteins, and providing a relatively homogenous sample for 
mass spectrometry. Unfortunately, despite advances in the automation of spot 
detection and quantification, these methods were only semi-quantitative, labour-
intensive, the data quality was highly user dependent and protein identifications were 
limited to a few dozen per experiment. 
1.7.7 MALDI-Imaging MS (MALDI-IMS) 
A major disadvantage of lysing tissue biopsies for down-stream mass spectrometry 
analysis is the loss of microscopic spatial information relating to protein expression.  
Epithelial-derived tumour cells exist, and in many cases are dependent on, the 
interactions and cellular context of their microenvironment360.  Understanding the 
changes in protein expression that occur within epithelial and stromal tumour 
compartments may unveil novel insights not apparent from analysis of the tumour 
biopsy in toto.  Similarly, cell types of one origin exhibit varied expression profiles 
across tumours reflecting mutational diversity and changes in oxygen tension and 
extracellular nutrient availability413.   
To capture this heterogeneity, MALDI techniques have been adapted to allow direct 
ionization and mass-spectrometry from tissue sections414.  By co-registering spectra 
and histological images, patterns of protein expression can be interpreted within their 
biological and cellular context.  The significant advantages of this imaging mass 
spectrometry method are offset by some of the limitations of other MALDI 
approaches.   
MALDI-IMS generates spectral features (m/z) which can be used to differentiate 
samples but does not identify proteins directly.  Hybrid approaches with downstream 
tandem mass spectrometry allow low mass proteins to be identified directly although 
proteome coverage has not yet reached parity with LC-MS/MS analysis of tissue 
lysates415.  A further significant limitation is in the resolution of ionization sources.  
Current technologies allow a minimum resolvable area of 10 µm but most analyses 
are practically limited to areas of 100 µm416.  This allows a granular expression map 
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to be generated but the goal of identifying subcellular expression patterns, for 
example at the tumour-stromal interface, remains elusive.          
1.7.8  Quantitative Shotgun Proteomics 
Advances in sample processing and instrumentation have enabled the development 
of quantitative shotgun proteomic methods.  These rely on lysis, digestion and 
usually fractionation of samples prior to liquid chromatography (LC) and MS/MS.  A 
labelling phase can be incorporated into the sample preparation stages prior to 
MS/MS or peptides can be quantified directly using label-free strategies417.    
1.7.9 Quantitative Shotgun Proteomics by Labelling 
1.7.9.1 Stable Isotope Labelling of Amino Acids in Culture (SILAC) 
Chemical labelling can take place at the protein or peptide level.  The use of stable 
carbon, hydrogen and nitrogen isotopes have allowed differential labelling of amino 
acids that by their mass differences are resolvable as discrete spectral peaks.  This 
approach, termed Stable Isotopic Labelling of Amino Acids in Culture (SILAC), 
allows the proteins in mammalian cells in culture to be isotopically labelled by the 
use of medium containing only “heavy” amino acids such as Leucine, Lysine and 
Arginine418.  A typical experiment would comprise one treated, “heavy”-labelled cell 
line and a control unlabeled, “light”, cell line.  Cell lysates would be mixed in a 1:1 
ratio and then subjected to standard LC-MS/MS workflow.  Peptides would be 
identified in the usual fashion and the relative expression between cell line 
conditions identified at the MS1 level by the ratio of heavy to light peptide ion 
intensities.  This approach has been shown to be reproducible across the proteome 
with relative standard deviations of protein ratios of ~30%417.  By using both heavy 
lysine and heavy arginine combinations, three conditions can be compared 
simultaneously.   
A disadvantage of SILAC approaches is the requirement for complete label uptake 
by cultured cells, which limits the application to cells which express stable 
phenotypes of interest across several passages.  The requirement for prior labeling in 
the conventional SILAC method also precludes the study of human tissues samples 
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although fully isotopically-labelled organisms have been described which may have 
application in disease models419-421. 
1.7.9.2 Super-SILAC 
A recently described variation of the SILAC method, termed super-SILAC, has 
potential application for the quantitative proteomic study of human cancer 
samples422.  In this procedure a mixture of cell lines derived from the cancer tissue of 
interest and approximately covering the expression profile of the tissue of interest are 
heavy-labelled using the SILAC method.  A mixture of lysates from these cell lines 
with a defined protein mass is spiked-in to each tissue lysate in a 1:1 ratio before 
digestion, fractionation and LC-MS/MS using standard procedures.  Peptide 
identification and quantitation then proceeds as for a standard SILAC experiment.  
The ratio of expression between heavy and light peptides is calculated for each tissue 
sample.  The constant SILAC spike-in mass provides a method of normalizing 
between experimental runs and also, by calculating the ratio of ratios, allows the 
relative expression between tissue types to be calculated423.  An advantage is the 
spike-in standard can be used in multiple experiments on multiple platforms and still 
allow normalization between experiments and, once the spike-in standard is 
generated, there is no further labelling steps or reagent costs.  A disadvantage is that 
the accuracy of SILAC is highest at ratios <2 and therefore a relatively close match 
to the tissue expression profile is required417.  SILAC media is not yet available for 
many primary cells and therefore primary human tissues or cancers with few 
available cell lines may be difficult to analyse with this technique.  Similarly, 
proteins specific to a particular tissue sample will not be quantified.           
1.7.9.3 Isotope-coded Affinity Tags (ICAT) 
In this method, the cysteine residues of reduced proteins are labelled with tags 
comprising a composite of a sulfhydryl reacting group, a deuterated linker, and a 
biotin affinity tag424.  Proteins from discrete samples can be differentially labelled as 
both “light” and “heavy” isotopes of the linker are available.  Labelled samples are 
then pooled and digested together.  Cysteine containing peptides are then enriched by 
avidin-affinity chromatography.  Peptides can then be further fractionated or directly 
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subjected to LC-MS/MS.  The different isotopes of the deuterated linker provide 
discrete mass peaks during MS1 analysis to allow differential expression analysis.     
Unfortunately only cysteine containing proteins can be studied, limiting proteome-
wide efforts and the bulky affinity group, biotin, introduces significant background 
into the MS/MS spectra425.  Furthermore, deuterated labels are more hydrophobic 
and therefore are differentially eluted during reverse phase LC, complicating the MS 
analysis426.  This technique still has a role, however, as the affinity enrichment step 
allows the study of low abundance proteins, not easily accessible by other methods.          
1.7.9.4 18O labelling 
Accurate quantitation can also be achieved by labeling at the peptide level.  An 
advantage of this strategy is that it can be applied to almost any sample.  In an 
approach that predates the SILAC method, samples for comparison are either 
proteolytically digested in 18O-containing water for the “heavy” sample or standard 
“light” water427.  As the protease, in most cases trypsin, cleaves the peptide bonds, 
the heavy isotope is incorporated so all tryptic peptides will be labelled.  The 
subsequent data analysis is identical to SILAC methods.  A disadvantage of this 
approach is the relative expense of H2
18O.              
1.7.9.5 Dimethyl isotopic labelling 
A further method uses standard and deuterium isotopes of formaldehyde to label the 
amino-terminus of peptides or the amino group of Lysine residues428.  Again the 
isotopes are resolved by their mass differences allowing peptide level quantitation 
from the MS1 scan.  A further limitation common to SILAC, 18O and Dimethyl 
labelling is that a maximum of three samples can be compared per mass spectrometry 
analysis.         
1.7.9.6 Isobaric peptide labelling 
Isobaric peptide labels offer greater multiplexing capabilities with 4-plex or 8-plex 
(Isobaric Tag for Relative and Absolute Quantification; iTRAQ)429 or 6-plex 
(Tandem Mass Tags; TMT)430 commercial kits available.  Both of these kits use the 
same underlying principle.   
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Each label consists of an amine reactive, N-hydroxy succinimide ester, balancing 
carbonyl linker and reporter ion components (Figure 1-7).  Tryptic peptides form 
amide linkages with the labels via N-termini or lysine residues.  A label with a 
different reporter is used for each different sample and all the samples are mixed 
prior to fractionation and LC-MS/MS.  Each label has the same total mass and 
chromatographic properties and therefore the LC retention time and mass/charge 
(m/z) separation of each sample are not differentially affected during the MS1 
scan429. 
Precursor ions are then sampled for MS/MS analysis and the ionized labeled peptides 
are fragmented with dissociation of the reporter ions from the balancing carbonyl 
linker.  The peptide fragments are detected generating mass spectra in the usual 
manner.  The reporter ions are also detected and as peaks at a predefined m/z.  For a 
four-plex iTRAQ experiment the reporters are detected at 114.1, 115.1, 116.1 and 
117.1 m/z429.  For a sixplex TMT experiment, the reporters are detected at 126.1, 
127.1, 128.1, 129.1, 130.1 and 131.1 m/z430.   
Assuming complete peptide labeling of each sample, the more abundant peptides 
within each sample will have accumulated more label.  When equal amounts of each 
sample are mixed and subjected to LC-MS/MS together, those samples with a greater 
original concentration of a particular peptide will produce higher reporter ion peak 
intensities in the MS/MS scan.  By comparing the relative reporter ion intensities, the 
relative peptide and therefore protein abundances in the original samples can be 
determined431.   
The multiplexing capabilities of isobaric labels are directly offset by the consequent 
dilution of each sample leading to challenges in identifying low abundance 
peptides406.  Samples also have to be lysed and digested separately which has the 
potential to introduce error.  In contrast, cell populations can be mixed prior to lysis 
in SILAC experiments.  The quantitative accuracy and dynamic range offered by 
isobaric labels are excellent, however, surpassing SILAC in a direct comparison417. 
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Figure 1-7 Schematic of the four-plex  iTRAQ peptide label.  A reporter group with a defined mass 
between 114 and 117 Da is connected to a balancing linker. Together the reporter and linkers have a 
fixed mass of 145 Da and they are connected to an amine reactive group which binds peptide amino-
termini and lysine residues.  The label is cleaved at the balancing linker during MS2 fragment ion 
generation to allow reporter ion detection.  Figure adapted from reference429    
  
1.7.10 Label-free Quantitative Shotgun Proteomics 
All sample manipulation steps during a proteomic workflow reduce the data yield 
due to loss of proteins432 and are additional sources of variation433.  Eliminating the 
sample processing steps to incorporate labels for quantitation is clearly an advantage 
and underlies the rationale to develop label-free methods of quantitation. 
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The total number of spectra matched to each peptide contributing to a protein 
identification, termed the spectral count, has been reported to correlate with absolute 
protein abundance434.  Various methods have been proposed to refine the spectral 
count such as normalising for protein length435, or combination scores including 
peptide count and fragment-ion intensity436.  For complex protein mixtures, spectral 
counts are still subject to significant between-run variability and are highly 
dependent on LC conditions and precursor ion selection.  As a result the quantitative 
reproducibility of spectral counting is inferior to isobaric labelling methods437.  
An alternative relies on the capture of precursor ion intensity as a function of time to 
produce an ion chromatogram.  The area under the ion chromatogram curve is 
linearly proportional to the peptide concentration438.  Challenges exist in applying 
this method across LC-MS/MS runs to allow differential analysis as the same peptide 
ion must be identified and quantified despite background noise, co-eluting peptides 
causing signal overlap, technical variations in retention time and total protein loading 
among other factors439. 
A simultaneous advantage and disadvantage of both label-free approaches is the 
requirement to analyse one sample per LC-MS/MS run.  This prevents sample 
dilution, provides maximum potential coverage and prevents the potential failure to 
identify dysregulated low abundance proteins that occurs with multiplexed 
approaches.  By comparing conditions across separate LC-MS/MS runs, however, 
the inherent changes in LC performance and the stochastic nature of protein 
identification by shotgun proteomics both contribute to data heterogeneity.  Until 
these concerns are addressed, labelling strategies will still be widely employed.            
1.7.11 Considerations for Cancer Tissues Proteomics. 
Proteomic methods have been most widely applied in human disease to the discovery 
of cancer biomarkers.  A typical experimental design compares the proteome of 
multiple tissue biopsies derived from cancer and corresponding normal tissue.  One 
challenge is to measure the proteome of samples that accurately reflect the in vivo 
expression profile.  Tissue biopsies undergo hypoxic stress which leads to apoptosis 
and proteolysis with increasing time at room temperature385.   For this reason, 
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biopsies are often snap-frozen in liquid nitrogen to temporarily inactivate enzymes 
prior to tissue lysis.  A recently described alternative is the rapid heat inactivation of 
tissue biopsies440.  For both methods, time is considered critical to prevent proteome 
degradation. 
The heterogeneity of cancer biopsies has prompted the search for methods to isolate 
homogeneous cell populations from tissue samples.  One such method, laser-capture 
microdissection (LCM), allows homogeneous cellular populations to be isolated 
from thin (<10 µm) frozen tissue sections441.  Although allowing the discrete analysis 
of the complex cellular components that comprise the tumour microenvironment,  the 
limited protein mass produced during microdissection necessitate multiple 
dissections to generate the 5,000-50,000 cells required for a typical shotgun 
proteomic experiment442.  LCM therefore remains a labour intensive method that has 
yet to become widely adopted for whole proteome analysis.       
A further challenge of studying the proteome of tissue biopsies is protein extraction.  
Membrane proteins are relatively hydrophobic and often prove insoluble in aqueous 
buffers.  The use of detergents can enhance membrane protein recovery but are 
incompatible with mass spectrometry due to signal distortion.  A hybrid method is 
reported to allow complete tissue proteome solubilisation using a detergent-
containing buffer followed by buffer exchange into a mass-spectrometry compatible 
solution on molecular weight cut-off filters443.  This method, termed filter-aided 
sample preparation (FASP) has also been successfully applied to LCM tissues444.   If 
validated across multiple human tissue types this method could allow standardization 
between studies, a significant limitation in the current proteomics literature.        
1.7.12   Quantitative Proteomics in OAC 
Although quantitative proteomic methods have now been applied across many cancer 
types no studies have yet identified and quantified proteins from OAC tissue de novo 
with subsequent selection of dysregulated candidates (Table 1-3).    Two studies have 
employed 2D gel electrophoresis of fresh frozen biopsy lysates.  One compared 
protein spot intensities between OAC and matched normal mucosal biopsies445 and 
the second compared spot intensities from tumours that did or did not show a 
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pathological response to chemoradiotherapy446.  A further study has used a similar 
approach with protein separation and quantitation in the liquid phase and selective 
identification of dysregulated candidates447.  Three studies have used MALDI-IMS to 
identify differential spectra features between tissue types and then gone on to 
subsequently identify a small number of these spectra. 
The minimal protein expression data provided in these reports limits the comparisons 
that can be made across other studies or other cancer types.  An additional advantage 
of generating proteomic expression data is that deranged signaling pathways can be 
identified using network analysis methods, potentially uncovering tractable 
therapeutic targets.  There is therefore a need for larger scale quantitative proteomic 
studies in OAC. 
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Table 1-3 Proteomic Studies in Oesophageal Adenocarcinoma 
Study 
Author 
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spots – 22 proteins 
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- - - 23  - 22 spectral features, 
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frozen biopsies 
 
- - 4 4  8 spectral features  
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1.8 Network Analysis  
A key limitation of proteomic methods is the lack of complete proteome coverage423.  
Only a subset of the expressed proteome can be measured in any experiment and a 
further subset of this quantified.  Biochemical properties and abundance play a small 
role in determining the likelihood of identification but otherwise this remains a 
stochastic phenomenon454.  Identifying the changes in signalling underlying a 
phenotype is hampered by incomplete coverage of network or pathway components 
and difficulties in determining serial changes in protein expression455. 
Network analysis methods can address this by uncovering dysregulated pathways 
from incomplete expression data.  This can be achieved if the underlying 
connectivity (edges) between genes or proteins (nodes) is described for that 
organism.  The control of the majority of human cellular signalling pathways, 
however, remains under investigation and new models of regulation are regularly 
being uncovered456.  Despite this, functional linkages have been described on a 
genome-wide scale for several organisms including humans.  Functional linkages can 
refer to direct protein-protein interaction457, co-regulation by a transcription factor458, 
similar biological activity459 or structural domain homology among other properties.  
In one example of a human functional linkage network, nodes are connected by 
functional linkages which summarise the evidence for a functional connection 
comprising protein-interaction data, co-expression, domain homology, shared 
ontologies and closely approximated genomic loci460.                
One approach to the use of functional linkage networks for proteomic data analysis is 
to generate clusters within the network using an algorithm that identifies highly 
connected nodes461.  Due to the strategy of network construction, these clusters 
represent functionally connected genes.  Dysregulated proteins identified by 
proteomics analysis are mapped onto these clusters along with a random resample 
from all identified proteins.  Statistically enriched clusters can then be identified 
using the dysregulated protein list462.   These clusters of functionally related genes 
represent a starting point for hypothesis directed protein expression mapping and 
subsequent confirmatory experiments.   
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1.9 Aims of This Project 
Oesophageal adenocarcinoma is an increasing problem in the UK and current 
systemic therapies are ineffective for the majority of patients.  The central aim of this 
study is to identify novel therapeutic targets for this cancer. A variety of strategies 
will be employed.  The finding of a high frequency of TP53 mutation in OAC 
suggests a synthetic lethal approach may be feasible by targeting PLK-1. 
Aim (i) To determine if PLK-1 represents a tractable therapeutic target in 
OAC using a panel of oesophageal cell lines representing the stages 
of oesophageal carcinogenesis. 
A key requirement for chemotherapeutic efficacy is to establish cancer cell 
cytotoxicity while minimising toxicity to non-transformed cells.  Identifying proteins 
that are specifically expressed on the surface of OAC cells may allow effective 
immunotherapeutic approaches and enhanced clinical staging protocols.  Proteomic 
strategies offer the potential to identify these proteins but mandate high quality tissue 
is used.    
Aim (ii) To establish a human oesophageal tissue bioresource to enable 
therapeutic target discovery. 
Aim (iii) To establish the optimal methods for quantitative oesophageal tissue 
proteomics. 
Aim (iv) Using these methods – define cancer specific targets for 
development using an immunotherapeutic approach. 
Incomplete proteome coverage can limit the identification of dysregulated signalling 
pathways.  Network analysis may complement quantitative proteomic strategies to 
reveal druggable targets. 
Aim (v) Use network analysis tools to define potential targetable pathways in 
OAC.   
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2.1.1 Chemicals and Solutions 
All stock solutions and additives used with cultured cells were purchased as sterile 
tissue-culture grade or were filtered using a 0.2 2µm syringe filter (Millex-GS, 
0.22 µm, Millipore) and hand-held syringe.  All chemicals and solutions were 
obtained from Sigma-Aldrich, Gillingham, UK unless otherwise stated. 
2.1.2 Replicates 
The number of experimental replicates undertaken has been indicated in the 
accompanying figure legends.  Technical replicates were defined as a repeat of the 
experiment using material derived from the same tissue culture plate or biological 
material.  Biological replicates refer to a repeat of the experiment using cells from a 
different tissue culture plate or biological material from a different patient.    
2.2 Cell Lines  
2.2.1 Cell Line Panels 
Cell line based research is commonly criticised for a lack of relevance to tumours in 
vivo.  This criticism is often based on the potentially confounding effect of artefacts 
induced by 2D culture.  Despite these concerns, a panel of breast cancer cell lines has 
been shown to model the majority of genetic features of human breast cancer89.  In 
addition, a panel of gastric cancer cell lines has revealed intrinsic molecular subtypes 
with differing drug sensitivities in human gastric cancer90.  Tissue-specific cell line 
panels therefore have the capacity to provide disease-relevant model systems and 
yield biological insight.      
2.2.2 Cell Line Sources 
The OE19 and OE33 cell lines (passage number 24 and 13) were purchased from the 
European Collection of Cell Cultures463.  The telomerase-immortalised (hTERT), 
non-transformed, non-dysplastic Barrett’s epithelial cell line - CP-A91, the OAC cell 
lines; FLO-1, JH-Eso-Ad1 and OACM5.1 C, and the Oesophageal Squamous Cell 
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Carcinoma cell line, KYSE-30, were generous gifts from Dr. Rebecca Fitzgerald 
(Cambridge).  Primary oesophageal squamous cells; HEEpiCs were purchased from 
ScienCell research Laboratories464.  The colorectal adenocarcinoma cell line, 
HCT116 was a generous gift from Dr. Bert Vogelstein (Baltimore) and the metastatic 
breast cancer cell line MCF-7 was purchased from the European Collection of Cell 
Cultures.   All frozen cell stocks were maintained in liquid nitrogen until 
resuscitation by rapid thawing and dispersion into warmed complete medium.  The 
characteristics of the oesophageal cells used are presented in Table 2-1. 
2.2.3 Cell Line Propagation 
All cell lines were maintained in a humidified incubator (Hera) at 37oC and 5% CO2 
and, with the exception of HEEpiCs, were grown on standard plastic tissue culture 
plates.  The cell lines OE19, OE33, OACM5.1 C, and KYSE-30 were grown in 
RPMI 1640 medium (Invitrogen), FLO-1 and MCF7 cells were propagated in 
DMEM (Invitrogen) and HCT116 cells were grown in McCoys 5A medium 
(Invitrogen).  RPMI, DMEM and McCoys 5A were supplemented with 10% (v/v) 
Foetal Calf Serum (FCS, Labtech International, Biosera) and 0.5 units/ml Penicillin 
+ 500 ng/ml Streptomycin (P/S, Invitrogen) to make complete growth medium.  The 
JH-Eso-Ad1 line was grown in MEM + 20% FCS and P/S.  CP-A cells were 
maintained in Keratinocyte Serum Free Media (KSFM, Invitrogen) supplemented 
with recombinant epidermal growth factor (EGF, 5 µg/L), bovine pituitary extract 
(BPE, 50 mg/L) (both Invitrogen) and P/S.  
For the propagation of HEEpiCs, tissue culture plates were first incubated with poly-
L-lysine, diluted from a sterile stock of 10 mg/ml (ScienCell) to 2 µg/cm2 in 
autoclaved water, for at least 1 hour at 37oC followed by aspiration of the poly-L-
lysine solution. Cells were then seeded from rapidly thawn, frozen stocks into poly-
L-lysine coated flasks containing warmed Epithelial Cell Medium-2 (EpiCM-2, 
ScienCell) supplemented with 1% Epithelial cell growth supplement-2 (EpiCGS-2, 
ScienCell) and P/S.   
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Table 2-1 Characteristics of Oesophageal Cell Lines and Primary Cells Used 
Characteristics 
Primary 
Cells Cell line 
HEEpiC CP-A OE19 OE33 FLO-1 OACM5.1 C JH-Eso-Ad1 KYSE-30 
Year Established 
(reference) 
- 200391 1993465 1993465 199185 1996466 1997467 1992468 
Derived From Oesophageal Epithelium 
Oesophageal 
Epithelium 
Primary    
Tumour 
Primary 
































- - No No No No No No 
Immortalised No Yes Yes Yes Yes Yes Yes Yes 
Generates 
Xenograft 
No No Yes85 Yes85 Yes469,470 Yes85 Yes85 Yes468 
TP53 Mutation Wildtype Wildtype N310K Frame C135Y C277F Frame G266E Exon 7 skipped471 
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Cell lines and primary cells were monitored daily using a bright-field inverted phase-
contrast microscope and the medium changed every 48 hours or as required.  Cells 
were maintained in an incubator specified for confirmed mycoplasma-free cells.  Cell 
cultures were confirmed to be mycoplasma negative by periodic testing using the 
luciferase-based MycoAlert™ Mycoplasma detection kit (Lonza) as per the 
manufacturer’s instructions.      
2.2.4 Cell Subculture  
For routine subculture, cell lines and primary cells were grown until 80-90% 
confluence.  For OAC, MCF7 and HCT116 cells growing on 10 cm plates, the 
culture medium was aspirated and cells washed once with 10 ml of Ca2+and Mg2+ 
free, sterile phosphate-buffered saline, (PBS, pH 7.4) followed by incubation for 5 
minutes at 37oC with 2.5 ml of 0.05% trypsin + 0.02% ethylene-diaminetetraacetic 
acid (EDTA).  Once the cells had detached, 7.5 ml of complete medium was added 
and a single cell suspension was achieved by mixing before diluting 1:10 in fresh 
medium on a new tissue culture plate.   
For subculture of CP-A cells, the growth medium was aspirated and cells washed 
once with 10 ml of PBS followed by incubation for 10 minutes at 37oC with 2.5 ml 
of 0.25% trypsin, 0.02% EDTA.  Once the cells detached, 7.5 ml of PBS + Soyabean 
Trypsin Inhibitor (STI, 250 mg/L, Invitrogen) were added and mixed thoroughly by 
pipetting.  The cell suspension was centrifuged for 5 minutes at 1,000 rpm in a 
swing-bucket centrifuge and the supernatant discarded.  The cell pellet was re-
suspended in complete medium and dispersed onto a new tissue culture plate at a 
1:10 dilution. 
For subculture of HEEpiCs, the growth medium was aspirated and the cells washed 
with 10 ml of sterile PBS.  A further 5 ml of sterile PBS was added to the cells 
followed by 5 ml of 0.05% trypsin, 0.02% EDTA and the cells incubated for 3 
minutes at 37oC.  The trypsin solution was then aspirated and added to 5 ml of FCS.  
After 60 seconds incubation at 37oC, 5 ml of trypsin neutralising solution (TNS, 
ScienCell) was added to the plate, mixed by pipetting, aspirated and then added to 
the FCS - trypsin mixture.  This was repeated with a further 5 ml of TNS and the 
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plate reviewed by bright-field microscopy to ensure the majority of the cells had 
been harvested.  The FCS – trypsin -TNS mixture was then centrifuged for 5 minutes 
at 1,000rpm, the supernatant discarded and the cell pellet resuspended in 10 ml of 
complete medium.  The cell suspension was then split 1:5 to 1:10 and seeded into 
fresh poly-L-Lysine coated plates, prepared in advance, ensuring a minimum seeding 
density of 2,000 cells/cm2.  HEEpiC cells senesce after 12-15 passages and were 
therefore only used up until the 10th passage. 
For subculture or harvest of cell lines or primary cells growing on smaller plates, 
proportionally smaller volumes were used. 
2.2.5 Cryopreservation  
For long-term preservation of cell stocks, cells were maintained in a cryopreservation 
mixture and stored in liquid nitrogen.  For OAC, MCF7 and HCT116 cells, a 
confluent 10 cm plate was trypsinised as previously but then centrifuged for 5 
minutes at 1,000 rpm.  The supernatant was discarded and the cells resuspended in 
2.5 ml of complete medium.  Cryovials containing a mixture of 0.5 ml of this cell 
suspension and 0.5 ml of cryopreservation solution (90% FCS: 10% DMSO) were 
then frozen overnight in an isopropanol bath at -80oC followed by transfer to liquid 
nitrogen. 
For CP-A cells and HEEpiCs the same procedure was followed for sub-culturing 
cells but the cell pellet was resuspended in 2.5 ml of complete medium.  Cryovials 
were then prepared with 0.5 ml of cell suspension and 0.5 ml of cryopreservation 
mixture consisting of either 40% complete KSFM, 10% DMSO, 50% FCS (CP-A) or 
Defined Animal Component-Free Freezing Medium (HEEpiCs, TCS Cellworks) and 
were then frozen in the same fashion as OAC cells. 
2.2.6 Harvesting of Cells 
OAC cells were harvested for down-stream assays by washing once with ice-cold 
PBS followed by scraping into 500 µL of ice-cold PBS using a disposable rubber 
plate scraper and centrifugation of the cell suspension in a bench-top centrifuge at 
3,000 rpm for 3 minutes.  After discarding the supernatant, the harvested cell pellet 
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was either used immediately or frozen in liquid nitrogen.  CP-A cells and HEEpiCs 
were harvested by trypsinisation as for subculture but cell pellets were resuspended 
in 0.5 ml of ice-cold PBS followed by centrifugation at 3,000 rpm for 3 minutes and 
subsequent identical treatment as OAC cell lines.   
2.2.7 Cell Line Verification 
Cell line misidentification and contamination was first reported over 4 decades 
ago472.  Despite repeated warnings in the literature, this continues to be a problem473.  
Indeed, three lines widely used as oesophageal adenocarcinoma cells; SEG-1, BIC-1 
and SK-GT-5, were recently identified to have been contaminated at an early passage 
and actually represent the lung cancer cell line H460, the colorectal adenocarcinoma 
cell line SW620 and the gastric fundus adenocarcinoma cell line SK-GT-2 
respectively85.  Unfortunately these cell lines continue to be inappropriately used as 
models for oesophageal adenocarcinoma with data from the discredited SK-GT-5 
cell line recently published supporting oesophageal cancer-specific hypotheses469. 
Historical challenges in verifying the origin of a cell line have now been minimised 
with the use of short tandem repeat (STR) genotyping and availability of large STR 
genotype databases and multiplex PCR assays474,475.  This method relies on 
heterogeneity between individuals in the number of tandem repeats at several 
genomic loci.  By using high sensitivity capillary electrophoresis to quantify PCR-
amplicon length from each locus, a “fingerprint” of alleles can be generated for a 
human DNA sample476.  The combination of alleles from 10 loci produces a 
signature with a random match probability of less than 1 in a billion477. 
2.2.8 Confirmation of Cell Line Identify 
For each oesophageal cell type, a confluent 10 cm plate or T75 flask was trypsinised, 
washed once in PBS and the cells pelleted.  Genomic DNA was extracted from the 
pellet using the Wizard® SV Genomic DNA Purification kit (Promega) as per the 
manufacturer’s instructions.   Briefly, cell pellets were lysed at room temperature 
(RT) using the Wizard SV lysis buffer and lysates added to DNA purification spin 
columns and centrifuged at 13,000 rpm for 3 minutes.  Spin columns were washed 
four times using the column wash buffer and then genomic DNA was eluted using 
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nuclease-free water warmed to 65oC.  The DNA concentration of eluates was 
determined by measuring the absorbance at 260 nm (A260) relative to absorbance at 
280nm (A280) using a NanoDrop 2000 UV-Vis spectrophotometer 
(ThermoScientific) and following the assumption that purified genomic DNA at a 
concentration of 50ng/µl has an absorbance of 1.0 absorbance units at 260 nm478.              
Genotypes were determined by short tandem repeat (STR) profiling using a 
commercial multiplex PCR assay covering 9 genomic loci; D7S820, D13S317, 
D16S539, D21S11, TH01, TPOX, vWA, CSF1PO and the Amelogenin locus for 
gender identification (Cell ID, Promega).  Multiplex PCR was carried out as per 
manufacturer’s instructions using a PTC-225 Peltier Thermal Cycler (MJ Research).  
DNA samples were de-identified by numbering and 2 ng of DNA used as a template 
in a final reaction volume of 25 µL.  A positive control sample of K562 DNA and a 
no template control were included as separate samples.  PCR products from each 
sample were then resolved by capillary electrophoresis (3130xl, Applied Biosystems) 
after spectral calibration using the PowerPlex Matrix Standards (Promega) and 
mixing with an internal lane standard.  Detected amplicon peaks were manually 
binned as alleles using the custom bin reference files (downloaded from 
www.promega.com).  For each sample, all the alleles confidently identified for each 
locus were recorded and then searched against the STR genotype database and 
published oesophageal STR genotypes85,474.  The origin of each sample was then 
predicted, blind to the original sample origin.  Samples were then re-identified and 
predictions and sample origins compared. 
2.2.9 Cell Counting   
To generate approximately consistent starting cell numbers for in vitro experiments 
across cell lines and conditions, cells were seeded at defined densities.  Cells were 
trypsinised from adherent cultures and re-suspended in 10 ml of complete medium.  
A 20 µL aliquot of this suspension was diluted 1:1 with Trypan Blue and incubated 
for 3 minutes at RT.  Cells were then counted using a haemocytometer with the 
number of viable cells per ml defined as; 2 x 104 x (the number of non-blue staining 
cells counted per 4x4 haemocytometer grid).  The mean of at least 4 counts was 
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taken and the original cell suspension diluted down to the desired final concentration 
with complete medium. 
2.2.10 X-Ray and Ultraviolet light (UV) exposure 
Cells were trypsinised and seeded in 6 cm plates at an initial density of 500,000 
cells/plate.  This initial density ensured plates were sub-confluent at the time of 
harvest.  Growth medium was changed 24 hours after seeding and experimental 
treatments were performed once plates were ~80% confluent (approximately the 4th 
day after seeding).  A sealed cabinet x-ray system (Faxitron) was used to deliver a 
calibrated gamma radiation dose at a rate of 2 Gy/min.  For UV-C treatment, cells 
were irradiated in a closed cabinet system at 70-80% confluence in 6 cm plates with 
the lids removed.   Cells were then harvested at intervals up to 24 hours after 
treatment by scraping into ice-cold PBS and centrifugation at 3,000 rpm for 3 
minutes followed by lysis of the cell pellet for protein extraction.   
2.2.11 Positive Control for p53 Response to DNA damage 
As a control for the effect of gamma irradiation on p53, a sub-confluent 10 cm plate 
of HCT116 cells was treated with gamma irradiation (10 Gy).  Cells were harvested 
by trypsinisation at 24 hours, pelleted and lysed using urea buffer.    
2.3 Protein Assays 
2.3.1 Cell Pellet Lysis 
Cell pellets were lysed in urea buffer comprising; 6.24 M Urea, 0.1 M Dithiothretiol 
(DTT), 0.05% Triton X-100, 25 mM NaCl, 20 mM HEPES-KOH (pH7.6), Complete 
Protease Inhibitor Cocktail (Roche), 5 mM NaF, 2 mM Na3VO4, 2.5 mM Na4P2O7 
and incubated on ice for 30 minutes.  Lysates were then clarified by centrifugation at 
13,000 rpm for 10 minutes and supernatants reserved and diluted to 2 µg/µL in lysis 
buffer after protein concentration determination.  
2.3.2 Protein Concentration Determination 
A Bradford assay was used to determine the protein concentration of cell lysates479.  
A dilution series of concentration standards across the range 4 mg/ml to 0.25 mg/ml 
was prepared by dissolving bovine serum albumin (BSA) in the lysis buffer used for 
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protein extraction.  Bradford reagent was prepared as a stock (0.1 g/L Coomassie 
Blue G-250 in 8.5% Phosphoric Acid and 5% Ethanol) and stored protected from 
light at 4oC479.  Bradford reagent was mixed with standards, samples of unknown 
concentration and lysis-buffer alone at a ratio of 200 µL: 1 µL, aliquoted in at least 
technical duplicate into the wells of a clear 96-well plate and incubated for 5 minutes 
at room temperature (RT) with vigorous shaking.  Sample absorbance at 595 nm 
(A595) was subsequently measured using a VICTOR
3 1420 multi-label plate reader 
(Perkin-Elmer).  Unknown sample protein concentrations were inferred by 
interpolation on a linear regression line created from the BSA standard absorbances 
after subtraction of background absorbance from lysis-buffer only mixtures.  Cell 
lysates were then diluted to 1.25 µg/µl or 2.5 µg/µl in distilled water (dH2O).    
2.3.3 SDS-PAGE 
Cell lysates were further diluted by the addition of 5x Sample Loading Buffer (SLB, 
Table 2-2) at a ratio of 4 µL lysate: 1 µL SLB and heated at 95oC for 5 minutes and 
then cooled on ice.   Recombinant purified p21 and MDM2 protein stocks were 
generous gifts from Dr. Jennifer Fraser (Edinburgh Cancer , Research Centre, 
Edinburgh) and Dr. Erin Worrall (Edinburgh Cancer Research Centre, Edinburgh) 
respectively.  Purified proteins were dissolved in 1xSLB and maintained at -80oC 
until required when 1 µL, diluted 1:10 in 1xSLB, was used.    
Lysates were loaded into a stacking gel and resolved by denaturing polyacrylamide 
gel electrophoresis (PAGE) using Bio-Rad gel apparatus and power packs, 1x 
sodium dodecyl sulphate (SDS) running buffer (Table 2-2) and a constant voltage of 
180 V into polyacrylamide running gels (Table 2-2) at the desired acrylamide 
concentration (8-15% v/v).  Electrophoresis was continued until the first protein 
molecular weight standard marker (Fermentas) reached the bottom of the gel.  Gels 
were then incubated with Coomassie stain for 60 minutes at RT and then overnight in 
destain solution, rinsed in dH2O, and dehydrated using a vacuum gel dryer (SCIE-
PLAS Gel Dryer, GD 4534, Scientific Laboratory Supplier) or used for western 
blotting. 
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Table 2-2 Buffer and Solution Constituents 
5 x Sample Loading Buffer 
250 mM Tris HCl (pH 6.8) 
50% v/v Glycerol 
5% w/v SDS 
0.5% w/v Bromophenol Blue 




30% Acrylamide (Protogel) 
(Diluted to required percentage v/v) 
375 mM Tris HCl (pH 8.8) 
0.1% w/v SDS 
0.1% w/v APS 




5% v/v Acrylamide mix 
125 mM Tris HCl (pH 6.8) 
0.1% w/v SDS 
0.1% w/v Ammonium Persulphate (APS) 




20% v/v Methanol 
10% v/v Glacial Acetic Acid in dH2O 
1x Running Buffer 
25 mM Tris HCl 
0.2 mM Glycine 
0.1% w/v SDS 
in dH2O 
 
1x Transfer Buffer 
25 mM Tris HCl 
0.2 mM Glycine 
20% v/v Methanol 
in dH2O 
 
3% BSA in TBS-T 
3% w/v BSA 
10 mM β-Glycerophosphate 
in Tris -buffered saline with 0.1% v/v Tween-20 
 
5% Milk in PBS-T 
5% w/v non-fat dry milk (Marvel) 
10 mM β-Glycerophosphate 
in Phosphate-buffered saline with 0.1% v/v Tween-20 
 
Coomassie Stain 
0.1% Coomassie Blue G-250 
10% v/v Glacial Acetic Acid 
40% v/v Methanol 
in dH2O 
 
Abbreviations – TBS-T (Tris-buffered Saline + 0.1% (v/v) Tween-20), PBS-T (Phosphate-buffered Saline + 
0.1% (v/v) Tween-20) 
Lysates were loaded into a stacking gel and resolved by denaturing polyacrylamide 
gel electrophoresis (PAGE) using Bio-Rad gel apparatus and power packs, 1x 
sodium dodecyl sulphate (SDS) running buffer (Table 2-2) and a constant voltage of 
180 V into polyacrylamide running gels (Table 2-2) at the desired acrylamide 
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concentration (8-15% v/v).  Electrophoresis was continued until the first protein 
molecular weight standard marker (Fermentas) reached the bottom of the gel.  Gels 
were then incubated with Coomassie stain for 60 minutes at RT and then overnight in 
destain solution, rinsed in dH2O, and dehydrated using a vacuum gel dryer (SCIE-
PLAS Gel Dryer, GD 4534, Scientific Laboratory Supplier) or used for western 
blotting. 
2.3.4 Western Blotting  
Resolved proteins and markers were transferred from gels to Hybond-C extra 
nitrocellulose membranes (Amersham Bioscience) in 1x transfer buffer using 
western blotting cassettes (Bio-Rad) and a constant current of 300 mA for 90 
minutes.  Membranes were then immediately blocked in 3% BSA in TBS-T or 5% 
Milk PBS-T for 90 minutes at RT with gentle shaking.  
2.3.5 Primary Antibody Conditions 
After blocking, membranes were incubated with primary antibodies as summarised 
in Table 2-3 and then washed four times, each for 5 minutes in 10 ml of PBS-T.  
2.3.6 Secondary Antibody Conditions 
For secondary detection of nitrocellulose membrane-bound primary antibodies, goat 
anti-mouse or goat anti-rabbit antibodies conjugated to either the IRDye™ 680RD 
(anti-mouse680 or anti-rabbit680; excitation 679nm, emission 702nm) or IRDye™ 
800CW (anti-mouse800 or anti-rabbit800; excitation 778 nm, emission 806 nm) near-
infrared fluorophores were used (Li-Cor Biosciences) at 1/2000 dilution in blocking 
buffer for 2 hours at RT protected from light.  Blots were then washed four times, 
each for 5 minutes in PBS-T at RT protected from light and then imaged using a dual 
fluorophore near-infrared detection system (Odyssey SA, Li-Cor Biosciences).   
2.3.7 Quantitative Western Blotting  
Western blotting has traditionally relied on enhanced chemiluminescence (ECL)-
based detection of bound secondary antibodies on either X-ray film or charge-
coupled device (CCD) cameras and subsequent densimetry-based measurement for 
relative quantitation.  This method has been considered semi-quantitative due to the 
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time-dependent signal variation as the ECL substrate is consumed, and the variability 
in band quantitation by densitometry480.  In contrast, the detection of fluorescence 
from fluorophore-conjugated secondary antibodies offers improved quantitative 
accuracy and can provide a linear response over a 1,000-fold dynamic range481.   The 
simultaneous use of both mouse and rabbit primary antibodies and secondaries with 
differing fluorophores allows relative quantitation of phosphorylated and non-
phosphorlyated protein isoforms from the same blot or from proteins isoforms that 
are present in the same band on ECL western blots482,483. 
Cellular proteins and the membranes used for western blotting exhibit 
autofluorescence in the visible light range but this is significantly reduced in the 
near-infrared spectrum484.  The use of fluorophore-conjugated secondary antibodies 
with emission spectra in the near-infrared range allows the detection of proteins by 
western blotting with similar or even improved sensitivity to enhanced 
chemiluminescence-based (ECL) methods and improved signal to noise ratio480.   
For quantitative western-blotting, membranes soaked in PBS-T were placed protein-
side down in a glass membrane carrier (Li-Cor Biosciences) and bubbles between the 
membrane and glass extruded by gentle pressure.  The membrane was then scanned 
on a Li-Cor Near Infrared Scanner (Odyssey, Li-Cor Biosciences) at 100 µm 
resolution as per manufacturer instructions with gain settings determined after a 
preview scan to ensure the detected signal was not saturated.  Bands were manually 
selected from scanned images using the Odyssey SA software (Li-Cor Biosciences).  
Relative band intensities were measured using the integrated intensity method to 
determine intensity relative to band area.  The same area was measured for all bands, 
ensuring in each case that the entire band was incorporated.  No image manipulation 
was used prior to intensity calculation.  The integrated intensity for β-Actin was 
measured on each blot as a loading control.  For comparison of protein expression 
between conditions or cell lines, the protein expression relative to β-Actin was used.   
For illustration of relative protein expression, the brightness and contrast of scan 
images were adjusted to allow visualization of both low and high abundance bands 
without intensity saturation and images exported in tagged image file format (TIFF).  
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The protein molecular weight markers were detectable as bands in the 700 nm 
channel and therefore provided a size reference for bands on scanned blots.  
Following image acquisition, membranes were either discarded or washed three 
times in PBS-T for 20 minutes each wash and then re-probed with further antibodies.    
2.4  Cell Viability Measurement 
2.4.1 CellTiter-Glo 
CellTiter-Glo™ (Promega) is a luminescence assay which lyses cells and produces 
light in proportion to the ATP released.  The very short half-life of free extracellular 
ATP allows viable cell number to be accurately measured with this method although 
this is intrinsically an endpoint assay485.  Cells were seeded into 96 well clear-
bottomed, black-walled plates (Costar) at variable densities with a final volume of 
100 µL/well.  A media-only control was included.  At the required time point, plates 
were removed from the incubator and allowed to equilibrate to RT for 30 minutes.  
CellTiter-Glo® reagent (100 µL, Promega) was added to the wells and mixed on an 
orbital shaker for 2 minutes.  The plates were left on the bench to equilibrate for a 
further 10 minutes before luminescence measurement using a Fluoroskan Ascent FL 
plate reader (Labsystems) with a 1000 ms integration time per well.  Following 
luminescence acquisition, the contents of each well were transferred to a 96 well, 
white-walled, white-bottomed plate (Costar) and a further reading taken.  The 
luminescence from media-only controls was used for background correction of the 
other readings.      
2.4.2 AlamarBlue 
AlamarBlue™ (Sigma), in contrast, can be used for serial measurements of cell 
number since the reagent can be washed-off without affecting viability486.  This inert 
soluble resazurin salt is reduced to the fluorophore resorufin by the metabolic 
reductase capacity of viable cells.  This reduction is proportional to the number of 
viable cells and can be measured as a change in fluorescence.      
Cells were seeded into 96 well clear-bottomed, black-walled plates (Costar) at 2 - 
10,000 cells/well with a final volume of 100 µL/well.  A media-only control was 
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included to allow subsequent background correction.  After 24 hours, 10 µL of 
sterile-filtered AlamarBlue (Invitrogen) was added and the plates incubated for a 
further 60 minutes at 37oC.  Plates were imaged using a standard fluorescence 
intensity protocol (excitation 540 nm, light 5%, Gain 100, Flashes 10, emission 
recorded at 590 nm) on a Wallac Envision 2101 plate reader (Perkin Elmer).  
Following measurement, the medium and AlamarBlue reagent were aspirated and the 
wells washed once with fresh medium.  
Drug aliquots (see 2.4.3 Drug Stocks) or vehicle were added to wells and, after 96 
hours incubation, a further AlamarBlue measurement was taken using the above 
protocol.  Fluorescence values were corrected for background fluorescence from 
medium only control wells. Final background-corrected fluorescence was then 
compared with initial background-corrected fluorescence on a well-by-well basis and 
the ratio of final/initial calculated and converted to a percentage of the initial value.  
Values >100 were taken to indicate cell proliferation and values <100 to indicate 
cytotoxicity.  Trimmed mean percentages +/- standard errors were calculated and 
normalised to DMSO-treated cells.   The performance of the AlamarBlue assay was 




Equation 1 Calculation of the Z-factor for assay performance (from reference 487).  σ= standard 
deviation, a = positive control, b = negative control. 
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Table 2-3 Antibody Conditions for Western Blotting 
Antibody Directed 








temperature Predicted Band(s) Size 
AGR2 Abnova, H00010551-MO3 Mouse Monoclonal 5% Milk, PBS-T 1/1000 16 hours, 4oC 17kDa
AGR2 Atlas Antibodies, HPA007912 Rabbit Polyclonal 5% Milk, PBS-T 1/1000 2 hours, RT 17kDa
AURKA New England, #4718 Rabbit Monoclonal 5% Milk, PBS-T 1/1000 16 hours, 4oC 47kDa
AURKA (cTerminus) Abcam, ab52973 Rabbit Monoclonal 5% BSA, TBS-T 1/8000 16 hours, 4oC 47kDa
β-Actin Sigma, AC-15 Mouse Monoclonal 5% Milk, PBS-T 1/5000 2 hours, RT 42kDa
BAX Santa Cruz, N20 Rabbit Polyclonal 5% Milk, PBS-T 1/500 48 hours, 4oC 23kDa
FBP1 Atlas Antibodies, HPA005857 Rabbit Polyclonal 5% Milk, PBS-T 1/250 16 hours, 40C 37kDa
GAPDH Abcam, ab9484 Mouse Monoclonal 5% Milk, PBS-T 1/1000 16 hours, 4oC 40kDa
GRP-78 Abcam, ab21685 Rabbit Polyclonal 5% Milk, PBS-T 1/1000 16 hours, 4oC 78kDa
GSTO-1 Abcam, 129106 Rabbit Monoclonal 5% Milk, PBS-T 1/1000 16 hours, 4oC 28kDa
HSP-27 Abcam, ab114067 Mouse Monoclonal 5% Milk, PBS-T 1/1000 16 hours, 4oC 27kDa
MDM2 Moravian Biotech, 2A10 Mouse Monoclonal 5% Milk, PBS-T 1/500 16 hours, 4oC 90kDa (MDM2) and          ~170kDa (non-MDM2) band488 
P21(WAF1) Calbiochem, EA10 Mouse Monoclonal 5% Milk, PBS-T 1/500 48 hours, 4oC 21kDa
P53 Moravian Biotech, DO-1 Mouse Monoclonal 5% Milk, PBS-T 1/5000 2 hours, RT or 16 hours, 4oC  53kDa 
P53 Moravian Biotech, CM1 Rabbit Monoclonal 5% Milk, PBS-T 1/1000 16 hours, 4oC 53kDa
PLK-1 Abcam, ab17056 Mouse Monoclonal 5% Milk, PBS-T 1/2000 16 hours, 4oC 67kDa
Rho GDI-2 Abcam, ab88317 Rabbit Polyclonal 5% Milk, PBS-T 1/500 16 hours, 4oC 23kDa
SAMHD-1 Abcam, ab119751 Mouse Monoclonal 5% Milk, PBS-T 1/250 16 hours, 4cC 72kDa
TGM-3 Sigma, HPA004728 Rabbit Polyclonal 5% Milk, PBS-T 1/500 16 hours, 4oC 77kDa
Anti-mouse680 and 800 Licor Biosciences Goat Polyclonal 5% Milk, PBS-T 1/2000 90 minutes, RT Mouse primary
Anti-rabbit680 and 800 Licor Biosciences Goat Polyclonal 5% Milk, PBS-T 1/2000 90 minutes, RT Rabbit Primary
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2.4.3  Drug Stocks 
Table 2-4 Drug Stocks Used For In Vitro Experiments 
Drug Name Source Stock Concentration (Solvent) 
PLK-1A Provided as purified dry compound after 
materials transfer agreement  with Cyclacel 
Pharmaceuticals Incorporated, Dundee 
10 mM (DMSO) 
BI2536 Axon Medchem BV, Groningen, Netherlands 10 mM (DMSO) 
Cisplatin Sigma Aldrich, Gillingham, UK 5 mM (PBS) 
Nutlin-3A Alexis Biochemicals, Exeter, UK  43 mM (DMSO) 
 
2.4.4 Comparison of Drug Effects 
Best-fit curves were iterated using the relative viabilities across a drug dose range 
and a variable-slope, four-parameter, sigmoidal curve-fitting algorithm (GraphPad 
Prism version 5.00 for Windows, GraphPad Software, San Diego, California, USA).  
The IC50 and corresponding 95% confidence intervals were automatically generated 
using this algorithm, the best-fit curve and the R2 value.  The best-fit line was also 
used to determine the maximal drug effect relative to baseline, summarised as; 
reduction in proliferation, cytostasis or cytotoxicity.     
2.4.5 Colony Formation Assay 
Cells were seeded in 10 cm plates in complete medium, allowed to adhere for 24 
hours and then the medium exchanged and supplemented with drug diluted from 
DMSO stock or DMSO only.  Cells were harvested after 72 hours by trypsinisation 
and defined numbers of trypan blue excluding (viable) cells seeded in 6cm plates in 
complete medium only.   
Plates were incubated in standard conditions with exchange of medium every 3-4 
days until DMSO control plates approached confluence.  The medium was then 
aspirated, plates washed once with 5 ml of PBS and cells fixed with 5 ml of ice-cold 
methanol for 5 minutes at RT.  The methanol was aspirated and plates left to air-dry 
for 1 hour at RT.   
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To stain colonies, plates were incubated with Giemsa stain (0.05% w/v in buffered 
methanol solution, pH 6.8, Sigma) for 20 minutes at RT, gently washed in tap water 
and then left to air dry.  Due to the diverse growth patterns of the oesophageal cells 
used, raw colony counts were considered uninformative and for comparison of drug 
effects, plates were simply photographed for visual comparison.  All plates at the 
same seeding density were fixed and stained at the same time.           
2.4.6 Death Commitment Assay 
Baseline viable cell number was calculated using AlamarBlue, 24 hours after seeding 
into 96 well, poly-L-lysine coated plates (final volume 100 µL; OE33, CPA 2,000 
cells/well; OE19 5,000 cells/well).  Drug dilutions from DMSO stock or DMSO 
(1/10,000) were added and an interim AlamarBlue assay performed after a further 24 
hours.  After 1 wash to remove the AlamarBlue, fresh medium or medium 
supplemented with drug or DMSO was added to the wells and culture continued for a 
further 72 hours before a final Alamar assay was performed.  Interim viability was 
normalised relative to baseline and final viable cell number calculated relative to the 
interim value so that when plotted, the x-axis represents no change from the interim 
value and the y-axis was scaled so a 100% change in viability was equivalent to the 
baseline cell number.   
2.4.7 In-Cell Western 
Cells were grown in poly-L-lysine coated 96 well plates.  After completing an 
AlamarBlue assay, growth medium was aspirated, cells washed in 200µL PBS and 
then fixed with 100% methanol for 5 minutes at 4oC.  Cells were then permeabilised 
by gentle shaking in PBS and 1% Triton X-100 for 5 minutes with this step repeated 
5 times.  
Wells were blocked with 5% BSA and 0.1% (v/v) Tween-20 for 2 hours at RT.  
Primary antibody incubation were for 16 hours (hrs) at 4oC in blocking buffer with 
antibodies to PLK-1 (ab17056, 1/200), the c-terminus of AURKA (ab52973, 
1/1000), GAPDH (ab9484, 1/200) or full length AURKA (#4718, 1/200). Secondary 
incubations were with anti-mouse800 or anti-rabbit800 antibodies (Li-Cor, 1/2000, 2 
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hrs RT, protected from light) or the DNA stain, DRAQ5 (Li-Cor, 1/10,000, 2 hrs RT, 
protected from light).   
Plates were scanned on the Li-Cor Near Infrared Scanner (Odyssey, Li-Cor 
Biosciences).  The 800 nm integrated intensity values were background-corrected 
using the fluorescence readings from secondary antibody-only treated wells. The 700 
nm DRAQ5 integrated intensity values were background corrected using readings 
from wells seeded with medium only (no cells).  The ratio of background corrected 
800nm/700nm intensity or 800nm /AlamarBlue intensity was calculated. 
2.4.8 Real-time proliferation measurements 
In 2D culture, the area covered by cells increases proportionately with cell number.  
This property is exploited in the xCELLigence system (Roche Diagnostics, Burgess 
Hill, UK) where plates lined with interdigitated gold electrodes are used to monitor 
impedance changes across the growth surface. Changes in impedance correlate 
directly with changes in cell number and allow real-time, label-free monitoring of 
proliferation in culture489. 
Real-time proliferation experiments were conducted on an xCELLigence RTCA DP 
instrument (Roche Diagnostics, Burgess Hill, UK) maintained in a humidified 
incubator at 37oC, 5% CO2.  For each experiment, 100 µL of complete medium was 
added to each well of a sterile DP 16 well plate (E-plate, Roche Diagnostics) and 
sterile water added to the well surround to aid local humidification of the well.  The 
plate was allowed to equilibrate to 37oC on the RTCA reader before a baseline 
impedance measurement was taken.   
Cells were seeded into wells with a final volume of 180 µL per well.  An impedance 
reading was taken every 15 minutes until the end of the experiment and background 
corrected to derive a cell-index.  Approximately 24 hrs after cell seeding, 20 µL of 
drug or DMSO was added and mixed by gentle pipetting.  For wash-off experiments, 
cells were incubated in drug or DMSO for 40-50 hours and then the medium 
aspirated, cells gently washed once with 200 µL fresh medium before a final 
incubation in 200 µL fresh medium for a further 90 hours.   
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Experiments were terminated when growth curves in any of the wells plateaued or at 
96 hours after drug wash-off, whichever was earlier.  At the end of the experiment, 
wells were checked by light microscopy to ensure there was no obvious infection and 
that cells had not become confluent during the experiment.  Cell index measurements 
were normalized to a point one to two hours after a change in conditions to exclude 
short-term fluctuations in impedance.  Changes in cell-index were assumed to 
represent changes in cell number.   
2.4.9 Validation of xCELLigence Viability Measurements 
Cells (CP-A, KYSE-30; 2500 cells per well) were seeded in E-plates and allowed to 
adhere for 24 hours before drug or DMSO addition. The mean final cell index at 96 
hours was calculated for each condition from technical duplicate wells.  Plates were 
removed from the incubator and allowed to equilibrate to RT for 30 minutes.  
Medium was then aspirated and cells lysed using 100 µL of CellTiter-Glo reagent 
per well.  After mixing on an orbital shaker for 2 minutes, lysates were transferred to 
a 96 well, white-opaque plate (Costar) along with a 1:1 mixture of CellTiter-Glo 
reagent and complete medium as a background control.  Plates were incubated at RT 
for a further 10 minutes before luminescence was recorded as previously described 
(2.4.1).   
2.4.10 Colony Outgrowth Assay 
Cells (CP-A, OE33 - 2,500 cells per plate; OE19 - 10,000 cells per plate) were 
seeded in 6 cm plates and allowed to adhere for 24 hours.  Drug dilutions or DMSO 
were added for 16 hours, plates washed once and then subsequently incubated in 
complete medium.  Plates were incubated in standard conditions with exchanges of 
medium every 3-4 days until DMSO control plates approached confluence (12 days).  
Colonies were then fixed and stained as previously described (2.4.5). 
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2.5 Gene Expression 
2.5.1 RNA extraction from cell lines 
Bench surfaces and pipettes were cleaned with RNaseZap (Ambion) to inactivate 
environmental RNases and standard precautions taken to minimize contamination 
during RNA purification and preparation.  RNA was extracted from cell pellets using 
the RNeasy Minikit (Qiagen) as per manufacturer’s recommendations.   
Briefly, pellets were lysed directly using 600 µL of Buffer RLT by pipetting and 
lysates centrifuged through Shredder mini spin-columns (Qiagen) to ensure complete 
lysis.  The flow-through was mixed 1:1 with 70% (v/v) Ethanol in RNase-free H20 
before the solubilized RNA was bound to silica membranes by centrifuging over 
RNeasy mini-spin columns (Qiagen).  After sequential spin-column washes, RNA 
was eluted into 30 µL of RNase-free H20 and the RNA concentration determined by 
measuring the A260 on a NanoDrop 2000 UV-Vis spectrophotometer following the 
assumption that purified RNA at a concentration of 40 ng/µl has an absorbance of 
1.0 absorbance units at 260 nm478.  An A260/A280 ratio of >1.8 was deemed acceptable 
RNA purity, otherwise extraction was repeated on a further cell pellet.  Eluted RNA 
was snap frozen in liquid nitrogen and then stored at -80oC until use. 
2.5.2 Reverse Transcription of RNA to cDNA 
Template complementary DNA (cDNA) was generated for each sample from 2 µg of 
total RNA in 7 µL of RNase-free H2O.  Sample RNA was heated to 65
oC for 5 
minutes and cooled on ice before addition to a reaction mixture (final volume 20 µL) 
consisting of; 
Sample RNA       100 ng/ µL 
Reverse Transcriptase buffer (Qiagen)   1x  
dNTP mixture  (Qiagen)    0.5 mM for each dNTP (Qiagen) 
oligo (dT) 12-18 primer (Invitrogen)   1 µM 
Protector RNase inhibitor (Roche)    10 Units 
DTT (Sigma)       10 mM 
Omniscript Reverse Transcriptase (Qiagen)   4 Units 
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This mixture was incubated at 37oC for 1 hour to yield cDNA which was quantified 
using a Nanodrop as previously described and then stored at -20oC until required. 
2.5.3 Quantitative real-time Polymerase Chain Reaction (qRT-PCR) 
To accurately measure relative changes in mRNA levels between conditions and cell 
lines, qRT-PCR is often performed.  Robust commercial assays allow the 
quantification of relative cDNA through the real-time measurement of the 
fluorescence derived from reporter dyes incorporated into gene-specific primers.   
Solaris™ (ThermoScientific) assays utilise a quencher-primer-fluorophore 
combination where fluorescence is only detected as primers specifically anneal to the 
complimentary DNA sequence and the quencher dissociates from the fluorophore490.  
With progressive PCR cycles, the cDNA incorporating, and between, the primer 
annealing sites is amplified.  The primers are in excess in the reaction and therefore 
the fluorescence measured is proportional to the cDNA concentration491.  At a set 
cDNA concentration, the primer fluorescence passes the limit of detection by the 
qRT-PCR instrument and with each increase in template concentration the 
fluorescence increases proportionately492.   
At a certain point, the cDNA, primers, and nucleotides are at optimal concentrations 
to allow maximally efficient DNA polymerisation.  At this point, termed the 
threshold cycle (Ct), there is an exponential increase in cDNA copy number and 
therefore fluorescence with each successive PCR cycle.  The Ct is proportional to the 
starting cDNA concentration and can be used as a surrogate for RNA abundance.  
The Ct is sensitive to variable cDNA loading prior to the PCR reaction. The gene 
expression relative to an invariant gene is therefore used; the ΔCt.  The metabolic 
gene GAPDH is often considered as a control gene, yet dynamic changes in GAPDH 
expression have been reported and it is therefore considered inappropriate as a qRT-
PCR control493.  Given the problems in selecting one invariant house-keeping gene 
for all reactions, the geometric mean of the Ct from two controls can be used
494. 
In a 100% efficient reaction, each PCR cycle would double the cDNA concentration 
and therefore a difference of 1 Ct represents a two-fold difference in the RNA 
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amount.  The RNA abundance relative to the baseline condition can therefore be 
determined as 2-ΔΔCt .  With a lower efficiency this becomes (1+efficiency)-ΔΔCt.   
The PCR amplification efficiency can be determined by calculating the gradient of 
the linear regression line passing through the ΔCt values from a template dilution 
series subjected to qRT-PCR using the primer of interest.  The amplification rate 
when the template concentrations are log10 transformed  can then be calculated as
495; 
	 10 /  
Where Amplification rate = Efficiency + 1. 
Pre-designed gene expression assays were used for all genes (Solaris, 
ThermoScientific).  Primer sequences are provided in (Table 2-5).  To compare 
relative gene expression between conditions, the ΔΔCt method was used
496.  Both β-
Actin and Ribosomal protein components have shown stable expression levels 
between normal oesophageal and cancer tissue497.  Ribosomal Protein S18 (RPS18) 
and β-Actin were therefore used to control for differences in cDNA loading between 
experiments.    
Each cDNA sample was run in technical quadruplicate for each primer with 125 ng 
of cDNA used per reaction.  A 2x mastermix was created for each primer containing 
the Solaris qRT-PCR primer, and a pre-mixed 2x solution of DNA Polymerase, 
dNTPs and reaction buffer (Solaris Mastermix, ThermoScientific).  Primer 
mastermix and cDNA were mixed in a 1:1 ratio by pipetting in white PCR tubes 
(BIOplastics, Netherlands) maintained on ice and then sealed using clear 
thermostable caps (BIOplastics, Netherlands).   
For each qRT-PCR reaction, a no template control was included for each primer by 
substituting RNase free H2O for cDNA and an RNA only control was included for 
each sample by substituting 125 ng of total RNA (used as the input for the reverse 
transcriptase reaction) for cDNA.  The primers for the genes (RPS18) and β-Actin 
were included as controls for all samples.        
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Reactions were commenced by heating to 95oC for 15 minutes (PTC-200, Thermal 
Cycler, MJ Research) followed by a PCR cycle consisting of; denaturation at 95oC 
for 15 seconds, combined annealing and extension at 60oC for 60 seconds with 
measurement of FAM fluorescence at the end of each annealing stage (Chromo4 
Continuous Fluorescence Detector, MJ Research).  A total of 40 PCR cycles were 
completed and then a melting curve obtained for the PCR products by stepwise 
increment of the reaction temperature from 60-95oC at 1oC per minute with 
fluorescence measurement after every temperature increment. 
The melting curves were reviewed for all wells and only those with smooth Gaussian 
curves consistent with the other wells using that primer were included for subsequent 
data analysis.   The no template control wells and RNA only wells were checked to 
ensure there was no fluorescence detected above background or melting curve 
consistent with PCR amplification. 
Once the wells were selected for subsequent gene expression analysis, a fluorescence 
threshold was manually selected incorporating the exponential phase of fluorescence 
amplification in all wells.  The cycle at which each sample crossed this threshold was 
automatically determined by the instrument software (Opticon 2, MJ Research) and 
was recorded as the Ct.  The mean Ct, standard deviation (SD) and coefficient of 
variation (% CV) were calculated for each sample, for each primer.  The geometric 
mean of the Ct’s for RPS18 and β-Actin was calculated and used as the invariant 
control for ΔCt calculations.  
To calculate the % CV and consequently the standard deviation of the ΔCt and the 
ΔΔCt, the standard deviation of the component Cts was propagated by summation in 
quadrature498.  Therefore the %CV for ΔCt for the two genes 1 and 2 becomes;  
 
% 	 	 	 	 	 
Equation 2. Summation in Quadrature. σ = standard deviation   
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2.5.4 RNA interference in Cell Lines 
Cells were seeded in standard tissue culture plates in complete medium and allowed 
to adhere overnight before exchanging the medium for antibiotic-free, supplemented 
(CP-As) or serum-containing medium (all other cells).   
For the optimisation of transfection, Opti-MEM reduced serum medium + Glutamax 
(Invitrogen) alone or mixed with Dharmafect 1 (ThermoScientific), Dharmafect 4 
(ThermoScientific), Lipofectamine 2000 (Invitrogen) or RNAiMAX (Invitrogen) 
were added to cells growing in antibiotic-free, serum or supplement-containing 
medium in 6-well plates at 50% confluence.  Viability was monitored visually by 
daily light microscopy for 72 hours post-transfection. 
For subsequent experiments using the RNAiMAX protocol, pools of 4 pre-designed 
siRNAs to genes of interest (Table 2-6) or a non-targeting, scrambled siRNA 
sequence (siGENOME, Non-Targeting siRNA#3, Dharmacon) were mixed in Opti-
MEM reduced serum medium + Glutamax (Invitrogen) and allowed to form 
complexes for 20 minutes at RT.  Complexes were added to the cell culture medium, 
gently mixed by pipetting (final siRNA concentration 25 nM, RNAiMAX final 
concentration 0.2% v/v) and cells incubated for a further 48 hours before harvesting 
for protein or RNA assays.  Dharmacon SMARTPools have previously been used 
successfully in oesophageal cancer cells355.   
To assess the effect of siRNA on cell viability, cells were seeded in poly-L-Lysine 
coated 96-well plates (CPA, OE33 - 5,000 cells/well; OE19 - 10,000 cells/well, final 
volume 100µL) and allowed to adhere for 24 hours.  A baseline measurement of 
viability was performed using the AlamarBlue method (2.4.2) and then the standard 
siRNA transfection protocol followed, as above.  A final AlamarBlue measurement 
was taken 96 hours after siRNA transfection.   
For transfection of Accell siRNA, cells were grown in standard complete medium in 
6 cm plates and a pool of 4 Accell siRNAs specific to the target gene (Table 2-6 
siRNA sequences) or a non-targeting scrambled sequence (Accell non-targeting 
control #1, Dharmacon) were diluted in complete medium from 100 µM stock and 
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added to the plates (final concentration; 1 µM).  Cells were harvested 48 hours after 
transfection for assay of RNA or protein expression. For viability assessment, 
measurements were made using the AlamarBlue method before transfection and 96 
hours after transfection in 96-well plates.  Transfection efficiency was assessed using 
FAM-labelled, non-targeting, scrambled sequence Accell siRNA (excitation 494 nm, 
emission 520 nm) and blue/UV light, bright-field microscopy with images acquired 
on a standard digital camera with a microscope attachment (Nikon,UK).        
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Table 2-5 qRT-PCR  Primer and Probe Sequences for Solaris Assays. 
Target 5’ to 3’ Forward primer 5’ to 3’ Reverse primer Probe Amplicon size base pairs (bp) 
PLK-1 CAACGGCAGCGTGCAGAT GCACAAGATGAGCTTGGT ACTTCTTCCAGGATCACACC 55 bp
TP53 CTCAGCATCTTATCCGAGTGGAAG TGGTACAGTCAGAGCCAACCTCA CCCTATGAGCCGCCTGA 120 bp
AURKA GCAAATGCCCTGTCTTACTG AGAGTGGTCCTCCTGGAA TACATGCTCCATCTTCC 146 bp
CDKN1A GCGACTGTGATGCGCTAA CCTCCAGTGGTGTCTCGGT GAACTTCGACTTTGTCACCG 87 bp
GRP-78 GAAGACTTTTCTGAGACCCTGAC GCTTCATAGTAGACCGGAAC GCTCAACATGGATCTGT 76 bp
OLFM-4 ATCGTGGCTCTGAAGACCAA ATGACCACAGCTCCCTGGAGT CCACCCTCCTCCCACTC 99 bp
GSTO1 ACCTGTGAGTACCTGGATGA AGCTTCCTACCAAGGATG GTTTTCTAAGGTGCCATC 124 bp
FBP1 TCCAACGACCTGGTTATGAAC AGACCACATATTTACCCCTT CATAGTGGAACCGGAGAAA 118 bp
SAMHD1 CGCAACTCTTTACACCGTAG TTTGAGGAAAGCATCTGT TGATACAATGATTACAG 81 bp
GAPDH GCCTCAAGATCATCAGCAATG CTTCCACGATACCAAAGTTGTC GCCAAGGTCATCCATGA 90 bp
RPS18 GTGATCCCTGAAAAGTTCCAG CACATGAGCATATCTTCGG CCATTAAGGGTGTGGGC 120 bp
β-Actin TGGAGAAAATCTGGCACCAC ACCGCGAGAAGATGACC GGTCTCAAACATGATCTGG 79 bp
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Table 2-6 siRNA sequences 
Target Source siRNA Sequences 
































PLK-1 Accell, SMARTPool, 
Dharmacon 
CCAUAUGAAUUGUACAGAA, CCAAGGUUUUCGAUUGCUC, 
CUGUCCUUUCCUUGGCUUU,  GUGGGACUCCUAAUUACA 
GAPDH Accell,  
Dharmacon 
Proprietary Control Sequence 
GAPDH siGENOME,  
Dharmacon 
Proprietary Control Sequence 
 
 
2.5.5 Statistical Comparisons of Viability and Gene Expression   
The mean viability or gene expression level between different conditions was 
assessed for statistical significance using a two-tailed, un-paired, Student’s t-test 
(GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego, 
California, USA).  Significance was defined as p<0.05.  
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2.6 Cell Cycle Analysis 
2.6.1 Cell Synchronisation, Treatment and Fixation 
Cells were seeded in 10 cm plates and grown in complete medium until ~50% 
confluent. To synchronise cells in G0 phase, complete medium was exchanged for 
serum or supplement-free medium and plates incubated for 48 hours before exchange 
for complete medium supplemented with either PLK-1A or BI2536, both diluted 
from a 10 mM stock made up in DMSO or DMSO alone.  At 24 hours after drug or 
DMSO treatment, cells were harvested by trypsinisation, resuspended in 10 ml of 
PBS and 500,000 cells (OE33, OE19) or 750,000 cells (CP-A, HEEpiC) pelleted by 
centrifugation for 5 minutes at 400 g and resuspended in 300 µL PBS.  Cells were 
fixed by drop-wise addition of 900 µL of ice-cold 70% (v/v) Ethanol in dH2O while 
vortexing.  Fixed cells were stored at 4oC for up to 7 days before Propidium Iodide 
(PI) staining.       
2.6.2 Propidium Iodide Staining 
Fixed cells were centrifuged for 5 minutes at 400 g and then resuspended in 5 ml of 
PBS before centrifugation again for 5 minutes at 400 g. The supernatant was 
discarded and cell pellets suspended in 300 µL Propidium Iodide staining solution 
(50 µg/ml Propidium Iodide and 100 µg/ml RNAse in PBS) and incubated at RT in 
the dark for 60 minutes. 
2.6.3 Flow Cytometry 
Propidium Iodide stained cells were injected into a BD Aria II Flow Cytometer with 
cellular fluorescence (excitation 488 nm, emission 635nm) recorded from forward 
and side-scatter detectors and manually gated using FACSDiva software version 
6.1.3 (BD Biosciences).  A minimum of 10,000 events were recorded for each 
sample.  Baseline cellular DNA content was assumed to present a diploid genome 
(2N) and the percentage of 4N and 2N cells calculated.  Cells with DNA content 
between 2N and 4N peaks were assumed to represent the S-phase fraction. 
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2.7 Immunohistochemistry 
2.7.1 OCCAMS TMA 
Archival formalin-fixed paraffin-embedded (FFPE) tissue blocks from oesophageal 
adenocarcinoma resection specimens were obtained from oesophago-gastric 
resection centres in Bristol, Birmingham, Papworth, Oxford and Glasgow as part of 
the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) 
collaborative network and used to create a tissue microarray (TMA) as described 
previously275.  Briefly, cores were cut using 1 mm punches from areas confirmed on 
Haematoxylin and Eosin stained sections to contain adenocarcinoma, normal 
squamous epithelium or Barrett’s oesophagus.  Cores were then embedded in 
paraffin blocks to construct the array.   For evaluation of p53 and PLK-1 staining, 
slides from the OCCAMS tissue microarray were made available for this project via 
a collaborative agreement with the OCCAMS Chief Investigator, Prof. Rebecca 
Fitzgerald (Cambridge).       
2.7.2 Immunohistochemistry (IHC) for PLK-1 and p53 
Sections (4 µm) were cut from the OCCAMS TMA blocks using a microtome, 
mounted on slides (VWR superfrost) and dehydrated at 56oC overnight before 
staining.  Antibodies were only used for IHC if target specificity could be confirmed.  
Staining for p53 and PLK-1 was performed by Mr. Johnny Ong (Cambridge) using a 
BOND automated immunostainer (Leica Microsystems).  This system combines the 
dewaxing, rehydration, antigen retrieval, blocking, primary and secondary antibody 
incubation steps in an automated workflow to allow efficient and reproducible 
sample processing.  For Bond automated staining, the following settings were used; 
Target Antibody Source, Product 
Number, Dilution 
Automated IHC Programme 
p53  Leica, NCL- L-p53-DO7, 1:50 
dilution 
IHC Protocol F + 3,3’-Diaminobenzidine (DAB) 
Enhancer.  Heat Induced Epitope Retrieval Solution 1 
(Citrate buffer at pH 6.0) for 30 minutes.  
PLK-1 Upstate, #05-844 (clone 35-
206), 1:7500 dilution 
IHC Protocol F + DAB Enhancer. Heat Induced 
Epitope Retrieval Solution 2 (EDTA based buffer pH 
9.0) for 30 minutes 
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2.7.3 IHC for Other Proteins 
For other targets, IHC was performed in Edinburgh using the following method.  
2.7.4 Optimisation of IHC conditions 
Formalin fixed tissue, surplus to diagnostic requirements was obtained from the 
resection specimens of prospectively-consented patients undergoing resection for 
oesophageal cancer (Ethical Approvals; 06/S1101/16, 10/S1402/33, NHS R&D 
Approvals; 2006/W/PA/01, see 2.8).  Tissue representing normal oesophagus, normal 
stomach and oesophageal adenocarcinoma were sampled from the oesophagogastric 
resection specimen by a consultant histopathologist.  Tissue pieces were then 
embedded in paraffin and used for optimization of IHC staining. 
Sections (4 µM) were cut by microtome from FFPE blocks and mounted on 
electrostatically-coated slides (Superfrost, VWR).  Slides were dehydrated at 56oC 
overnight before dewaxing and rehydration by incubation at RT in a series of 
solvents (Table 2-7). 
Table 2-7 Dewaxing and Rehydration of FFPE sections. 
Solvent  
(In Order of Incubation) 
Incubation Time  
(Room Temperature) 
Xylene 2 x 5 minutes 
Ethanol (Absolute) 2 x 2 minutes 
Ethanol (90% v/v in dH2O) 2 minutes 
Ethanol (70% v/v in dH2O) 2 minutes 
H2O Until Antigen Retrieval (maximum 60 minutes) 
 
Antigen retrieval and primary antibody dilutions were optimized using sections from 
OAC tissue and a “checkerboard” titration of conditions (Table 2-8).  Antigen 
retrieval was performed in citric acid buffer (1.8 mM Citric Acid, 8.2 mM Sodium 
Citrate in dH20, pH 6.0) in 50 mL Coplin jars incubated in a water bath set to 101
0C 
or in a pressure cooker filled with 1000 ml citric acid buffer, pre-heated to 95oC and 
then microwaved at 1000W power for 5 minutes.  Slides were left to cool in antigen 
retrieval buffer for 20 minutes.     
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Citrate Buffer (pH 
6.0) for 20 minutes 
water bath @95oC 
Citrate Buffer (pH 
6.0) for 40 minutes 
water bath @95oC 
Citrate Buffer (pH 
6.0) for 5 minutes 
pressure cooker. 
1/50     
1/100     
1/200     
No Primary     
 
Endogenous tissue peroxidase activity was blocked by incubation in 3% (v/v) 
Hydrogen peroxide (H2O2) in dH2O for 10 minutes with stirring, followed by rinsing 
in water.  If initial conditions produced prominent background staining, an additional 
blocking step was added using 200 µL of Serum-Free Protein Block (SFPB, DAKO) 
per slide for 20 minutes at RT.   
Blocked slides were incubated with primary antibody in antibody diluent (DAKO) 
for 1 hr at RT (200 µL per slide) followed by TBS for 5 minutes and incubation with 
undiluted Envision secondary antibody solution (DAKO) for 30 minutes at RT.  
Slides were again washed in TBS and then incubated in 3,3’-Diaminobenzidine 
chromogen  (DAB, DAKO) for 10 minutes at RT before rinsing in water.  
Slides were all counter-stained in Haematoxylin solution (5% w/v Aluminium 
Potassium Sulphate, 1% Haematoxylin w/v, 0.2% w/v Sodium iodate, 2% v/v Glacial 
Acetic Acid) for 30 seconds, rinsed in tap water , blued in Scott’s Tap Water 
substitute (Leica) for 30 seconds and rinsed again in tap water.  Slides were then 
finally dehydrated in a series of graded solvents (Table 2-9). 
Table 2-9 Dehydration of stained FFPE sections. 
Solvent 
(In Order of Incubation) 
Incubation Time 
(Room Temperature) 
Ethanol (70% v/v in dH2O) 1 minute 
Ethanol (90% v/v in dH2O) 1 minute 
Ethanol (Absolute) 2 x 1 minute 
Xylene 2 x 1 minute 
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Coverslips (Fisher) were mounted onto slides using DPX mountant and the staining 
pattern was scored after drying using the following criteria;   
Intensity of positive (brown) staining - 3 points for maximum intensity to 0 points for 
no positive staining. 
Lack of background staining - 3 points for no background staining to 0 points for 
intense widespread background staining. 
Relative positive staining to background ratio – Slides with the strongest positive 
staining may also feature non-specific background staining that clouds interpretation.  
A compromise between strength of positive staining and strength of background 
staining is often needed to provide the clearest picture.  This was scored from 3 
points for good demonstration with no non-specific staining, to 0 points for no target-
specific positivity but strong widespread non-specific staining. 
Scores were tabulated across the checkerboard titration.  Conditions with the highest 
scores were further optimised by the addition of blocking stages, change of antigen 
retrieval conditions or primary antibody dilutions.  Once optimal conditions were 
achieved for each antibody using OAC tissue, the staining pattern across normal 
oesophagus and normal stomach was examined and conditions further optimized 
until a consistent pattern was observed on at least 2 independent occasions.  The 
optimised conditions used for candidate staining are summarised in (Table 2-10).  
For acquisition of images from stained slides, a digital slide scanner was used (Ariol, 
Leica). 
2.7.5 Confirmation of Expression in FFPE Tissue 
For the confirmation of protein expression by IHC, two sections (4 µm) were cut 
from blocks representing normal oesophagus, normal stomach, adenocarcinoma, 
lymph nodes involved with metastatic adenocarcinoma (if present) and uninvolved 
nodes.  One slide was stained using the appropriate primary antibody and an 
optimized protocol (Table 2-10) and a no primary control slide was included for each 
protein.  
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20 mins WB H2O2 10 mins then 
SFPB 20 mins 




5 mins PC H2O2 10 mins then 
SFPB 20 mins 




20 mins WB H2O2 10 mins then 
SFPB 20 mins 




20 mins WB H2O2 10 mins then 
SFPB 20 mins 
1/600 in diluent Inflammatory 




No AR, H2O2 10 mins then 
SFPB 20 mins 




5 mins PC H2O2 10 mins then 
SFPB 20 mins 
1/300 in diluent Squamous 
epithelium 
WB – Water Bath, PC – Pressure Cooker, AR –  Antigen Retrieval, SFPB – Serum Free Protein Block,  
  
The staining pattern of each tissue component on the slides was tabulated and slides 
reviewed independently by a Consultant Upper GI Pathologist (Dr. Vicki Save, 
Edinburgh) to confirm the accuracy of scoring.   
 
2.7.6 Scoring of TMA Staining 
Stained slides from the TMA were scanned using a digital slide archival system 
(MIRAX SCAN, Zeiss, Cambridge UK) and images scored using the Allred scoring 
system499.  Using this method, two scores are generated for each core, one for the 
relative intensity of staining and one for the approximate proportion of tumour cells 
staining (Table 2-11). For p53 IHC scoring, cores were also scored with a predicted 
genotype of wt, null or mutant.   
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Table 2-11 Allred Scoring System Adapted for Oesophageal TMA Scoring 
Proportion Score + Intensity Score 










0% 0 Nil 0   
~1% 1 Low 1   
~10% 2 Medium 2   
~33% 3 High 3   
~66% 4     
~100% 5     
 
Total Allred histoscores for PLK-1 and p53 staining and p53 genotypes from two 
independent scorers (this author and Dr. Rudolf Nenutil, Brno, Czech Republic) were 
tabulated for each slide and TMA maps subsequently used to associate cores from 
the same tumour together.  
2.7.7 Confirmation of IHC Scoring Pattern and p53 Genotype 
The accuracy of p53 allele prediction from the IHC staining pattern was assessed on 
a small sample of tumours undergoing whole-genome sequencing as part of the 
International Cancer Genome Consortium (ICGC) Oesophageal Cancer Genome 
Project500.  The p53 allele status was determined for each of these tumours as part of 
the standard mutation calling algorithm and verified by targeted amplicon 
resequencing (Prof. Rebecca Fitzgerald, manuscript submitted).           
2.7.8 Assessment of Inter-observer Agreement 
Both scorers independently assessed the same images and provided predicted p53 
genotypes and Allred histoscores for all cores on the TMA slides.  The Kappa 
coefficient was used to assess the degree of interobserver agreement for p53 
genotypes501.  A kappa of 1.0 indicates perfect inter-observer agreement and 0 
indicates no agreement above that expected by chance.  An example calculation is 
provided for the theoretical example in Table 2-12. 
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Table 2-12 Two Observer Example for p53 Genotype Prediction 
   Observer 2  
  Wildtype Mutant Null 
 Wildtype a b c 
Observer 1 Mutant d e f 
 Null g h i 
 
	  
a b c d e f g h i  
∗ ∗ ∗  




Equation 3 Calculation of Kappa 
 
For assessment of the agreement of inter-observer histoscores for each core and 
median histoscores from the three cores for each tumour, the Spearman correlation 
coefficient was calculated using GraphPad Prism (version 5.00 for Windows, 
GraphPad Software, San Diego, California, USA).               
2.7.9   Ovarian Cancer TMA staining 
A tissue microarray created from 99 ovarian cancers comprising serous, mucinous 
and endometrioid adenocarcinomas with known p53 genotypes was subjected to 
PLK-1 IHC by Dr. Rudolf Nenutil (Brno, Czech Republic).  Five patients had 
undergone neoadjuvant chemotherapy and the remainder were chemotherapy naive.  
The same staining protocol was used as for the oesophageal TMA.  Scoring was 
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undertaken by a single observer (Dr. Nenutil), blinded to the p53 genotype of the 
tumour.      
2.7.10 Comparison of Median Histoscores 
Median tumour histoscores were compared for groups defined by predicted or actual 
TP53 genotypes using the Kruskal-Wallis test of significance calculated using 
GraphPad Prism (version 5.00 for Windows, GraphPad Software, San Diego, 
California, USA). 
2.8 Prospective Collection of Tissue, Blood and Data 
2.8.1 Regulatory Approvals 
An Oesophageal Tissue Bank (EOTB) was created to facilitate translational research.   
This was established under the wider framework of the Edinburgh Experimental 
Cancer Medicine Centre (ECMC).  Prospectively obtained ethical (REC references 
06/S1101/16 and 10/S1402/33) and NHS Lothian Research and Development (R&D 
ID 2006/W/PA/01) approvals were in place (see Appendix).  Under these approvals, 
fresh frozen tissue, surplus to diagnostic requirements, was collected from 
consenting patients undergoing attempted curative therapy for OAC.   
2.8.2 Patient Recruitment   
The identification and recruitment of eligible patients was integrated into the weekly 
South-East Scotland Oesophagogastric Cancer Multidisciplinary meeting.  Standard 
operating procedures (SOPs) outlining the process of patient eligibility 
determination, consent, blood and tissue collection are provided in the Appendix.     
In brief, patients were approached after the diagnosis of localized oesophageal 
adenocarcinoma and the decision to pursue attempted curative therapy incorporating 
surgical resection.  After outline of the process of tissue and blood collection, 
informed consent was obtained. Blood was collected and processed according to the 
SOP and de-identified clinical data obtained from patient records and stored on a 
bespoke secure database.  The integration of clinical data, tissue and blood collection 
into the standard clinical care pathway is summarised in Figure 2-1. 
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2.8.3 Tissue collection 
At the time of surgery, resection specimens were obtained fresh and transported to 
the pathology department.  Biopsies representing macroscopically normal 
oesophagus and stomach along with adenocarcinoma tissue were collected from 
resection specimens by a Consultant Upper-GI pathologist.  Biopsies were collected 
directly into low binding cryovials and snap frozen and maintained in liquid nitrogen 
in a storage facility or on dry ice during transport and as long as possible up until use 
to minimize proteolytic degradation. 
2.9 Proteomics 
2.9.1 Tissue Handling  
All preparation of tissue samples for proteomic studies was performed using keratin-
free consumables including low-residue keratin-free tips (Maxymum Recovery tips, 
Thistle Scientific) with standard precautions to minimize keratin contamination.  
Biopsies were maintained in liquid nitrogen or on dry ice until lysis.  All buffers 
were prepared in positive pressure fume-hoods.   
2.9.2 Protein Extraction from Human Tissue Biopsies-Pilot Study 
For the pilot study, a protocol previously applied to breast cancer tissue was adapted 
for use with oesophageal biopsies431.    Pieces of snap frozen oesophageal tissue, 4-5 
mm3 in size were placed in 2 ml, autoclaved, low-binding micro-centrifuge tubes 
(Axygen, Maxymum Recovery, Corning) containing sterile 5 mm steel beads.  Lysis 
buffer (80-150 µL, 500 mM triethylammonium bicarbonate (TEAB), pH 8.5 and 
0.05% (v/v) SDS, both mass spectrometry (MS) grade) was added to the tubes in a 
volume proportional to biopsy size.  Biopsies were then immediately homogenized 
using a bead-mill homogeniser (Retsch, Qiagen) for 2 cycles each of 2 minutes at 25 
Hz.  The homogenate was transferred to a fresh low-binding 1.5 ml tube (Maxymum 
recovery, Thistle Scientific) and kept on ice before sonication using a needle 
sonicator at a power of 25W, with the cycle set at 30 x 0.1 s, 30 s pause and 30 x 0.1 
s.  Sonicated samples were left for 75 minutes on ice and then centrifuged at 14,000 
g, for 20 mins at 4oC.  Supernatants (lysate) were snap-frozen and stored in liquid 
nitrogen until use.  
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Figure 2-1 Edinburgh Oesophageal Tissue Bank (EOTB) Pathway.  Patients staged with localised OAC, undergoing attempted curative treatment were approached for 
consent for tissue and blood donation of research purposes.  The integration of tissue and data collection into the clinical care pathway is summarised.  MDT – 
Multidisciplinary Team, Rx - Treatment 
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2.9.3 Protein Extraction from Human Tissue Biopsies – 
Subsequent Studies 
To enhance proteome coverage, a modified method of tissue lysis was developed 
based on the published Filter-Aided Sample Preparation (FASP) protocol443.  This 
method has two key features; tissues are lysed in a buffer containing a high detergent 
concentration to improve protein solubilisation, and then the buffer is exchanged to a 
trypsin and MS-compatible solution by centrifugation of lysates through molecular 
weight cut-off filters.   
2.9.4 Optimisation of Tissue Lysis Conditions.  
2.9.4.1 Tissue Handling 
Samples of mouse small intestine were collected from 12 mice culled after 
pentobarbital anaesthesia as part of an independent, ethically-approved research 
project (Courtesy of Dr. Chris Lucas, Queen’s Medical Research Institute, 
Edinburgh).  Biopsies were snap-frozen on dry ice and weighed by subtraction into 2 
ml homogenisation tubes (Matrix A or Matrix D, MP Bio).  
2.9.4.2 Homogenisation 
Detergent-free lysis buffer (DFLB, 100 mM Tris- HCL, 100 mM DTT, pH 7.6), 
Complete buffer (SDSB, 100 mM Tris- HCL, 100 mM DTT, 4% (v/v) SDS, pH 7.6) 
or no buffer were added to the tubes prior to homogenisation at RT by rapid shaking 
in a bench-top homogenizer (FastPrep-24, MP Bio) for 40 seconds at 6 ms-1.  Tubes 
were then centrifuged for 15 s at 13,000 rpm in a bench-top centrifuge to re-collect 
homogenised material. Complete buffer, SDS or no buffer were added to the tubes to 
complete the lysis.  Tubes were then gently mixed by rotation for 20 minutes at RT 
before sonication or proceeding directly to buffer exchange.   
2.9.4.3 Sonication 
 Lysates were sonicated on ice using a needle sonicator (Bioruptor) for 30 seconds at 
maximum amplitude.   Sonicated lysates were heated for 5 minutes at 95oC and then 
transferred to low-binding micro-centrifuge tubes (Eppendorf) before centrifugation 
at 14,000 g for 5 minutes at 20oC. 
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Methods   127 
2.9.4.4 Buffer Exchange 
Clarified lysates were diluted in 200 µL urea solution (8 M urea in 100 mM Tris 
HCl, pH 8.5) in 30 kDa nominal molecular weight cut-off filter (NMWCO, 
Millipore; 30µL lysate per filter) and then centrifuged for 15 minutes at 14,000 g at 
20oC.  The residuates were re-diluted by the addition of a further 200 µL of urea 
solution and again centrifuged for 15 minutes at 14,000 g at 20oC.  For optimization 
experiments, a 25 µL aliquot of buffer exchanged residuate was used for protein 
concentration determination (see 2.9.6).  
2.9.4.5 Lysate Alkylation and Urea Dilution 
For each filter, the residuate (buffer-exchanged lysate) was mixed with 100 µL of 50 
mM iodoacetamide in urea solution and incubated in the dark at RT for 20 minutes.  
Alkylated lysates were then centrifuged at 14,000 g for 10 minutes at 20oC and again 
diluted by the addition of 100 µL of urea solution before centrifugation again at the 
same settings for 15 minutes.  This step was repeated twice and then residuates 
mixed with 100 µL of 50 mM triethylammonium bicarbonate (TEAB) to dilute the 
urea and centrifuged at 14,000 g for 10 minutes at 20oC, repeating this step twice.   
2.9.4.6 Tryptic Digestion 
The residuate from one identically treated filter column was used to determine the 
protein concentration and the remaining filter columns used for on column tryptic 
digestion.  Vials of lyophilised trypsin (20 µg/vial, Promega) were reconstituted in 
10 µL of 1 M HCl and then diluted to 20 µg/ml in 20 mM TEAB and 9% (v/v) 
acetonitrile in dH2O. Trypsin was added to buffer-exchanged lysates in a ratio of 
100:1 (lysate protein mass (mg) : trypsin mass (mg)).  Filter units were sealed with 
Parafilm (Camlab) and incubated overnight at 370C.        
2.9.5 Application of the Modified FASP protocol to Human Tissue  
Pieces of snap-frozen oesophageal or gastric tissue between 30mg and 60mg in 
weight were disrupted at RT in low-binding micro-centrifuge tubes containing 1mm 
ceramic beads (Matrix D, MP Bio) by rapid shaking in a bench-top homogenizer 
(FastPrep-24, MP Bio) for 40 seconds at 6ms-1.  The homogenisation step was 
repeated once if the tissue was not completely disrupted.  Homogenates were 
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dissolved in FASP lysis buffer (4% w/v SDS, 100 mM Tris/HCl, 100 mM DTT, pH 
7.6) at a ratio of 20 : 1; (lysis buffer (µL) : tissue weight (mg)) by re-pipetting and 
then gently mixed by rotation for 20 minutes at RT.  
Sonication, lysate clarification, buffer exchange, alkylation and dilution were 
performed as previously (see 2.9.4.3 and 2.9.4.5) with several lysate aliquots buffer-
exchanged for each tissue sample. The NMWCO filter residuates from the same 
tissue samples were aspirated from the filter units and pooled for protein 
concentration determination.  
 
2.9.6 Determination of Protein Concentration from Tissue 
Lysates. 
Lysate protein concentrations were determined using a modified Lowry procedure502 
(RC-DC, Bio-Rad) as per manufacturer’s recommendations.  A dilution series from 4 
mg/ml to 0.125 mg/ml of BSA in 50 mM TEAB was used to generate a standard line 
by linear regression of background-corrected absorbances.  Sample protein 
concentrations were then inferred by interpolation of background corrected 
absorbances on the standard regression line.    
2.9.7 Preparation of Tryptic Peptides from Lysates –  Pilot Study. 
Each tissue lysate was diluted to 5 µg/ µL in lysis buffer (500 mM TEAB (pH 8.5) 
and 0.05% (v/v) SDS) and then an 8µ L aliquot diluted with 32 µL of 6 M urea in 
100 mM TEAB (pH 8.0).  Proteins were then reduced for 1 h at 37°C by the addition 
of 2 µl 50 mM tris-(2-carboxyethyl) phosphine hydrochloride (TCEP) in dH2O.  The 
reduced lysates were alkylated by the addition of 1 µL Iodoacetamide (400 mM) and 
incubated for 30 minutes at RT, protected from light.  Lysates were then further 
diluted with 67 µL of 100 mM TEAB and digested with trypsin (MS grade, 
Promega; final concentration 0.167 µg/µL, protein : enzyme ratio of 20 : 1) overnight 
at 37oC. 
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2.9.8 Preparation of Tryptic Peptides from Lysates – Modified 
FASP method 
Vials of lyophilised trypsin were reconstituted as previously and added to pooled 
lysates in a ratio of 100:1 (Lysate protein mass (mg) : Trypsin mass (mg)).  The pH 
of the final mixture was confirmed to be between 7.5 and 8.5.  Eppendorf tubes were 
sealed with Parafilm and tryptic digestion conducted overnight at 37oC.       
2.10 Quantitative Proteomics using Isobaric Labeling 
2.10.1 Isobaric Labeling of Tryptic Peptides 
Tryptic peptide mixtures from each tissue sample were independently labeled with 
one of the 6 TMT reagents (ThermoScientific) according to manufacturer’s 
instructions.  For the pilot study, two equal aliquots containing a mixture of all 4 
samples were labeled with the two remaining tags as an internal control to define the 
level of technical variation.  For further experiments, each tissue type from one 
patient was labeled in technical duplicate.  Labeled samples were pooled and then 
evaporated to dryness in a vacuum centrifuge (SpeedVac, ThermoScientific). 
Peptides were labelled with TMT reporters, fractionated by OFFGEL 
electrophoresis, and analysed by liquid chromatography - tandem mass spectrometry 
(LC - MS/MS) by Dr. Alex Scherl and Mr. HuiSong Pak (Centre Médical 
Universitaire, Geneva) on a linear ion trap-Orbitrap hybrid mass spectrometer (LTQ-
Orbitrap Velos, ThermoScientific) equipped with an ultra-high pressure, liquid 
chromatography (UPLC) system (nanoACQUITY, Waters). 
2.10.2 Peptide Fractionation for TMT Experiments 
TMT-labeled peptides were reconstituted in 200 µL dH2O (MS grade, Sigma) and 
desalted on a Macro SpinColumn C18 (Harvard Apparatus) before evaporation by 
vacuum centrifugation.  Peptides were reconstituted in 1 x OFFGEL solution (a 
proprietary solution containing a mixture of urea, thiourea, DTT, glycerol and Tris-
based buffer, Agilent) and applied to an immobilised pH gradient (IPG) dry strip (13 
cm, pH 3–10, linear; GE Healthcare) set up with a 12-well frame for the pilot study 
and 24-well frame for subsequent experiments.  Peptides were then fractionated 
according to their isoelectric point by OFFGEL electrophoresis with a  maximum 
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current of 50 µA and power of 200 mW until 20 Vh were reached (3100 OFFGEL 
Fractionator, Agilent)503.  The fractions were collected and desalted on a Micro 
SpinColumn C18 (Harvard Apparatus) before evaporation to dryness under speed-
vacuum and storage at -20 °C until LC-MS/MS.   
2.10.3 Liquid Chromatography for TMT Experiments 
Dried, desalted peptides were reconstituted in 5% (v/v) acetonitrile, 0.1% (v/v) 
Formic Acid (FA) in dH2O and ~0.5 µg loaded onto a homemade 100 µm internal 
diameter, 20 mm long trapping column packed with 200 Å, 5 µm Magic C18 AQ 
(Michrom, Auburn, CA, USA).  Trapped peptides were eluted into a 750 µm internal 
diameter, 150 mm long analytical column packed with 100 Å, 5 µm Magic C18 AQ 
(Microcom).   
For UPLC, peptides were separated using a variable solvent gradient created by a 
combination of 0.1% (v/v) FA in H2O (solvent A) and 0.1% (v/v) FA in acetonitrile 
(solvent B).  The gradient was run as follows: 0–1 mins, 95% (A) and 5% (B), 1-56 
mins, 65% (A) and 35% (B), 66-76 mins, 20% (A) and 80% (B) using a flow rate of 
220 nL/min.  
2.10.4 Mass Spectrometry for TMT Experiments  
Peptides were analysed in positive ion mode after electrospray ionisation. For MS 
survey scans, the OT resolution was set to 60,000 and the ion population was set to 5 
× 105 with an m/z window from 400 to 2,000. 
For precursor ion analysis (MS1), a maximum of 3 ions with the greatest peak 
intensities were selected for both collision-induced dissociation (CID) and high-
energy C-trap dissociation (HCD) in the LTQ with analysis in the OT.  For fragment 
ion analysis (MS2) in the LTQ, the ion population was set to 7× 103 (isolation width 
of 2 m/z) while for MS2 detection in the OT, it was set to 2 × 105 (isolation width of 
2.5 m/z ), with resolution of 7,500, first mass at m/z = 100, and maximum injection 
time of 750 ms. The normalized collision energies were set to 35% for CID and 60% 
for HCD.  
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2.11 Data analysis for TMT Experiments 
2.11.1 Protein Identification 
Protein identifications were made using the Easyprot platform (v2.3 build 720, Swiss 
Institute of Bioinformatics)504.   Data manipulation was performed using Excel 
(Version 14.0.6129.5000, Microsoft Office Professional 2010), R (version 2.15.1, 
General Public License), and custom scripts written in Perl (version 5.18.0, General 
Public License).  Example code is provided in the Appendix.   
The Easyprot platform proceeds as follows: peak lists were generated from Thermo 
RAW files using ReAdW (ThermoFinnigan) and CID and HCD spectra were merged 
for simultaneous identification and quantification505.  For the pilot study, the three 
technical replicates were pooled and peaklist files were searched against the 
uniprot_sprot database (2011_2 of 8-feb-2011) specifying Homo sapiens taxonomy 
and using Phenyx peptide spectrum matching software (Swiss Institute of 
Bioinformatics).  For subsequent TMT experiments, peaklist files were searched 
against the Uniprot Human Reference Proteome (release 09/01/2013, containing 
87,613 entries) using Phenyx.  This reference database comprises both manually 
reviewed (UniprotKB/Swissprot) and unreviewed sequences (UniprotKB/TrEMBL).   
For database searching, the precursor ion tolerance was set to 10 parts per million 
(ppm). TMT-modified peptide N-termini and lysines (additional 229.1629 Da) and 
oxidized methionines were set as variable modifications.  Carbamidomethylation of 
cysteines was set as a fixed modification. Trypsin was selected as the digestion 
enzyme, with one potential missed cleavage accepted.  A minimum peptide length of 
6 amino acids was required with a minimum peptide z-score of 4. 
All datasets were searched separately, once in a forward and once in a reversed 
database.  A peptide z-score threshold was then calculated to maintain the false 
positive peptide ratio below 1%. Using Phenyx search scores this approach has been 
reported to slightly overestimate the true false-positive ratio506.  For the pilot study, 
only proteins matching two unique peptide sequences were kept.  To maximise 
proteome coverage for subsequent experiments, a single unique peptide was accepted 
for protein identification.    
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2.11.2 TMT Quantitation 
2.11.2.1 Reporter Ion Extraction 
For relative protein quantitation, the TMT reporter intensities were extracted for each 
peptide.  An isotopic purity correction was performed within Easyprot for each 
reporter on the basis of the isotopic distribution of the sixplex-TMT reporters 
provided by the manufacturer.  Isotopic purity equations were calculated using 
Maple software (Maple 11, Maple Inc., Waterloo, Canada). 
2.11.2.2 Relative Protein Expression 
For the pilot TMT experiment, a tumour to normal oesophageal (TvO) ratio was 
calculated for each peptide for the first patient as the ratio of 126 to 127 reporter ion 
intensities and similarly for the second patient as the ratio of 129 to 130 reporter ion 
intensities.  An estimate of technical variation was obtained for each peptide through 
the ratio of 128 to 131 intensities.    
For the subsequent TMT experiments, two strategies were employed.  For the first 
comparison of mFASP TMT data from patients 44 and 46 with PAcIFIC data, the 
geometric mean of all tumour peptide reporter ions (126 and 127) was calculated for 
each protein.  The same was performed for all normal oesophageal and normal 
gastric reporters (oesophageal; 128 and 129, gastric; 130 and 131).  The tumour : 
normal oesophageal (TvO) and tumour :  normal gastric (TvG) ratios of geometric 
mean reporters was then calculated for each protein.  The peptide level variance was 
not considered in this initial analysis, as this was unavailable for the comparator 
spectral counts.      
For subsequent comparisons, TvO and TvG ratios were calculated for each peptide as 
the ratio of 126 to 128 reporter intensities and 126 to 130 reporter intensities 
respectively.  This was repeated for 127/129 (TvO) and 127/131 (TvG) reporter ions 
as a technical replicate.  The geometric mean peptide TvO and TvG ratios were then 
calculated for each protein to derive an estimate of the relative protein expression 
between patient-matched tissue types.  The geometric mean of ratios was used in 
preference to the arithmetic mean to limit the skew introduced by outlier ratios507.  
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The variance of each ratio and the number of peptides contributing to the mean ratio 
were included in significance calculations.    
Isoforms of some proteins were represented in the reference databases used for 
peptide spectrum matching.  For several genes, more than one protein isoform was 
potentially detected.  The evidence for isoform specific expression could not be 
empirically determined from the results of peptide spectrum matching and isoform 
specific protein identifiers could not easily be mapped to unique transcripts.  For this 
reason, the peptides corresponding to different isoforms of a parent protein were 
pooled and the reporter intensity ratios considered together under the parent protein 
identifier.  The number of unique proteins identified may therefore be 
underestimated.   
2.11.3 Assessment of Technical Variability 
The log2 ratios of technical replicate reporters were calculated for each peptide.  
Differences from 0 in the median log2 ratio arise principally due to variations in the 
initial peptide concentration of samples labelled with each reporter ion.  A further 
small potential contribution could be from differential loss or detection of reporter-
labelled peptide during fractionation and LC-MS/MS analysis.  This systematic error 
was minimised by normalisation following the assumption that for each technical 
replicate ratio the median (log2 ratio) should be 0.   
The variance of the median normalised ratios was used to compare the variability 
across experiments.  By calculating the standard deviation from the combination of 
all technical replicate ratios, an estimate of the range of ratios expected through 
technical variation could also be determined.   
2.11.3.1 Deriving a Mean Expression Value – Subsequent Experiments 
A meta-analysis approach using a fixed-effect model was employed to derive a mean 
expression value across experiments508.  The inverse of the variance in peptide 
reporter ratios was used to weight the contribution of protein expression from a 
particular experiment to the mean.  In this manner, experiments detecting a large 
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number of peptides all with similar relative tissue expressions for a single protein 
contribute a greater proportion to the mean expression value.  




Equation 4 Weighting used for the contribution of each experiment to the mean.  σ2 = the variance in 
peptide ratios. 
 




Equation 5 Calculation of the Weighted Mean. K=total number of experiments the protein was 
quantified in. Xi = the expression in experiment i. Wi = the weight for experiment I (see Equation 4). 
 





Equation 6  Variance of the Weighted Mean 
 
The intra-experimental variance associated with a protein expression ratio could not 
be determined for proteins identified by a single peptide.  These proteins may show 
tissue-specific expression, however, and they were included in the analysis.  The un-
weighted arithmetic mean and variance of the ratios across experiments was 
calculated for these proteins.     
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2.11.3.2 Assessing the Distribution of Ratios 
The distributions of the mean, median-normalised, log2 TvO, TvG, and technical 
replicates ratios (TvT, OvO, GvG) were examined using histograms and boxplots.  
To formally test for normality, both the Shapiro-Wilks and Lillefors tests were 
used509,510.  To test ratios for homoscedastiscity (equal variances), the Fligner-Killeen 
test was applied511.   
To determine the false positive performance of the normality tests, random normally 
distributed variables with the same mean, SD and sample size for the TvO, TvG, 
TvT, OvO, GvG ratios were generated using the R function Rnorm.  A sample of 
5000 numbers from these variables selected randomly, with replacement, was tested 
for normality using both the Shapiro-Wilks and Lillefors tests.   
2.11.3.3 Prediction of Dysregulated Proteins at the Population Level 
The geometric mean ratio of TvO and TvG peptide reporter intensities was 
calculated for each protein, and the arithmetic mean calculated across experiments to 
derive a global mean ratio.  The variance of this ratio was determined from biological 
replicates and the number of biological replicates contributing to the mean used as 
“n”, giving a maximum of 7.  To assess technical variation, the TvT and OvO ratios 
or TvT and GvG ratios were pooled and the arithmetic mean and variance across 
experiments calculated.  The number of biological replicates contributing to each 
technical replicate ratio was as “n” giving a maximum of 14 for each pooled mean. 
2.11.3.4  Calculation of Significantly Dysregulated Proteins 
Welch’s t-test was used to test the hypothesis that the relative protein expression 
between tissues was not different from relative protein expression between technical 
replicates, within the experimental data.  This p-value was considered as the 
probability the protein was not differentially expressed within the experimental data 
(the intra-experimental probability).  The same test was also applied to determine the 
probability that the relative protein expression between tissues across experiments 
was not different from the relative protein expression between technical replicates 
across experiments512.  This p-value was considered the inter-experimental 
probability that the protein was not differentially expressed.    
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For the calculation of intra-experimental probability, the “n” was defined as the 
number of peptides contributing to the mean ratio.  For inter-experimental 
probability, “n” was defined as the number of patient’s samples contributing to the 
mean ratio.  The Welch’s t statistic was calculated for each protein for the difference 
between the mean TvO or TvG ratio and pooled mean TvT and OvO or TvT and 
GvG ratios (Equation 7).  For the pilot experiment Welch’s t statistic was calculated 
for each protein for the difference between the TvO ratio and the technical replicate 




Equation 7 Welch's t statistic. X1 = mean TvO or TvG ratio, X2= mean TvT and OvO or TvT and GvG ratios, 
or for the pilot experiment the technical replicate ratio. σ2 = variance, n=number (as defined in the text).  




Equation 8 Calculation of the degrees of freedom for Welch's t test (from reference514). 
The degrees of freedom were calculated for each protein using Equation 8 and t 
tables were then used to calculate p-values.  All protein p-values were pooled and 
then false discovery rate (FDR)-corrected using the Benjamini-Yekuteili method515.  
Significance was defined as an FDR-corrected p<0.05.      
2.11.4 Protein Identity Mapping 
Protein databases use database-specific identifiers (IDs) to denote a single unique 
protein sequence.  These can vary both between databases and between versions of 
the same database.   To compare proteomics experiments using different databases 
for peptide spectrum matching, protein identifiers were mapped to Uniprot accession 
numbers (AC).  International Protein Index (IPI) identifiers from proteins identified 
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in the PAcIFIC experiments were mapped to Uniprot Accessions using the web-
based Uniprot mapping tool516.  
For unmapped IDs (~5% of the total) a manual search was performed and a Uniprot 
archive reference assigned to proteins not represented in the Uniprot database.  When 
different IPI numbers corresponded to several isoforms of a protein, the spectral 
counts were summed for each experiment leaving a total count for all the proteins 
derived from one gene for each experiment.  For the TMT experiments, all the 
peptides corresponding to various isoforms of a protein were summed under the 
parent protein denoted with one unique AC.  This generated a list of unique Uniprot 
AC references with corresponding TMT and PAcIFIC quantitative data.   
For ontology and network analysis, the Uniprot accession numbers were mapped to 
Entrez GeneIDs using reference tables downloaded from Ensembl, the National 
Centre for Biotechnology Information (NCBI) Entrez Gene service and the Human 
Genome Organisation Gene Nomenclature Committee (HGNC) web-servers and 
custom Perl and R scripts. For selected cases, manual searches were conducted using 
the Uniprot and Entrez websites517.  
2.11.5 Protein Subcellular Localisation    
The subcellular localisation of identified proteins was determined from the 
UniprotKB database.  A summary description of protein localisation was generated 
from the primary localisation; defined as the first localisation listed in the Uniprot 
database.  Only limited conclusions could be drawn from this summary localisation 
as proteins are rarely confined to one subcellular compartment and not all identified 
proteins were annotated.  Localisation options were restricted to; Cell membrane, 
Cytoplasm, Cytoplasmic Vesicle, Nucleus, Mitochondrion, Endoplasmic Reticulum 
(ER), Golgi, Secreted and unavailable.  For ambiguous primary localisations, the 
further localisation data were reviewed and the most appropriate of the summary 
options selected. 
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2.11.6 Identifying Prior Evidence for Protein Expression in 
OAC and Other Cancers 
A literature search was performed using the Pubmed database518. A literature base 
was obtained by searching all of the Pubmed records using the Medical Subject 
Headings (MeSH); oesophagus, oesophageal, OAC, Barrett’s, esophageal, 
esophagus, EAC linked by an OR operator together with the MeSH; adenocarcinoma 
OR cancer.  Dysregulated proteins were individually searched against this literature 
base and matches reviewed.  Proteins were searched against published microarray 
studies of OAC60,61,171,277 using the Oncomine database (v 4.4.3)519 to determine if 
the genes were significantly dysregulated between OAC and normal oesophagus 
(FDR-corrected p<0.05).  Proteins were also searched manually against the reported 
results from two existing proteomic studies using OAC tissue447,449.   If no evidence 
for dysregulation in OAC was identified using this strategy a Pubmed literature 
search was performed to identify evidence of dysregulation in any other cancer.     
2.11.7 Hierarchical Clustering of Expression Data 
Unsupervised hierarchical clustering was performed using the hclust function in R 
(version 2.15.1).  In this function, each sample is initially assigned to an independent 
cluster.  An agglomerative method is then used to combine the pair of clusters with 
the shortest Euclidean distance until only one cluster remains520.  Each new cluster 
was represented by a branch on the dendrogram and the distance between branches 
was proportional to the Euclidean distance between clusters.  
2.11.8  Label-Free Quantitative Proteomics 
For label-free proteomic analysis, the precursor acquisition independent from ion 
count (PAcIFIC) method was used with some modifications404. 
2.11.9 Sample Preparation 
Tryptic peptides were generated from tissue samples using the modified FASP 
method (mFASP, see 2.9.5).  Following overnight proteolysis with trypsin, the 
digestion buffer was evaporated by vacuum centrifugation (SpeedVac) and tryptic 
peptides resuspended in 200 µL dH2O.  This was repeated twice before the dried 
tryptic peptides from each tissue sample were finally resuspended in 5% (v/v) 
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acetonitrile, 0.1% (v/v) FA in dH20 and desalted on a Macro SpinColumn C18 
(Harvard Apparatus). Peptides were eluted and then evaporated to dryness by 
vacuum centrifugation.  Dried peptides were resuspended in 5% (v/v) acetonitrile, 
0.1% (v/v) FA in dH2O to a concentration of 67 µg/ml based on the predicted protein 
input to the tryptic digests, calculated from the protein concentrations. 
PAcIFIC LC-MS/MS was performed by Dr. Young-Ah Goo, (University of 
Washington, Seattle) on an LTQ-Orbitrap mass spectrometer (LTQ-Orbitrap, 
ThermoScientific) equipped with a UPLC system (nanoACQUITY, Waters).  
2.11.10 Liquid Chromatography for PAcIFIC  
Resuspended peptide samples were loaded by injection at 6 μL/min for 2.5 minutes 
onto a 200 µm internal diameter, 20 mm long trapping column (New Objective, 
Woburn, MA, USA) packed with 200 Å, 5 µm Magic C18 AQ (Michrom, Auburn, 
CA, USA).  Trapped peptides were then eluted at 2.5 µL/min using a variable solvent 
gradient into a 200 µm internal diameter, 150 mm long analytical column (New 
Objective) packed with 100 Å, 5 µm Magic C18 AQ (Michrom).  The gradient was 
created using a combination of 0.1% (v/v) FA in dH2O (solvent A) and 0.1% (v/v) 
FA in acetonitrile (solvent B).   
Each peptide sample was injected from the analytical column into a captive spray 
ionisation (CSI) source (Bruker, Billerica, MA, USA) and subjected to tandem mass 
spectrometry (MS/MS) with 34 repeat injections using the following variable 
gradient: 0 – 34 mins, 95% (A) and 5% (B); 34-37 mins at 58% (A) and 42% (B); 
37-37.75 mins, 15% (A), 85% (B); 37.75-43 mins, 95% (A) and 5% (B).     
2.11.11 PAcIFIC Mass Spectrometry 
For each injection, a series of 30 sequential precursor ion windows incrementing in 
steps of 1.5m/z were selected.  For each window, an isolation width of 2.5m/z was 
used and all precursor ions per window subjected to CID with collision energy set to 
35% and the same fragment ion detection method used as for the TMT experiments.  
Precursor ions from the range 400 m/z to 1420 m/z were analysed across 34 sample 
injections to yield a complete PAcIFIC MS/MS analysis in just over 24 hours.  
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2.12 Data Analysis for PAcIFIC Experiments 
2.12.1 Peptide Identification 
For the analysis of PAcIFIC data, Thermo RAW spectral files for each sample 
injection were converted to mzXML files (34 files in total per sample) and peak lists 
were generated and searched with Sequest software521 against the IPI human 
database (version 3.49, containing 74017 entries).  
For database searching, oxidised methionines were set as variable modifications and 
carbamidomethylated cysteines were set as fixed modifications.  The proteolytic 
enzyme was specified as trypsin with one missed cleavage permitted and the 
precursor mass tolerance was defined as 3.75 Da.   
2.12.2 Protein Identification 
Protein identifications were made using the Transproteomic pipeline (TPP) suite of 
tools522. Sequest results were converted to pepXML files and peptide identification 
probabilities computed with PeptideProphet522.  For all individual sample searches 
(34 pepXML files), a threshold of peptide probability was identified to maintain the 
false discovery rate (FDR) <1%.   
Protein identifications were then made from the pool of pepXML files for each 
patient sample using the ProteinProphet statistical model522.  Only proteins with two 
unique peptides were accepted and when peptides matched to multiple members of a 
protein family, the protein family was summarised as a protein group with a single 
Uniprot identifier.   The number of spectra identified per protein was automatically 
extracted from the pepXML files during analysis with the TPP.  This spectral count 
was used as a measure of protein abundance. 
2.13 Network Analysis 
2.13.1 Mapping Identified Proteins to Functional Clusters 
The Linghu functional linkage network was filtered at a likelihood ratio threshold of 
>5.0 and >20 (LR5+ and LR20+ respectively).  The filtered networks were then 
clustered using the MCL algorithm523 using sequential inflation values from 2.0 to 
6.0.  The total list of unique proteins identified in each experiment and the lists of 
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differentially regulated proteins were mapped to the unique list of genes in the 
filtered network with the matching genes retained.  For each dysregulated gene list, a 
control list containing the same number of genes was generated by random selection 
from the total list of mapped genes.  This process was repeated 10,000 times and the 
results concatenated into a control gene list file.  Dysregulated and control lists were 
checked to ensure there were no genes unique to the list type.  The differentially 
regulated and control gene lists were then mapped to the LR5+ and LR20+ clusters at 
each inflation value. 
2.13.2 Identifying Significantly Enriched Clusters 
The mapped clusters for dysregulated and control lists were compared and a FDR-
corrected p-value calculated for the probability that the dysregulated gene mapping 
could have occurred through random chance (see Appendix B for R commands and 
custom Perl scripts).  Clusters were considered significantly enriched if the FDR-
corrected p-value was <0.1.  Cluster gene membership and connectivity were then 
obtained from the original LR5+ or LR20+ clusters and networks and significantly 
enriched clusters visualised using Cytoscape524. 
2.13.3 Cluster Visualisation 
For Cytoscape networks, all nodes were binned into 9 categories according to their 
TvO and TvG expression and the nodes filled according to the colour assigned to the 
appropriate bin.  Networks were structured using the yFiles organic or Cytoscape 
edge-weighted spring-embedded strategy with manual manipulation to minimise 
overlapping nodes and enhance the clarity of presentation.        
The biological process ontologies for each cluster were determined using the online 
tool; Database for Annotation, Visualisation and Integrated Discovery (DAVID, 
version 6.7)525.  The ontologies were ranked by the significance of enrichment 
calculated using the DAVID online method and corrected for multiple hypothesis 
comparisons by the Benjamini-Hochberg method526.  The top three processes with an 
FDR-corrected p<0.05 were retained to annotate the clusters.  A summary describing 
the functional class of the genes was also produced from manual inspection of the 
gene membership of the cluster. 
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2.13.4 Pathway Mapping 
To visualise the context of dysregulated genes within known biological pathways, 
the dysregulated genes (intra-experimental FDR-corrected p<0.05) were mapped to 
the Kyoto Encyclopedia of Genes and Genomes (KEGG, version 66.1) online 
pathway database using the KEGGArray tool527.  Genes were coloured within the 
pathway context according to either TvO or TvG expression using a 7-point colour 
scale. 
Genes more than 2-fold upregulated in both TvO and TvG comparisons were also 
analysed using the online Search Tool for the Retrieval of Interacting Genes/Proteins  
(STRING, version 9.05)528.  A network was constructed using multiple edge-types 
derived from various curated sources including co-publication, co-expression and 
experimental demonstration of protein-protein interaction from various external 
databases.   
To enhance connectivity between small clusters generated from the supplied genelist, 
nodes were inferred using the STRING algorithm which derives a probabilistic 
confidence score for the likelihood an inferred node is functionally linked to 
experimentally observed nodes.  A minimum score of 0.99 was required so there was 
very high confidence in the functional association between inferred nodes and the 
experimental data.  The inferred nodes could be used to strengthen the evidence for a 
molecular process or pathway within an incomplete dataset to provide a basis for 
hypothesis testing.  For network visualization, unconnected nodes and peripheral 
nodes were removed from the network to generate one connected cluster, structured 
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3.1 Chapter Aims 
 
a) To evaluate the expression of PLK-1 in a panel of 
oesophageal cell lines and oesophageal tissue and correlate 
the findings with TP53 genotype.  
 
b) To develop a method to accurately determine cytostatic 
from cytotoxic phenotypes in cell lines. 
 
c) To assess the effect of PLK-1 siRNA and kinase inhibition on 
viability in oesophageal cell lines. 
 
d) To evaluate strategies to enhance the therapeutic window 







 Evaluation of PLK-1 as a Therapeutic Chapter 3:
Target in OAC 
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3.2 Introduction  
It is proposed that the DNA damage checkpoint at the G2/M transition may represent 
a fragile point for targeted therapy in oesophageal cancer (1.3.8).     PLK-1 controls 
the exit from this checkpoint and selective inhibitors are in early phase clinical trials.  
In oesophageal cancer, only OSCC cells have been therapeutically targeted with 
PLK-1 inhibitors (1.5.12).  The role of PLK-1inhibition and strategies to enhance the 
therapeutic window between oesophageal adenocarcinoma and non-transformed 
oesophageal cells will be examined in this chapter.   
3.2.1 Cell Lines as Cancer Models      
Immortal cell lines can be used to test the effect of inhibitors or genetic changes on 
viability, proliferation and other dynamic properties not assessable directly in tissue 
biopsies.  By using cell lines derived from the tissues representing the stages of 
oesophageal carcinogenesis, it is hoped that cancer cell-specific phenotypes can be 
uncovered.  The rationale being that the cell lines, although not isogenic, represent, 
in part at least, the epigenetic and transcriptional background of human oesophageal 
tissue.  Changes only present in the cancer cell lines may represent therapeutic 
targets with intrinsic cancer-specificity and therefore a lower potential for systemic 
toxicity.  
3.3 Results  
3.3.1 Verification of a panel of oesophageal cell lines 
STR genotyping was undertaken to verify the identity of the cell lines selected to 
represent the histological stages of oesophageal carcinogenesis (Table 3-1).  The 
results demonstrate an exact match for the observed and predicted alleles for all the 
cell lines.  In CP-A, OE33 and FLO-1 cells not all of the predicted alleles were 
confidently identified.  No contradictory alleles were observed, however, supporting 
the verification of these cell lines.  A comprehensive search of cell line STR 
genotype databases produced no matches for the HEEpiC cell genotype providing 
reassurance that the cells are primary cells rather than a cancer cell line.  As a further 
verification step, the growth pattern and cell morphology observed by light 
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microscopy was confirmed to agree with images available through the European 
Collection of Cell Cultures463. 
The oesophageal cancer cell lines are all predicted to exhibit loss of p53 function due 
to TP53 mutation85,471.  In contrast, both CP-A cells and HEEpiCs possess wild-type 
p53.  In cells with wild-type p53, gamma and UV radiation induce p53 and 
downstream transcriptional target expression including MDM2, p21 (WAF1) and, in 
the case of irreparable DNA damage, effectors of the apoptotic machinery including 
BAX529.  Wild-type p53 can be inactivated in cancer by MDM2 overexpression and 
therefore identification of the wild-type allele  is not enough to confirm p53 
function530.  To demonstrate p53 functional status, the response to DNA damage was 
examined in CP-A and OE33 cell lines with predicted wild-type and mutant TP53 
respectively.  CP-A cells were initially exposed to both gamma and UV-C radiation 
at variable doses and then p53 and p21 expression examined after 24 hours by 
western blotting.  CP-A cells exhibited the expected dose-dependent increase in both 
p53 and p21 expression in response to DNA damage from both UV-C and gamma 
irradiation (Figure 3-1).  The highest UV dose produced a lower p21 response which 
may reflect secondary compensatory mechanisms activated in the 24 hours between 
exposure and measurement. 
OE33 and CP-A cells were irradiated at a dose of 10 Gy and cells harvested for 
western blotting at serial intervals over 48 hours to avoid missing the induction of 
p53 target genes.  There was a gradual and maintained induction of p53 expression 
from 2 hours until at least 48 hours after gamma irradiation in the CP-A cells (Figure 
3-2).  This was accompanied by an induction in MDM2, p21 and lastly BAX 
supporting the presence of functional p53 in this cell line (Figure 3-3).  The time 
course of gene induction mirrors previous reports in MCF-7 breast cancer cells531. 
In contrast, the OE33 cell line exhibited no change in the expression of p53 or p53 
transcriptional targets (Figure 3-2, Figure 3-3).  This fits with the loss of p53 
transcriptional activity due to a mutation in the DNA-binding domain (C135Y).  
Together these data support the expected p53 functional status of the oesophageal 
cells used in this study (Table 2-1). 
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Table 3-1 STR Genotype Profiling of Oesophageal Cells.  ATCC – American Tissue Culture Collection, DSMZ -Deutsche Sammlung von Mikroorganismen und 
Zellkulturen, JCRB - Japanese Collection of Research Bioresources, RIKEN – Japanese Institute of Physical and Chemical Research 
 Sample 
Allele at STR Locus 
D21S11 THO1 TPOX vWA Amelogenin CSF1PO D16S539 D7S820 D13S317 D5S818 
HEEpiC Observed 29,30 9.3 8, 11 14,16 X,Y 12 11,12 8,9 12,13 11,13 
HEEpiC Predicted474 No Match Found on a Search of 2455 Cell Line STR Genotypes from ATCC, DSMZ, JCRB and RIKEN databases 
CP-A Observed 27,31.2 7,9.3 8,9 17 X,Y 12 12,13 7,8 14 11,12 
CP-A Predicted532 - 7,9.3 8,9 17 X,Y 12 12,13 7,8 12,14 11,12 
OE19 Observed 30 8,9 8 16,17,18 X 11,13 12,13 8 9,11 11,14 
OE19 Predicted85 30 8,9 8 16,17,18 X 11,13 12,13 8 9,11 11,14 
OE33 Observed 29,31.2 7 8 17 X 10,11 12 9,10 14 11 
OE33 Predicted85 29,31.2 7,8 8,11 17 X 10,11 12 9,10 14 11 
OACM5.1 C Observed 28,31 6,9.3 8 19,20 X 10,13 10,11 8 11,12 12 
OACM5.1 C Predicted85 28,31 6,9.3 8 19,20 X 10,13 10,11 8 11,12 12 
FLO-1 Observed 30,32.2 6 9,11 16  11 12,13 8 11 12,14 
FLO-1 Predicted85 30,32.2 6 9,11 16 X 11 12,13 8 11 12,14 
JH-Eso-Ad1 Observed 30 6,7 8,9 18,19 X 10 10,12 10,12 11 11 
JH-Eso-Ad1 Predicted85 30 6,7 8,9 18,19 X 10 10,12 10,12 11 11 
KYSE-30 Observed 28 9 8,9 16,18,19 X 10 10,12 11,11.3 9 11 
KYSE-30 Predicted474 - 9 8,9 16,18,19 X 10 10,12 11,11.3 9 11 
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Figure 3-1 Response of CP-A Cells to DNA Damage.  (A) CP-A cells were harvested at 24 hours after 
treatment, pellets lysed in urea buffer and 20 μg of protein (10 μg protein for HCT116 cells for p53 blot) 
used for SDS-PAGE (p53 - 12% agarose gel; p21 -15% agarose gel) and western blotting. After blocking 
in 5% Milk, PBS-T, membranes were probed with primary antibodies to p53 (DO-1) or p21 and then in 
both cases β-Actin.  Secondary incubations were with Anti-mouse800 (p53, B-Actin) and Anti-mouse680 
(p21).  HCT – urea lysate from HCT116 cells, 24 hours after gamma irradiation (10 Gy).  (B) Using Odyssey 
SA software, the band intensity (dominant band for p53) relative to β-actin from the same lane was 
used to quantify protein expression and then presented relative to the expression in untreated cells.  
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Figure 3-2  Comparison of the p53 response to DNA Damage in CP-A (A) and OE33 (B) Cell Lines. Cells were treated by gamma irradiation (10 Gy) and then harvested at 
fixed intervals. Pellets were lysed in urea buffer and 20 μg of protein (10 μg for HCT) used for SDS-PAGE (MDM2, p53 - 8% agarose gel; p21, BAX -15% agarose gel) and 
western blotting.  HCT - urea lysate from HCT116 cells harvested 24 hours after gamma irradiation (10 Gy). P - Purified recombinant p21 and MDM2 protein.  
Membranes were probed sequentially with primary antibodies to MDM2 and p53 (CM-1) or p21 and BAX and then, in both cases, β-Actin.  Secondary incubations were 
with Anti-mouse800 (MDM2, p21, β-Actin) and Anti-rabbit680 (p53, BAX).      
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Figure 3-3 Quantitation of Protein Expression from Figure 3-2.  The dominant band intensity was 
determined for each protein.  For MDM2 expression in CP-A cells, the ~90 kDa band corresponding to 
the lower band from HCT116 cells and of similar size to the purified recombinant MDM2 protein was 
quantified.  For p53 expression in CP-A cells, the dominant band corresponding to the p53 band in 
HCT116 cells was quantified.  Expression was normalised to β-actin from the same lane and then 
relative to the protein expression in untreated cells.        
3.3.2 Expression of PLK-1 in Oesophageal Cancer 
The expression of PLK-1 was next investigated across the oesophageal cell line 
panel.  PLK-1 expression was confirmed, as expected, to be higher in cells with 
mutant p53 (Figure 3-4)220.  To confirm this was not simply an in vitro artefact, the 
expression of PLK-1 was also examined in oesophageal tissue representing the stages 
of Barrett’s carcinogenesis.  The specificity of the PLK-1 antibody used for this 
study (clone 35-206) was first determined by transfection of CP-A cells with siRNA 
to PLK-1 and quantitative western blotting.   
Initial attempts at siRNA transfection in CP-A cells resulted in significant 
cytotoxicity, limiting the yield of cells and potentially leading to secondary, non-
siRNA mediated effects on gene transcription.  A comparison of transfection regimes 
was made with subjective visual assessment of cytotoxicity by light microscopy 
(Table 3-2).  This revealed RNAiMAX produced the least cytotoxicity in both CP-A 
and OE19 cells and this reagent was used for all subsequent experiments. 
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Figure 3-4 PLK-1 Expression in Oesophageal Cells.  Cells were harvested from subconfluent plates and 
lysed in urea buffer before SDS-PAGE (20 μg protein per lane, 10% agarose gel) and western blotting.  
Membranes were sequentially incubated with antibodies to PLK-1, anti-mouse800, β-Actin and anti-
mouse680. 
Table 3-2 Comparison of Cytotoxicity from Transfection Reagents.   
Cell Line 
Visual Assessment of Cytotoxicity, 48 hours after media supplementation.
(+++ = highly cytotoxic, - = no effect) 








2000 (0.25% v/v) 
RNAiMAX 
(0.325% v/v) 
CPA - +++ +++ ++ +
OE19 - + + +/- +/-
 
The specificity of the PLK-1 antibody (clone 35-206) was confirmed by the observed 
reduction in expression of the ~67 kDa band predicted to be PLK-1 after treatment 
with siRNA specific to PLK-1 (Figure 3-5).  As a positive control for transfection, 
CP-A cells were also treated with siRNA to GAPDH and this reduced the expression 
of the single ~35 kDa band detected, confirming both the transfection conditions and 
the specificity of this antibody towards GAPDH (Figure 3-5).    
There was also an apparent reduction in PLK-1 protein expression after transfection 
of non-targeting scrambled siRNA.  Off-target effects of siRNA have been widely 
reported in the literature and can be mediated by partial complementation of 
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scrambled sequences533,534.  Evaluation of PLK-1 mRNA expression was undertaken 
to examine this.    
Relative changes in PLK-1 mRNA levels between conditions can be determined by 
qRT-PCR if the PCR amplification efficiency is known.  The gradients of the linear 
regression lines from a cDNA dilution series were used to calculate the reaction 
efficiencies as; PLK-1 = 90%, AURKA = 91% and β-Actin = 91% (Figure 3-6).  For 
subsequent gene expression assays using this method, a reaction efficiency of ~90% 
was assumed.  As a further validation of the ΔΔCt method the ΔCt was found to be 
relatively constant for both PLK-1 and a second mitotic kinase; AURKA, across a 
wide range of input cDNA concentrations (Figure 3-6 (B)).  
Quantitative real-time PCR was undertaken to confirm that the siRNA pools 
targeting PLK-1 and GAPDH specifically reduced PLK-1 and GAPDH mRNA 
levels and to investigate if non-targeting siRNA reduced PLK-1 mRNA expression.  
This demonstrated that both gene-specific siRNA pools significantly reduced 
expression but both the non-targeting, scrambled siRNA sequence and the siRNAs 
directed against GAPDH were associated with lower PLK-1 gene expression (Figure 
3-7).  This provides evidence for a non-specific effect of siRNA transfection on 
PLK-1 expression.    
The relative expression of PLK-1 was next examined in tissue cores from an 
oesophageal tissue microarray.  The same antibody confirmed to be specific for 
PLK-1 by western blot was used for IHC and, after optimisation of staining 
conditions, slides containing cores representing normal oesophagus (n=6), Barrett’s 
(n=3) and OAC (n=12) were stained (Figure 3-8). 
This revealed the majority of cells were negative for PLK-1 in normal squamous 
oesophagus.  A few scattered PLK-1 positive cells were noted predominantly in the 
basal proliferative zone (Figure 3-8 (i)).  Similarly in Barrett’s crypts, a few isolated 
clusters of positive cells were noted but the majority were negative for PLK-1 (lower 
half of the core in Figure 3-8 (ii)).  The OAC tissue, in contrast, revealed a higher 
frequency of PLK-1 positive cells. There was a more heterogenous staining pattern 
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across the OAC tissues with a range from ~10% to >50% of cells staining strongly 
positive (Figure 3-8 (iii), (iv)).  Although the number of tissue samples assessed was 
relatively small, these data suggest that PLK-1 is over-expressed in OAC relative to 
surrounding normal tissues and that the oesophageal cell line panel may recapitulate 
the in vivo expression pattern.  
Loss of p53 has been associated with upregulation of PLK-1 in vitro and this may 
explain the cell line and oesophageal tissue findings.  Clarifying the relationship 
between p53 mutation and PLK-1 expression in vivo may allow those tumours with 
the highest PLK-1 expression, and potentially greatest sensitivity to PLK-1 
inhibitors, to be identified using genetic testing. 
 
 
Figure 3-5 Protein Expression in CP-A cells after siRNA Transfection. (A) Cells were transfected with 
vector only, a scrambled non-targeting sequence (NTC), or siRNA targeting GAPDH or PLK-1 and 
harvested after 48 hrs.  Pellets were lysed in Urea buffer before SDS-PAGE (20 μg protein per lane, 10% 
agarose gels) and western blotting.  Membranes were sequentially incubated with antibodies to PLK-1 
or GAPDH and then anti-mouse800 followed by β-Actin and anti-mouse680. (B)Protein expression 
normalised to β-actin and relative to vector treated cells.    
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Figure 3-6 Evaluation of qRT-PCR Performance.  (A) Efficiency of qRT- PCR was calculated using a 
dilution series of cDNA from a single stock.  Points and error bars represent the Mean +/- SEM from 3-4  
technical  replicates.  Linear regression after log10 transformation of cDNA concentrations revealed 
gradients and R2  of; PLK-1 = -3.591, R2 = 0.9954; AURKA =-3.556, R2 = 0.9919; β-Actin = -3.565, R2 = 
0.9924.   (B) Calculation of gene  expression using ΔCt of PLK-1 or AURKA relative to β-Actin over a range 
of input cDNA concentrations.  Best fit linear regression lines are illustrated.  
      
Figure 3-7 Effect of siRNA on Gene Expression in CP-A cells.  RNA extracted from cell pellets treated 
identically to those from Figure 3-5 were used for qRT-PCR assays.  Bars represent mean +/- SEM from 
technical quadruplicates.   
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Figure 3-8  The Expression of PLK-1 in Oesophageal Tissue Cores .One hundred fold magnification 
images representative of; (i) normal squamous oesophagus - 6 cores; (ii) non-dysplastic Barrett’s -  3 
cores; (iii) + (iv) OAC - 12 cores.  The arrow represents the squamous epithelial basal proliferative zone. 
A tissue microarray created from a large cohort of oesophageal adenocarcinomas was 
used to determine the expression of PLK-1 in oesophageal tissues with wild-type and 
mutant p53.  The TP53 genotype for these tumours was unknown.  A method of 
inferring the genotype from the p53 immunohistochemical staining pattern has, 
however, been reported193.  This relies on stabilisation of mutant p53 protein which is 
detected as nuclear over-expression in tissue sections206.  The availability of highly 
sensitive and specific antibodies to p53 allows the detection of low level wild-type 
expression535,536.  This allows TP53 deletion mutants to be detected due to the 
absence of protein expression in comparison to wild-type stromal expression.  Co- 
staining with the p53 transcriptional targets p21 and MDM2 has been reported to 
improve the prediction of wild-type and null status in selected cases. 
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3.3.3 Determining TP53 genotype in OAC using IHC 
The p53 staining pattern was determined in a tissue microarray consisting of 
triplicate cores from 356 oesophageal adenocarcinomas.  Example staining patterns 
for tumours predicted to have p53 deletion mutations (null), p53 wild-type (wt) and 
mutant (mt) genotypes are demonstrated in Figure 3-9.   
During the TMA construction, three cores from each tumour were cut and were 
embedded on separate TMAs.  Sections from each of these arrays were stained and 
the core images distributed to two independent scorers (this author and Dr. Rudolf 
Nenutil, Pathologist, Brno, Czech Republic), blinded to the location of the replicate 
cores on the arrays. Although triplicate cores were cut from each tumour, not all 
cores contained diagnostic material and some cores were lost during the staining 
process, reducing the total number of scorable cores.  The correlation between 
predicted genotypes from both scorers was assessed (Table 3-3).   
Table 3-3 Inter-observer Correlation of Predicted TP53 Genotypes for OAC TMA cores 
   Observer 2 
(expert) 
 
  Wildtype Mutant Null 
 Wildtype 106 30 8 
Observer 1 
(non-expert) 
Mutant 49 501 0 
 Null 0 0 186 
    
The kappa statistic for the prediction of genotype across 880 scorable cores was 
0.8194, indicating excellent inter-observer agreement.  Disagreements generally 
arose from the classification of intermediate staining tumours as either wild-type or 
mutant and low staining tumours as either wild-type or null.  Further staining with 
antibodies to p21 and MDM2 was not undertaken due to limitations of material but 
may have helped to resolve these classifications. 
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Total Allred histoscores for p53 were also compared for these cores.  The inter-
observer spearman correlation coefficient was 0.900 for individual cores and 0.8880 
for the median score per tumour (both p<0.0001).  This indicates p53 IHC is robust 
enough to be reliably applied by both expert histopathologists and non-expert 
scorers.  When the p53 histoscores were plotted, three peaks in frequency were 
demonstrated corresponding to predicted mutant, wild-type and null (Figure 3-10A).  
Although inter-observer agreement was excellent, discordant genotype predictions 
within the three cores from the same tumour were observed.  These are likely to be 
due to a combination of genetic and staining heterogeneity and both intra and inter-
observer variability.   
As the contribution of each of these factors was unknown, tumours were classified as 
having either confident or low-confidence genotypes.  Tumours with confident p53 
genotypes were defined as having unanimous predictions from both scorers across all 
cores (n=208).  The remaining tumours were considered to have low-confidence 
genotypes (n=148).  The median histoscores for tumours with confident predicted 
p53 genotypes formed more distinct groups corresponding to mutant, wild-type and 
null genotypes (Figure 3-10B).   
The accuracy of genotype predictions was assessed using actual p53 genotypes from 
22 tumours present on the array that had been subjected to whole-genome 
sequencing.  When the IHC data for these tumours were examined, three groups of 
median histoscores corresponding to wild-type, mutant and null were evident with 
some overlap in the classifications (Figure 3-10C).  The separation of histoscores 
became clearer although still not definitive when only those tumours with confident-
predicted genotypes were considered.  This may reflect subtle interpretation of the 
subcellular staining pattern by the observers during the determination of predicted 
p53 genotype.   For example, moderate nuclear positive p53 staining was considered 
more likely to represent a p53 mutation than cytoplasmic staining.  The accuracy of 
classifications using confident-predicted genotypes was assessed from the predicted 
and actual genotypes (Table 3-4). 
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 Table 3-4 Comparison of Actual and Predicted Genotypes 
  Confident Predicted Genotype 
  Wildtype Mutant Null 
Actual 
Wildtype 1 1 0 
Mutant 0 10 3 
 
From these data the confident prediction of mutant p53 genotype is 100% sensitive 
and 93% specific for actual p53 mutation.  Only limited conclusions can be drawn 
from this analysis as the frequency of wild-type tumours was low.  Using confident 
predicted genotypes across the OCCAMS TMA, only 10.1% of tumours were 
predicted to have the wild-type allele with 20.2% predicted to have mutations leading 
to loss of p53 expression and the remainder predicted to have stabilising mutations.      
 
3.3.4 Expression of PLK-1 in OAC according to TP53 genotype 
The classification of tumours into predicted p53 wt, mt and null by IHC was 
considered acceptably accurate and the expression of PLK-1 was determined by IHC 
on the same array.  Inter-observer variability was higher but still acceptable for PLK-
1 scoring (Spearman correlation coefficient for median tumour PLK-1 histoscore = 
0.5156; p<0.0001).  In contrast to p53 histoscores, there was an approximately 
Gaussian distribution of PLK-1 histoscores (Figure 3-11A).            
This pattern was observed because all tumours exhibited some PLK-1 staining and 
the main source of variation was in the frequency of positive cells.  When median 
PLK-1 histoscores were compared between groups defined by predicted TP53 
genotype, those tumours with predicted mutant p53 exhibited significantly higher 
PLK-1 expression (Figure 3-11B, p=0.0448).   
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Figure 3-9 Representative Images of TMA Cores Stained for p53. Cores were predicted to have (A) p53 null, (B) p53 wt and (C) p53 mt genotypes.
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Although only tumours with confident predicted TP53 genotypes were used in this 
comparison and the validity of this method is proposed, the p53 genotype of this 
cohort has not been definitively determined.  No large cohort of TP53 genotyped 
OACs was available to assess PLK-1 expression.  In an attempt to validate these 
findings and assess their applicability outside oesophageal cancer, the correlation of 
PLK-1 expression and TP53 status was tested in an external cohort of ovarian 
cancers with known TP53 genotypes.  
PLK-1 expression also followed Gaussian distribution in ovarian tumours (Figure 
3-11C).  When median ovarian tumour PLK-1 histoscores were compared between 
groups defined by actual TP53 genotype, PLK-1 expression was again found to be 
significantly higher in tumours with mutant p53 (Figure 3-11D, p=0.0279).   
The differential expression of PLK-1 in OAC compared to surrounding tissues may 
represent a unique dependency on PLK-1 for proliferation or cell survival.  This 
could be tested by examining the viability of cells representing the stages of 
oesophageal carcinogenesis after reduction of PLK-1 levels by siRNA.  To undertake 
this, a viability assay demonstrating a linear response with cell number was required. 
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Figure 3-10 Distribution of OAC p53 histoscores from the OCCAMS TMA. The median p53 histoscore across all cores, from both scorers is plotted. (A) All tumours (n = 
356). (B) Tumours with confident (unanimous) predicted genotypes. (C) The median histoscores of tumours with confirmed p53 genotypes from genome sequencing.  
Those tumours with confident predicted (n = 15) and low-confidence predicted genotypes from IHC (n = 7) are highlighted.
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Figure 3-11 PLK-1 Expression in OAC and Ovarian Tumours. (A) Median PLK-1 tumour histoscore from 
two independent observers (B) Scatterplot of median PLK-1 histoscores in tumours classified according 
to predicted TP53 genotype (confident predictions only n=208).  (C) Median PLK-1 histoscore in ovarian 
tumours with known TP53 genotypes (n=99). (D) Scatterplot of median PLK-1 histoscores in tumours 
classified according to actual TP53 genotype. (B,D) Grey bars represent median value, * p=0.0448, 
**p=0.0279.                            
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3.3.5 Identification of an Optimal Viability Assay   
The CellTiter-Glo assay was initially tested and provided a linear response with 
increasing cell number (r2>0.99, Figure 3-12).  Assays relying on luminescence 
detection are often performed in white opaque plates to enhance signal detection.  
Unfortunately these plates do not allow periodic monitoring of cell growth in culture.  
To compare the effect of plate type on CellTiter-Glo readings, reaction mixtures 
from the CellTiter-Glo assay were transferred from the clear-bottomed, black-walled 
wells of a 96-well tissue culture plate to the white-walled, white-bottomed wells of a 
96-well plate and luminescence re-measured.  An approximately 10-fold increase in 
signal intensity was observed when the white plates were used (data not shown).  
When the relative signal intensities were compared, however, no change in the 
response of the assay was detectable between plates (Figure 3-12 A).  This indicates 
reliable performance with oesophageal cells in a 96-well format.  
The disadvantage of the CellTiter-Glo assay is that the reagent lyses cells and 
therefore only provides endpoint measurements.  Preliminary experiments 
demonstrated variability in seeding density across cell lines due to difficulties in 
generating a uniform single cell suspension.  By measuring final cell number only, 
variations in initial seeding density are not controlled.  Determining the final cell 
number relative to the initial cell number was thought to be relevant as treatments 
that reduce the cell number below the initial seeded number were considered “truly” 
cytotoxic.  In contrast, treatments that produce a reduction in cell number compared 
to untreated cells but allow an increase in cell number from baseline were considered 
either partially cytotoxic or cytostatic.   
The AlamarBlue reagent is reported to be water-soluble and non-toxic in both the 
native and the reduced fluorescent form486.  This allows the reagent to be washed off 
by serial dilution in fresh tissue culture medium and allowed an initial measurement 
of cell number after cells have adhered to tissue culture plates and before treatment.  
After the treatment period a final cell number measurement can be taken, allowing 
the effect of the treatment to be normalised for initial cell number on a well by well 
basis and revealing both growth inhibitory and truly cytotoxic phenotypes. 
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Figure 3-12 Comparison of CellTiter-Glo and AlamarBlue.  CP-A cells were seeded into clear-bottomed 
black-walled 96 well plates at a range of densities and incubated for 24 hours.  (A) Luminescence was 
measured (arbitrary units) after addition of CellTiter-Glo reagent.  Reaction mixtures were transferred to 
white 96-well plates and luminescence measured again.  Background corrected luminescence was 
normalised to the maximum value.  (B)  For the Initial Alamar experiment, an AlamarBlue measurement 
was taken 24 hours after seeding, the cells washed and then incubated in fresh medium for a further 72 
hours  followed by a final AlamarBlue measurement.  Alternatively a final AlamarBlue measurement 
was taken 96 hours after seeding without an initial Alamar measurement or a change of medium.  
Background-corrected fluorescence from the final AlamarBlue measurement is plotted.  (A,B) Points 
represent trimmed means +/- SD from 8 technical replicates. Linear regression lines are displayed. (B) 
The gradients of best fit lines were not significantly different (ANOVA, p=0.8847).     
    
Figure 3-13 AlamarBlue Response in Oesophageal Cells.  Cells were plated in poly-L-Lysine coated clear-
bottomed, black-walled, 96-well plates and allowed to adhere for 24 hours.  An AlamarBlue 
measurement was taken and background-corrected fluorescence calculated. Best-fit linear regression 
lines are shown.  Points represent trimmed mean +/- SEM of 8 technical replicates.      
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Using CP-A cells, AlamarBlue was found to produce a linear response with 
increasing cell number, similar to CellTiter-Glo (Figure 3-13B). Importantly, an 
initial measurement of cell number followed by reagent wash-off did not 
significantly affect the final viability measurement compared to untreated cells 
(Figure 3-12 B).  A linear response with increasing cell number was also 
demonstrated in primary oesophageal cells (Figure 3-13 A), and OE33 cells (Figure 
3-13 C) with a low coefficient of variation and excellent assay performance (Z-factor 
0.736-0.954).  As a further control, wells treated with a non-ionic surfactant to 
induce cell death (5% v/v final concentration Triton-X-100) exhibited minimal 
AlamarBlue-induced fluorescence above background (data not shown).  This 
confirms AlamarBlue allows specific and accurate measurement of viable cell 
number and this method was employed for subsequent viability assays.      
3.3.6 The Effect of PLK-1 siRNA on Viability 
The effect of selective PLK-1 gene knockdown on oesophageal cell viability was 
examined using the AlamarBlue method to enable a comparison of final and initial 
cell number.  The optimised siRNA transfection regimen expected to significantly 
reduce PLK-1 expression at the mRNA and protein level was used (Figure 3-5, 
Figure 3-7).  Knock-down of PLK-1 significantly reduced cell number compared to 
transfection vector and scrambled siRNA treated CP-A, OE19 and KYSE-30 cells 
(Figure 3-14).  When the same transfection protocol was applied with HEEpiC and 
OE33 cells, the transfection reagent induced significant cytotoxicity so that the effect 
of the siRNA could not be confidently determined (Figure 3-15 A).  Attempts with 
other lipid-based transfection reagents produced similar results.   
Cell-permeant siRNA (Accell®, Dharmacon) does not require lipid-mediated 
transfection and early reports of its use have suggested high transfection efficiency in 
primary cells, with reduced cytotoxicity compared to other transfection regimes537.  
Accell siRNA uptake efficiency was assessed by transfection of FAM-labelled 
scrambled siRNA with blue and white light bright-field images captured at 48 hours.  
This demonstrated uptake of the fluorophore in the majority of cells, suggesting the 
transfection protocol was effective (Figure 3-15 C,D).   
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Accell siRNA was then transfected into OE33 and HEEpiC cells and significantly 
reduced cytotoxicity compared to RNAiMAX was observed (Figure 3-15 B), 
although there was still a significant reduction in cell number compared to untreated 
controls.  When a pool of siRNAs to PLK-1 was transfected, viability was further 
reduced compared to non-targeting scrambled sequence siRNA and siRNA to 
GAPDH in both HEEpiC and OE33 cells.  In HEEpiC cells, siRNA to GAPDH also 
reduced viable cell number compared to a non-targeting control.  This may be a 
consequence of the sensitivity of HEEpiC cells to transfection, dependency on 
GAPDH for proliferation or off-target effects of the siRNA. 
From these data, transfection of siRNA to PLK-1 reduced viable cell number in all 5 
cell types tested.  The magnitude of reduction with respect to baseline cell number 
was, however, variable.   
 
Figure 3-14 The Effect of siRNA to PLK-1 on Oesophageal Cell Viability.  After a baseline viability 
measurement using AlamarBlue, cells were treated with unsupplemented complete medium (No 
Treatment), RNAiMAX (Vector), scrambled non-targeting siRNA (NTC), or  siRNA targeting GAPDH or 
PLK-1.  Viability was assessed at 96 hours post-transfection and was normalised to No Treatment values.  
Bars represent mean +/- SEM of 6-12 technical replicates.  The baseline viable cell number relative to the 
final viable cell number is presented for comparison. *, **, *** p<0.001 (unpaired, two tailed student’s t-
test), compared to vector treated cells.
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Figure 3-15 (A, B) Comparison of the Effect of RNAiMAX (A) and Accell siRNA (B) on Viability at 96 hours.  The experimental protocol was identical to Figure 3-14.  NTC = 
non-targeting control siRNA.  Bars represent mean +/- SEM of 6-12 technical replicates.  Baseline viability is presented for comparison.  *siPLK-1 vs NTC, p=0.0011, 
**siPLK-1 vs. NTC p<0.001, (both unpaired, two-tailed student’s t-test).  (C, D) Assessment of Accell transfection efficiency.  HEEpiC cells were transfected with FAM-
labelled (C) or unlabelled (D) non-targeting scrambled sequence siRNA.  After 48 hours the medium was exchanged and images acquired using a digital camera and 
an inverted phase-contrast microscope with either white light (left images) or blue/UV light illumination at low power (C, 10x objective) or high power (D, 40x 
objective). 
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3.3.7 Combining Viability and Gene Expression Measurements  
To correlate the degree of PLK-1 suppression with viability, the In-Cell Western 
method was applied.  In this technique, cells are fixed and permeabilised after siRNA 
treatment and viability measurement and then quantitative immunofluorescence 
performed to measure protein expression.    The permeabilisation stage of the In-Cell 
Western method required several washes with detergent containing buffer.  Despite 
coating the 96 well plates with poly-L-Lysine, most OE33 cells detached during this 
process and the In-Cell Western method was deemed unfeasible for this cell type. 
To test the robustness of this method, protein expression was measured for several 
proteins by measurement of fluorescence at 800 nm from conjugated secondary 
antibodies.  The ratio of fluorescence at 800 nm to fluorescence at 700 nm from the 
DNA stain, DRAQ5 was calculated for a range of cell densities.  It was assumed that 
for most genes, protein expression should remain constant relative to cell number 
across a range of subconfluent cell densities in 96 well plates.  Changes in viable cell 
number should not therefore change relative protein expression.  For comparison of 
viable cell number measurements, fluorescence at 800 nm was also normalised to 
relative viability assessed by AlamarBlue assay prior to In-Cell Western.   
Data were obtained for both CP-A and OE19 cells with minimal background 
fluorescence detectable in the secondary only and no-cell controls (Figure 3-16 A).  
Despite the favourable signal to noise ratio for fluorescence detection, there was 
significant variability in the 800/700 ratios across the cell densities (Figure 3-16 B).  
No pattern was observed with increasing cell number for any of the primary 
antibodies.  The CP-A cells proved more reliable than the OE19 cells, potentially due 
to the flat epithelial growth pattern and resistance to detachment.   
The variability in response was also evident when AlamarBlue fluorescence was 
used to normalise for cell number confirming that DRAQ5 fluorescence was not the 
only source of variation.  The difference in variability between primary antibodies 
suggests either the target proteins exhibit highly variable expression pattern or the 
variability is due to the indirect method of protein detection.  To confirm reduced 
protein expression after siRNA treatment, the In-Cell Western technique would need 
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to demonstrate accurate and sensitive measurement across oesophageal cell lines.  
These data do not support this.  To measure viability and confirm gene knockdown 
after siRNA treatment, parallel experiments in 6-well plates with identical conditions 
were therefore performed.  
Due to the effect of PLK-1 gene knock down on cell number, there were insufficient 
cells remaining 96 hours after treatment to allow RNA and protein expression 
analysis.  To confirm sufficient gene knockdown, protein and RNA expression were 
therefore assessed 48 hours after treatment.   
Using the optimised cell-specific siRNA conditions, PLK-1 gene expression could be 
effectively suppressed in all cell types and a corresponding significant reduction in 
viable cell number was observed after 96 hours treatment (Figure 3-17).  A reduction 
in PLK-1 mRNA expression but not viability was observed with non-targeting 
siRNA transfection in CP-A, OE19 and KYSE-30 cells.   
These data support the critical role of PLK-1 in oesophageal cell proliferation.  PLK-
1 has been reported to mediate cell cycle effects through both protein-protein 
interactions and substrate phosphorylation232,538. A reduction in protein expression 
would affect both mechanisms.  The role of substrate phosphorylation can be 
specifically investigated using inhibitors of PLK-1 kinase activity. 
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Figure 3-16 Evaluation of the In-Cell Western Method to combine viability and protein expression measurement.   Cells were seeded at a range of densities including a 
no cell control (Media) by serial dilution from the same cell solution and grown in standard media for 48 hours. AlamarBlue and then In-Cell Western assays were 
performed.  (A) Licor scan images obtained after In-Cell Western of OE19 cells using DRAQ5 and antibodies to GAPDH, AURKA (NEB, #4718) or secondary antibody 
only. (B) Scatterplots of 800/700 nm ratios for OE19 and CPA cells across the range of densities after In-Cell Western with antibodies to AURKA NEB (#4718), AURKA AB 
(ab52973), GAPDH or PLK-1. Bars represent medians with coefficient of variation (CV) presented as a percentage of the median.  (C) Scatterplots of 800 nm AlamarBlue 
Fluorescence after In-Cell Western in OE19 cells using the same conditions as (B). 
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Figure 3-17 The Effect of siRNA to PLK-1 on Oesophageal Cell Viability.  (A)Cells were treated in 96-well 
plates. Vector = RNAiMAX; CP-A, OE19, KYSE-30 or complete medium; HEEpiC, OE33. NTC = Non-
targeting scrambled RNA (Dharmacon; CP-A, OE19, KYSE-30 or Accell; HEEpiC, OE33). siPLK-1 = a pool of 
4 siRNAs targeting PLK-1 (Dharmacon; CP-A, OE19, KYSE-30 or Accell; HEEpiC, OE33). Viability was 
assessed using the AlamarBlue method at 96 hours post-transfection.  Bars represent trimmed mean of 
≥ 8 technical replicates +/- SEM.  (B,C) Cells were treated in 6 cm plates using identical conditions to (A), 
harvested for RNA (B) or protein (C) extraction at 48 hours post-transfection.  (B) RNA expression was 
determined by qRT-PCR.  Bars represent mean +/- SEM of 4 technical replicates.  (C) Lysates (30 μg 
protein per lane)  were resolved by SDS-PAGE (8% gels) and subject to quantitative western blotting by 
sequential incubation with primary antibodies to PLK-1, Anti-mouse800, β-Actin and Anti-Mouse680 
antibodies (Odyssey SA, Licor Biosciences).  The image is a cropped membrane scan (100 μM resolution) 
from the 800 nm (green) and 700 nm (red) channels. *p<0.001, **p=0.012 compared to vector treated.          
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3.3.8 Evaluation of PLK-1 Inhibitors 
The first in class PLK-1 inhibitor, BI2536, mimics the response of cells to PLK-1 
RNA depletion and is a potent and specific inhibitor of polo-like kinases290.  For this 
study, a novel PLK-1 inhibitor was also obtained with a shorter half-life and a greater 
specificity for PLK-1 over other polo-like kinases (PLK-1A).  This compound is 
derived from a pyrimido-diazepinone scaffold and, similar to BI2536, competes with 
ATP for the ATP-binding domain of PLK-1539.  This blocks the kinase activity but 
not protein interactions with the polo-box domain.  The PLK-1A compound is 
reported to have greater selectivity for PLK-1 over other polo-like kinases compared 
to BI2536 (Table 3-5)540.  Human pharmacokinetic data are not yet available for 
PLK-1A as the compound has not yet been tested in phase I trials, but the half-life 
(t1/2) in rats is reported as 0.3 hours.  A study using animal pharmacokinetic data 
from 30 compounds and comparing various prediction models found human drug 
half-life could be predicted, with an average 1.79 fold error, from the function; 
 
	 0.906	 	 0.723 
Equation 9 Prediction of Human Drug Half-life from Rat Data (from Reference541) 
 
 
Using this function, an appropriate drug dosing regimen could be predicted in 83% 
of cases.  Applying this equation, the predicted human half-life would be 1.8 hours 
(estimated error range 1 – 3.2 hours).  A comparative study of platinum-based 
compound plasma half-lives reported a 1.25-2.9 fold increase in half-life in humans 
compared to mice542.  Directly translating these data and assuming drug half-lives in 
mice and rats are equivalent, the predicted human plasma half-life after intravenous 
infusion of PLK-1A would be between 0.4-0.9 hours. In either case, BI2536 would 
be predicted to have a roughly 10 fold greater half-life in vivo.     
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Table 3-5 Properties of PLK-1 Inhibitors – Adapted from Reference540  
Compound 
IC50 (nM) for Polo-like Kinases 
Plasma Terminal 
Elimination            
Half-life (hr) 
Kinase 
PLK-1 PLK-2 PLK-3 
PLK-1A 14 (1x) 231 (17x) 206 (15x) Rat = 0.3 
BI2536 7 (1x) 20 (3x) 11 (1.5x) Human = 20-30hrs315 
     
To confirm the inhibitors produced the expected phenotype, cells were treated for 24 
hours and cell cycle changes profiled by flow cytometry after propidium-iodide 
staining543.  Both the PLK-1 inhibitors produced an accumulation of 4N cells 
consistent with activation of the G2/M checkpoint (Figure 3-18).  This was noted in 
non-transformed and cancer cell lines and suggests that the tested compounds are 
bona fide PLK-1 inhibitors. 
 
Figure 3-18 The Effect of PLK-1 Inhibitors on Oesophageal Cell Cycle Stage.  Cells were synchronised by 
serum or supplement starvation and then released into complete medium with either DMSO, PLK-1A (1 
μM) or BI2536 (50 nM).  Cell cyle profiles were then determined after 24 hours by propidium iodide 
staining and flow cytometry.  Results are representative of two biological replicates.    
The effects of the PLK-1 inhibitors on viability were next examined in oesophageal 
cells using the AlamarBlue method.  This revealed dose-dependent reduction of 
viable cell number for both PLK-1A and BI2536 in all oesophageal cell types (Figure 
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3-19, Figure 3-20).  Comparing initial and final cell numbers after 96 hours of 
treatment, both PLK-1A and BI 2536 appear to induce a reduction of proliferation 
rather than true cytotoxicity.       
To confirm a cytotoxic phenotype could be detected using the AlamarBlue method, 
cells were treated with the DNA-crosslinking agent Cisplatin.  This drug forms the 
basis for the current neoadjuvant and palliative chemotherapy regimens used in 
oesophageal cancer and is cytotoxic to proliferating cells due to the formation of 
DNA-adducts and the induction of apoptosis544.  Unfortunately, the therapeutic 
efficacy of this drug is limited by a number of side-effects including nephrotoxicity, 
neurotoxicity and ototoxicity545.  All oesophageal cells tested exhibited dose-
dependent cytotoxicity with Cisplatin treatment, providing evidence this method may 
allow the discrimination of cytotoxic and cytostatic drug effects (Figure 3-21). 
When the relative responses of the cell lines were considered, cancer cell lines were 
more sensitive to PLK-1 inhibitors than HEEpiC cells (Table 3-6).  The Barrett’s cell 
line CP-A and the cancer cell lines demonstrate an equivalent sensitivity to BI2536 
whereas the CP-A cell line was marginally less sensitive to PLK-1A than the cancer 
cells, although the relative differences in sensitivities are small.  In contrast, the 
cancer cell lines and non-transformed cells exhibited similar sensitivities to Cisplatin, 
confirming non-selective activity of this drug.  
Table 3-6 Comparison of IC50 Values Across Oesophageal Cell Types 
 HEEpiC CP-A OE33 OE19 KYSE-30 
BI2536         
IC50 (nM) 




0.50         
(0.32-0.78) 
0.36         
(0.24-0.46) 
0.54         
(0.36-0.72) 
0.55         
(0.36-0.74 
PLK-1A        
IC50 (nM) 




0.71         
(0.48-0.94) 
0.50         
(0.33-0.67) 
0.42         
(0.27-0.57) 
0.48         
(0.32-0.63) 
Cisplatin     
IC50 (μM) 




0.97         
(0.69-1.24) 
1.34         
(0.88-1.81) 
1.81         
(0.67-2.94) ~0.30
* 
Values in parentheses are 95% Confidence Intervals. *Approximate value only as poor quality curve fit 
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Figure 3-19 The Effect of BI2536 on Oesophageal Cell Viability.  Cells were seeded in 96-well plates (HEEpiC – 10,000 cells per well, CP-A - 2,000 cells per well, OE19, 
OE33, KYSE-30 – 5,000 cells per well) and viability was measured after 24 hours (baseline viability).  BI2536 dilutions or DMSO were added and viability was measured 
again at 96 hours after treatment. Points represent trimmed mean values (+/- SEM) from 4 biological replicates each consisting 8 technical replicates.  Means were 
normalised to baseline viability and then DMSO treated controls.   IC50 values, 95% confidence intervals (in parenthesis) and the R2 for best fit curves are displayed.      
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Figure 3-20 The Effect of PLK-1A on Oesophageal Cell Viability.  Cells were seeded in 96-well plates (CP-A - 2,000 cells per well, HEEpiC – 10,000 cells per well, OE19, 
OE33, KYSE-30 – 5,000 cells per well) and viability was measured after 24 hours (baseline viable cell number).  PLK-1A dilutions or DMSO were added and viability was 
measured again at 96 hours after treatment.  Points represent trimmed mean values (+/- SEM) from 4 biological replicates each consisting 8 technical replicates.  
Means were normalised to baseline viability and then DMSO treated cells.   IC50 values, 95% confidence intervals (in parenthesis) and the R2 for best fit curves are 
displayed. 
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Figure 3-21 The Effect of Cisplatin on Oesophageal Cell Viability. Cells were seeded in 96-well plates (HEEpiC – 10,000 cells per well, CP-A - 2,000 cells per well, OE19, 
OE33, KYSE-30 – 5,000 cells per well) and viability measured after 24 hours (baseline viable cell number).  Cisplatin dilutions or PBS were added and viability was 
measured again at 96 hours after treatment.  Points represent trimmed mean values (+/- SEM) from 1 experiment consisting 8 technical replicates.  Means were 
normalised to baseline viability and then DMSO treated controls.   IC50 values, 95% confidence intervals (in parenthesis) and the R2 for best fit curves are displayed.
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Evaluation of Polokinase 1 as a Therapeutic Target in OAC  177 
These data suggest oesophageal cancer and Barrett’s cells may be more sensitive to 
PLK-1 inhibition than HEEpiC cells.  The therapeutic window, although narrow on 
the basis of the AlamarBlue data alone, suggests that tumour-specific effects may be 
achievable with careful dosing schedules.  The dose-responses observed are in the 
constant presence of the inhibitor.  This phenotype may not be observed, however, 
with the fluctuating tumour drug concentrations observed in vivo.  
A colony formation assay was performed to investigate if the therapeutic window 
was altered after drug removal.  Cells were incubated in PLK-1 inhibitor or vehicle 
for 72 hours, trypsinised and seeded in fresh media at several densities (Figure 3-22).   
This revealed complete inhibition of colony formation after treatment with 100 nM 
BI2536 in OE33 and CP-A cells and in contrast, no appreciable reduction in colony 
formation at 10 nM.  This pattern of sensitivity closely correlates with the 
AlamarBlue dose-response curves (Figure 3-19).  The OE19 cell line also showed a 
significant reduction in colony formation at the higher BI 2536 dose and only a small 
reduction in colony number at 10 nM (Figure 3-22).  In contrast the OE33 cells 
appeared more sensitive to PLK-1A treatment than CP-A cells with OE19 cells 
showing an intermediate response. 
The complete inhibition of colony formation is surprising as the AlamarBlue dose-
response curves suggested both inhibitors significantly reduce but do not abolish 
proliferation.  In the colony formation assay, all of the plates were seeded with viable 
cells as assessed by trypan blue exclusion.  Even in the absence of proliferation, 
some staining would be expected.  The combination of trypsinisation and drug 
removal appears to induce cell death.     
To investigate if drug removal alone reduces viable cell number, the AlamarBlue 
method was adapted for a death commitment assay (DCA).  In this assay, 
AlamarBlue measurements were taken before drug addition, after 24 hours of drug 
exposure and again 72 hours after either continued drug exposure or after drug 
withdrawal.  If fewer viable cells were present at the end compared to the interim 
point this suggested cell death was occurring546.         
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Figure 3-22 Colony Formation Assay After PLK-1 Inhibitor Treatment. Cells were treated with a PLK-1 inhibitor or vehicle at the doses shown and then trypsinised and 
equal numbers of viable cell seeded in fresh media.  Plates at each seeding density were fixed and stained for colonies when vehicle treated cells approached 
confluence.  Seeded viable cell number; A = 1x104 (CP-A, OE33), 5x104 (OE19); B = 1/10 dilution of A; C = 1/100 dilution of A.  Images representative of 2 independent 
experiments.       
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Figure 3-23 Death Commitment Assay After 24 hours PLK-1 Inhibitor Treatment.  Cells were treated with BI2536 or PLK-1A for 24 hours and then either treated with 
fresh media or drug at the same concentration for a further 72 hours.  Points represent trimmed mean change in viability from the interim point (after 24 hours drug 
treatment) +/- SEM from 8 technical replicates from 2 independent experiments.  Values have been normalised so 100% on the Y-axis represents the pre-treatment 
viable cell number. 
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After treatment with PLK-1A for 24 hours, further drug treatment did not change cell 
proliferation compared to media alone in CP-A cells (Figure 3-23).  In contrast in 
OE33 and OE19 cells, pulsed PLK-1A exposure appeared to enhance the anti-
proliferative effect compared to persisting treatment.   
The results of treatment with BI2536 in the DCA show some similarity with those of 
PLK-1A.  At higher doses with both treatments, there is little additional cell growth 
in any of the oesophageal cells after 24 hours drug exposure regardless of subsequent 
treatments.  The results from treatment with lower doses of BI2536 appear to show 
proliferation in all the cell types with an enhanced anti-proliferative effect after 
pulsed exposure in the CP-A and OE19 cells and reduced effect in the OE33 cells. 
Real-time imaging of PLK-1 inhibitor uptake and removal in cells is not currently 
possible.  To explore if the wash-off protocol was adequate to allow drug removal, a 
compound that exhibited a reversible growth phenotype was required.  The MDM2 
antagonist Nutlin-3A has been reported to induce a reversible growth arrest in 
epithelial cancer cell lines with wt p53 but not those with mutant p53547,548.  This is 
thought to be secondary to selective p53-induction due to the blockade of the 
MDM2-p53 interaction which usually leads to p53 degradation.  The effect of 
Nutlin-3A on viability was examined in oesophageal cells.   
This revealed dose-dependent cytotoxicity in all three cell types with a 6 fold and 2.5 
fold greater sensitivity in the CP-A (wt p53) cells than OE33 and OE19 cells (both 
mutant p53) respectively (Figure 3-24).  The death commitment assay revealed 
proliferation to a similar extent in all cells when washed and grown in fresh medium, 
irrespective of the prior dose of Nutlin-3A.  This suggests the washing protocol in the 
DCA is sufficient to remove a drug and allow growth recovery.  
Given the proliferation of cells after Nutlin-3A removal, the enhanced proliferation 
of CP-A and OE19 cells treated continuously with low doses Nutlin-3A compared to 
those treated with pulsed Nutlin-3A is surprising.  This suggests either low dose 
Nutlin-3A promotes growth or, as previously, there may be a systematic bias towards 
reduction in observed viable cell number with pulsed drug exposure in the DCA. 
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Figure 3-24 Effect of Nutlin-3A on Oesophageal Cell Viability.  Lower figures – Cells were treated for 24 hours and then a Death Commitment Assay (DCA) was 
performed in an identical fashion to Figure 3-23.  Points represent trimmed mean change in viability from the interim point, 24 hours after drug treatment, +/- SEM 
from 8 technical replicates in one experiment.   Values have been normalised so 100% on the Y-axis represents the pre-treatment viable cell number.  Upper figures – 
the baseline and final viability data from cells treated for 96 hours with Nutlin-3A or DMSO as part of the DCA are presented as dose-response curves (calculations 
identical to Figure 3-19).           
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To establish if changing culture media creates an artefact that can explain the 
apparent cell death commitment after pulsed drug administration, real-time 
monitoring of cell number was employed using an orthogonal cell proliferation assay 
(xCELLigence).  Initial studies revealed greater sensitivity for changes in cell 
number using cell lines that grew with an adherent epithelial morphology.  Therefore 
the results of pulsed PLK-1 inhibitor exposure on cell proliferation were determined 
with the CP-A and KYSE-30 cell lines because of their adherent growth pattern.  
The process of removal from the incubator, drug addition or wash-off and plate 
replacement on the RTCA DP instrument led to significant changes in impedance 
readings that stabilized after 1-2 hours further incubation.  These could be secondary 
to cells being detached from the culture surface, fluctuations in the plate temperature 
and/or contact area between the plate and the impedance monitor.  To prevent these 
changes influencing the subsequent results, readings were normalized to a point 
between one and two hours after drug addition or wash-off when cell index 
measurements had stabilized.  Therefore change in cell number caused by 
detachment during washing would be accounted for and only subsequent changes in 
cell number due to proliferation or cell death would affect the normalized cell index.    
A caveat with the xCELLigence technique is that changes in cell morphology, 
including those that are expected with drugs that block cells in mitosis or at the 
G2/M checkpoint, change impedance.  Therefore, although unlikely, the results may 
represent drug-induced cell morphology changes rather than effects on proliferation. 
To confirm xCELLigence cell index measurements represent viable cell number 
changes, a comparison was made with another viability assay.  The E-plate wells are 
lined with electrodes and therefore fluorescence or colorimetric measurements, 
including the AlamarBlue method, cannot be used.  Cells can be lysed in the E-plates 
with CellTiter-Glo reagent and the lysate transferred to white opaque 96 well plates 
without significant change in relative viability measurements (Figure 3-12A).  The 
final cell index after a 96 hour treatment with BI2536 was compared to the CellTiter-
Glo measurement obtained from the same wells (Figure 3-25).     
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Comparison between relative viable cell number estimates from the xCELLigence 
cell index and CellTiter-Glo revealed an excellent correlation (CP-A, Pearson R2 = 
0.9602, p<0.0001 and KYSE-30, Pearson R2 = 0.9918, p<0.0001).  This confirms 
xCELLigence cell index is a reliable arbiter of viable cell number and could be used 
to monitor cell proliferation in real-time.      
To allow a reasonable period of cell recovery after drug wash-off without DMSO 
treated wells becoming confluent, a small starting number of cells was used for both 
cell lines.  For the CP-A cell line, 1,000 cells was the minimum number that was 
compatible with subsequent proliferation.  The KYSE-30 cell line showed a slightly 
more rapid growth rate than CP-A cells (Figure 3-26A, Figure 3-27A) and 
approximately 250 cells were used per well.   
PLK-1A produced a dose-dependent reduction in proliferation, in both cell lines in 
keeping with previous results.  The small number of KYSE-30 cells meant changes 
in cell index were small with greater variability in the dose response determination 
(Figure 3-27B, D).  In both cell types, however, there were clear changes in the 
growth pattern of cells in the presence of PLK-1A and after PLK-1A wash-off.  CP-
A cells proliferated in 200 nM PLK-1A but cell death was observed after drug wash-
off (Figure 3-26B, C).  The effect was even more marked in the KYSE-30 cell line 
with cells showing proliferation in 200 nM and 500 nM PLK-1A and cell death after 
drug wash-off (Figure 3-27 B, C).  
When the growth rate per hour was normalised to DMSO treated cells, there was a 
statistically non-significant decrease in the IC50 for CP-A cells from 190 nM to 145 
nM after drug wash-off.  In contrast the IC50 showed a significant decrease from 430 
nM to 70 nM (Figure 3-27 D, E; p = 0.0188, two-tailed t-test) in KYSE-30 cells.  
This suggests an enhanced therapeutic effect for this drug in vitro with pulsatile 
rather than continuous exposure.  
The response of CP-A cells to BI2536 was also assessed using the xCELLigence 
method in the same fashion as PLK-1A (Figure 3-28).  This revealed a similar 
pattern to previous results obtained using the AlamarBlue method with dose-
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dependent inhibition of proliferation.  The IC50 for reduction of proliferation when 
cells were incubated with the drug was unchanged when the drug was washed off, 
although cell death was observed at higher drug concentrations after drug removal.  
Therefore it appears that pulsed administration of PLK-1 inhibitors does not 
significantly enhance or reduce the anti-proliferative effect in CP-A cells but may 
augment the anti-proliferative effect and induce cell death in oesophageal cancer 
cells.  
To evaluate if a shorter pulse of treatment with PLK-1 inhibitors could enhance the 
therapeutic window between CP-A and adenocarcinoma cell lines, a colony 
outgrowth assay was performed (Figure 3-29). 
This revealed dose-dependent inhibition of colony growth in all cell lines.  There was 
a small reduction in colony growth in OE33 cells after 6.3 nM BI 2536 treatment and 
no appreciable effect in CP-A or OE19 cells.  With 25 nM BI 2536 treatment, there 
was significant inhibition of colony growth across all cell lines.  This is in close 
agreement with the AlamarBlue dose-response curves (Figure 3-19) and confirms a 
narrow dose range between no effect and maximal effect for this drug.  This also 
suggests little change in the sensitivity of oesophageal cells to this drug with pulsed 
rather than constant administration in agreement with the real-time proliferation data 
(Figure 3-28).            
Similar to previous findings with the colony formation assay, OE33 cells showed 
enhanced sensitivity to the PLK-1A compound compared to CP-A and OE19 cells.  
Reduced colony outgrowth was observed in OE33 cells after pulsed administration of 
16 nM PLK-1A with no effect in CP-A and OE19 cells and there was almost 
complete eradication of OE33 colony growth after 63 nM PLK-1A treatment with 
only a small reduction in colony growth in CP-A and OE19 cells.  This is in contrast 
to findings with the AlamarBlue assay where persistent proliferation was observed 
with 50 -100 nM PLK-1A treatment in all three cell lines (Figure 3-20).  
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Figure 3-25 Comparison of Viable Cell Number Estimation by xCELLigence and CellTiter-Glo.  (A) After 24 
hours incubation on E-plates, (A) CP-A or (B) KYSE-30 cells were treated with BI2536 or DMSO and final 
cell index calculated, 96 hours after drug addition.   CellTiter-Glo measurements were obtained from the 
same wells.  Bars represent mean +/- SEM of technical duplicates normalised to DMSO treated cells. 
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Figure 3-26 Real-time Monitoring of CP-A Proliferation after PLK-1A Treatment.  (A) Cells (1,000 per well) were seeded and allowed to proliferate for 24 hours.  The 
mean change in cell index per hour across the wells +/- SEM is displayed.  (B) PLK-1A was then added and proliferation monitored continuously as the change in cell 
index over 48 hours.  Proliferation continued to be monitored for 90 hours after the drug was washed off (C). (B, C) Lines represent mean of technical duplicates; values 
less than zero represent a decrease in cell number.  (D, E) The change in cell index per hour in the presence of drug (D), or after drug wash-off (E) normalised to DMSO 
treated cells.  Points represent mean +/- SEM from technical duplicates.  IC50 values, 95% CI (in parenthesis) and the R2 for best fit curves are displayed.  (F) Composite of 
(D) and (E).        
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Figure 3-27 Real-time Monitoring of KYSE-30 Proliferation after PLK-1A Treatment.   (A) Cells (250 per well) were seeded and allowed to proliferate for 24 hours.  The 
mean change in cell index per hour across wells +/- SEM is displayed.  (B) PLK-1A was then added and proliferation monitored continuously as the change in cell index 
over 42 hours.  Proliferation continued to be monitored for 90 hours after the drug was washed off (C). (B, C) Lines represent mean of technical duplicates; values less 
than zero represent a decrease in cell number.  (D, E) The change in cell index per hour in the presence of drug (D), or after drug wash-off (E) normalised to DMSO 
treated cells.  Points represent mean +/- SEM from technical duplicates.  IC50 values, 95% CI (in parenthesis) and the R2 for best fit curves are displayed.  (F) Composite of 
(D) and (E).       
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Figure 3-28 Real-time Monitoring of CP-A Proliferation after BI2536 Treatment.  Cells (1,000 per well) 
were seeded and allowed to proliferate for 24 hours.  BI2536 or DMSO was added and proliferation 
monitored continuously as the change in cell index over 48 hours.  The drug was then washed off and 
proliferation monitored for a further 96 hours. The change in cell index per hour in the presence of drug 
(blue points, drug), or after drug wash-off (red points, wash-off) normalised to DMSO treated cells is 
presented.  Points represent mean +/- SEM from technical duplicates.  IC50 values, 95% CI (in 
parenthesis) and the R2 for best fit curves are displayed.   
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Figure 3-29 Colony Outgrowth Assay.  Cells were plated in complete medium (CP-A, OE33 – 2,500 cells 
per plate; OE19 – 10,000 cells per plate), allowed to adhere and then treated for 16 hours with drug or 
DMSO followed by incubation in complete medium.  Plates were fixed and stained for colonies when 
vehicle treated cells approached confluence (12 days after drug wash-off). 
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3.4 Discussion 
 Both STR genotypes and p53 functional status were used to verify the oesophageal 
cell lines used in this study.  Using these bona fide cell lines, PLK-1 was 
demonstrated to be over-expressed in the transformed compared to non-transformed 
cells.  Higher expression of PLK-1 has been previously demonstrated between OSCC 
cell lines and HEEpiC cells using a different anti-PLK-1 antibody (clone 36-298)270.  
The specificity of the antibody used in this study was confirmed by siRNA and 
western blotting.  
Transfection of non-targeting scrambled siRNA and siRNA to GAPDH produced a 
reduction in PLK-1 expression.  This may either be due to a direct interaction with 
PLK-1 transcripts, although this is far less likely from both scrambled and siGAPDH 
sequences, or a consequence of secondary effects of siRNA on cell cycle progression 
or other cellular processes linked to mitosis.  A change in cell cycle stage could have 
significant effects on PLK-1 expression as transcript levels have been shown to peak 
in OAC cells just prior G2/M phase276.   
The expression of PLK-1 in the cell line panel could be explained by differential 
rates of proliferation.  The oesophageal cells tested exhibit in vitro doubling times of 
between 18 and 32 hours.  This is in stark contrast to in vivo human tumours which, 
in many cancer types, exhibit doubling times of several weeks to months with only 1-
2% of cells dividing at any point549.  When mRNA expression has been measured, 
however, PLK-1 has been found to be upregulated in OAC and OSCC cell lines and 
tumours compared to normal squamous cells and tissue271,275,276. Overexpression of 
PLK-1 in oesophageal tumours has also been associated with poorer prognosis and 
increased risk of lymphatic metastasis268,275.   
PLK-1 was shown to be overexpressed in OAC tissue compared to Barrett’s and 
normal squamous epithelium by IHC.  This provides some evidence that the cell line 
panel may recapitulate some of the features of the in vivo tissues.  Loss of p53 
function may be responsible for the upregulation in PLK-1 as this has been 
demonstrated previously in vitro 220,340.  Supporting this, the oesophageal cell lines 
with the highest PLK-1 expression possess p53 mutations.  These cancer cell lines 
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also possess other genetic changes relative to the CP-A and HEEpiC cells that 
together create the transformed phenotype.   No oesophageal adenocarcinoma cells 
lines are available with wild-type p53 to assess the direct impact of loss of p53 on 
PLK-1 expression in this cell type.   
Assessing PLK-1 expression across a large panel of oesophageal adenocarcinomas 
with both wild-type and mutant p53 may allow the impact of this genetic change on 
PLK-1 expression to be determined.  There are a myriad of genetic changes in these 
tumours but, with a large enough cohort, it would be expected that those features not 
correlated with TP53 mutation will be equally represented in tumours with wild-type 
and those with mutant alleles.   
Using the OCCAMS TMA consisting of cores from 356 OACs, TP53 genotype and 
PLK-1 expression were assessed.  Using a sub-group of 58% of the tumours, TP53 
mutation was unanimously predicted in 90% of the tumours.  This high figure in part 
reflects the greater ease in identifying mutant p53 tumours compared to wild-type 
p53 tumours using p53 IHC alone.  A p53 mutation frequency of 72% was, however, 
identified in a recent exome-sequencing study of 149 oesophageal adenocarcinomas 
from American patients550.  A further amplicon re-sequencing study in 99 patients 
supports these findings with a mutation frequency of 71% (Prof. Rebecca Fitzgerald, 
personal communication).  In support of the IHC method, the sequencing data from a 
small selection of the TMA cases largely confirmed the IHC predictions.  Definitive 
TP53 sequencing of the entire cohort would have clarified the accuracy of the 
predictions.  This would require DNA extraction from the FFPE tissue, further 
reducing the availability of this highly limited resource and re-sequencing the entire 
TP53 gene in over 300 tumours would have been prohibitively expensive.  
PLK-1 expression was found to be significantly elevated in oesophageal 
adenocarcinomas with predicted mutant TP53 compared to those tumours with 
predicted wild-type p53.  This was in agreement with the previous findings 
comparing non-transformed oesophageal cells (wild-type p53) and oesophageal 
cancer cell lines (mutant p53) and benign and malignant oesophageal tissues (Figure 
3-4, Figure 3-9 ).  These findings were reproduced in ovarian cancers with known 
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TP53 genotype.  This suggests the previous findings in OAC were not simply an 
artefact of the method used to predict TP53 genotype.    Together these data suggest 
mutation of p53 is associated with upregulation of PLK-1 in vivo.   
To provide definitive proof for the association between TP53 function and PLK-1 
expression in oesophageal cancer, a panel of isogenic cell lines would be required 
and these have not yet been developed.  Another possibility would be to replace p53 
function in an OAC cell line with a mutant allele and evaluate PLK-1 expression.   
Unfortunately many mutant p53 isoforms exhibit dominant negative effects by 
binding to and inactivating wild-type proteins202,551.  Exogenous expression of wild-
type protein may not, therefore, rescue p53 function.  A further complicating factor 
would be the requirement for careful calibration of wild-type p53 expression as 
supra-normal p53 activity is associated with diverse physiological changes in vivo 
including premature aging and resistance to cancer development552,553. 
To examine if p53 mutation and subsequent higher PLK-1 expression conferred 
greater sensitivity to PLK-1 inhibition, both siRNA to PLK-1 and PLK-1 inhibitors 
were tested in transformed and non-transformed oesophageal cells with measurement 
of viability.  The AlamarBlue assay was used because this exhibited a linear response 
with increasing cell number and initial viability measurements did not influence final 
viable cell number determination. 
Viability experiments were optimised for 96-well plates.  After siRNA transfection 
to PLK-1, insufficient cells were present at the end of the experiment to allow 
subsequent RNA expression profiling or protein expression analysis by western 
blotting.  AlamarBlue assays allow downstream assays to be performed including the 
In-Cell western method554.  When this method was applied with CP-A and OE19 
cells, however, a high coefficient of variation in the determination of PLK-1 
expression was observed.  Subsequently, parallel rather than serial assays of 
viability, gene and protein expression were performed. 
When scrambled siRNA sequences (siGENOME, Non-Targeting siRNA#3, 
Dharmacon) were transfected into oesophageal cells, PLK-1 mRNA was reduced 
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(Figure 3-17).  This is likely to be a sequence specific phenomenon as it was 
observed to a similar extent in all 3 cell types and not observed in vector treated cells 
or when a different sequence was used (OE33, HEEpiC cells; Accell, non-targeting 
sequence #1, Dharmacon).  To mitigate the off-target effects of siRNA, individual 
sequences could be transfected as pools of 4 sequences were used. This may 
eliminate the non-specific interacting sequence.  Failing that, the use of lentiviral 
vectors to generate stable, inducible shRNA expressing cell-lines may prevent non-
specific effects although this would be at the expense of significantly increased 
generation time. 
Despite the effects of the non-targeting control on mRNA expression, viability was 
unchanged, with the exception of HEEpiC cells, between vector and non-targeting 
control treated cells. This suggests, as expected, it is only the reduction in PLK-1 
protein expression that is associated with a reduction in viability.   
It was difficult to directly correlate absolute protein levels and viability but the cell 
line with the lowest reduction in PLK-1 protein expression, OE33, also exhibited the 
lowest decrease in viability.  No clear discrimination between transformed and non-
transformed cells could be determined from the siRNA experiment.  
Two PLK-1 inhibitors were assessed, BI2536 and a novel, shorter half-life, 
compound PLK-1A.  Both compounds produced the expected G2/M arrest after 24 
hours and a reduction in proliferation was observed after 96 hours treatment in a both 
non-transformed and transformed cells.   The degree of selectivity of a drug for 
cancer cells over normal and haematopoietic tissues can be considered as the 
therapeutic index.  Cell lines derived from the same tissue, with a presumed highly 
similar genetic background, except for key transformative changes, have been used 
in this investigation in an attempt to reveal cancer cell selectivity.  It is hypothesised 
that drugs affecting only the oesophageal cancer cell lines would exhibit a high 
therapeutic index in vivo.   
OAC cell lines were twice as sensitive to the PLK-1 inhibitors as primary squamous 
cells although in the presence of the drug, cell numbers continued to increase even at 
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the highest doses tested.  In contrast, cisplatin produced the expected cytotoxic 
response with minimal discrimination between cancer and non-transformed cells.  
The response to PLK-1 inhibitors could be due to a predominantly cytostatic rather 
than cytotoxic action of the drugs.  A combination of proliferation and cell death 
could, however, produce the same results and real-time monitoring would be 
required to confirm this.    
The colony formation and DCA were used to assess the effect of drug removal on 
subsequent viability.  After treatment with PLK-1A, OAC cells showed a greater 
reduction in proliferation in the DCA after drug wash-off compared to CP-A cells.   
There was some similarity with the BI2536 treatment although significant variability 
was noted and further biological replicates would be required before the significance 
of these results can be determined.       
A possible explanation for these data is that the wash-off has some effect in 
removing the drug and that this triggers a differential response in the 
adenocarcinoma cells.  This is supported by the enhanced sensitivity of OE33 cells to 
PLK-1A observed in the colony formation assay (Figure 3-22).  The persisting 
increase in viable cell number after pulsed and continuous PLK-1A treatment agrees 
with previous observations that this treatment has a net cytostatic, rather than 
cytotoxic, effect in the time scale of this assay (Figure 3-20).  The lack of viable 
colonies after 1 µM PLK-1A treatment in OE33 cells could be due to delayed cell 
death (Figure 3-22). 
In the DCA, cells at the interim viability assay stage have been pre-treated for 24 
hours in conditions that have been previously shown to significantly induce G2/M 
arrest (Figure 3-18).  As cells approach mitosis, there is a change in morphology that 
would be expected to reduce cell adhesion and therefore facilitate detachment during 
washing555.  A further possibility to explain the reduced apparent proliferation after 
pulsed drug exposure would be that cells have been washed off after the interim 
viability assay and a reduced final viable cell number is just a consequence of the 
washing steps.  The same number of washing steps was, however, employed for both 
pulsed and continuous drug exposed cells and it is reasonable to expect the effect to 
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be constant across groups.  A systemic bias towards cell detachment and the death of 
detached cells with pulsed exposure could, in theory, explain the findings of an 
apparent enhanced anti-proliferative effect after drug removal.   
The single wash after the interim AlamarBlue measurement may also be insufficient 
to wash-off the PLK-1 inhibitors and the results observed may not reflect the in vivo 
phenotype after pulsed administration.  The wash protocol appeared, however, to be 
adequate to reverse the phenotype of Nutlin-3A.     
A surprising result from the DCA was the cytotoxic effect of Nutlin-3A on cells with 
mutant p53.  It is expected that Nutlin-3A would not change the phenotype of OE33 
cells as mutant p53 is stabilised and non-functional (B).  Similarly, OE19 cells 
possess a frameshift p53 mutation which produces a truncated protein which is 
predicted to lack the tetramerisation domain thought to be critical for p53-mediated 
transactivation556.   
The initial specificity of Nutlin-3A for disruption of the MDM2-p53 interaction has 
now been questioned in several reports.  Cells with mutant p53 have shown induction 
of apoptosis in response to Nutlin-3A treatment220.  This appears to be through 
activation of the p53 homolog p73 via direct disruption of p73-MDM2 binding or 
induction of p73 expression by E2F1353,557,558.  A proteomic study has also revealed 
widespread dysregulation of the MDM2 interactome by Nutlin-3A559.         
Monitoring cell proliferation in real-time using the xCELLigence assay permitted the 
observation of cell death commitment as a decrease in cell index on drug withdrawal 
(Figure 3-26C, Figure 3-27C).  This finding helps to explain the lack of colonies 
observed in the OE33 cell line after 1 µM PLK-1A treatment (Figure 3-22).   
The IC50 values calculated from the xCELLigence data for the KYSE-30 cell line 
differ from those calculated with a significantly higher number of replicates using the 
AlamarBlue method.  The absolute values calculated from the xCELLigence data 
may vary with subsequent repetition.  The obvious change in proliferation rate 
induced by drug wash-off provides sufficient evidence, however, that the observed 
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enhanced effect of PLK-1A after drug removal is not simply an artefact of cells 
being washed off with the change of media (Figure 3-22, Figure 3-23).   
The enhancement of sensitivity on withdrawal of PLK-1A was more marked with the 
oesophageal cancer cell line KYSE-30 than the non-transformed CP-A cell line.  
This was confirmed in OAC cell lines by the colony outgrowth assay.   
The mechanism of cell death was not investigated in this study.  Previous reports in 
ESCC have suggested PLK-1 suppression can induce apoptosis via induction of 
Caspase-3269.  This could be confirmed in OAC cell lines after pulsed PLK-1 
inhibitor treatment by western-blotting through the demonstration of PARP cleavage 
and pro-caspase-3 reduction or through flow-cytometry and demonstration of a sub 
G0/G1 peak560.  Caspase-3 activation can also be demonstrated using a specific 
luminescence assay561 or even in live cells using a fluorescence biosensor562.        
Minimal changes in sensitivity were observed after wash-off of BI2536 in the 
xCELLigence assay and colony outgrowth assay.  Both compounds inhibit kinase 
activity by competing for ATP-binding; although PLK-1A is reportedly more 
selective for PLK-1 over PLK-2 (Table 3-5).   
Early phase clinical trials of BI2536 demonstrate dose limiting haematological 
toxicity and tumour response rates have been limited.  A mechanism to explain the 
relative non-selective in vivo cytotoxicity of BI2536 can be proposed on the basis of 
the recent publication of a new PLK-1 inhibitor, SBE13, that traps the protein in an 
inactive conformation and has exclusive specificity towards PLK-1563.  Testing of 
SBE13 on various non-transformed cells in vitro produced no cytotoxicity and only 
transiently slowed cell progression in stark contrast to BI2536563 .  This lends weight 
to the hypothesis that drugs with higher specificity for PLK-1 may have preferential 
in vivo phenotypes.   
A further possibility lies in the drug half-life.  The sensitivity to PLK-1A was shown 
to be enhanced by pulsed administration as a 72 hour (Figure 3-22), 48 hour (Figure 
3-26, Figure 3-27), 24 hour (Figure 3-23 lower figures) or a 16 hour treatment 
(Figure 3-29) compared to 96 hour continuous exposure (Figure 3-20).  This effect 
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appears to be specific to PLK-1A over BI2536  and may be due to the estimated 10-
fold shorter half-life.       
In conclusion, methods to enhance the specificity of kinase inhibitors may be 
successful enough to allow effective patient treatment with minimal toxicity but 
kinase inhibitors, especially those directed at cell cycle genes, are always likely to 
affect cycling cells to an extent.  Other targets may however, exhibit more specific 
expression profiles.  If a target could be identified that is exclusively expressed on 
oesophageal cancer cells and is available on the cell surface, anti-cancer cytotoxic 
antibodies could be developed that in theory should not produce any off-target 
effects.   An approach to identify cancer specific protein expression using a 
proteomic method is described in the next chapter. 
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4.1 Chapter Aims 
 
a) To evaluate if quantitative proteomic data can be obtained 
from snap frozen oesophageal adenocarcinoma and 
matched normal oesophageal tissue. 
 
b) To evaluate the technical and biological reproducibility of 
the method. 
 
c) To evaluate the quantitative accuracy of the method by 
comparing expression data with immunohistochemistry 
from the same tissues. 
 
d) To compare the relative expression of quantified proteins 
between patient-matched tissues with published work to 
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Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Identifying OAC-specific Protein Expression by Shotgun Proteomics 199 
4.2 Introduction 
The previous chapter built on published work identifying PLK-1 as a potential 
synthetic lethal candidate with mutant p53 and established PLK-1 as a candidate 
therapeutic target in OAC.  Despite the encouraging data with the short half-life 
compound, systemic toxicity is still a significant concern with PLK-1 inhibitors due 
to the ubiquitous role of this kinase in the cell cycle.  Narrowing the range of tissues 
targeted could enhance the therapeutic index. 
Cytotoxic antibodies directed against tumour-specific proteins provide potentially 
highly specific therapies.  This chapter will investigate the use of quantitative 
proteomics to identify tumour-specific proteins from human oesophageal tissue 
samples.  By measuring protein expression directly, tissue-specific changes in 
protein abundance from post-transcriptional mechanisms are accounted for, 
providing an advantage over transcriptome-based approaches.   
Changes to the extracellular microenvironment can lead to significant changes in 
tumour cell phenotype, potentially via relative changes in protein abundance360.  
Human tissue samples were therefore used rather than oesophageal cell lines to 
attempt to capture the in vivo expression profile of OAC cells.  As pre-analytic 
factors, such as warm ischaemic time, can have a significant bearing on the 
quantitative data obtained from proteomic studies, a high-quality tissue resource was 
established for this study564.  Tissue samples were collected from prospectively-
consented patients undergoing resection for OAC and snap –frozen.       
4.2.1 Quantitative Proteomics 
Accurate relative peptide quantitation can be achieved in shotgun proteomics by the 
use of isobaric peptide labels.  For this study, Tandem Mass Tags (TMT, Proteome 
Sciences) were used allowing up to six different samples to be compared 
simultaneously430.  To reduce sample complexity and enhance the number of 
confident protein identifications, tryptic peptide mixtures were fractionated. An 
orthogonal combination of fractionation by isoelectric point using OFFGEL 
electrophoresis and retention time on a reverse phase chromatographic column was 
utilised565.   
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4.3 Results 
4.3.1 Tissue samples 
Tissues from two clinically-matched patients differing only significantly in the 
number of lymph node metastases were used for this study.  The clinical 
characteristics of each patient are summarised in Table 4-1.  TMT-labelled tryptic 
peptides from snap-frozen OAC and patient-matched normal squamous epithelium 
from both patients were pooled, fractionated by OFFGEL electrophoresis and then 
each of the 12 fractions analysed three times by LC-MS/MS.  Mass spectra from all 
experiments were pooled and analysed together using the Easyprot platform504.  
Table 4-1 Clinical Characteristics of Patients Donating Samples for this Study 
 Patient 
 15 17 
Gender Male Male 
Age 63 52 
Comorbidities Nil Nil 
Histology Adenocarcinoma Adenocarcinoma 
Location OGJ Siewert Type I OGJ Siewert Type I 
Neoadjuvant Therapy 2xCisplatin, 5-Fluorouracil (2xCF) 
1xCF (Abandoned due to  
Acute Left Leg Ischaemia) 
Post-Chemotherapy Radiological 
Response Evaluation (CT) Stable Disease Stable Disease 
Surgery Ivor-Lewis Oesophagectomy 
Ivor-Lewis  
Oesophagectomy 
Maximum Tumour Diameter 45 mm 43 mm 
Distance to Proximal and Distal Margins >1 mm >1 mm 
Distance to Circumferential Margin 0.2 mm 0.4 mm 
Differentiation Poor Poor 
Histological Lymphovascular Invasion Yes Yes 
Histological Venous Invasion Yes Yes 
Histological Perineural Invasion Yes Yes 
Resection Complete R1 R1 
T stage T3 T3 
Number of Positive Nodes 17 0 
Total Number Nodes Resected 29 19 
AJCC Stage IIIC IIB 
Alive at Time of Analysis No Yes 
Overall Survival From Diagnosis 19.8 months 27.4 months (censored) 
AJCC – American Joint Committee on Cancer, OGJ – Oesophagogastric Junctional Tumour, R1- Resection 
Microscopically Incomplete, CT – Computed Tomography. 
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4.3.2 Peptide and Protein Quantitation 
A total of 1,097 proteins were identified with a peptide FDR<1% and two unique 
peptides per protein.  The mean peptide reporter ratios between OAC and normal 
oesophagus (TvO) for each protein, for each patient were calculated and the ratios 
normalized so the median log2 ratio = 0. The normalized distributions are shown in 
Figure 4-1   
Figure 4-1 Histograms of Median Normalised Protein Ratios for each Patient and for Technical 
Replicates. Note the differing x-axis scales.  
 
The protein ratios for each patient and for the technical replicate showed 
approximately Gaussian distributions but the variances differed significantly 
(Fligner-Killeen p<0.05).  The TvO ratios were therefore compared to the technical 
replicate ratios using Welch’s statistic.  Welch’s modified t-test is a parametric 
statistic that can be applied to compare two means from approximately normally 
distributed populations with unequal variances to test the hypothesis that the means 
are the same512.  This statistic is also relatively robust to deviation from normality 
when the sample size is large.  For patient 15, 526 proteins and for patient 17, 529 
proteins were significantly dysregulated (FDR-p <0.05) with 430 proteins 
dysregulated in both patients.  The distribution of proteins by TvO ratio and FDR-
corrected p-value is displayed for each patient in Figure 4-2 (see Methods 2.11).  
This highlights, as expected, that the majority of proteins with a p>0.05 have an 
unchanged expression between OAC and normal oesophagus or were only quantified 
by a few peptides.  
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Figure 4-2 Volcano Plots Illustrating the Distribution of Proteins According to TvO ratio and FDR-
corrected p-value. Points represent proteins and are scaled according to the number of peptides 
quantified.  FDR correction was performed with the Benjamini-Yekutieli method566.   
4.3.3 Comparison of Protein Expression Between Patients 
The relationship between the TvO ratios from each patient was next examined.  The 
correlation in TvO ratios between patients was good (Figure 4-3, Pearson Correlation 
Coefficient = 0.6726, p<0.001) which is reassuring given the close clinical match for 
the patients.  The number of lymph node metastases was significantly different 
between patients, however, and this is the clinical variable with the strongest 
association with prognosis117.  Proteins differentially expressed in primary tumours 
associated with extensive lymph node metastases may be associated with targetable 
pathways with a role in metastasis.  The outliers were therefore annotated for further 
consideration (Figure 4-4). 
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Identifying OAC-specific Protein Expression by Shotgun Proteomics 203 
 
Figure 4-3 Comparison of TvO ratios from Patient 15 and Patient 17. Each point represents a protein.  The position on the plot is determined by the Log2 TvO expression 
ratio for each patient.   
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Figure 4-4 Comparison of Proteins with Significantly Dysregulated TvO Ratios.  Each point represents a protein.  The position on the plot is determined by the Log2 TvO 
expression ratio for each patient.  Only proteins with an FDR-p<0.05 are displayed and selected outliers have been annotated with gene names. 
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4.3.4 Evaluation of Significantly Dysregulated Proteins 
Proteins differentially up or down-regulated in patient 15 but relatively unchanged in 
patient 17 were considered.  Although no definitive conclusions can be drawn from 
this comparison, proteins involved in extracellular matrix homeostasis were 
dysregulated between patients including Cathepsin B (CTSB), Fibulin-1 (FBLN1), 
Fibulin-5 (FBLN5), Fibrillin-1 (FBN1) and Fibronectin (FN-1).  Matrix remodelling 
is a common feature during cancer cell invasion and metastasis and the down-
regulation of FBLN1 and FBLN5 has been associated with oncogenesis in prostate, 
gastric and liver tissue567-569.  CTSB, a cysteine protease, has also been implicated in 
cancer invasion and metastasis and may be a target for cancer-specific imaging 
probes570-573. 
This suggests the comparative proteomic approach may yield insight into the biology 
of OAC and uncover cancer-specific drug targets.  To examine how the quantitative 
results from this study compare with the published literature on OAC, the 
significantly dysregulated proteins (FDR-corrected p <0.05 in either p15 and p17) 
were ranked by the sum of TvO ratios and the top 150 proteins upregulated in both 
p15 and p17 considered in greater detail.  A selection of these proteins along with a 
summary of the evidence for their upregulation in OAC or cancer in general is 
provided in Table 4-2.  A smaller selection of proteins down-regulated in both 
patients was also examined.  The complete list of significantly dysregulated proteins 
and the accompanying TvO ratios, technical replicate ratios, FDR-corrected p-values 
and number of peptides quantified is presented in the Appendix. 
4.3.5 Validation of TMT Quantitative Accuracy 
This comparative proteomic approach relies on the quantitative accuracy of the 
isobaric TMT ratios.  To test this, six proteins predicted to be upregulated and two 
proteins predicted to be down-regulated by varying degrees in both patients’ tumours 
were selected for validation by immunohistochemistry (IHC).  These proteins are 
highlighted in purple in Table 4-2 and their relative expression in comparison to 
other significantly dysregulated proteins demonstrated in Figure 4-5.           
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Identifying OAC-specific Protein Expression by Shotgun Proteomics 206 
Table 4-2 Selected Significantly Dysregulated Proteins. Examples of the evidence either from hypothesis directed research or published microarray data supporting the 
expression profile are provided in the corresponding references.   Candidates selected for IHC are coloured purple. 
Upregulated Proteins 
Protein Name 






Patient 17     
FDR p-value 
Evidence of 
Dysregulation in OAC 
Evidence of Dysregulation 
in other Cancers 
Galectin-4 3.56 1.40E-09 3.91 3.54E-09 Yes60,61,277   
Polymeric immunoglobulin receptor 5.43 0.026467 2.36 0.00366 Yes574  
Anterior gradient protein 2 homolog (AGR2) 1.90 1.19E-22 6.06 1.15E-09 Yes60,61,171,277 Yes575 
Fructose-1,6-bisphosphatase 1 2.67 2.61E-05 3.91 0.00013 Yes60,61,277 Yes (down-regulated)576,577 
Lymphocyte-specific protein 1 3.38 0.000174 2.48 0.000331  Yes578 
Coactosin-like protein 2.46 1.37E-09 2.62 1.18E-10  Yes579 
Olfactomedin-4 4.01 0.013774 1.60 0.019976 Yes60,61,277  
Gastricsin 0.74 3.05E-09 8.42 0.000431  Yes580 
Signal transducer and activator of transcription 1-alpha/beta 2.40 1.63E-12 2.45 1.62E-10 Yes60,61,171,277 Yes581 
Cathepsin D 2.60 1.35E-23 2.19 6.32E-25 Yes582  
Coronin-1A 2.44 6.06E-12 2.27 3.69E-09  Yes583 
Deleted in malignant brain tumours 1 protein 4.24 0.06183 1.25 0.005391 Yes584  
Protein disulphide-isomerase A4 2.35 8.18E-17 2.25 4.16E-15 Yes 60,61,171,277  
Keratin, type II cytoskeletal 8 2.22 5.19E-09 2.34 1.02E-08 Yes 60,61,171,277  
Keratin, type I cytoskeletal 18 1.91 1.32E-08 2.41 6.39E-07 Yes585  
Cathepsin Z 2.29 0.003016 1.98 0.004004 Yes 60,61,171,277  
Deoxynucleoside triphosphate triphosphohydrolase (SAMHD1) 2.30 8.44E-05 1.94 5.66E-06 Yes 171  
Rho GDP-dissociation inhibitor 2 (D4GDI) 2.24 0.000149 1.93 0.000382 Yes 447  
Thymidine phosphorylase 2.29 8.59E-09 1.88 1.98E-08 Yes586  
Interferon-induced guanylate-binding protein 1 1.92 0.006879 2.15 0.024065  Yes587 
Proliferating cell nuclear antigen 1.67 0.000113 2.47 0.001047 Yes588  
Retinal dehydrogenase 1 1.46 1.11E-18 2.78 1.20E-07 Yes 449  
Argininosuccinate synthase 1.36 0.00011 2.59 0.00704 Yes589  
Proteasome activator complex subunit 1 2.13 1.34E-09 1.64 2.61E-10 Yes448  
Continued overleaf…. 
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Dysregulation in other 
Cancers 
High mobility group protein B1 2.12 0.00205 1.63 0.010973  Yes590 
Protein disulphide-isomerase A3 2.06 2.31E-30 1.68 3.13E-28   Yes591,592 
Plastin-2 1.98 3.66E-08 1.68 2.67E-08  Yes593 
Endoplasmin 1.85 7.29E-17 1.76 5.72E-16 Yes594  
Annexin A4 2.06 0.060022 1.54 0.014045 Yes60,61,169,277   
Voltage-dependent anion-selective channel protein 1 1.99 0.000969 1.42 0.000276 Yes277   
Cathepsin B 2.19 0.022038 1.25 0.000199 Yes595,596 Yes573 
Heterogeneous nuclear ribonucleoproteins A2/B1 1.76 7.40E-15 1.51 2.50E-14  Yes597 
Calreticulin 1.52 4.97E-11 1.60 1.50E-07  Yes598,599 
Tumour protein D52 1.54 0.001337 1.48 0.000751  Yes600 
Glutathione S-transferase omega-1 (GSTO-1) 1.51 0.001498 1.45 0.002081 Yes447,601  Yes602 
Inorganic pyrophosphatase 1.50 0.001059 1.42 0.024315 Yes447  
60 kDa heat shock protein, mitochondrial 1.50 1.16E-15 1.43 9.48E-15 Yes447  Yes603 
Peptidyl-prolyl cis-trans isomerase B 1.59 0.06734 1.30 0.004522 Yes449  
Cofilin-1 1.47 5.25E-11 1.35 3.69E-08  Yes604 
78 kDa glucose-regulated protein (GRP-78) 1.40 1.66E-14 1.39 6.98E-10 Yes 60,277,446,594   
Down-regulated Proteins 
Cornulin 0.1097 1.27E-27 0.17886 1.03E-30 Yes605  
Keratin, type II cytoskeletal 4 0.150119 1.48E-43 0.137715 1.20E-42 Yes606  
Involucrin 0.174528 3.06E-18 0.150044 1.57E-21 Yes607,608  
Transglutaminase 3 (TGM-3) 0.196284 4.51E-19 0.147945 1.75E-17 Yes609  
Protein S100-A8 0.229294 4.39E-26 0.157754 1.63E-25 Yes610  
Small Proline Rich Protein 3 0.297078 0.00010673 0.253345 6.09E-05 Yes60,61,277  
Heat shock protein beta-1 (HSP-27) 0.431919 8.39E-27 0.281171 9.63E-33 Yes625  
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Figure 4-5 Comparison of Significantly Dysregulated Protein TvO Ratios.  Each point represents a protein.  The position on the plot is determined by the Log2 TvO 
expression ratio for each patient.  Only proteins with an FDR-p<0.05 are displayed and proteins selected for IHC are coloured red and annotated with their gene 
names.  Points have been scaled according to the number of quantified peptides. 
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Confirming the specificity of antibodies used for IHC is important to prevent false 
positives.  Antibodies predicted to be suitable for both western blotting and IHC 
were sought for each of the 8 candidate proteins.  A panel of oesophageal cells lines 
incorporating the various stages of oesophageal carcinogenesis were then used to 
evaluate the relative expression of each candidate (Figure 4-6A).   
Bands of the predicted molecular weight were detected for each candidate 
confirming the sensitivity of the primary antibodies.  Similar to the tissue expression 
profiles, there was generally higher expression in the adenocarcinoma cell lines for 
AGR2, D4GDI and SAMHD1 compared to primary squamous and Barrett’s cells 
although some heterogeneity was observed.  In contrast both HSP-27 and TGM3 
were expressed at higher levels in primary squamous cells and a doublet band was 
observed specifically in squamous cells with the TGM3 antibody suggesting 
differential regulation of the protein between these cells and the other cell lines.  
Ubiquitous expression of varying levels was observed for GSTO-1, GRP-78 and 
HSP-27 consistent with their roles in redox homeostasis or as chaperones.  
To confirm the specificity of the antibodies to proteins predicted to be upregulated in 
OAC, siRNA was transfected into cell lines expressing the relevant genes.  Western 
blots demonstrated a significant reduction in the band intensity at the predicted 
molecular weight for SAMHD1, AGR2, D4GDI and GRP78 when siRNA targeted to 
the corresponding gene was transfected.  This confirmed the specificity of the 
antibodies towards these targets.  A minimal reduction was observed with siRNA to 
GSTO-1.  This may be due to poor mRNA targeting of the transfected siRNA 
sequence, a long protein half-life, non-transcriptional control of protein abundance, 
or poor antibody specificity.   
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Figure 4-6 Expression of Candidates in a Panel of Oesophageal cells and Validation of Antibodies for IHC.  (A) Lysates from each of the representative cell types 
growing under basal conditions were resolved by SDS-PAGE (20μg per lane using 8-12% gels) and western blots probed with the indicated primary antibodies before 
scanning using a Li-Cor imaging system.  (B) KYSE-30 cells (GRP-78), OE33 cells (D4GDI, AGR2, SAMHD1) or CPA cells (GSTO-1) were transfected with siRNA or vector 
alone and harvested at 72 hours post-transfection.  Lysates were then resolved by SDS-PAGE and western blotting carried out as previously.    
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The evaluation of FBP-1 expression was more difficult as two initial antibodies 
detected multiple bands at higher molecular weights but none at the predicted weight 
of 37 kDA (data not shown).  A third antibody (Atlas Antibodies, HPA005857) 
detected a band of the appropriate molecular weight amongst multiple others and this 
band was highly expressed in the breast cancer cell line MCF7 (Figure 4-7 B), 
previously published as expressing FBP1611.  When MCF7 cells were transfected 
with siRNA to FBP1, there was a reduction in the intensity of the 37 kDa band 
confirming the specificity of this antibody (Figure 4-7 A).  This gene has been shown 
to be overexpressed in OAC compared to normal oesophagus at the mRNA level 
(Table 4-2)61 and therefore qRT-PCR was performed confirming the results of 
western blotting (Figure 4-7C).  
 
Figure 4-7 Evaluation of FBP1 Expression in a Panel of Oesophageal Cell Lines.  (A) Western blot of FBP1 
expression in MCF7 cells transfected with siRNA or vector alone and harvested at 72 hours post-
transfection (30μg/lane).  The arrow represents the predicted molecular weight of FBP1.  (B) Expression 
of FBP1 in a panel of cell lines.  Lysates from each of the representative cell types growing under basal 
conditions were resolved by SDS-PAGE (20μg per lane using a 10% gel) and western blots probed with 
the FBP1 antibody before Li-Cor scanning at high amplification (Over Exposed) or normal amplification 
(Short Exposure).  (C) Relative FBP1 mRNA expression in a panel of cell lines grown under basal 
conditions.  Error bars represent the SEM of 4 technical replicates from one biological replicate.  Note the 
Y-axis is on a log scale.       
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Six candidates; AGR2, GRP-78, SAMHD1, D4GDI, TGM3 and HSP-27, were 
selected for validation of relative expression by IHC.  After optimization of antigen 
retrieval conditions and primary antibody dilutions, sections from FFPE tissue blocks 
of the original resection specimens used to derive the fresh tissue samples for 
proteomic analysis were stained (Figure 4-8 - Figure 4-14).   
All four of the proteins predicted to be upregulated in OAC compared to normal 
oesophagus showed higher expression in the tumour sections compared to squamous 
epithelium.  Similarly the proteins with TvO ratios less than 1; HSP-27 and TGM3, 
showed the highest expression in squamous epithelium confirming the quantitative 
proteomic accuracy (Figure 4-12, Figure 4-13).   
AGR2 was expressed in OAC and gastric epithelial cells with no evidence of 
expression in normal squamous cells (Figure 4-8).   GRP-78 was also overexpressed 
in OAC cells both in the primary tumour and involved lymph nodes (Figure 4-10) 
compared to squamous epithelium.   SAMHD1 showed more widespread nuclear 
expression but was upregulated in OAC cells in the primary tumour and in lymph 
node metastasis (Figure 4-11).   
When gastric epithelial sections were examined, several staining patterns were 
identified.  Homogeneous cytoplasmic staining was observed in all or scattered basal 
epithelial cells of the gastric crypts.  This was a common finding with the staining 
characteristics associated with a false positive result612.  This is supported by the 
appearance of this pattern in the “no primary” gastric slide for patient 17 (Figure 
4-14).  Presumed true positive gastric epithelial cytoplasmic staining was seen with 
AGR2 and presumed true positive nuclear staining was seen with SAMHD1 (Figure 
4-8, Figure 4-11).  Some DAB positivity was noted in the gastric epithelium in the 
slides stained for GRP-78 but this was more likely to represent false positive staining 
(Figure 4-10).           
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Figure 4-8  IHC staining pattern for AGR2.  Representative images highlighting the staining pattern from various tissues are demonstrated for each patient.  Details of 
the staining protocol are provided in Methods 2.7.  The observed TvO expression ratios are provided.  
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Figure 4-9 IHC staining pattern for D4GDI.  Representative images highlighting the staining pattern from various tissues are demonstrated for each patient.  Details of 
the staining protocol are provided in Methods 2.7.  The observed TvO expression ratios are provided.  
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Figure 4-10 IHC staining pattern for GRP-78.  Representative images highlighting the staining pattern from various tissues are demonstrated for each patient.  Details 
of the staining protocol are provided in Methods 2.7.  The observed TvO expression ratios are provided.  
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Figure 4-11 IHC staining pattern for SAMHD1.  Representative images highlighting the staining pattern from various tissues are demonstrated for each patient.  Details 
of the staining protocol are provided in Methods 2.7.  The observed TvO expression ratios are provided.  
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Figure 4-12 IHC staining pattern for HSP-27. Representative images highlighting the staining pattern from various tissues are demonstrated for each patient.  Details 
of the staining protocol are provided in Methods 2.7.  The observed TvO expression ratios are provided.  
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Figure 4-13 IHC staining pattern for TGM3. Representative images highlighting the staining pattern from various tissues are demonstrated for each patient.  Details of 
the staining protocol are provided in Methods 2.7.  The observed TvO expression ratios are provided.  
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Figure 4-14 IHC staining pattern with no primary antibody. Representative images highlighting the background staining pattern from various tissues are 
demonstrated for each patient.  Details of the staining protocol are provided in Methods 2.7.  
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Positive staining for D4GDI was also observed in the gastric slides (Figure 4-9). This 
was limited to small stromal cells typical of lymphocytes.  Indeed, strong nuclear and 
cytoplasmic D4GDI positivity was observed in similar stromal cells in the tumour with 
no staining in the epithelial cells.  Consistent with expression in lymphocytes, D4GDI 
was also highly expressed in lymphoid follicles in both uninvolved and involved nodes 
(Figure 4-9).     
A relatively homogeneous staining pattern was observed for all the proteins except 
HSP-27. This protein was most highly expressed in squamous epithelium but staining 
across both patients’ tumours was variable with some tumour cells negative and some 
showing high perinuclear and cytoplasmic positivity (Figure 4-15).  HSP-27 positivity 
was also observed in muscle tissue, endothelial cells and stromal fibroblasts (Figure 
4-16B).  Strikingly, HSP-27 was highly over-expressed in epithelial-derived tumour 
cells within lymph node metastases (Figure 4-16A). 
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Figure 4-15 Heterogeneous Tumour Expression of HSP-27. (A) Area within patient 15's tumour with low 
HSP-27 expression.  (B) Area within patient 15's tumour with high HSP-27 expression.  Normal 
squamous epithelium is seen on the lower left (A) and right (B) of the images. 
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Figure 4-16 Expression of HSP-27 in a Lymph Node Metastasis from patient15 (A) and Normal 
Oesophageal Submucosal Tissue (B).  (B) Normal squamous epithelium is on the right and Muscularis 
Mucosa is in the centre of the image.  
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4.3.6 Discussion 
To the author’s knowledge, this is the first study of protein expression in OAC tissue 
to utilize a purely shotgun proteomic approach.  The confident identification and 
quantification of over 1,000 proteins demonstrated the potential power of this 
approach even when applied directly to human oesophageal tissues.  Significantly 
higher numbers of identifications were made compared to 2D-gel or MALDI-based 
approaches with selective target identification.  The technical reproducibility of TMT 
labeling and isobaric quantitation was also high.  This suggests further biological 
rather than technical replicates would be required to address the main source of 
variability.   
Reassuringly, at least a fifth of the upregulated proteins in this experiment have prior 
published evidence of upregulation in OAC.  Many of the remainder have an 
established role in other cancers.  Selected down-regulated proteins were also found 
to have previous published evidence of expression in oesophageal squamous 
epithelium.  This supports the assertion that bona fide proteins have been identified 
as dysregulated using this quantitative proteomic method.  The role of novel 
dysregulated proteins remains to be determined by further work, but the potential for 
therapeutic approaches is clear.    
Candidates were selected for validation by IHC and antibody specificity confirmed.  
Although only OAC and normal squamous tissue were sampled for the proteomic 
experiment, protein expression was examined across a range of tissues from the 
resection specimens.   
AGR2 has previously been reported to be expressed in human stomach and other 
columnar-epithelial tissues with overexpression in Barrett’s epithelium and OAC 
with no expression in squamous epithelia613-616.  Despite this widespread expression, 
AGR2 may still be a therapeutic target as it has been reported to regulate cancer cell 
invasion, potentially via cathepsin-B and D expression575,617.  Supporting this, AGR2 
expression was observed in the metastatic OAC cells in the lymph nodes of patient 
15 (Figure 4-8). 
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The nuclear expression of SAMHD1 and expression in non-epithelial cells in both 
involved and uninvolved lymph nodes may reflect the reported role of this protein in 
modulating the immune response in T cells618.  No role has yet been described for 
SAMHD1 in cancer and this would be worthy of further study.   
GRP-78 has also been previously demonstrated to be upregulated in OAC and plays 
a key role in the regulation of the unfolded-protein response594,619.  Using an elegant 
membrane protein enrichment strategy, a change in localization from the ER to the 
cell membrane has been noted in cancer cells for several chaperones including GRP-
78374.  This raises the possibility of immunotherapeutic strategies directed against 
this protein.  The staining for GRP-78 appeared to be predominantly cytoplasmic in 
the sections examined, however, membrane staining is often difficult to determine by 
IHC especially when cytoplasmic staining co-exists.  Further examination of the 
subcellular expression of GRP-78 in OAC compared to Barrett’s, gastric and 
squamous cells by confocal immunofluorescence microscopy would help to clarify 
this.  A further possibility would be to target GRP-78 directly and specific inhibitors 
have been described620. 
D4GDI was over-expressed in OAC sections compared to slides from normal 
squamous tissue.  The D4GDI positive cells appeared, however, to be lymphocytes 
rather than epithelial-derived tumour cells.  This expression pattern has been 
observed for D4GDI with a different antibody in a database of protein expression; 
the human protein atlas616 and an early multi-tissue study suggested expression was 
restricted to haematopoietic cells621.  
Divergent roles for D4GDI have subsequently been proposed in the literature with 
some evidence for a role in the suppression of metastasis in bladder cancer622 and in 
contrast a pro-invasive role in gastric cancer623.  One previous proteomic study 
suggested D4-GDI was overexpressed in OAC compared to Barrett’s epithelium at 
both the mRNA and protein level.  In contrast to the data presented in this work 
(Figure 4-9), the IHC images in the published study showed apparently cytoplasmic 
and membrane staining in epithelial cells with minimal stromal positivity in OAC.  
The D4GDI antibody used was a “rabbit anti-ARHGDIB antibody at 1:50 dilution 
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Identifying OAC-specific Protein Expression by Shotgun Proteomics 225 
(Abnova Corp.)”.  Confusingly the paper has been cited in association with a mouse-
polyclonal antibody (H00000397-A01) on the Abnova website624.  No details of the 
optimization steps taken with this antibody were provided in the publication and it is 
difficult therefore to confirm the specificity or the identity of the Abnova antibody 
used. 
Variable expression for D4-GDI was noted in the panel of oesophageal cell lines 
(Figure 4-6) and this may reflect context-dependent regulation.  Staining for D4-GDI 
in a larger number of oesophageal tumours would be required to establish greater 
confidence over the cell specific expression profile. 
The heterogeneous staining pattern for HSP-27 suggests this protein may exhibit 
dynamic regulation throughout the process of carcinogenesis.  A study on breast 
cancer stem cells identified an association between the stem-cell phenotype and 
HSP-27 expression.  Suppression of HSP27 expression has also been reported to 
reduce the expression of the EMT-associated markers snail and vimentin625.  In 
support of a role for HSP-27 in EMT, stimulation of human peritoneal mesothelial 
cells to undergo EMT with TGF-β1 increased HSP-27 expression626.  The same 
finding was also demonstrated in an independent study on lung cancer cells627.  
Further recent work on prostate cancer cells expanded on this by establishing a 
requirement for HSP-27 in IL-6 mediated EMT.  HSP-27 was also more highly 
expressed in poorly differentiated prostate cancers, and inhibition of HSP-27 using 
an anti-sense oligonucleotide reduced the metastasis of prostate cancer cells in a 
nude mouse xenograft model.  Importantly, the same anti-sense oligonucleotide 
reduced circulating tumour cell counts in a phase I clinical trial in patients with 
metastatic castration-resistant prostate cancer628.      
HSP-27 has previously been shown to be over-expressed in squamous oesophageal 
epithelium compared to Barrett’s and OAC but no heterogeneity in tumour 
expression was described in this study629.   In contrast, HSP-27 mRNA expression 
increased from non-dysplastic Barrett’s samples through dysplasia to 
adenocarcinoma with the highest levels observed in poorly differentiated 
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adenocarcinomas630.     Similarly in OSCC, HSP-27 expression was increased in 
poorly differentiated relative to moderate or well differentiated tumours631. 
A study on OAC using reverse-phase protein arrays has demonstrated low expression 
of  three isoforms of phosphorylated HSP-27 are associated with a poor prognosis632.  
Interestingly, expression of total HSP-27 appeared to follow the reverse pattern but 
the findings could not be verified by IHC. 
Together these data implicate HSP-27 in tumour progression and metastasis, 
potentially associated with EMT.  This proteomic study provides the first evidence of 
HSP-27 upregulation in lymph node metastasis in OAC and hints at a potential 
mechanism of metastasis through dedifferentiation to a more mesenchymal 
phenotype.  Further investigation of the expression of EMT markers and HSP-27 in 
lymph node metastasis and circulating tumour cells are required in a larger cohort to 
confirm these findings.  If verified, modulation of this pathway could provide a 
compelling strategy to limit metastasis in OAC. 
In conclusion, even with the limited patient numbers in this first study, candidate 
therapeutic targets have been proposed, confirming the potential power of this 
comparative proteomic approach.  However, the proteome coverage of the pilot study 
was relatively low when compared to all potential proteins encoded by the human 
genome.  Enhancing proteome coverage may reveal more specific targets and may 
yield greater insight into the underlying pathways dysregulated in this cancer.  
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5.1 Chapter Aims 
 
a) To evaluate if the altering the tissue lysis method enhances 
proteome coverage.  
 
b) To determine if a label-free, data-independent proteomic 
method can enhance proteome coverage compared to data-
dependent strategy.  
 
c) To develop a strategy to combine quantitative data from 
label-free and isobaric labelling (TMT) proteomic 
experiments. 
 
d) To estimate the probability a protein is not expressed in a 






 Enhancing Oesophageal Tissue Chapter 5:
Proteome Coverage 
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5.2 Introduction 
In the previous chapter, quantitative shotgun mass spectrometry was demonstrated to 
be both accurate and sensitive enough to identify tissue-specific protein expression 
from human oesophageal biopsies.  Although interesting candidate therapeutic 
targets were proposed, none demonstrated entirely OAC-specific expression.  This 
chapter will explore strategies to improve the number of protein identifications 
(proteome coverage) from shotgun mass spectrometry experiments.  It is predicted 
that by evaluating greater numbers of candidates there will be a higher probability of 
identifying tumour-specific proteins.    
5.2.1 Intrinsic Limits in the Mass Spectrometry Observable 
Proteome 
The most recent data release of the Human PeptideAtlas encompasses proteins 
identified from 12,629 unique genes454. This global collaborative project has used 
over 43 million peptide-spectrum matches from 470 experiments to make these 
identifications.  The prior release utilized 14 million peptide-spectrum matches to 
identify proteins from 11,524 genes.  The trebling in data volume required to 
increment the number of protein identifications by less than 10% suggest the 
maximum number of proteins identifiable by standard shotgun mass spectrometry 
methods is being approached.  Indeed, there are intrinsic biochemical limits to the 
number of peptides detectable by mass spectrometry.  For example, highly 
hydrophobic proteins, membrane proteins, and highly basic proteins are all unlikely 
to be detected by shotgun MS methods454.  This may explain why the MS detectable 
proteome is not yet equivalent to the protein-coding genome. 
The scanning frequency and mass resolution of a mass spectrometer further restrict 
the number of detectable peptides from a sample. Fractionation is therefore often 
employed to reduce sample complexity to enhance coverage.  Recent significant 
advances in instrument technology have produced high mass accuracy, high scanning 
speed instruments that in combination with orthogonal fractionation method are 
capable of identifying over 10,500 proteins from a single cell line sample396,423.   
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5.2.2 Role of Fractionation 
In samples with several milligrams of protein, extensive fractionation methods can 
be applied to enhance the dynamic range of coverage.  One study used several 
orthogonal methods to identify serum proteins over 12 log10 orders of magnitude in 
native concentration402. Fractionation by OFF-GEL electrophoresis was employed to 
generate 12 peptide fractions from the pooled samples in the previous chapter.    To 
enhance this method, further separation of peptide mixtures could be achieved by 
increasing the number of OFF-GEL fractions to the current limit of 24.         
5.2.3 Use of Detergents for Tissue Lysis 
Enhancing proteome solubilisation could further improve proteome coverage.  The 
previous study used a lysis buffer with 0.05% (v/v) SDS; the maximum detergent 
concentration compatible with direct tryptic digestion.  Higher detergent 
concentrations could enable the solubilisation of more hydrophobic proteins but in 
addition to creating problems with enzymatic digestion, SDS and many other 
detergents ionise readily and can corrupt peptide mass spectra. The lysis buffer can, 
however, be exchanged to a trypsin and MS compatible solution using molecular 
weight cut-off filters.  An application of this technique has been termed Filter-Aided 
Sample Preparation (FASP)443.        
5.2.4 Optimising the Detection of Tumour-Specific Proteins 
The expression in gastric epithelium of some of the proteins over-expressed in OAC 
compared to normal squamous epithelium highlights a limitation in the original 
experimental design.  Identified proteins with a high TvO ratio may be expressed in 
all glandular rather than squamous epithelia, may be specifically under-expressed in 
squamous epithelia, or may be specifically expressed in adenocarcinoma tissue.  
Tractable therapeutic candidates may be more likely to be identified in the latter 
category but using the TvO ratio alone, they cannot be discriminated from proteins in 
the other categories. 
If OAC, normal oesophagus and gastric tissue from the same patient were analysed 
together, protein expression could be defined by both tumour vs. normal oesophageal 
(TvO) and tumour vs. normal gastric (TvG) comparisons.  Using this method, 
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proteins selectively upregulated in OAC could be more easily identified since those 
proteins expressed in all columnar epithelial tissues should be expressed at similar 
levels in both gastric and OAC tissue or at higher levels in gastric tissue.  
5.2.5 A Systematic Sequencing Approach 
Shotgun proteomic experiments most commonly use a data-dependent workflow.  
This requires that precursor (peptide) ions be detected in the MS1 phase386.  For the 
pilot study, this approach was followed and a maximum of the top three precursor 
ions in each MS1 scan were selected for fragmentation and detection in the MS2 
phase.  There are limitations in the data-dependent method as all precursor ions 
cannot be selected for fragmentation in the time scale of a standard chromatographic 
peak.  Similarly, some peptides ions are below the limit of detection and are never 
selected for fragmentation405. 
A possible method to overcome these limitations is to define precursor ion m/z 
ranges (windows) and to fragment and sequence all the precursor ions within the m/z 
range.  By systematically screening through large precursor m/z ranges, peptides 
from a potentially wider dynamic range of expression can be identified.  This data-
independent approach has been termed Precursor Acquisition Independent From Ion 
Count (PAcIFIC)404.  A limitation of the method is the requirement to perform 
multiple LC runs to cover the full m/z range.  Improvements in instrument 
sequencing speeds and optimized LC gradients have reduced the protocol time from 
over 4 days to just over 24 hours per sample406.                 
5.3 Results 
5.3.1 Evaluation of Proteome Extraction Methods 
As the FASP method has not previously been applied to oesophageal tissue, the 
tissue lysis protocol was first optimized using snap frozen mouse small intestinal 
tissue to provide homogeneous, reproducible tissue samples with a similar 
composition to human gastrointestinal tissue.  Buffer compositions and the steps 
from the FASP protocol were applied as published with minor modifications to suit 
local equipment.  Differing sequences of lysis buffer addition and homogenization 
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were initially tested.  From this initial experiment, a biopsy weight of at least 2 mg 
and a ratio of at least 15:1 lysis buffer (µL) : biopsy weight (mg) appeared to yield 
the most protein (Table 5-1).  The addition of needle sonication for 30s after biopsy 
lysis increased the final protein yield after buffer exchange by approximately two 
fold (data not shown).   
The published FASP protocol describes on-column tryptic digestion followed by 
centrifugation to collect the resultant tryptic peptides.  To evaluate this method, two 
mouse small intestine biopsies (A, 28.9 mg and B, 30.2 mg) were homogenised dry 
and dissolved in complete lysis buffer added at a 20:1 ratio. Lysates were then 
sonicated and 30 µL of clarified lysate buffer-exchanged, alkylated and diluted in 
TEAB as per the FASP protocol.   
Lysates were digested on-column by overnight incubation with trypsin and then 
centrifuged.  The protein concentrations of the NMWCO filter residuate and filtrate 
revealed the majority of the protein mass was retained in the filter (Table 5-2).  The 
method was therefore modified so that the residuate was aspirated and digested off-
column, resulting in an improved yield (Table 5-2).  Off-column digestion was 
subsequently used for all human tissue proteomic experiments.     
The original FASP protocol specified the use of 10 kDa NMWCO filters.  A 
subsequent investigation revealed minimal protein loss but a significant reduction in 
protocol time with the use of 30 kDa filters633.  To evaluate if significant protein loss 
occurs during FASP and to confirm the efficacy of tryptic digestion, the off-column 
tryptic digests detailed in Table 5-2 and the corresponding buffer exchanged lysates 
were resolved by SDS-PAGE.  Images of the Coomassie-stained gels confirm 
significant concentrations of proteins <30 kDa are retained during the FASP 
procedure and the off-column trypsin digestion generates an almost complete 
digestion (Figure 5-1).  The enhanced yield from sample sonication is also evident. 
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Volume of lysis buffer 
added pre 
homogenisation (μL) 
Volume of 10% (v/v) SDS 




















Small Bx 1:5 24.9 125 DFLB 83 208 1:7.5 Minimal x X 
Medium Bx 1:5 35.5 178 DFLB 118 296 1:7.5 1.13 333 9.4 
Large Bx 1:5 38.6 193 DFLB 127 320 1:7.5 1.14 365 9.4 
Small Bx 1:10 26.5 265 DFLB 176 441 1:15 0.17 75 2.8 
Medium Bx 1:10 31.7 317 DFLB 209 526 1:15 2.09 1099 34.7 
Large Bx 1:10 41.8 418 DFLB 275 693 1:15 1.23 852 20.4 
Small Bx 1:20 11.7 234 DFLB 154 388 1:30 0.38 147 12.6 
Medium Bx 1:20 26.4 528 DFLB 348 876 1:30 1.06 929 35.2 
Large Bx 1:20 34.4 688 DFLB 454 1142 1:30 0.77 879 25.5 
Dry + Small Bx 21.1 X 211 SDSB 211 1:10 1.68 354 16.8 
Dry + Medium Bx 35.9 X 359 SDSB 359 1:10 2.07 743 20.7 
Dry + Large Bx 61.8 X 618 SDSB 618 1:10 2.11 1303 21.1 
Medium Bx 1:10 27.4 274 SDSB X 274 1:10 1.49 408 14.9 
SDS buffer only x 200 SDSB X 200 1:10 0.0 x X 
DFLB – Detergent-free Lysis buffer, SDSB – Complete lysis buffer (DFLB + 4% SDS)
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Table 5-2 Comparison of Digestion Conditions for two Mouse Small Intestine Biopsies  
Starting Tissue 
Sample 




A  Y Filtrate 0.062 
A Y Residuate 0.144 
A Y Off-Column 0.504 
    
B Y Filtrate 0.058 
B Y Residuate 0.109 




Figure 5-1 Effect of Buffer-Exchange, Sonication and Tryptic Digestion on Protein Size Distribution. 
Lysates were buffer exchanged, alkylated, and diluted using the modified FASP protocol.  Samples 
before and after off-column tryptic digestion were resolved by SDS-PAGE (16μL of undiluted lysate and 4 
μL of 5x Sample Loading Buffer per lane, 10% agarose), and the gel stained with Coomassie blue before 
scanning. The highlighted band in the Tryptic digests is presumably trypsin (predicted molecular weight 
(MW) 24 kDa).   
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5.3.2 Comparison of modified FASP (mFASP) and initial methods.  
To evaluate the effect of this change in lysis method on proteome coverage, the 
modified FASP protocol was applied to samples from two further patients (44 and 
46).  To improve the probability of identifying tissue-specific proteins, patient 
matched OAC, normal oesophageal and gastric tissue were all lysed and processed 
using the modified FASP (mFASP) protocol before TMT-labeling. Peptides from 
each tissue type were labeled in technical duplicate, incorporating all six TMT 
reporters and therefore analyzing all the tissues from one patient together in the same 
LC and mass spectrometry run.  Technical replicate labeling was incorporated to 
allow the degree of technical variation to be determined on an individual sample 
basis.  To attempt to further enhance proteome coverage, labeled peptides from all 
the tissues from each patient were pooled and then 24 fractions resolved by OFF-
GEL electrophoresis.  As this increased the time to run a single patient’s samples to 
over 24 hours, only a single LC-MS/MS run was performed for each fraction and the 
data for all fractions pooled.  Protein identifications were made as previously using 
the Easyprot platform.  The initial and modified TMT workflows are shown in 
Figure 5-2.  
The total number of protein IDs and their contributions from the initial experiment 
and the subsequent mFASP TMT experiments are demonstrated in Figure 5-3.  This 
shows that only 110 of the total 2168 proteins were unique to the initial experiment 
and that 1,542 proteins were detected in at least two experiments.  The combination 
of the mFASP method and the increased number of OFFGEL fractions appears, 
therefore, to significantly increase the number of protein identifications.  
5.3.3 Comparison of PAcIFIC and TMT shotgun proteomic 
methods 
To evaluate if a systematic shotgun proteomic sequencing method could further 
enhance proteome coverage, PAcIFIC LC-MS/MS was applied to tryptic peptides 
generated using the mFASP method.  Eleven days of mass spectrometry time were 
available for this analysis.  Although it was anticipated that the additional analysis of 
patient-matched gastric tissue along with OAC and normal oesophageal tissue would 
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aid the identification of tumour specific proteins, this would limit the PAcIFIC 
analysis to 3 patients.  Biological variability was shown to be a potentially significant 
factor in the initial TMT experiment and therefore OAC and normal oesophageal 
tissue from five patients were analysed.  The PAcIFIC workflow is summarised in 
Figure 5-4.   
A total of 3,019 proteins were identified across all PAcIFIC samples.  The PAcIFIC 
mass spectra were searched against an International Protein Index (IPI) database and 
therefore proteins were denoted with an IPI reference number.   The TMT data, 
however, were searched against the Swissprot curated database and proteins were 
denoted with a Uniprot Accession number (AC).  Although different databases were 
searched, both TMT and PAcIFIC experiments used conservative identification 
strategies requiring two different peptides per protein and maintaining an FDR of 
less than 1%.  To compare experiments, the PAcIFIC IPI reference numbers were 
mapped to 2,936 unique AC identifiers.  In comparison, the mFASP TMT 
experiments yielded 2,058 unique AC identifications with 1,483 proteins identified 
in both experiments.      
The individual TMT and PAcIFIC experiments are compared in Table 5-3.  The 
highest numbers of protein identifications were observed in the mFASP TMT 
experiments.  TMT quantification appears to offer a significantly greater quantitative 
dynamic range than label-free quantitation using spectral counting. 
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Figure 5-2  Summary Experimental Protocol for TMT Proteomic Experiments.  Tryptic peptides from each tissue type were labelled with TMT reporters as demonstrated. 
The protocol on the left was followed for the pilot TMT experiment and the right for all subsequent experiments.  Abbreviations: ACC – Adenocarcinoma biopsies, Oes – 
normal squamous oesophageal biopsies, Sto – normal gastric biopsies, mFASP – modified Filter-Aided Sample Preparation.  TMT – Tandem Mass Tags.  LC – Liquid 
Chromatography, MS/MS – Tandem Mass Spectrometry. 
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Figure 5-3 Overlap of Protein Identifications between Initial (Red) and mFASP TMT experiments (purple 
and green).     
 
Figure 5-4 Summary of PAcIFIC Workflow.  Samples were processed using the mFASP method and then 
analysed using by PAcIFIC LC-MS/MS.  Proteins were identified and quantified using the Trans-
Proteomic Pipeline (TPP) suite of tools.  
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15+17 T,N Standard TMT OFFGEL,  
12 fractions 
1097 6.7 
44 T,N,G mFASP TMT OFFGEL, 
 24 fractions 
1924 6.9 
46 T,N,G mFASP TMT OFFGEL,  
24 fractions 
1579 7.0 
23 T mFASP PAcIFIC Nil 1879 2.25 
23 N mFASP PAcIFIC Nil 1183 2.48 
26 T mFASP PAcIFIC Nil 1408 2.21 
26 N mFASP PAcIFIC Nil 923 2.34 
27 T mFASP PAcIFIC Nil 1585 2.23 
27 N mFASP PAcIFIC Nil 1095 2.43 
32 T mFASP PAcIFIC Nil 1471 2.29 
32 N mFASP PAcIFIC Nil 1050 2.49 
45 T mFASP PAcIFIC Nil 1003 2.37 
45 N mFASP PAcIFIC Nil 977 2.31 
Quantitative Dynamic Range was calculated as the highest TMT reporter ion intensity divided by the lowest or the 
highest spectral count divided by the lowest spectral count.  T – Tumour, N- Normal Oesophagus, G- Normal Gastric.   
 
5.3.4 The Effect of the mFASP protocol on protein solubilisation. 
To explore if the mFASP method improved proteome coverage by enhancing 
membrane protein solubilisation, the primary subcellular loci for proteins identified 
via each experimental method were compared.  Summary localization data were 
available for 921 out of 1,097 proteins (84%) identified in the pilot TMT study and 
1,732 out of 2,058 proteins (84%) in the mFASP TMT data.  For the PAcIFIC 
experiments, 1,963 of the 2,936 proteins mapped to Uniprot Accessions had 
localisation data (67%).  The primary subcellular localisation for proteins identified 
following each experimental method are summarised in Figure 5-5.      
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Figure 5-5 Summary of Primary Subcellular Localisation of Proteins Identified via Each Proteomic 
Method.  See Methods 2.11.5 for mapping details.  
This demonstrated that the mFASP method produced an  increase in the 
identification of cell membrane proteins and proteins primarily localized to 
subcellular membrane bound structures; cytoplasmic vesicles (lysosomes, 
endosomes, peroxisomes, etc.), the ER, golgi and mitochondria.  Based on this 
limited analysis, this suggests that the mFASP method does indeed enhance the 
solubilisation of membrane proteins.    
5.3.5 Combining Proteomic Datasets 
Seven patients’ samples had been processed using the mFASP method.  Clinical data 
for these patients are summarized in Table 5-4.  Combining the results from mFASP 
TMT and PAcIFIC experiments may enhance the probability of identifying tumour 
specific proteins.   
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Table 5-4 Clinical Characteristics of Patients Donating Samples for mFASP Proteomic Experiments. 
Patient 
 23 26 27 32 45 44 46 




Gender Male Male Male Male Male Male Male 
Age 57 53 60 57 78 59 67 
Histology ACC ACC ACC ACC ACC ACC ACC 
Location OGJ Type I OGJ Type I Lower Oes OGJ Type I OGJ Type I OGJ Type II OGJ Type I 
Neoadjuvant 

















Surgery ILO ILO ILO ILO ILO ILO ILO 
Maximum 
Tumour Diameter 46mm 35mm 40mm 94mm 40mm 38mm 70mm 
Distance to PRM 
and DRM >1mm >1mm >1mm >1mm >1mm >1mm >1mm 
Distance to CRM 5.5mm 0.9mm 1.0mm 0.1mm 0.0mm 4.2mm 0.0mm 
Differentiation Moderate Poor Poor Poor Poor Moderate Poor 
Lymphovascular 
Invasion 
Y N Y Y Y Y Y 
Venous Invasion Y N N Y Y N N 
Perineural 
Invasion N Y N Y Y N Y 
T stage T2 T3 T3 T3 T3 T2 T4a 
Number of 
Positive Nodes 0 2 7 7 6 2 8 
Total Number 
Nodes Resected 43 14 20 19 16 27 18 
AJCC Stage IB IIIA IIIC IIIC IIIB IIB IIIC 
Alive at Time of 















Abbreviations. , 2xCF - 2 cycles of Cisplatin and 5-Fluorouracil,  ILO – Ivor-Lewis Oesophagectomy, AJCC – 
American Joint Committee on Cancer, OGJ – Oesophagogastric Junctional Tumour, PRM – Proximal resection 
margin, DRM – Distal resection margin, CRM – Circumferential resection margin, Y-Yes, N-No. 
 
5.3.6 Generating a Matrix of Unique Quantified Proteins 
The protein identifications (IDs) from TMT and PAcIFIC experiments were first 
combined into a list of unique Uniprot ACs with corresponding abundance data.  
Proteins from 3,549 unique genes were identified and quantified in OAC or normal 
oesophageal samples from at least one of the seven patients.  It is apparent from 
Table 5-3 that each proteomic experiment only measured a subset of the proteins in 
the tissue lysate. In the total set of identified proteins each protein may therefore 
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have been identified (and quantified) between one and seven times.  The differing 
scales, dynamic range and quantitation methods preclude combining values for 
proteins across all experiments by arithmetic methods. 
5.3.7 Combining quantitative proteomic datasets with 
overlapping protein identifications 
Strategies for combining quantitative expression datasets have been developed for 
application in microarray analysis.  A popular method is quantile normalization, 
where proteins are ranked within an experiment based on their abundance and this 
rank replaced with the corresponding value calculated from the mean of the rank-
ordered samples634.  This method normalises the experimental distributions and 
allows experiments with differing quantitation methods to be combined, enhancing 
the power of the analysis.  Proteins not observed in an experiment cannot, however, 
be ranked by quantile normalization.   
The ratio of protein expression between tissues is scale-independent. This ratio could 
be used to compare relative protein expression between tumour and normal samples 
across PAcIFIC and TMT experiments.  To generate this combined expression value, 
only tumour vs. normal oesophageal expression ratios can be used, since gastric 
tissues were not assessed by PAcIFIC.  Ratios, however, also require quantitation 
values for both samples.  When the peptide reporter ratios were combined for each 
protein for the TMT experiments, no tissue specific expression was observed and so 
ratios were calculable for all proteins.  Conversely, in the PAcIFIC experiments, over 
a quarter of the identified proteins were only observed in the OAC samples.  Dealing 
with missing observations is a central problem in proteomic informatics and will be 
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5.3.8 Dealing with Missing Observations 
There are two situations where missing values occur in the combined proteomic 
dataset; 
(1) A protein is not observed in any experiment for a tissue type.  “7 zero” =  7z 
(2) A protein is observed in some of the PAcIFIC experiments. “False negative” 
= FNeg 
To consider these situations some assumptions will be made: 
(a) Each sample from a tissue type is effectively a technical replicate (biological 
variation is ignored).  More specifically each tissue sample is regarded to contain 
very similar proteins and there are very few experiment-specific proteins.   
(b) A subset of the total human (normal) proteome will be expressed in each tissue 
type (c.f. all tissues expressing all proteins.).  A tissue type may therefore contain 
tissue-specific proteins. 
(c) There is a biochemical bias in peptide and therefore protein identification by mass 
spectrometry.  This bias is assumed to be equivalent in all tissues so that there is an 
equal probability of a protein being identified from one tissue compared to another.    
When a protein is not detected in any of the normal tissue experiments but detected 
in many or all of the tumour tissue experiments the protein is more likely to be truly 
not expressed in normal tissue (a true negative) than if the protein is only detected in 
one of the tumour samples.    
5.3.9 The False Negative (FNeg) 
In situation 2 and following assumption a, it can be concluded that if a protein has 
been observed once in a tissue sample, all subsequent missed identifications must be 
false negatives.  The true expression value could be estimated for that tissue by using 
the observed values.   
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The relationship between the probability of a false negative and protein abundance 
was assessed.  The false negative rate was calculated on a per protein basis for 




Terr = the false negative rate in tumour  
Nerr = the false negative rate in normal oesophagus  
Ft = the frequency of observation of a protein in the seven experiments for tumour 
tissues. 
Fn= the frequency of observation in normal tissues. 
Terr and Nerr can take one of 8 discrete values from 0 – 1 (0/7, 1/7, 2/7 … 6/7, 7/7).  
The case of Terr or Nerr = 1 will be considered subsequently as the 7 zero problem. 
To assess the relationship between Nerr, Terr and protein abundance, data from all 
seven experiments were evaluated.  Protein abundance was estimated from the 
geometric mean of peptide reporter intensities from the TMT experiments as the 
dynamic range and accuracy were considered superior to spectral counts (Table 5-3).   
Surprisingly, when protein abundance was plotted against Ft (1-Terr) and Fn (1-
Nerr), there appeared to be no relationship (Figure 5-6A).  This suggests that protein 
identification was not biased by abundance.  The probability of each identification 
rate was also calculated for each tissue type (Figure 5-6B).  A bimodal distribution 
for identification frequency was identified for each tissue type, with a group of 
ubiquitously identified proteins in both tumour and normal tissues.  There also 
appeared to be a bias towards OAC protein identification with fewer proteins 
identified exclusively in normal oesophagus.  This may reflect the higher numbers of 
protein identifications in the PAcIFIC tumour samples compared to the normal 
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oesophageal samples (Table 5-3).   To examine the relationship between Ft and Fn 
the conditional probability of Ft for a given Fn and vice versa were plotted (Figure 
5-7).    
There was a good correlation between Ft and Fn providing some support for the 




Figure 5-6 (A) Notched boxplots demonstrating protein abundance by frequency of identification in 
tumour (Ft) and normal oesophageal (Fn) tissues.  The whiskers represent the maximum or minimum 
values or 1.5 times the inter-quartile range if outliers (circles) extend beyond this.  The notches 
approximate 95% confidence intervals of the median635.   (B) Relative proportion of proteins identified at 
each frequency.
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Figure 5-7 The Joint Probability of Ft and Fn. (A) As Fn varies, the corresponding  probability of each Ft is 
displayed using the colour scale. (B) As Ft varies the corresponding  probability of each Fn is displayed. 
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5.3.10 A Statistical Framework to Identify True Negatives 
In situation (1) and from assumption (b), not observing a protein in seven 
experiments (7z) may represent a true or false negative.  From assumption (c) if 
Fn=0 then as Ft approaches 1 the probability of a true negative is more likely.  An 
estimate of the probability of a true negative given the Ft (or Fn) was therefore 
sought as this may allow false negative data to be excluded.      
Considering several conditions, initially in normal tissue; 
NE = a protein is not expressed in the normal tissue.  Observing 7z for this protein 
would be a true negative. 
Fn = the frequency of identification in the normal tissue 
Fx = the frequency of identification across tissues – ie. a co-ordinate Ft,Fn 
The probability that a protein is not expressed in normal tissue given an Ft, Fn co-
ordinate can be expressed as | .  This is the true negative probability and 
will allow an Ft threshold to be determined above which proteins will be considered 
to not be expressed in the normal tissue i.e. tumour specific.  The data for proteins 
with Fn = 0 and an Ft below this threshold will be discarded. 
Expanding this expression using Bayes theorem636 gives; 




Defining each component of this equation; 
|  = the probability of obtaining the Ft,Fn co-ordinate given that the protein 
is not expressed in normal tissue.   
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The probability of a protein not being expressed is zero when the protein has been 
observed at least once.  For all values of Ft,Fn where Fn ≠ 0,	 |  will be 0 
and, from Equation 10, |  will also be zero.   
 = the probability of obtaining the given Ft, Fn co-ordinate across the tumour 
and normal oesophageal proteomes (when normal protein databases are used).  The 
size of these proteomes are unknown but a conservative strategy would be to take the 
best estimate of the current total MS observable proteome (Y) from  the human 
PeptideAtlas; 12,629 proteins423.  Therefore	  can be estimated as the total 
number of proteins with Ft,Fn divided by 12,629.   
 = the probability that a randomly selected protein is not expressed in normal 
tissue.  This can be defined as 1-(N/Y) where N is the total number of proteins 
expressed in the normal oesophageal tissue.  
As true negatives can only be identified if values of	  are Ft>0/7,Fn0/7 or 
Fn>0/7,Ft0/7 only these proteins are considered.  The probability of a specific Ft given 
Fn0/7 in our data set is demonstrated in Table 5-5. 
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The probability of the co-ordinate combination Ft,Fn0/7 can be considered as the sum 
of the probability of achieving the combination when the protein is not expressed and 
the probability of achieving the combination when the protein is expressed but has 
been missed.  
(ie. Total probability = true negative probability + false negative probability) 
This is expressed algebraically for the combination Ft,Fn0/7 as; 
, /
, /
, /  
Equation 11 
Where; 
, /  = the probability of obtaining an Ft, Fn0/7 combination given 
that the protein has been missed (not detected) in normal tissue.  
	= the probability that a protein has been missed in the normal tissue. 
5.3.11 The Effect of Relative Proteome Size on pFt and pFn 
 is proportional to the relative sizes of the tumour proteome and normal 
proteome.   
This is illustrated in Figure 5-8;  
							  
Intuitively proteins with an Ft1/7Fn0/7 and an Ft2/7Fn0/7 are expected to be 
predominantly in the “N” area and proteins with an Ft6/7Fn0/7 or Ft7/7Fn0/7 to be 
predominantly in the “T” area”.   
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In the example in Figure 5-8A, N= 400 proteins and T = 600 proteins.  For the 
purposes of this example, following assumption (c), it is suggested that 50% of 
proteins in N have an Ft1/7Fn0/7 and Ft2/7Fn0/7 and 5% have an Ft6/7Fn0/7 or Ft7/7Fn0/7.  
In contrast it is proposed that 10% of proteins in T have an Ft1/7Fn0/7 and Ft2/7Fn0/7 
and 50% of T have an Ft6/7Fn0/7 or Ft7/7Fn0/7.   
Figure 5-8 Hypothetical Examples of (A) High and (B) Low Mean Ft.  The outer area (T) represents 
proteins only expressed in tumour tissue and the inner area (N) represents proteins expressed in both 
tumour and normal tissues.  
The probability of Ft1/7Fn0/7 and Ft2/7Fn0/7 for this hypothetical dataset (T+N = 1000 
proteins) can be calculated from Equation 11 as;  
(0.1 x 0.6) + (0.5 x 0.4)  
= 0.26 
In the same fashion, the total probability for Ft6/7Fn0/7 or Ft7/7Fn0/7 is calculated as; 
 (0.5 x 0.6) + (0.05 x 0.4) 
= 0.32  
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So with an Ft6/7Fn0/7 or Ft7/7Fn0/7 in this experiment and using the probabilities 
provided, the true negative probability can be calculated.  This is the probability the 
protein is in T, given the observed data (Fx);    |  
From Equation 10;  
|      




Which for Fx = Ft6/7Fn0/7 or Ft7/7Fn0/7  
= 0.3/0.32  
= 0.9375 
In this example, these proteins would be considered likely true negatives (not 
expressed in the normal tissue). 
In contrast when Fx = Ft1/7Fn0/7 or Ft2/7Fn0/7; 
|   = 0.06/0.2  
= 0.3 
In this example there is a reasonable probability the proteins are false negatives (are 
expressed in normal tissue but have been missed) and the data would be discarded.  
In the second illustration (Figure 5-8 B) values of N = 800 proteins, T= 200 proteins 
are proposed with the same probabilities of Ft1/7Fn0/7 or Ft2/7Fn0/7 and Ft6/7Fn0/7 or 
Ft7/7Fn0/7 for each tissue type. 
The total probability of Ft1/7Fn0/7 or Ft2/7Fn0/7 would be;  
= (0.1*0.2) + (0.5*0.8)   
= 0.42 
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and for Ft6/7Fn0/7 or Ft7/7Fn0/7  
= (0.5*0.2) + (0.05*0.8)  
= 0.14 
Therefore |  when Fx= Ft6/7Fn0/7 or Ft7/7Fn0/7 ; 
= 0.714  
and when Fx = Ft1Fn0 or Ft2Fn0 ; 
= 0.05 
The loss of predictive power in the second example is due to the larger set of proteins 
with a higher false negative probability (Ft1Fn0 of Ft2Fn0).   In situation (1) if 
assumption (c) holds true it can be appreciated that the mean Ft|Fn0/7 will directly 
correlate with the proportion of false negative proteins. 
This generalisation is supported if a theoretical complete sampling of tumour and 
normal oesophageal proteomes is imagined.  In this scenario the false negative rate 
should tend towards zero and the average Ft for an Fn=0 will tend towards 1.  In the 
converse situation with a sparse dataset there will be many examples of proteins with 
an Ft1Fn0 or Ft2Fn0 and it will be unclear if they are true or false negatives. 
5.3.12 Derivation of an Estimate of False Negative 
Probability 
Expanding the false negative probability term , |  from equation 2 
using Bayes theorem gives; 
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Using Equation 11 and Equation 12 the following can be derived; 
, / |




This simplifies to; 
, / |




From Equation 10; 
| , / 	





Finally simplifying to; 
 
| , / 	1 | , 0/7  
Equation 13  
Note: the proposal to consider conditional probabilities under a Bayesian framework and the original 
derivation of Equation 13 was from Dr. Ian Overton (IGMM, Edinburgh).  The assumptions follow from 
the Cox-Jaynes axioms637. 
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| , /  cannot be calculated from our data as it is unclear which 
proteins with an Fn0/7 are true negative and which are false negatives.   
Following assumption (a), all proteins with an Fn>0 are assumed to be present in all 
normal tissue samples.  It is proposed that the probability of a protein being missed 
in the experiments on normal tissue at a given Ft; | , , can be estimated 
as the proportion of missing quantitation values in the normal samples at the given 
Ft.   
Following this; | , /  can be estimated by | .  
| 	can be calculated as the average 1 |   for all proteins 
where	 0 (Table 5-6).   
Table 5-6 False Negative Probability of Fn for Ft 
Ft pMn|Ft,Fn0 pNE|Ft,Fn0 
0 0.8012 0.1988 
1/7 0.8095 0.1905 
2/7 0.7009 0.2991 
3/7 0.6189 0.3811 
4/7 0.5147 0.4853 
5/7 0.4136 0.5864 
6/7 0.2820 0.7180 
7/7 0.0846 0.9154 
 
Following these assumptions, it can be concluded that the probability of a protein 
being a false negative is <10% when Ft = 7/7.  Therefore all proteins with Ft7/7|Fn0/7 
are taken forward and the remainder are excluded from further analysis.   In a similar 
fashion a cut off of Fn7/7| Ft0/7 was deemed to represent an acceptable probability of 
being missed (p=0.0778, Table 5-7).  This left 2,425 proteins with an expression 
value for each tissue in at least one experiment or likely to represent a true negative. 
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0/7 0.7723 0.2277 
1/7 0.7344 0.2656 
2/7 0.5990 0.401 
3/7 0.4500 0.55 
4/7 0.3855 0.6145 
5/7 0.3336 0.6664 
6/7 0.2090 0.791 
7/7 0.0778 0.9222 
 
For proteins determined to be true negatives an expression value of 10-3 was 
substituted to allow ratios to be calculated.  For the remainder, the geometric mean 
TvO ratios were then determined for each protein, for the PAcIFIC data and TMT 
data separately.  There was a poor correlation between TvO ratios from TMT and 
PAcIFIC experiments although the intra-experimental correlation was good (Figure 
5-9).  This is further illustrated by the surprisingly limited relationship between 
protein abundance assessed by mean TMT reporter ion intensity or spectral count 
(Figure 5-10).   
The method of quantitation appears to have a significant bearing on the final tumour 
to normal ratio such that the methods cannot be combined.  The calculations of pMn 
and pMt for a given Ft or Fn were therefore reconsidered for the PAcIFIC data alone.     
The initial finding of the independence of Ft and Fn from predicted abundance 
(Figure 5-6A) was re-examined using only the PAcIFIC data (Figure 5-11).  This 
demonstrates that when spectral counts are used, tumour protein abundance was 
found to correlate with Ft (Pearson’s Correlation Coefficient (PCC) =0.6192, 
p<0.01) and normal protein abundance correlates with Fn (PCC = 0.6124).  
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Figure 5-9 Correlation of TMT and PAcIFIC TvO Ratios.  R23 = Ratio for patient 23’s samples, R26 – Ratio 
for patient 26’s samples etc.  The boxes have been shaded according to the Pearson’s correlation 
coefficient between samples (see key). 
 
Figure 5-10 Correlation of Spectral Counts and TMT Reporter Ion Intensities for (A) Normal Oesophageal 
Tissue, (B) OAC Tissue
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Figure 5-11 Correlation of Spectral Counts and Frequency of Observation in PAcIFIC data for (A) Normal Oesophageal Tissue and (B) OAC Tissue.
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5.3.13 False Negative Probability Re-Examined. 
 
The false and true negative probabilities were previously considered using Bayesian 
statistics to derive Equation 13; 
| , / 	1 | , 0/7  
 
The Bayesian approach has the advantage of allowing liberal assumptions around 
tumour and normal protein identification probabilities638.  
If protein identifications are considered independent and random events the 
probability of a false negative can also be evaluated from a frequentist perspective. 
For all proteins the total probability (pT) can be considered as;  
 
Where; 
pID = probability of a protein being identified; 
pNoID = probability of a protein not being identified   
Which can be expressed as; 
 
Where; 
pNE = probability of a protein being not expressed; 
pMs = probability of a protein being expressed but missed. 
For a single (random) protein the pID from normal tissue can be estimated as Fn. 
In the PAcIFIC dataset there are 3 scenarios;  
i) Fn = 5/5, ii) Fn = 0/5 and iii) Fn=1-4/5 
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For  i) pT = 1 and Fn = 1 so pNoID must equal zero. 
 ii) pT=1, Fn = 0 and therefore pNE + pMs = 1 and pNE = 1- pMs 
 iii) pT=1, and therefore 1= Fn + pNE + pMs.   
 From assumption (a) we know that pNE must = 0 so therefore;  
1  
Equation 14 
The probability of not identifying a protein from a sample is related to technical 
factors such as peptide biochemical properties, database searching, instrument 
variables etc.  It is therefore predicted that Fn will correlate with Ft for non-tissue 
specific proteins (i.e. Fn ≠0 and Ft ≠0) fitting assumption (c). 
This is found to be true for the PAcIFIC data (PCC = 0.53574). 
With this correlation, proteins with the same Ft are predicted to have a similar Mn.  
This probability can be estimated as the mean (1-Fn) for all proteins for a given Ft.  
The uncertainty in this probability can be estimated by assuming a Poisson 
distribution. 
The calculated pMn is the probability that a protein at a given Ft will be missed in 
the normal tissue in one experiment.  This is the same (on average) as the number of 
missed identifications in a series of independent experiments.  
From Equation 14 above; 
| 1 |  
Equation 15 
 
The	  can therefore be calculated for the various levels of Ft. 
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It is assumed, given the correlation of Ft and Fn, and that experiments are 
independent and identical, the  for 4 nulls when the fifth is detected is the same 
as the probability for 4 nulls when the fifth is missed.  Using this logic, the 
probability of 5 nulls can simply be estimated as the probability of 1 null5. 
These assumptions can be checked by calculating the predicted probability of 2, 3 
and 4 zeroes and the observed probability for various levels of Ft. 
The average (1-Fn) was calculated for the set of proteins with Fn≠0.    
Average (1-Fn) = pMn = 0.3745 
The converse calculation was performed for the set of proteins where Ft≠0 
Average (1-Ft) = pMt = 0.4599 
If experiments are independent and the probability of missing a protein is constant 
then the predicted and observed probabilities will follow the same distribution (Table 
5-8).  This is not the case and therefore the average pMn cannot be used to infer the 
pMn for 5 consecutive experiments.  It can be concluded that the Bayesian approach 
should be preferred for the calculation of pMn or pMt.   
Table 5-8 Comparison of Predicted and Actual pMn per Number of Observations 
Predicted Missed n=1 Missed n=2 Missed n=3 Missed n=4 Missed n=5
Normal 
Predicted pMn 0.3745 0.1403 0.0525 0.0197 0.0074 
pMn (actual) 0.1305 0.1077 0.1514 0.2681 
Lower Poisson CI 95% 0.1136 0.0925 0.1332 0.2437 
Upper Poisson CI 95% 0.1490 0.1247 0.1714 0.2944 
Tumour 
Predicted pMt 0.4599 0.2115 0.0972 0.0447 0.0205
pMt (actual) 0.1298 0.1452 0.1695 0.3426 
Lower Poisson CI 95% 0.1165 0.1311 0.1542 0.3207 
Upper Poisson CI 95% 0.1440 0.1603 0.1858 0.3656 
 
The pMn|Ft was calculated using Bayesian methods for the PAcIFIC dataset (Table 
5-9).  It was estimated that the probability of missing a protein given an Ft of 5/5 is 
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close to 10% and these proteins could reasonably be considered true negatives.  For 
Ft<5/5 it was unclear if the protein had been missed or was truly not expressed. 
High abundance proteins are more likely to be detected and therefore useful data may 
be gained by selecting high abundance proteins from groups with a lower Ft.  The 
pMn was calculated for the subgroups of proteins with abundances above and below 
the median geometric mean spectral count for each Ft (Table 5-9).  There was a 
lower pMn with greater abundance at each Ft.  The pMn was next calculated for each 
decile of protein abundance determined from the Log10 geometric mean spectral 
count, and for all proteins above an abundance threshold (Table 5-10).      
With each increasing decile of tumour protein abundance, the pMn decreased.  The 
pMn was plotted for incrementing thresholds of tumour protein abundance (Figure 
5-12).  From this curve, a cut-off representing a pMn of 10% was determined as a 
Log10 Tumour spectral count > 0.905 (Geometric mean spectral count >8.1).  This 
corresponds to 47 proteins (3.6%) in the set Ft|Fn0/5 (total n=1302 proteins).  In 
comparison, the set of Ft5/5 |Fn0/5 only contains 34 proteins which, using the Bayesian 
model, have an estimated pMn of 12%. 
The effect of combining abundance and Ft was next examined to identify if the 
number of proteins selected with a pMn <10% could be increased.  Each Ft was then 
subdivided according to percentile abundance and pMn calculated (Table 5-11).   
Within each Ft category a threshold was iterated above which the observed pMn 
<10%.  The number of proteins in the set Ft|Fn0/5 for each of these groups was then 
calculated, giving a total of 24 (Table 5-12). 
From these analyses, the greatest number of proteins with a pMn<10% can be 
selected by using an abundance criteria alone.    
To determine if the same holds true for pMt, the same analysis was performed for 
deciles of normal protein abundance (Table 13).  This demonstrated an abundance 
threshold around the 90th percentile defined proteins with a pMt of <10%.  In the set 
of Fn|Ft0/5 this identifies 8 proteins (3%) as being true negatives.  Using the Bayesian 
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model, seven proteins were identified in the set Fn5/5|Ft0/5 with an estimated pMt of 
12%.  There were only 32 proteins in the combined set Fn3/5-5/5|Fn0/5 negating any 
benefit in subdividing categories by abundance.  So similar to pMn|Ft, using an 
abundance threshold alone is the preferred criteria for identifying normal specific 
proteins.       









pMn|Ft     lower 
50% Abundance 
pMn|Ft     upper  
50% Abundance 
0/5 0.6893 253 0.6438 0.7369 NA NA 
1/5 0.5860 157 0.5332 0.6422 0.6509 0.5510 
2/5 0.5023 213 0.4607 0.5471 0.5385 0.4679 
3/5 0.4292 226 0.3914 0.4695 0.4874 0.3645 
4/5 0.3235 277 0.2940 0.3552 0.3842 0.2623 
5/5 0.1207 545 0.1079 0.1346 0.1949 0.0463 
 
Table 5-10 pMn for Deciles of Abundance and for All Proteins Above an Abundance Threshold 
Proteins within 








0-10% 0.55 All 0.3183 
10-20% 0.5 >0.389 (10%) 0.2976 
20-30% 0.4840 >0.477 (20%) 0.2779 
30-40% 0.4169 >0.539 (30%) 0.2437 
40-50% 0.3603 >0.619 (40%) 0.2101 
50-60% 0.3338 >0.692 (50%) 0.1803 
60-70% 0.2350 >0.759 (60%) 0.1420 
70-80% 0.1915 >0.853 (70%) 0.1107 
80-90% 0.1103 >0.976 (80%) 0.0704 
90-100% 0.0288 >1.195 (90%) 0.0288 
TSC - Tumour Spectral Count 
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Figure 5-12 The Effect of PAcIFIC Tumour Spectral Count on pMn. 
 
 
Table 5-11 pMn|Ft for Geometric Mean Spectral Count Percentiles 
Ft 
Geometric Mean Tumour Spectral Count (Percentile) 
>10% >15% >20% >40% >50% >60% >70% >80% >90% >95% >99% >99.9%
1/5    0.5510 0.5510 0.5510 0.5461 0.56 0.5417 0.6 0.5333 0.8 
2/5    0.4906 0.4679 0.4419 0.4412 0.4314 0.4381 0.4727 0.2667 0.4 
3/5    0.3773 0.3649 0.3596 0.3281 0.2875 0.25 0.2 0 0 
4/5    0.2683 0.2596 0.2288 0.2048 0.1893 0.15 0.157 0 0 
5/5 0.1014 0.094 0.0825 0.0556 0.0463 0.0348 0.0171 0.0183 0.0110 0 0 0 
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Table 5-12 Number of Proteins Identified with pMn <10% using combined Ft and Abundance 
Thresholds 
Ft Threshold of Mean Log10 TSC pMn 
Number of Proteins for 
Ft|Fn0 
5/5 >0.61 0.0994 22 
4/5 >1.165 0.0667 0 
3/5 >1.124 0 2 
TSC – Tumour Spectral Count 
 
Table 5-13 pMt for All Proteins above an Abundance Thresholds  
Mean Log10 Normal Spectral Count (percentile) pMt 
All 0.2816 
>0.0 (40%) 0.2816 
>0.3010 (50%) 0.2816 
>0.3890 (60%) 0.2373 
>0.5000 (70%) 0.1838 
>0.6571 (80%) 0.1540 
>0.9624 (90%) 0.1037 
 
The predicted tumour and normal-specific proteins are detailed in Table 5-14 and 
Table 5-15.  These proteins were added to the data set Ft ≠ 0, Fn ≠ 0 to generate a 
final complete set of PAcIFIC quantified proteins (n=1473).  Several of these 
proteins had been identified in the initial TMT study as highly expressed in tumour 
tissue compared to normal oesophagus, increasing confidence in this selection 
method (see discussion).      
 
 
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Enhancing Oesophageal Tissue Proteome Coverage 264 
Table 5-14 Predicted Tumour Specific Proteins from PAcIFIC data. 
Uniprot ID Protein name Primary Subcellular location 
ACDSB_HUMAN Short/branched chain specific acyl-CoA dehydrogenase,  Mitochondria 
ACSL5_HUMAN Long-chain-fatty-acid--CoA ligase 5  Mitochondria 
AGR2_HUMAN Anterior gradient protein 2 homolog  Secreted 
AIFM1_HUMAN Apoptosis-inducing factor 1 Mitochondria 
ANX11_HUMAN Annexin A11  Cytoplasm 
CO4A_HUMAN Complement C4-A  Secreted 
EF1G_HUMAN Elongation factor 1-gamma  
F16P1_HUMAN Fructose-1,6-bisphosphatase 1   
H13_HUMAN Histone H1.3 Nucleus 
HCDH_HUMAN Hydroxyacyl-coenzyme A dehydrogenase Mitochondria 
HUWE1_HUMAN E3 ubiquitin-protein ligase HUWE1 Cytoplasm 
HV319_HUMAN Ig heavy chain V-III region JON  
IGHG1_HUMAN Ig gamma-1 chain C region Secreted 
ITIH2_HUMAN Inter-alpha-trypsin inhibitor heavy chain H2 Secreted 
K1C20_HUMAN Keratin, type I cytoskeletal 20 Cytoplasm 
LEG2_HUMAN Galectin-2   
LEG4_HUMAN Galectin-4   
MUC2_HUMAN Mucin-2  Secreted 
MUC5A_HUMAN Mucin-5AC  Secreted 
MUC6_HUMAN Mucin-6  Secreted 
NOMO2_HUMAN Nodal modulator 2 ER membrane 
OLFM4_HUMAN Olfactomedin-4  Secreted 
PERE_HUMAN Eosinophil peroxidase  Cytoplasmic granule 
PIGR_HUMAN Polymeric immunoglobulin receptor  Cell membrane 
ROA3_HUMAN Heterogeneous nuclear ribonucleoprotein A3  Nucleus 
SUIS_HUMAN Sucrase-isomaltase, intestinal Cell membrane 
SYVC_HUMAN Valine--tRNA ligase   
TOP2A_HUMAN DNA topoisomerase 2-alpha Cytoplasm 
VILI_HUMAN Villin-1 Cytoplasm 
B3KM80_HUMAN Nucleolin, isoform CRA_c  
Q5TB52_HUMAN 3'-phosphoadenosine 5'-phosphosulfate synthase 2  
Q6FHB6_HUMAN Annexin   
B7Z8A9_HUMAN 
cDNA FLJ51166, highly similar to Matrix 
metalloproteinase-9 
 
Q6FH49_HUMAN Nicotinamide N-methyltransferase protein  
Q9HBC6_HUMAN Intestinal mucin 2  
Q6IB91_HUMAN PCK2 protein  
Q8NC03_HUMAN cDNA FLJ90630 fis, clone PLACE1003438  
A8KA66_HUMAN 
cDNA FLJ78485, highly similar to Homo sapiens 
epidermal growth factor receptor pathway substrate 8 
 
Q5R209_HUMAN Carbamoylphosphate synthetase I  
Q6I9V1_HUMAN DPEP1 protein  
Q3KT79_HUMAN Alpha-methyl-acyl-CoA racemase  
Q53SB2_HUMAN Putative uncharacterized protein RPIA (Fragment)  
B4DE36_HUMAN Glucose-6-phosphate isomerase  Cytoplasm 
B3KMX0_HUMAN 
cDNA FLJ12837 fis, clone NT2RP2003228, highly similar 
to DNA replication licensing factor MCM4 
 
E9PH38_HUMAN 
Serine/threonine-protein phosphatase 2A 65 kDa 
regulatory subunit A alpha isoform 
 
B2R778_HUMAN 
cDNA, FLJ93317, highly similar to Homo sapiens 
cadherin 17 
 
Q5U0I7_HUMAN Serine/threonine-protein phosphatase   
Protein names and subcellular location are provided from Uniprot Annotations. 
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Table 5-15 Predicted Normal Specific Proteins from PAcIFIC data. 
Entry name Protein names Primary Subcellular location 
ACTB_HUMAN Actin, cytoplasmic 1 (Beta-actin)  Cytoplasm  
ARP2_HUMAN Actin-related protein 2 (Actin-like protein 2) Cytoplasm  
CMA1_HUMAN Chymase (Alpha-chymase) (Mast cell protease I) Secreted 
DSG1_HUMAN Desmoglein-1 (Cadherin family member 4)  Single-pass type I membrane protein. 
LMOD1_HUMAN Leiomodin-1 (64 kDa autoantigen 1D)  Cytoplasm 
A1L0V1_HUMAN ACTN1 protein (Fragment)  
B7Z797_HUMAN cDNA FLJ56799, highly similar to Sciellin  
Q6LD69_HUMAN Elafin (Fragment)  
Protein names and subcellular location are provided from Uniprot Annotations. 
The Log2 Tumour: Normal ratios were again calculated for TMT and PAcIFIC 
experiments independently with a quantitation value of 10-3 substituted for predicted 
true negative proteins.  The correlation between TMT and PAcIFIC TvO ratios 
remained poor (Figure 5-13).   
 
Figure 5-13 Correlation of TMT and PAcIFIC TvO Ratios.  Proteins quantified in both experiments are 
plotted according to their Log2 TvO ratios. Nominally tumour or oesophageal specific proteins from the 
PAcIFIC data have been included. 
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5.3.14 Comparison of Spectral Counting and Isobaric 
Quantitation 
To further assess the relationship of spectral counts and TMT reporter ion intensities, 
spectral counts were extracted for the peptide-spectrum matching files from the 
mFASP TMT experiments.  To maximise the number of quantifiable peptides, a 
liberal protein identification threshold was used with a peptide false discovery rate of 
<5% and 1 unique peptide per protein accepted.  Spectral counts were available for 
3,310 proteins identified in experiment p44 and 2,735 proteins in experiment p46.   
The mean log10 gastric reporter ion intensity was calculated for each protein and then 
compared to the log10 spectral count on a per protein basis.  Only a weak correlation 
was observed between spectral counts and mean reporter ion intensities derived from 
the same peptide-spectrum matching file (Figure 5-14).  The limited correlation may 
be secondary to differences in the quantitative distributions (Figure 5-15).  Spectral 
counts show a reciprocal distribution with most proteins demonstrating a spectral 
count of 1.  In contrast, the TMT reporter ion intensities approach a Gaussian 
distribution.     
The correlation between patients using the same quantitation method was also 
assessed.  This revealed a significantly greater concordance (Figure 5-16).  This 
suggests both methods are internally consistent but not comparable.  For subsequent 
analyses, PAcIFIC and TMT datasets were therefore considered independently. 
The TvO ratios from both datasets showed Gaussian distributions and were median-
normalised.  As different dynamic ranges were observed between TMT and PAcIFIC 
data, both datasets were normalised to generate z-scores (dividing all ratios in each 
experiment by the experimental standard deviation so the experimental distributions 
become equivalent). The complete list of 2,455 quantified proteins and the z-scores 
for each experiment are provided in the Appendix.   
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Figure 5-14 Correlation of TMT Reporter Intensity and Spectral Count for Patient 44 (p44) and Patient 46 
(p46).  Proteins are plotted as points  according to their log10  spectral count and mean log10 TMT 
reporter intensity for gastric tissue.  Spearman correlation coefficients; p44 = 0.215 (p<0.01); p46 = 0.255 
(p<0.01).   
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Enhancing Oesophageal Tissue Proteome Coverage 268 
    
Figure 5-15 Distributions of Spectral Counts and TMT Reporter Intensities for Patient 46 (p46). Frequency 
histograms are shown according to the log10 spectral count or log10 reporter ion intensity.   Data 
representative of patient 44.  
Figure 5-16 Correlation of Spectral Counts and Gastric TMT reporter Intensities for Patient 44 (p44) and 
Patient 46 (p46). Proteins quantified in both patients were plotted according to their log10 spectral count 
or mean log10 TMT reporter intensity for gastric tissue.   Spearman correlation coefficients; spectral 
counts = 0.8753 (p<0.0001), TMT reporter intensities = 0.7869 (p<0.0001). 
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5.4 Discussion 
Following the successful application of quantitative shotgun proteomics to 
oesophageal tissue in the previous chapter, attempts were made to enhance the 
number of protein identifications.  The combination of doubling the number of 
OFFGEL fractions and applying the mFASP tissue lysis method led to an increase in 
proteome coverage.  The increase in identifications was also associated with an 
increase in the proportion of membrane proteins identified.  This likely due to the use 
of a higher detergent concentration in the lysis buffer, enhancing the solubilisation of 
hydrophobic proteins.   
The published FASP method describes on-column tryptic digestion which has the 
advantage of minimising sample transfer and potentially reducing protein loss.  In 
this study, off-column digestion appeared more efficient.  Failure of tryptic digestion 
using the on-column method could explain retention of the majority of the protein 
mass in the NMWCO filters.  When the identical protocol was applied off-column, 
however, the tryptic digestion appeared near-complete.  Failure of filtration of the 
tryptic peptides after on-column digestion appears to be the most likely explanation.    
A further surprising feature of the mFASP protocol was the preservation of proteins 
with an apparent molecular weight <30kDa despite the use of 30kDa NMWCO 
filters.  This finding has been previously demonstrated and the reason is not yet clear 
although it may reflect post-translational protein modifications including 
glycosylation and phosphorylation that restrict the passage through the filter633.  An 
alternative is that partial protein folding or aggregation is achieved in solution and 
this prevents filtration.  The presence of detergent, the reducing agent DTT and high 
urea concentration would, however, be expected to maintain proteins in a denatured 
state.  Conversely, SDS contamination was not observed in the mass spectra 
suggesting this had been effectively filtered from the lysates.  
The mFASP TMT method appeared to enhance both proteome coverage and 
quantitative dynamic range compared to PAcIFIC.  This was unexpected as the TMT 
experiments required 30 hours of mass spectrometry time to analyse three samples 
from the same patient.  In contrast a single sample was analysed over 24 hours with 
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the PAcIFIC method.  The increased data acquisition time and data-independent 
work-flow in the PAcIFIC method has previously been reported to enhance proteome 
coverage404,406,639.  The superior performance of TMT may reflect the beneficial 
reduction in sample complexity produced by fractionation.  In support of this, the 
combination of strong-cation exchange fractionation and high mass accuracy 
Orbitrap mass spectrometry has recently been reported to yield over 7,000 protein 
identifications from a single laser capture micro-dissected sample640. 
To enhance the power of subsequent analyses, an attempt was made to combine all 
the proteomic datasets.  Tumour to normal oesophageal expression ratios allowed 
quantitative data obtained via different approaches to be combined.  Missing data 
from the PAcIFIC experiments limited the application of this method and represents 
a fundamental problem in proteomic informatics.  A Bayesian statistical approach, 
developed in collaboration with Dr. Ian Overton, was found to offer superior 
performance over a frequentist strategy in the estimation of the probability a protein 
was not expressed in a tissue.   
Bayesian statistical methods have become widely used in recent years with a myriad 
of applications across biological, environmental, computer and even political 
sciences641.  A method to deal with missing proteomic data from 2D gels has 
previously been developed.  In this study a likelihood-based approach out-performed 
parametric statistics applied using a frequentist framework642.  A further study 
addressing the same problem also supported the use of a likelihood estimate643.  In 
that work, protein abundance was determined from spot volume on 2D gels and was 
correlated with the frequency of spot detection in a series of 2D gels.  This supports 
the finding of a correlation between abundance and Ft or Fn in this study.      
The Bayesian method was applied to the PAcIFIC dataset to derive a threshold of 
tumour protein abundance (Ft) at which the absence of normal protein detection was 
thought to be unlikely (p<0.1) to represent a missed identification.  The reverse was 
also applied for normal protein abundance and the tissue specific proteins (Table 
5-14, Table 5-15) added to the dataset of proteins with at least one identification in 
each tissue type.   
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Several candidate tumour specific proteins (Anterior Gradient 2, Polymeric 
Immunoglobulin receptor, Mucin-2) have been previously independently identified 
as highly expressed in OAC compared to normal oesophagus in the pilot TMT study 
(Table 4-2).  Other candidates (Villin, Sucrase Isomaltase) have been previously 
reported to be specific for intestinal type epithelium and highly expressed in Barrett’s 
and OAC644,645.  This supports the validity of the method to identify truly tissue 
specific proteins.  Evaluation of the novel candidates by IHC would allow the 
accuracy of this approach to be fully determined.                  
A poor correlation was observed between spectral counts from the PAcIFIC 
experiments and mean reporter ion intensities from the TMT experiments. This may 
reflect fundamental differences between spectral counting and isobaric methods of 
quantitation.  In particular, spectral counting has only moderate reproducibility 
between technical replicates and has significantly lower accuracy than isobaric 
methods437.    
To address this, spectral counts and reporter ion intensities were compared from the 
same peptide-spectrum matches.  This revealed a persistently poor correlation 
between methods.  Interestingly the correlation was significantly improved when the 
same method was compared across patient data sets.  This suggests a lack of 
compatibility between these quantitative methods.  It was concludes that the datasets 
should therefore be treated separately.   
One possibility for the poor correlation between PAcIFIC and TMT TvO ratios lies 
in the method used for TMT analysis.   To obtain a summary TvO ratio for a protein, 
the geometric mean of all tumour peptide reporter ion intensities was calculated and 
then the geometric mean of all normal oesophageal peptide reporter ion intensities 
before the TvO ratio was derived.  For most proteins, tryptic digestion would be 
expected to produce peptides in a one to one ratio and therefore, if all peptides are 
detected, reporter ion intensities generated by each peptide from the same protein 
should be roughly equivalent.  However, some peptides are more easily ionisable and 
are therefore preferentially detected, leading to higher reporter ion intensities.  The 
geometric mean may not be the best summary representation of all the reporter ion 
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intensities from one protein if the distribution is heavily skewed.  Spectral counts, 
although still subject to significant limitations as a quantitative method, would not be 
influenced by fragment ion intensity.      
The ratio of reporter ion intensities for each peptide relies only on the starting 
amount of peptide from each tissue type labelled and, as the same peptide is 
quantified from each tissue type, this ratio is independent of any bias in peptide 
detection probability.  For this reason, in subsequent TMT analyses (Chapter 7), the 
ratio of reporter intensities was first calculated for each peptide and then the 
geometric mean of all peptide ratios calculated.  This normalises for potential 
differences in fragment ion detection. 
In conclusion, dysregulated proteins identified from these experiments may be 
targets for immunotherapy and could be validated individually for tissue-specific 
expression by IHC.  This would require an extensive effort and tissue resource to 
complete.  If a targetable oncogenic pathway is upregulated in OAC, several 
members of that pathway may be dysregulated.  Unfortunately, incomplete 
proteomic datasets make the identification of dysregulated pathways a challenge.  
One approach to tackle this involves network analysis and will be examined in the 
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6.1 Chapter Aims 
 
a) To define functional clusters in a human functional linkage 
network. 
 
b) To define groups of dysregulated proteins from PAcIFIC and 
TMT datasets and map them to functional clusters. 
 
c) To identify enriched functional clusters as evidence of 
enriched biological functions in the dysregulated protein 
lists. 
 
d) To visualise the functional clusters in a network and identify 






 Network Analysis of Quantitative Chapter 6:
Proteomic Data 
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6.2 Introduction 
Quantitative protein expression studies from human tissue have the potential for 
greater functional relevance compared to microarray or next-generation sequencing 
derived transcriptomic data.  This advantage may be offset by the difficulties in 
interpreting the incomplete datasets generated.  Dysregulated proteins can be 
annotated and considered on an individual candidate basis as performed in the initial 
TMT study.  This labour-intensive approach is untenable for large datasets.  
Network analysis offers the possibility to identify components of functional 
pathways from lists of dysregulated proteins.  This allows candidate dysregulated 
pathways to be selected for more detailed investigation using hypothesis-directed 
approaches such as those applied in Chapter 3.  The method is based on the same 
principle underlying gene set enrichment analysis (GSEA); the technique where 
genes are annotated with a functional ontology and enriched ontologies are identified 
from gene lists646.   
Despite the frequent use of GSEA in cancer proteomic studies, novel therapeutic 
targets are rarely identified as the ontologies often describe generic cellular processes 
e.g. cell cycle regulation, rather than druggable pathways and the pathway context is 
not appreciated.  By using a functional linkage network as the background rather 
than gene ontologies, enriched functional modules can be identified by “seeding” the 
network using a list of genes.  This approach is similar to the published gene-network 
enrichment strategy647,648.  The network connections can also be preserved with this 
method, allowing potential regulatory interactions to be revealed.  This approach will 
be employed in this chapter using the quantitative proteomic data derived from 
PAcIFIC and mFASP TMT experiments.   
6.2.1 A Human Functional Linkage Network for Biological Process 
Discovery 
The largest published human functional linkage network (FLN), referred to as the 
Linghu network460, will be used for the analysis in this chapter.  The edges of this 
network were constructed using Bayesian statistics to incorporate and weigh the 
evidence for a functional link across 16 different domains (Table 6-1).  The complete 
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network consists of 21,657 nodes (genes) and 22,388,609 edges with a likelihood 
ratio of greater than 1 (implying greater evidence for than against a functional 
linkage).   
Table 6-1 Data sources used to construct the Linghu FLN. Adapted from reference460 







Curated human PPI from HPRD, BIND, BioGRID, IntAct, 
MIPS, DIPS, and MINT649-655 90,352 10,281 
Y2H 
PPI from high-throughput yeast two-hybrid 
experiments656 
2,611 1,522 
MS PPI from large-scale mass spectrometry experiments657 2,046 1,159 
DDI Protein pairs containing interacting protein domains658,659 6,933,469 13,454 
Co-expression Expression correlation from multiple large-scale expression datasets660-663 5,110,798 16,287 
Domain 
Sharing 
Proteins pairs sharing same protein domains664 2,064,262 17,328 
Phylogenetic Gene pairs having correlated phylogenetic profiles665 18,086 2,607 
Gene Loci 
Gene pairs located close to each other along the 
chromosome660 
10,070 1,365 
Fusion Protein pairs fused into one single protein in other species660 361 361 
Yeast 
Functional associations mapped from seven types of 




Functional associations mapped from four types of 
functional genomics data in worm through gene 
orthology666 
96,911 5,737 
Fly Functional associations mapped from three types of fly functional genomics data through gene orthology660 139,984 5,966 
Mouse-rat 
Functional associations mapped from three types of 
rodent functional genomics data through gene 
orthology660 
254,477 11,789 
Text Mining Co-occurrence in PubMed abstracts660 518,716 12,286 
Molecular 
Function 
Gene pairs sharing same molecular function terms in 
GO667 6,937,725 7,863 
Cellular 
Component 
Gene pairs sharing same cellular component terms in 
GO667 5,591,796 12,503 
Abbreviations. PPI – protein-protein interaction, HPRD - Human Protein Reference Database, BIND - Biomolecular 
Interaction Network Database, BioGRID - Biological General Repository for Interaction Datasets, IntAct – European 
Bioinformatics Institute Molecular Interaction Database, MIPS - Mammalian Protein-Protein Interaction Database, 
DIPS – Database of Interacting Proteins, MINT – Molecular Interaction Database, Y2H – Yeast two hybrid assay, DDI 
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6.2.2 Identifying Functional Clusters  
The Markov clustering algorithm, MCL can be used to uncover functional groups 
(clusters) within biological networks523.  This  unsupervised clustering method has 
been widely applied in bioinformatics and has been comprehensively reviewed668.  
Briefly, this algorithm uses a random walk strategy to identify groups of genes with 
high connectivity.  Within a functional linkage network such as the Linghu network, 
these groups contain genes defined by similar functional properties and can be 
considered as functional clusters.  The size of clusters identified by MCL can be 
determined by a user-definable inflation value.  
6.3 Results 
6.3.1 Generating Functional Clusters in the Linghu Network.  
The original Linghu network was designed to be inclusive and contains many edges 
with relatively low levels of biological evidence.  The network was therefore filtered 
at 2 more stringent levels of likelihood ratio (LR); LR ≥ 5 and LR ≥ 20 (LR5+, 
LR20+) to ensure edges (functional interactions) had high or very high levels of 
evidence.  These filtered networks were then subjected to Markov clustering using 
the MCL algorithm668 to generate clusters of genes with similar biological functions.  
This was performed with inflation (I) values from 2.0 to 6.0 to generate clusters of 
varying size.  The effect of varying the MCL I-value on the number of clusters in 
both filtered networks is demonstrated in Figure 6-1. 
6.3.2 Defining Differentially Expressed Genes from Proteomic 
Datasets 
The Uniprot Accessions for proteins identified from the PAcIFIC and mFASP TMT 
experiments (protein IDs) were mapped to Entrez GeneIDs and searched against the 
genes in the LR5 and LR20 Linghu networks (for details see Methods 2.11.4).  The 
mapped genes were used for subsequent analyses.  For the PAcIFIC and mFASP 
TMT lists, false discovery rate (FDR) corrected p-values were calculated for each 
protein z-score using the Benjamini Hochberg method526 (details of R commands 
provided in Appendix B). Lists of proteins with an FDR-corrected p<0.1 and FDR-
corrected p<0.05 were generated.  As an alternative strategy, the magnitude of 
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relative TvO expression was used deferring statistical confidence estimation to the 
network analysis stage.  Thresholds of either 1.5 fold or 2 fold dysregulated were 
selected and all proteins outside these thresholds included, irrespective of the FDR-
corrected p-value. 
Differentially expressed gene lists and corresponding random resamples containing 
the same number of genes were then mapped to the clusters generated from the LR5+ 
and LR20+ FLNs at each I-value (details of Perl scripts and R commands provided in 
Appendix B).  FDR-corrected p-values were calculated for each cluster using a 
previous described method462.  
6.3.3 Optimising Network Likelihood Ratio and Cluster Inflation 
Value. 
To determine the optimal I-value for the identification of enriched clusters, two 
thresholds were used; an FDR-corrected p-value <0.1 and an arbitrary threshold 
incorporating only clusters with greater than 20 genes and >10% of the genes 
mapped.  The number of clusters fulfilling these criteria for both TMT and PAcIFIC 
experiments, across the range of I-values and dysregulated protein lists, was 
calculated (Table 6-2).  
The LR20+ network provided very limited coverage of the identified proteome and 
was not considered any further.  The clusters from I-values above 5.0 were discarded 
from the LR5+ network for the same reason.  The remaining results across I-values, 
and differentially expressed thresholds are displayed in Table 6-2.   An FDR-
corrected p<0.1 allowed more clusters to be identified at each I value than the 
arbitrary cut-off.   
Network complexity and visual information delivery are inversely related. The 
cluster connectivity and size varied significantly with the I-value.  Network 
visualisations were therefore reviewed and an optimal threshold iterated for each 
example where significantly enriched clusters were identified, balancing enriched 
cluster number, size and connectivity.  The optimal range for visual information 
delivery for the TMT experiments was an I-value between 2 and 3 using the 1.5 fold 
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up and down regulated gene lists.  For the PAcIFIC dataset the optimal range was an 
I-value of between 2 and 2.5 with the 2 fold up and down regulated lists.   
Visualisations of these networks were created in the open-source Cytoscape 
environment647 using force-directed and spring-embedded approaches to produce the 
optimal grouping of functional clusters (Figure 6-2 to Figure 6-5). 
For each of the networks, the cluster function was summarised using DAVID 
biological process gene ontologies669.  The low FDR-corrected p-values for DAVID 
gene ontologies emphasises the relative enrichment of functionally similar genes 
within Markov clusters generated from the Linghu FLN (Table 6-3 and Table 6-4). 
 
 
Figure 6-1 Effect of MCL Inflation Value on Cluster Number.  Increasing inflation value increases the 
number of clusters generated but each cluster is correspondingly smaller in size.   
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Table 6-2 Number of Mapped Clusters in the LR5+ network.  The number of mapped genes is provided 
for each experiment and for each differentially expressed list in parenthesis.  The number of clusters 
identified with each strategy is displayed across inflation values, for each differentially expressed list.     
Number of Clusters Mapped with an FDR-corrected p<0.1 
Differentially Expressed List (TvO) Inflation Value 
TMT (2047 unique mapped GeneIDs) 2 2.5 3 3.5 4 4.5 5 
1.5 fold up-regulated (150) 9 8 6 9 8 4 7 
1.5 fold down-regulated (232) 6 6 7 8 7 8 8 
2 fold up-regulated (30) 1 2 2 2 1 2 2 
2 fold down-regulated (67) 3 2 2 3 2 0 3 
FDR corrected p<0.1 up-regulated (10) 2 3 2 3 3 3 3 
FDR corrected p<0.1 down-regulated (5) 2 1 0 0 0 0 0 
FDR corrected p<0.05 up-regulated (9) 2 3 2 3 3 3 3 
FDR corrected p < 0.05 down-regulated (4) 3 3 2 1 2 2 1 
PAcIFIC (1451 unique mapped GeneIDs) 2 2.5 3 3.5 4 4.5 5 
1.5 fold up-regulated (645) 2 1 0 0 0 1 0 
1.5 fold down-regulated (539) 2 1 0 0 0 0 0 
2 fold up-regulated (543) 33 2 0 1 1 1 1 
2 fold down-regulated (405) 4 2 1 0 0 0 0 
FDR corrected p<0.1 up-regulated (47) 0 0 0 1 0 1 0 
FDR corrected p<0.1 down-regulated (31) 2 2 2 2 2 2 2 
FDR corrected p<0.05 up-regulated (47) 0 0 0 1 0 1 0 
FDR corrected p < 0.05 down-regulated (27) 1 1 1 1 1 1 1 
Number of Clusters Mapped with Cluster >20 Genes, >10% Mapped Genes 
Differentially Expressed List (TvO) Inflation Value 
TMT (2047 unique mapped GeneIDs) 2 2.5 3 3.5 4 4.5 5 
1.5 fold up-regulated (150) 5 3 3 3 3 3 3 
1.5 fold down-regulated (232) 5 5 4 3 3 2 3 
2 fold up-regulated (30) 0 0 0 0 0 0 0 
2 fold down-regulated (67) 1 1 1 1 1 0 2 
FDR corrected p<0.1 up-regulated (10) 0 0 0 0 0 0 0 
FDR corrected p<0.1 down-regulated (5) 0 0 0 0 0 0 0 
FDR corrected p<0.05 up-regulated (9) 0 0 0 0 0 0 0 
FDR corrected p < 0.05 down-regulated (4) 0 0 0 0 0 0 0 
PAcIFIC (1451 unique mapped GeneIDs) 2 2.5 3 3.5 4 4.5 5 
1.5 fold up-regulated (645) 2 1 0 0 0 1 0 
1.5 fold down-regulated (539) 2 1 0 0 0 0 0 
2 fold up-regulated (543) 8 2 0 1 1 1 1 
2 fold down-regulated (405) 2 1 1 0 0 0 0 
FDR corrected p<0.1 up-regulated (47) 0 0 0 0 0 1 0 
FDR corrected p<0.1 down-regulated (31) 0 0 0 0 0 0 0 
FDR corrected p<0.05 up-regulated (47) 0 0 0 0 0 0 0 
FDR corrected p < 0.05 down-regulated (27) 0 0 0 0 0 0 0 
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Figure 6-2  Significant Functional Clusters Identified using the TMT1.5 fold Up-Regulated Genes and the Linghu Network.  Dysregulated genes were mapped to the 
LR5+ network clustered at an I-value of 2.5.  Nodes have been filled according to the TvO expression value (see legend).  Node outline corresponds to the cluster 
membership from the original LR5+ network.  The biological process ontology (italics), a summary description of the cluster genes, and the FDR-corrected p-value for 
the cluster enrichment are provided for each cluster (see Methods 2.13.2 and 2.13.3).       
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Figure 6-3 Significant Functional Clusters Identified using the TMT1.5 fold Down-Regulated Genes and the Linghu Network.  Dysregulated genes were mapped to the 
LR5+ network clustered at an I-value of 2.5.  Nodes have been filled according to the TvO expression value (see legend).  Node outline corresponds to the cluster 
membership from the original LR5+ network.  The biological process ontology (italics), a summary description of the cluster genes, and the FDR-corrected p-value for 
the cluster enrichment are provided for each cluster (see Methods 2.13.2 and 2.13.3).    
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Figure 6-4 Significant Functional Clusters Identified using the PAcIFIC 2 fold Up-Regulated Genes and the Linghu Network.  Dysregulated genes were mapped to the 
LR5+ network clustered at an I-value of 2.5.  Nodes have been filled according to the TvO expression value (see legend).  Node outline corresponds to the cluster 
membership from the original LR5+ network.  The biological process ontology (italics), a summary description of the cluster genes, and the FDR-corrected p-value for 
the cluster enrichment are provided for each cluster (see Methods 2.13.2 and 2.13.3). 
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Figure 6-5 Significant Functional Clusters Identified using the PAcIFIC 2 fold Down-Regulated Genes and the Linghu Network.  Dysregulated genes were mapped to the 
LR5+ network clustered at an I-value of 2.5.  Nodes have been filled according to the TvO expression value (see legend).  Node outline corresponds to the cluster 
membership from the original LR5+ network.  The biological process ontology (italics), a summary description of the cluster genes, and the FDR-corrected p-value for 
the cluster enrichment are provided for each cluster (see Methods 2.13.2 and 2.13.3).
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Network Analysis of Quantitative Proteomic Data 284 
Table 6-3 Analysis of Significantly Enriched Clusters in the TMT Dataset 
















Summary Gene Class 















129 3 - 20 [immune response] 





108 4 2 24 [proteolysis] [1e-20] Cysteine-type 
Endopeptidases 








302 4 - 10 [acute inflammatory response] [ns] Endopeptidase Inhibitors







141 8 - 18 [keratinocyte differentiation] 























Summary Gene Class 
51 2 25 51 [coenzyme metabolic process] 
[energy generation] 





52 1 20 51 [proton transport] 
[ATP synthesis] 










Solute carrier family 25 
proteins 
69 1 27 38 [fatty acid metabolism] 




226 - 9 13 [oxidation reduction] 




412 - 4 7 [oxidation reduction] [4e-5] Cytochrome-c 
components 
39 - 30 62 [mitochondrial electron transport] 
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Table 6-4 Analysis of Significantly Enriched Clusters in the PAcIFIC Dataset 
















Summary Gene Class 
11 21 5 151 [RNA splicing] 
[mRNA processing] 





35 15 1 63 [vesicle mediated transport] 





Clathrin and vesicle 
related  
















Summary Gene Class 
141 - 9 17 [keratinocyte differentiation] 





Small proline rich 
proteins 
8 12 19 176 [cytoskeletal organisation] 
[calcium ion transport] 








6.3.4 Evaluation of the Stein Network 
To the author’s knowledge, the Linghu network represents the highest genome 
coverage functional linkage network available.  To verify the findings from the 
Linghu FLN, an independent published FLN was used; the Stein network670.  This 
high coverage human functional linkage network was constructed using 
human651,652,671, fly652, worm652 and yeast652 protein- protein interaction databases, 
domain-domain interations672, gene co-expression661, shared gene ontology 
biological process annotations673, and text mining for published protein-protein 
interactions not present in other databases674.  The complete and filtered Linghu 
networks and the Stein network are compared in Table 6-5.  
Table 6-5 Comparison of Human Functional Linkage Networks 
Network Network Node 
Identifier 
Nodes Edges Edge Represents 
Linghu (LR 1+) GeneID 21,657 22,388,609 Functional Linkage (16 domains) 
Linghu  (LR5+) GeneID 16,231 530,388 Functional Linkage (16 domains) 
Linghu  (LR20+) GeneID 10,342 69,649 Functional Linkage (16 domains) 
Stein (Complete) Uniprot AC 10,957 209,988 Functional Linkage (9 domains) 
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All quantified and dysregulated proteins from both mFASP TMT and PAcIFIC 
experiments were mapped against the unique Uniprot Accessions (AC) in the Stein 
network (Table 6-6).  The MCL method was again used to cluster the Stein network 
at I-values 2.0 to 6.0.  Significant clusters were identified for the TMT 1.5 fold and 
PAcIFIC 2 fold dysregulated gene lists in the same fashion as for the Linghu network 
(Table 6-7).  For the PAcIFIC data, an I-value of 2.5 and for the TMT data, an I-
value of 4 were selected as optimal.  The cluster members and cluster edges were 
extracted from the Stein network and were used to create network visualisations in 
Cytoscape, in the same manner as the enriched LR5+ clusters from the Linghu 
network (Figure 6-6 to Figure 6-8).  The biological process ontologies for the 
significantly enriched clusters are summarised in Table 6-8 and Table 6-9.   
 
Table 6-6 Mapping of TMT and PAcIFIC Datasets to the Stein Network 















2,058 1,472 154 232 543 408 
Stein 
Protein List 





980 (67%) 114 
(74%) 
162 (69%) 348 (64%) 278 (68%) 
 
 
Table 6-7 Enriched Clusters in the Stein Network 
For each differentially expressed list, the number of Uniprot ACs searched is provided in parenthesis.     
Significant Enriched Clusters (FDR-corrected p<0.1)  
Differentially Expressed List (TvO) Inflation Value 
TMT (1565 unique mapped Uniprot 
ACs)
2 2.5 3 3.5 4 4.5 5 5.5 6 
1.5 fold up-regulated (114) 5 5 2 3 6 6 6 6 5 
1.5 fold down-regulated (162) 8 9 7 8 7 7 8 7 7 
PAcIFIC (980 unique mapped 
Uniprot ACs) 
2 2.5 3 3.5 4 4.5 5 5.5 6 
2 fold up-regulated (348) 1 1 0 1 0 0 0 0 0 
2 fold down-regulated (278) 1 1 1 0 0 0 1 0 0 
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Figure 6-6 Significantly Enriched Clusters Identified in the PAcIFIC Dataset Mapped onto the Stein Network.  Gene lists were separately mapped to the Stein network 
clustered at an I-value of 2.5.  Enriched clusters are displayed together for comparison.  Nodes have been filled according to the TvO expression value (see legend).  
Node outline corresponds to the cluster membership from the original Stein network.  The biological process ontology (italics), a summary description of the cluster 
genes, and the FDR-corrected p-value for the cluster enrichment are provided for each cluster (see Methods 2.13.2 and 2.13.3) 
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Figure 6-7 Significantly Enriched Clusters Identified in the TMT 1.5 fold Up-Regulated Genes Mapped to the Stein Network.  Genes were mapped to the Stein network 
clustered at an I-value of 4.0.  Nodes have been filled according to the TvO expression value (see legend).  Node outline corresponds to the cluster membership from the 
original Stein network.  The biological process ontology (italics), a summary description of the cluster genes, and the FDR-corrected p-value for the cluster enrichment 
are provided for each cluster (see Methods 2.13.2 and 2.13.3) 
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Figure 6-8 Significantly Enriched Clusters in the TMT 1.5 fold Down-Regulated Genes Mapped to the Stein Network. Genes were mapped to the Stein network clustered 
at an I-value of 4.0.  Nodes have been filled according to the TvO expression value (see legend).  Node outline corresponds to the cluster membership from the original 
Stein network.  The biological process ontology (italics), a summary description of the cluster genes, and the FDR-corrected p-value for the cluster enrichment are 
provided for each cluster (see Methods 2.13.2 and 2.13.3) 
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Table 6-8 Enriched Clusters in the Stein Network Identified using the TMT Dataset 


















Summary Gene Class 
276 5 - 7 [epidermis development] 
[ectoderm development] 





42 2 - 27 [transcription regulation] 




55 4 1 24 [antigen processing and presentation of 
peptide antigen via MHC class I] 





HLA Class I genes 
83 6 - 15 [antigen processing and presentation via 
MHC class I] 
NA (proteins all from 
one gene) 
HLA Class I genes 
37 6 - 25 [antigen processing and presentation of 
peptide antigen via MHC class I] 





HLA Class I genes 
99 3 - 15 [complement activation] 
[humoral response] 























Summary Gene Class 
19 - 30 48 [mitochondrial electron transport] 
[ATP synthesis coupled electron transport] 














120 - 8 13 [proton transport] 
[energy coupled proton transport] 






219 - 7 8 [electron transport chain] 
[mitochondrial electron transport] 







322 - 5 6 [cell redox homeostasis] 
[oxidation reduction] 






918 - 3 3 [ethanol oxidation] 
[drug metabolic process] 
ns Alcohol 
dehydrogenases 
929 - 3 3 [cellular aldehyde metabolic process] ns Aflatoxin aldehyde 
reductases 
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Table 6-9 Enriched Clusters in the Stein Network Identified using the PAcIFIC Dataset 















Summary Gene Class 







PAcIFIC 2 fold down-regulated genes mapped onto the Stein network, clustered @ I2.5. 
7 9 26 114 [cell adhesion] 
[integrin-mediated signalling pathway] 







The enriched clusters from the Stein network showed highly similar biological 
functions to the enriched clusters from the Linghu LR5+ network.  These networks, 
although similar in scope, used different sources and methods to define the network 
edges.  Therefore the clusters generated by MCL would be expected to contain 
different nodes.  Identifying clusters characterised by similar biological process 
ontologies provides strong support for the dysregulation of these pathways in OAC 
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6.4 Discussion 
This study has adapted strategies originally developed for gene-set and gene-network 
enrichment analysis to identify functional pathways from incomplete proteomic 
datasets.  Genome-scale functional linkage networks460,670 were clustered to generate 
biological functional clusters – verified by the significant enrichment of DAVID 
biological process ontologies among the members of each cluster.  After iteration of 
the optimal network size and cluster inflation-value, significantly enriched clusters 
could be identified from both mFASP TMT and PAcIFIC datasets.   In the TMT up-
regulated gene list, the identified clusters were enriched for antigen processing and 
immune regulatory genes.  The original samples were biopsies of human tumours, 
and therefore proteins may be detected from epithelial-derived tumour cells, 
infiltrative immune cells or other stromal components.   
Tumour associated inflammation has been demonstrated in many cancers and in 
some cases may drive the oncogenic phenotype675,676.  The complexities of the 
immune – cancer cell synapse are still being uncovered with evidence for a symbiotic 
relationship with tumour cell mediated recruitment of bone marrow derived immune 
cells677 and tumour-associated  macrophages promoting the oncogenic phenotype of 
epithelial derived tumour cells675,678,679.  The observed enriched processes may 
therefore reflect an upregulation of genes in stromal immune cells or in the 
epithelial-derived cells.     
A transgenic mouse model with constitutively active IL-1β expressed in the 
oesophagus and squamous fore-stomach phenocopies the human Barrett’s 
carcinogenesis sequence102.  This suggests oesophageal inflammation is critical in the 
development of OAC.  Modulating this axis may lead to successful preventative and 
therapeutic strategies and exploitation of the tumour-immune cell synapse as a 
druggable interface is an emerging field.    
Intriguingly a large cluster of metabolic genes associated with aerobic metabolism 
were identified from the down-regulated gene list.  It could be speculated this is a 
consequence of the Warburg effect680.  Greater numbers of samples would be 
required to confirm this as a generalised phenomenon.   
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Fewer significant clusters could be identified from the PAcIFIC dataset but similar to 
the TMT dataset, significant changes in keratin-related genes were observed between 
cancer and normal squamous tissues.  The observation of significantly up-regulated 
RNA processing and splicing-related genes may provide support for the observation 
of alternative spliced and novel transcripts between cancer and normal tissues681,682.  
The enriched clusters derived from the Linghu network were interpreted as 
representing enriched biological processes in the dysregulated gene lists.  The cluster 
membership will be a direct consequence of the original network topology and 
therefore the identified biological processes may change with network connectivity.  
An independent human functional linkage network, the Stein network, analysed in 
the same manner identified highly similar biological processes670.  This adds strength 
to the conclusion that these processes are truly dysregulated in OAC tissue.  A caveat 
for this approach is that well studied genes and their interactors are over-represented 
in the databases used to construct both networks.  This leads to higher network 
connectivity for these genes and a greater likelihood of representation in the clusters.   
Novel biological processes in contrast will not be identified and would require 
alternative approaches.      
For both the Linghu and Stein FLNs, the TMT data provided the greatest number of 
enriched clusters and number of genes mapped to each cluster.  To evaluate if these 
findings and other novel functional clusters could be observed in a larger cohort, a 
further 5 patient’s samples were processed by mFASP and then subjected to TMT 
LC-MS/MS using the same method as the two patient’s samples in this analysis.  The 
analysis of the combined mFASP TMT data will be considered in the final chapter.  
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7.1 Chapter Aims 
 
a) To combine the results from seven patients’ samples 
analysed by the optimised mFASP TMT method. 
 
b) To define the technical and biological variability of this 
method. 
 
c) To define dysregulated and potentially tissue-specific 
proteins using expression data from OAC, normal 
oesophagus and normal stomach. 
 
d) To undertake a network analysis of these quantitative data 
to validate previous findings and uncover targetable 





 Application of the Optimised Proteomic Chapter 7:
Method to OAC and Matched Normal 
Tissues 
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7.2 Introduction 
Previous chapters have confirmed accurate, sensitive quantitative protein expression 
data can be produced from human oesophageal tissue samples by shotgun 
proteomics.  The optimised mFASP TMT method was associated with the greatest 
proteome coverage and quantitative dynamic range.  A network analysis using data 
from two patients identified significantly dysregulated biological processes.  To 
validate and extend these findings, data was generated from a further five patients’ 
samples using the same sample preparation and proteomic analysis method.  This 
chapter will consider the data for all seven patients’ tissues processed by mFASP 
TMT. 
Differential expression is commonly considered between two tissue types.  The 
comparisons between adenocarcinoma and normal squamous epithelium in the 
previous studies revealed many dysregulated proteins, some of which represent 
proteins associated with glandular differentiation and some associated with 
oncogenesis.  Glandular associated proteins may be expressed in gastric and 
intestinal epithelium and may not represent tractable targets for therapy as toxicity 
due to intestinal epithelial damage would be expected. 
To enhance the probability of identifying tissue-specific proteins, patient-matched 
normal gastric tissues were included with OAC and normal squamous tissues.   
Multi-tissue proteomic profiling has recently been described using mouse tissue and 
relative quantitation by a super-SILAC approach683. In this study, snap-frozen 
biopsies from 28 tissue types were subjected to shotgun proteomics with a spike-in, 
heavy-labelled mixture of all tissues obtained from the SILAC mouse.  By 
comparing the relative expression of proteins across tissues, tissue-specific 
expression could be highlighted.  The oesophagus was not included in this profiling 
effort although gastrointestinal tissues with columnar epithelia showed similar 
expression patterns.  This suggests that including columnar epithelium-lined gastric 
tissue along with squamous and OAC tissue may allow the separation of common 
“glandular” associated proteins from true cancer-associated proteins.            
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7.3   Results 
7.3.1 TMT reporter ion intensities 
The clinical data for each patient donating tissue for this study are summarised in 
Table 7-1.  Peptides from each tissue type from a single patient had been labelled 
independently with two TMT reporters (Figure 5-2).  These technical replicates were 
analysed independently.   
Table 7-1 Clinical Characteristics of Patients Donating Tissue for mFASP TMT proteomics 
Patient (P) 
















Gender Male Male Male Male Female Male Male 
Age 59 67 65 41 52 60 58 
Histology ACC ACC ACC ACC ACC ACC ACC 
Location OGJ Type II OGJ Type I 
OGJ Type 
II 
OGJ Type I OGJ Type I 
OGJ Type 
II 
Oes Lower  
Neoadjuvant 
Therapy 






















38 mm 70 mm 40 mm 50 mm 83 mm 52 mm 35 mm 
Distance to 
PRM and DRM 
>1 mm >1 mm >1 mm >1 mm >1 mm >1 mm >1 mm 
Distance to 
CRM 
4.2 mm 0.0 mm 0.0 mm 0.3 mm 3.0 mm 1.0 mm 1.0 mm 
Differentiation Moderate Poor Poor Poor Poor Poor Poor 
Lymphovascula
r Invasion 
Y Y Y Y N Y Y 
Venous 
Invasion 
N N N Y N N N 
Perineural 
Invasion 
N Y Y Y N Y Y 
T stage T2 T4a T3 T3 T2 T3 T3 
Number of 
Positive Nodes 
2 8 16 7 1 7 3 
Total Number 
Nodes Resected 
27 18 28 28 23 21 37 
AJCC Stage IIB IIIC IIIC IIIC IIB IIIC IIIB 
Alive at Time of 
Analysis 





















Abbreviations: 2xCF - 2 cycles of Cisplatin and 5-Fluorouracil,  ILO – Ivor-Lewis Oesophagectomy, AJCC – American Joint 
Committee on Cancer, OGJ – Oesophagogastric Junctional Tumour, PRM – Proximal resection margin, DRM – Distal 
resection margin, CRM – Circumferential resection margin., Y-Yes, N-No, CT – Computed Tomography. 
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The TMT reporter ion fold changes of over 107 were detected confirming the high 
quantitative dynamic range of this method (Table 7-2). An example distribution of 
tumour peptide reporter ion intensities is shown in Figure 7-1.  This shows a complex 
bimodal distribution for the raw reporter intensities.  This was apparent for all the 
tissue types analysed.  This may reflect an enrichment of low abundance peptides 
produced by OFF-GEL fractionation.  The ratio of reporters, however, followed a 
Gaussian distribution (C) and therefore parametric statistics were used to assess the 
ratios between tissue types.   
Table 7-2 Dynamic Range of TMT Reporter Intensities (Peptide FDR 1%, 1 Unique Peptide per Protein) 
Patient Samples P44 P46 48 P51 P53 P60 P61 
Maximum Reporter Ion 
Fold Change   
7.7x107 7.7x107 2.12x107 9.09x107 3.44x107 5.87x107 2.38x107 
 
7.3.2 Assessment of Technical Variation 
The distribution of technical replicate ratios for each experiment is summarised in 
Table 7-3.  This demonstrates the small degree of systematic error in the ratios from 
most experiments.  This error is likely to be secondary to slight variations in the total 
amount of peptide from each sample labelled with each TMT reporter.  After median 
normalisation, the log2 ratios all followed an approximately Gaussian distribution 
centred on 0 (Figure 7-2).              
The variability in technical replicate ratios from each experiment and the 
combination of all experiments is shown in Figure 7-3.  The combination of technical 
replicate ratios from all experiments provides a robust estimate of the technical 
variability and provides a possible method to determine a statistical threshold 
signifying differential expression.  Using this method, a median normalised log2 
expression ratio greater than 0.8515 or less than -0.8515 from the mean would be 
predicted to have a <5% probability of arising through technical variation alone.  The 
corresponding 1% and 0.1% confidence limits are demonstrated in Table 7-4.  
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Application of the Optimised Proteomic Method to OAC and Matched Normal 
Tissue 298 
 
Figure 7-1 Example Distributions of Peptide Reporter Intensities.  A – 127 reporter intensity. B - 126 
reporter intensity.  C – Ratio of 127/126 intensities. 
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Table 7-3 Technical Replicate Ratios by Experiment.  Each patient tissue sample was labelled in 
technical duplicate.  The Mean, Median and standard deviation of raw and Log2 ratios of peptide 
reporter ion intensities is reported for each sample.  
Reporter 
Ratio  










SD of Log2 
ratios 
Number of  
ratios 
P46 126/127 0.9522869 0.9424203 0.1209093 -0.1058829 0.2263472 40872 
P46 128/129 0.9212349 0.9871393 0.1063501 -0.1228993 0.1685073 40861 
P46 130/131 1.089402 1.157752 0.4982529 0.1182558 0.4093816 40447 
P44 126/127 0.9214896 0.9542108 0.2071119 -0.1058829 0.2263472 37862 
P44 128/129 1.00383 0.924225 0.1988749 -0.06216656 0.4231987 37737 
P44 130/131 1.096927 1.132269 0.4987867 0.1681628 0.2956012 37149 
P48 126/127 1.519258 1.472785 0.3015153 0.5190464 0.376901 43892 
P48 128/129 0.9099537 0.975992 0.4419535 -0.1146072 0.496436 42480 
P48 130/131 1.647579 1.654255 0.6915029 0.6566526 0.474313 42343 
P51 126/127 1.021262 1.011923 0.1523257 -0.000425345 0.23806 40838 
P51 128/129 1.026764 1.188478 0.6881133 0.1359064 0.517445 39768 
P51 130/131 0.7734064 0.8630549 0.6577253 -0.3010062 0.378115 39387 
P53 126/127 0.9662025 0.9532796 0.1298938 -0.08014842 0.1944109 40786 
P53 128/129 1.304138 1.279188 0.2433199 0.3180678 0.3874888 40337 
P53 130/131 1.360151 1.367582 0.3605723 0.4310588 0.2251194 39933 
P60 126/127 1.116098 1.102766 0.1609282 0.1235559 0.244673 34014 
P60 128/129 0.8904177 0.8918027 0.1081798 -0.1788884 0.225214 34050 
P60 130/131 0.7532126 0.8004937 0.4092182 -0.3634508 0.265779 33478 
P61 126/127 1.453871 1.431918 0.1848371 0.5027554 0.234084 35377 
P61 128/129 0.9727497 0.9595118 0.1423883 -0.08037295 0.2790071 35282 
P61 130/131 1.305033 1.345982 0.5784023 0.3787494 0.3411583 34916 
All Ratios 1.023174 1.119116 0.4491993 0.09435871 0.4344242 811809 
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Figure 7-2 Example Distribution of Median Normalised Reporter Ratios from Patient 46.  Technical 
replicate ratios are reported from adenocarcinoma (A), normal oesophagus (B) and normal stomach 
(C).  Theoretical normal distributions with the same mean and SD are displayed as solid black lines 
highlighting the leptokurtotic distributions. 
 
Figure 7-3 Technical Variation by Experiment.  The technical replicate ratios from each tissue from each 
patient are displayed. Points represent the mean ratio after median normalisation.  Bars represent the 
standard deviation.  
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Table 7-4 Confidence Intervals for Differential Expression Using the Combined Dataset 
Probability of arising through technical variation Confidence Intervals around the Mean Log2 Ratio 
P<0.05 0.8514558,  -0.8514558 
P<0.01 2.326348, -2.326348 
P<0.001 3.090232, -3.090232 
   
The relatively low degree of technical variability is emphasised when the ratios of 
technical replicates for single patient’s samples are compared (Figure 7-4A).  This 
high correlation of Log2 ratios between technical replicates was present across all 
experiments (Figure 7-4B, median Pearson correlation coefficient [PCC] = 0.9811, 
p<0.001).  There was also a generally good correlation between biological replicates 
when TvO ratios were considered (median PCC = 0.555, p<0.001) but not between 
TvO and TvG ratios (median PCC = 0.0115, p>0.05).  This underscores the diversity, 
at least in protein expression, of the tissues studied.  The good correlation between 
biological replicates is reassuring and demonstrates concordance of the proteomes 
from histologically similar tissues.   
Unsupervised hierarchical clustering was performed to further examine the 
differences between biological and technical replicates (Figure 7-5).  Technical 
replicates were all clustered as pairs with a suggestion of a subgroup consisting of 
patients 46, 61 and 44 although the distance on the dendrogram to the other patients 
was small.  No obvious clinical features were identified in these three cases 
compared to the other patients (Table 7-1) although this study is underpowered to 
detect the effect of subtle clinical differences on protein expression. 
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Figure 7-4 Correlation of Technical Replicates.  A- Median-normalised log2 ratios were compared for the two technical replicates of the samples from p44. TvO = 
adenocarcinoma to normal oesophagus log2 ratio. TvG = adenocarcinoma to normal gastric log2 ratio.  B – A boxplot summarising the median (line) and 5th and 95th 
percentiles for the Pearson’s correlation coefficients (PCC) for technical replicates across all experiments (n=14).    
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Figure 7-5 Correlation of Normalised Log2 Tumour : Normal Tissue Ratios.  The Pearson’s Correlation Coefficient (PCC) was calculated between each experiment and 
represented in the heat map.  Unsupervised hierarchical clustering was performed using an agglomerative complete linkage method to generate the similarity 
dendrogram (left).  This demonstrates the greatest correlation was observed between technical replicate ratios with a clear separation between TvO and TvG ratios.    
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7.3.3 Tissue-specific protein expression. 
To identify tumour specific expression, ratios were compared between multiple 
tissue types.  The analysis method used the ratio of reporter intensities to determine 
relative expression, yet for proteins where no reporter ion is observed for one or 
more tissue types, a ratio cannot be calculated.  These proteins are potentially tissue 
specific and therefore all candidates were reviewed where a peptide was detected 
with reporter expression in only one or two of the patient-matched normal 
oesophagus, normal gastric and adenocarcinoma samples.  In the context of the 
expression profile of other peptides from the same proteins and other experiments, no 
proteins could be identified with tissue exclusive expression.   
7.3.4 Protein Identifications 
Proteins represented by a total of 6,349 different Uniprot accession numbers were 
quantified in at least one experiment.  Due to a small degree of redundancy between 
TrEMBL and Swissprot accessions in the reference database, these corresponded to 
proteins from 6,339 unique genes. A total of 744 proteins were quantified in all 
experiments.  The protein identifications per experiment are shown in Table 7-5.  Of 
the 6,339 quantified proteins, 6,221 could be mapped to an Entrez GeneID.  The 
unmapped proteins were either Uniprot entries removed since the reference database 
release, uncharacterised proteins or immunoglobulins.   
Table 7-5 Protein Identifications by Experiment 









Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Application of the Optimised Proteomic Method to OAC and Matched Normal 
Tissue 305 
7.3.5 Evaluation of Expression Across Experiments 
The confidence in the expression value (TvO or TvG ratio) for each protein varies 
with the number and distribution of peptide ratios contributing to that expression 
value.  A protein may have been quantified in up to 14 experiments across all seven 
patients’ tissues in this study.  A mean expression value across studies was therefore 
sought.   
For the 4,181 proteins identified by more than one peptide in more than one 
experiment, the weighted mean and variance of the log2 TvO and TvG ratios were 
calculated across all experiments (see Methods 2.11.3.1).  For the proteins only 
identified by a single peptide, the un-weighted mean and variance were calculated 
across experiments.  Those proteins identified by a single peptide and only in a single 
experiment were considered low confidence identifications and were excluded from 
the combined analysis (n=14). 
By combining the expression ratios between OAC, normal squamous epithelium and 
normal gastric epithelium it was hoped proteins expressed generically in glandular 
tissues would be identified.  The two ratios for each protein were used to produce a 
two-dimensional map with vectors of TvG expression on the x-axis and TvO on the 
y-axis (Figure 7-6).   
 
7.3.6 Differential Expression 
To define differentially expressed proteins, the quantitation thresholds derived from 
technical replicates could be applied (Table 7-4) and proteins outside those limits 
accepted as dysregulated.  When considering several thousand protein expression 
values, however, there is considerable potential for a type I statistical error due to 
multiple hypothesis testing.  As the accuracy of quantitation also varied from protein 
to protein, a protein-wise calculation of significance with a false discovery rate 
correction was sought.  
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Figure 7-6 Protein Expression According to Tissue Type.  Each point represents a protein defined by Log2 
Tumour vs. Normal Oesophageal (TvO) and Tumour vs. Gastric (TvG) ratios.  The density contours 
describe the distribution of over-plotted points surrounding the origin 
 
For each protein, the ratios for each tissue comparison were derived from a variable 
number of experiments and, for each experiment, from a variable number of 
peptides.  The variance in the mean ratio and the number of peptides contributing to 
the mean were used to test the hypothesis that, within the experimental data 
observed, the TvO or TvG ratio for that protein was not significantly different to the 
ratio produced from the comparison of technical replicates (TvT, OvO and GvG).  
The probability associated with a statistical test of this hypothesis was denoted as the 
“intra-experimental probability”.   
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It was predicted that given the relative accuracy of TMT-based quantitation, the large 
number of peptides assessed, and the histological differences between tissue types, 
many proteins would show significantly different expression between tissues.  Many 
proteins were quantified in less than half of the experiments, however, and the degree 
to which the confidently determined expression values simply represent normal 
fluctuation between biological samples is much less certain (Figure 7-7). 
 
Figure 7-7 Frequency of Differentially Expressed Protein Quantitation Across Experiments.  Only proteins 
with an intra-experimental FDR-corrected p<0.05 were considered.  
To predict which proteins may be dysregulated in all oesophageal adenocarcinomas 
when compared to normal squamous and gastric epithelium it was assumed the 7 
patients tissues were representative, random samples of the total population and the 
population protein abundance was normally distributed.  The probability that a 
protein was not differentially expressed was calculated from the comparison of TvO 
or TvG ratios and technical replicate ratios using the number of patients as the “n”.  
This probability was termed the “inter-experimental probability”.  
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A potential method to calculate the intra and inter-experimental p-value for each 
protein would be to apply the Analysis of Variance (ANOVA) test across TvO, TvG 
and technical replicate ratios.  This would determine if proteins showed significantly 
different expression between the ratios and post-hoc tests could identify which 
comparisons were significant.  This method assumes covariates are normally 
distributed and have an equal variance.  The distributions of protein ratios is 
summarised in Figure 7-8A.   
Formal testing of deviation from a normal distribution can be accomplished with 
Shapiro-Wilks or Lillefors tests.  Both these tests revealed a significant deviation 
from a normal distribution for all the ratios (p<10-10 for all ratios, both tests).  Many 
described tests of deviation from normality exhibit high sensitivity when a high 
sample number is used, however, and even small deviations from the theoretical 
normal distribution can be identified.  The sensitivity of these tests was verified 
when randomly selected, normally distributed variables containing 6,349 numbers 
with the same mean and standard deviation as the experimentally determined ratios 
were subjected to normality testing (Table 7-6).  As these variable were selected to 
fit a normal distribution using computational methods, the predicted percentage of p-
values <0.05 from the normality tests should be <5%.  Tests prone to false positives 
would demonstrate a higher proportion than this.  Both tests demonstrated over-
sensitivity across all ratios (Table 7-6).             
Table 7-6 Percentage of incorrect results (p<0.05) from normality tests using simulated normally-
distributed data.  
 Ratio Determining the Mean and SD of the Simulated Variable 
 TvO TvG TvT OvO GvG 
Shapiro-Wilks 64.9% 61.4% 38.6% 31.6% 37.4% 
Lillefors 51.3% 26.3% 20.1% 41.7% 18.4% 
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From closer examination of the histograms of expression ratios, it appears the 
distributions are only approximately normal with some evidence of leptokurtosis 
(Figure 7-2, Figure 7-8A).  The variance of leptokurtotic distributions is 
overestimated using standard calculations and this could lead to a conservative 
estimate of the number of dysregulated proteins.  ANOVA has, however, been shown 
to be relatively robust to small deviations from normality if the sample variances are 
approximately equal684.   
A global test for the equivalence of sample variances, the Fligner-Killeen test, 
demonstrated significant differences between sample variances (p<10-10).  This can 
be seen graphically in Figure 7-8B where there is a clear difference in the variance 
between the technical replicates and the TvO and TvG ratios.  
The combination of deviation from normality and heteroscedascity make ANOVA 
testing inappropriate.  Welch’s test is a parametric statistic that can be applied to 
compare two means from approximately normally distributed populations with 
unequal variances to test the hypothesis that the means are the same512.  Similar to 
ANOVA, this statistic is also relatively robust to deviation from normality when the 
sample size is large.  Welch’s test was therefore applied to compare the mean TvO 
ratio to the global mean of TvT and OvO ratios or similarly the mean TvG ratio to 
the global mean of TvT and GvG ratios for each quantified protein.  In this fashion 
both intra and inter-experimental p-values were calculated for all proteins with the 
false-discovery rate controlled using the Benjamini Yekutieli method566.  
7.3.7 Evaluation of Inter-Experimentally Dysregulated Proteins 
Proteins commonly dysregulated across experiments were considered more 
compelling targets for therapy as they may be relevant to a larger proportion of 
patients.  The proteins with an inter-experimental FDR-corrected p <0.05 for TvO 
ratios are demonstrated in Figure 7-9. Similarly proteins with an inter-experimental 
FDR-corrected p<0.05 for TvG ratios are demonstrated in Figure 7-10.  No proteins 
showed an inter-experimental FDR-corrected p-value <0.05 for both TvO and TvG 
ratios.  This highlights the limitations imposed by the small sample size on the power 
to predict dysregulated proteins in OAC using the inter-experimental p-value alone. 
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A more liberal, and potentially more informative approach, is to use the intra-
experimental FDR-corrected p-values combined with ratio thresholds to define 
significantly dysregulated proteins.  The outliers identified using this approach may 
simply represent random biological variation, however, by also incorporating prior 
knowledge such as previous studies of protein expression in OAC or known roles in 
cancer,  compelling candidates can be shortlisted for validation.  
7.3.8 Evaluation of Intra-Experimentally Dysregulated Proteins 
For intra-experimental comparisons, proteins with an FDR-corrected p-value >0.05 
for either TvG or TvO ratios were removed leaving 3,082 significantly dysregulated 
proteins. The distribution of these proteins is plotted in Figure 7-11 .   
When the candidates previously examined by IHC are superimposed, it can be seen 
that the TvG dimension assists in the discrimination of proteins expressed in both 
OAC and gastric epithelium (Figure 7-12).  From this 2D map, it becomes clear that 
certain areas, defined by a specific expression profile are populated with proteins that 
appear to share similar properties such as tissue expression.  To further assess the 
utility of this expression map to reveal tissue specific expression, several proteins 
with well validated tissue expression profiles were selected.  Their distribution on the 
expression map highlights regions associated with gastric and normal squamous 
oesophageal specific expression (Figure 7-12).
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Figure 7-8 (A) Histograms showing the distribution of normalised Log2 ratios. Note the differing x-axis (log) scales.  (B) Boxplots of the same data.   Boxplot whiskers 
represent 1.5 Interquartile ranges above or below the 75th and 25th percentiles respectively.  Unfilled circles represent outlier points.  
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Figure 7-9 Proteins Significantly Dysregulated between Tumour and Normal Oesophageal Tissue. Significance was defined as an inter-experimental FDR-corrected 
p<0.05 for the comparison of TvO and the mean of TvT and OvO ratios.  Proteins have been labelled with their gene names and plotted according to their log2 
expression ratios. 
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Figure 7-10 Proteins Significantly Dysregulated between Tumour and Normal Gastric Tissue.  Significance was defined as an inter-experimental FDR-corrected p<0.05 
for the comparison of TvG and the mean of TvT and GvG ratios. Proteins have been labelled with their gene names and plotted according to their log2 expression 
ratios. 
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Figure 7-11 Distribution of Significantly Dysregulated Proteins.  Significance was defined as intra-experimental FDR-corrected p<0.05 for the comparison of TvO and 
the mean of TvT and OvO ratios and for the comparison of TvG and the mean of TvT and GvG ratios.  Proteins have been plotted according to their log2 expression 
ratios and points sized according to the number of experimental observations. 
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Figure 7-12 The Expression of Proteins Previously Validated by IHC and Selected Examples with Known Tissue Expression.  Points are identical to Figure 7-11 but have 
been highlighted in selected cases according to published tissue specific expression or previous validation of tissue expression by IHC and annotated with gene names.    
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Figure 7-13 Annotation of Proteins Highly Expressed in Tumours Compared to Normal Oesophageal and Gastric Epithelium. Points are identical to Figure 7-11 but only 
proteins within a selected expression range are shown.  Proteins have been annotated with gene names and are sized according to the number of experimental 
observations. 
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Figure 7-14 Summary of expression thresholds used to define groups of proteins for network analysis.  Thresholds have been superimposed onto Figure 7-11.
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Closer annotation of the proteins with high expression in tumours relative to both 
normal oesophageal and gastric epithelium reveals several compelling potential 
therapeutic targets (Figure 7-13, see discussion).  A number of these were identified 
in the candidate tumour specific list derived from the PAcIFIC data using the 
Bayesian method (Table 5-14).    
It was predicted that proteins with particular tissue expression profiles would be 
located in discrete regions on the 2D map.  Thresholds were created to select proteins 
with specific expression profiles (Figure 7-14).  To further evaluate the function of 
proteins within these provisional tissue specific expression areas, a network analysis 
was undertaken.  Groups of proteins, defined by the expression thresholds, were 
mapped to the Linghu network460 as previously described (Methods 2.13).   
7.3.9 Network Analysis 
Six lists of significantly dysregulated genes, with potentially tissue-specific functions 
were mapped to the LR5+ Linghu FLN (Figure 7-14).  Only genes with an intra-
experimental FDR-corrected p<0.05 were included.  The number of significant 
clusters (p<0.1) identified for each list is demonstrated Table 7-7.  An inflation value 
(I-value) of 5 was selected as providing the optimal balance between the number of 
clusters and the network complexity. The biological process ontologies for the 
significantly enriched clusters are shown in Table 7-8.  Network visualisations are 
provided in Figure 7-15 to Figure 7-20. 
Table 7-7 Number of Significant Clusters Identified Across MCL Inflation-Values using the mFASP TMT 
data 
Number of Significantly Enriched Clusters (FDR-corrected p<0.1)  
Differentially Expressed List  Inflation Value 
Combined mFASP TMT Intra-FDR p<0.05 2 2.5 3 3.5 4 4.5 5 5.5 6 
Both TvO and TvG 1.5 fold up-regulated 5 5 5 4 6 5 5 4 5 
Both TvO and TvG 2 fold up-regulated 3 1 2 2 3 3 3 2 3 
Both TvO and TvG 1.2 fold down-regulated 7 0 6 4 7 6 2 7 0 
Both TvO and TvG 1.5 fold down-regulated 0 1 1 1 4 1 3 0 0 
Gastric Specific 0 4 3 1 1 2 2 2 2 
Oesophageal Specific 3 4 5 5 6 6 6 0 0 
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Table 7-8 Significant Clusters from the mFASP TMT Dysregulated Protein Lists Mapped onto the Linghu 
FLN  clustered at an MCL Inflation value of 5.0.  
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Table 7-9 Significant Clusters from the TMT Dysregulated Lists Mapped onto the Linghu Network clustered at an 
MCL Inflation value of 5.0 (continued). 
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Figure 7-15 Significantly Enriched Functional Clusters in the Genes with both TvG and TvO > 1.5.  The top biological process ontology for each cluster is detailed in 
italics, a summary of the cluster functional class and the FDR-corrected p-value for the enrichment of the cluster are displayed.  Nodes have been filled according to 
TvO and TvG expression so that proteins up-regulated > 1.5 fold in tumours compared to normal oesophagus have been filled red, pink or green depending on their 
TvG ratio and so on.   Node outlines correspond to cluster membership.     
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Figure 7-16 Significantly Enriched Functional Clusters in the Genes with both TvG and TvO > 2. The top biological process ontology for each cluster is detailed in italics, 
a summary of the cluster functional class and the FDR-corrected p-value for the enrichment of the cluster are displayed. Nodes have been filled according to TvO and 
TvG expression as in Figure 7-15 with node outlines corresponding to cluster membership. 
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Figure 7-17 Significantly Enriched Functional Clusters in the Genes1.2 fold down-regulated in both TvO and TvG. The top biological process ontology for each cluster is 
detailed in italics, and a summary of the cluster functional class and the FDR-corrected p-value for the enrichment of the cluster are displayed.  Nodes have been filled 
according to TvO and TvG expression as in Figure 7-15 with node outlines corresponding to cluster membership. 
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Figure 7-18 Significantly Enriched Functional Clusters in the Genes 1.5 fold Down-regulated in both TvO and TvG. The top biological process ontology for each cluster 
is detailed in italics, a summary of the cluster functional class and the FDR-corrected p-value for the enrichment of the cluster are displayed.  Nodes have been filled 
according to TvO and TvG expression as in Figure 7-15 with node outlines corresponding to cluster membership. 
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Application of the Optimised Proteomic Method to OAC and Matched Normal Tissue 325 
 
Figure 7-19 Significantly Enriched Functional Clusters in the “Oesophageal Specific” Genes. The top biological process ontology for each cluster is detailed in italics, 
and a summary of the cluster functional class and the FDR-corrected p-value for the enrichment of the cluster are displayed.  Nodes have been filled according to TvO 
and TvG expression as in Figure 7-15 with node outlines corresponding to cluster membership. 
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Figure 7-20 Significantly Enriched Functional Clusters in the “Gastric Specific” Genes. The top biological process ontology for each cluster is detailed in italics, and a 
summary of the cluster functional class and the FDR-corrected p-value for the enrichment of the cluster are displayed.  Nodes have been filled according to TvO and 
TvG expression as in Figure 7-15 with node outlines corresponding to cluster membership.
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One cluster identified in the 1.5 fold up-regulated network contained proteins 
associated with cell adhesion.  This cluster contained both highly up and down-
regulated proteins and was also identified using the 1.5-fold down-regulated gene 
list.  The functional connectivity, relative expression and node identity are illustrated 
in Figure 7-21.  The network has been manually scaled to reveal the connectivity and 
prevent node overlap.  The network exhibits high connectivity, in keeping with a 
cluster containing members with closely related functions.  Despite this, groups of 
proteins with predicted similar functions show divergent TvO and TvG expression 
ratios within the cluster.  This suggests dynamic changes between cancer and normal 
tissues within these functional groups and a more complex regulatory structure.  
These dynamic changes are often visualised using a canonical pathway model 
incorporating feedback loops.  Unfortunately the regulation of many of these genes is 
not well described, although there is some evidence for dysregulation of some of the 
cluster members in cancer685,686.  This limits the current possibilities for a pathway-
based visualisation incorporating the whole cluster and further studies are needed to 
clarify the roles of these nodes in OAC.  
Similar to the previous network analysis, a striking feature of the clusters identified 
from the down-regulated gene lists is the widespread down-regulation of genes 
associated with oxidative phosphorylation and aerobic metabolism (Figure 7-17, 
Figure 7-18).  As previously suggested, this may be evidence for the Warburg effect 
in this cancer680,687.  Clusters associated with aerobic metabolism were also identified 
from the “gastric-specific” gene list (see discussion).  Changes in the expression 
levels of metabolic enzymes may lead to cancer-specific vulnerabilities that may be 
therapeutic targets. To visualise the changes in metabolic enzyme expression in 
greater detail, all of the significantly dysregulated proteins were mapped to KEGG 
metabolic pathways (Figure 7-22, Figure 7-23 and Figure 7-24).  This confirmed 
widespread downregulation of metabolic enzymes involved in aerobic respiration.  
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Application of the Optimised Proteomic Method to OAC and Matched Normal Tissue 328 
 
Figure 7-21 Relative Expression and Functional Connections of Genes in the Cell Adhesion Cluster (from Figure 7-15 and Figure 7-18).  The figure legend demonstrates 
the corresponding Log2 expression associated with the central (TvO) and outer (TvG) colour of each node.  Proteins lacking expression data have been coloured grey 
and labelled with yellow text.  Nodes have also been scaled in size according to the number of experimental observations and are labelled with gene names.    
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Figure 7-22 TvG Expression Mapped to KEGG Glycolytic and Pyruvate Metabolic Pathways.  All significantly dysregulated proteins (TvO and TvG intra-experimental 
p<0.05) were mapped to KEGG identifiers and the associated TvG expression used to colour nodes in the KEGG metabolic pathways (mapping detailed in the legend).  
Similar patterns were observed with TvO expression mapping.  Boxes represent metabolic enzymes labelled with KEGG identifiers, circles represent metabolites 
(annotated by name), and arrows represent reactions.    
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Figure 7-23 TvG Expression Mapped to the KEGG Citric Acid Cycle Pathway.  All significantly dysregulated proteins (TvO and TvG intra-experimental p<0.05) were 
mapped to KEGG identifiers and the associated TvG expression used to colour nodes in the KEGG metabolic pathways (mapping detailed in the legend).  Similar 
patterns were observed with TvO expression mapping.  Boxes represent metabolic enzymes labelled with KEGG identifiers, circles represent metabolites (annotated by 
name), and arrows represent reactions.    
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Figure 7-24 TvG Expression Mapped to the KEGG Oxidative Phosphorylation Pathway. All significantly dysregulated proteins (TvO and TvG intra-experimental p<0.05) 
were mapped to KEGG identifiers and the associated TvG expression used to colour nodes in the KEGG metabolic pathways (mapping detailed in the legend).  Similar 
patterns were observed with TvO expression mapping.  Boxes represent individual components of the metabolic enzyme complexes labelled with KEGG identifiers. 
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7.3.10  Generating De Novo Networks from Gene Lists 
The previously applied network analysis method has used an existing functional 
linkage network to identify enriched clusters associated with biological functions.  
This method is well suited to incomplete datasets derived from proteomic studies as 
only a few cluster members are required to identify that cluster as enriched.   
A further method to identify enriched functional pathways associated with 
dysregulated genes is to generate a network de novo from a dysregulated gene list 
using databases incorporating functional interaction data.  This approach can 
employed using the STRING database528.  Network connectivity can be enhanced by 
sequentially adding nodes with a high probability of interaction with the existing 
network members.  Again this network method compensates for the incompleteness 
of a dataset.  The STRING database also incorporates edge directionality if this data 
is available.  Similar to the KEGG pathway analysis (Figure 7-22, Figure 7-23 and 
Figure 7-24) this can aid network interpretation although relative node expression 
cannot yet be visualised within STRING networks, limiting this feature. 
The STRING database was used to construct a network from the 2 fold TvO and 
TvG up-regulated genes.  When nodes with a very high probability of functional 
interaction were included (STRING score of ≥0.99)688, a single highly connected 
network could be generated (Figure 7-25).  This network suggests a central role for 
signalling via the epidermal growth factor family of receptor tyrosine kinases. 
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Figure 7-25 Inferred Network within the 2-fold TvO and TvG upregulated proteins with an intra-experimental FDR-p < 0.05.  Edges and Inferred nodes were created 
using the STRING database.  Unconnected and peripheral nodes have been removed.  Nodes have been arbitrarily sized and coloured.  Functional interactions have 
been summarised using various edges of different colours (see legend).  A highly connected central network is apparent.   
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7.4 Discussion 
This chapter has integrated previous work optimising tissue lysis and proteomic 
methods to analyse tissues from seven patients.  The identification of over 6,000 
proteins makes this the most extensive proteomic dataset in oesophageal cancer and 
emphasises the power of the mFASP TMT strategy.  However, incomplete proteome 
coverage remains a significant limitation of shotgun proteomic studies and less than 
1,000 proteins were identified in common between all samples.  The technical 
reproducibility of protein quantitation was very high and a strategy was developed to 
identify significantly dysregulated proteins by comparison of TvO and TvG ratios 
with the corresponding technical replicates. 
The combination of TvO and TvG ratios for each quantified protein allowed the 
generation of a 2D expression map.  This map highlighted a group of potentially 
tumour-specific proteins (Figure 7-13).  Although these have not been validated in 
this study, several have been previously shown to be over-expressed in OAC and 
represent potential therapeutic targets689.  Indeed, immunotherapeutic trials are 
already underway with agents directed against EpCAM690, GPA33691,692 and 
MAGE693 proteins in other cancer types.  If the expression of these can be validated 
to be specific to OAC cells over surrounding tissues, there would be a compelling 
rationale to investigate these agents in OAC. 
Examination of the 2D expression map suggested that genes with similar functions 
appeared in similar areas.  This may be due to co-ordinated expression of 
functionally similar genes, e.g. neutrophil cytosol factors and melanoma antigens.  
This has been demonstrated previously in gene expression analysis and forms the 
basis of some methods used to infer gene function and visualise data694,695.  It could 
be hypothesised that genes closely approximated on the map are likely to exhibit 
similar functions and this property could be used to infer function when it is not 
known.  A network analysis was conducted to explore the biological processes 
associated with selected areas on the 2D expression map.   
As previously discussed, an inflammatory infiltrate is commonly observed in OAC.  
Both the 1.5 and 2 fold upregulated lists from this analysis show enriched clusters 
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involved in the immune response.  This supports the previous findings of enriched 
immune regulatory genes.  Similarly, genes associated with RNA processing were 
enriched in both 1.5 fold and 2 fold upregulated lists in keeping with the previous 
network analysis.  This may be secondary to an increased demand for functional 
protein associated with cell growth.  In that case a concomitant enrichment in genes 
associated with protein translation and processing would be expected; although these 
clusters may be missed due to incomplete proteome coverage.  Another possibility is 
that increased splicing of immature transcripts is present in OAC cells.  Indeed one 
study reported over 50% of proteins demonstrated tissue-specific alternatively 
spliced isoforms when normal and cancer biopsies are compared696.  These 
alternative-splice variants may be therapeutic targets or cancer-specific biomarkers in 
their own right as an independent proteomic study suggested681.      
The network analysis also confirmed widespread downregulation of genes associated 
with oxidative metabolism, suggestive of the Warburg effect.  Higher levels of 
NADH dehydrogenase expression were noted in gastric epithelium compared to both 
tumour and normal oesophageal tissue.  There may be gastric-specific metabolic 
changes responsible for this although this has not previously been described.  
Alternatively, the identified clusters may reflect a systemic difference in the tissue 
composition of biopsies.  Muscle has been shown to express slightly higher levels of 
NADH dehydrogenases compared to gastrointestinal epithelium697.  The stomach 
contains a thicker muscle layer than the oesophagus and if biopsies contained a 
higher proportion of muscle this may explain the relatively higher expression of 
theses enzymes.  Both squamous oesophageal and tumour biopsies were taken 
tangentially to the muscle layer to prevent compromise of the circumferential 
resection margin.  Therefore muscle was a relatively small component of the biopsies 
from these tissue types.  Due to the pliability of the gastric mucosa in fresh resection 
specimens, biopsies were often taken perpendicular to the mucosal surface.  An 
imbalance in the muscle component of biopsies could potentially explain the 
observed expression pattern for NADH dehydrogenases but would not account for 
the other metabolic clusters dysregulated between both tumour and normal 
oesophagus and tumour and normal gastric epithelium.   
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Gastric-specific epithelial markers including gastric intrinsic factor and mucin 
5AC697,698 also exhibited higher expression in gastric tissue compared to both OAC 
and normal oesophagus suggesting a significant proportion of each biopsy must have 
been epithelial.  Frozen sections of each biopsy were reviewed by a consultant upper-
GI pathologist prior to sample processing and no significant differences in relative 
epithelial/stromal composition were noted.   The sections only demonstrate one plane 
through the biopsy, however and differences could still exist.  To confirm the cellular 
origin of NADH dehydrogenase expression, IHC on patient matched normal gastric, 
oesophageal and OAC tissue could be performed.               
Protein expression was visualised in the context of KEGG pathway maps.  If it is 
assumed that metabolic enzyme expression correlates with reaction flux, the 
metabolism of glucose to pyruvate appeared unaffected between adenocarcinoma and 
normal gastric tissue (Figure 7-22).  Similar appearances were observed between 
OAC and normal oesophageal tissue (not shown).  The fate of pyruvate appeared to 
be significantly altered between the tissues with the conversion to lactic acid 
preferred in cancer cells over the generation of Acetyl-Coenzyme A (Acetyl-CoA).  
This would be expected to have significant consequences in shuttling glycolytic 
metabolites away from the citric acid cycle.  Indeed this switch is further emphasised 
by the observation of a widespread suppression of citric acid cycle enzymes and 
electron transport chain components (Figure 7-22 and Figure 7-23).  Interestingly the 
normally gluconeogenic reaction converting oxaloacetate to the pyruvate precursor 
phosphoenol pyruvate appears preserved.  This generates a potential exit pathway for 
Acetyl-CoA generated from fatty acid metabolism or oxaloacetate generated from 
Aspartate or Asparagine.   
These findings are in keeping with reports of rewired metabolic networks in cancer 
cells.  The reasons for the shift in metabolism of pyruvate to lactic acid over 
oxidative phosphorylation are still a matter of debate.  Convincing evidence has been 
provided for a survival advantage for tumour cells within their microenvironment 
produced by extracellular acidification699.  The 18-fold lower yield of ATP from 
fermentation of glucose to lactic acid compared to complete oxidation to CO2 via the 
citric acid cycle and electron transport chain is often mooted as the paradox of the 
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Warburg effect in a potentially resource-limited situation such as the tumour 
microenvironment.  The resolution of this paradox has been proposed from 
substantially increased rate of ATP production by fermentation of glucose to lactic 
acid, resulting in a higher total yield per unit time than if oxidative phosphorylation 
is employed700.  A diversion of glycolytic metabolites to generate nucleotides, amino 
acids and lipids to allow cell replication has also been proposed as a beneficial 
consequence680.  
The consequence of the metabolic changes in OAC cells also generates potential 
therapeutic targets.  Glucose uptake is consistently elevated in OAC and forms the 
basis for the clinical staging investigation exploiting positron detection from the 
glucose analogue 18Fluorodeoxyglucose701.  Due to the hydrophilic nature of glucose, 
cellular uptake relies on transmembrane transporters.  The GLUT1 glucose 
transporter has been published to be over-expressed in OAC compared to non-
dysplastic Barrett’s epithelium and surrounding normal tissue702,703.  Consistent with 
this, GLUT1 was 1.2 fold over-expressed in OAC compared to normal squamous 
epithelium and 3.9 fold over-expressed in OAC compared to gastric epithelium.  
Both therapeutic antibodies and small molecule inhibitors of GLUT1-mediated 
glucose transport have been developed and demonstrate anti-cancer effects704,705.  A 
significant challenge with GLUT1 based therapies is the off-target effect of 
suppression of glucose uptake by erythrocytes and neuronal cells although this 
toxicity was not reported in one recent study of a small molecule GLUT1 
antagonist706. 
The KEGG pathway analysis revealed pyruvate metabolism to be a key difference 
between OAC and normal tissues (Figure 7-22 and Figure 7-23).  The availability of 
glycolytic metabolites for biomass production can in part be governed by the rate of 
conversion from phosphoenolpyruvate to pyruvate by pyruvate kinase.  This enzyme 
is active as a tetramer and two isoforms; PKM1 and PKM2, are generated by 
alternative splicing of primary transcripts from the same gene.  Pyruvate kinase 
isoform detection was limited in this study by the requirement to detect peptides 
specifically derived from the variable exon resulting in a 40 amino acid segment 
unique to each isoform.  A more specific, targeted proteomic method  such as 
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selective reaction monitoring would be preferable for accurate quantification of 
tissue isoform expression455.  Pyruvate kinase has been implicated in the metabolic 
switch between cancer and non-transformed cells; although the relative contribution 
of each isoform is still controversial707,708.  While the PKM1 isoform is constitutively 
active, PKM2 can be allosterically controlled by variety of methods including direct 
binding by glycolytic metabolites709.  This allosteric regulation of PKM2 has been 
shown to have a direct effect on cellular proliferation with the PKM2 activator, 
fructose 1,6-bisphosphate completely abrogating cell growth in vitro710.  Activators 
of PKM2 therefore present compelling candidates as anti-cancer agents711.   
In this analysis, V-Type ATPases were not down-regulated along with other 
components of the electron transport chain (Figure 7-24).  This may reflect their 
diverse role in transmembrane proton transport outside of mitochondrial oxidative 
phosphorylation and potential pro-oncogenic functions712.  Reflecting this, a selective 
inhibitor of V-Type ATPases prevents invasion and metastasis and induces cancer 
cell apoptosis713,714.   
A de novo network was generated using the 2 fold TvO and TvG upregulated gene 
list and the STRING database.  With the addition of high confidence inferred nodes, 
a network dominated by EGF-family receptor signalling was created.  There are 
caveats associated with this finding, however, as random resamples of the identified 
non-dysregulated proteins were not compared with the dysregulated proteins to 
confirm the specificity of the association with EGF-family genes.  This approach, 
employed in the previous network analysis (Chapter 6), would control for the 
potential bias towards identifying highly studied proteins such as receptor tyrosine 
kinases.     
Nevertheless, several previous studies have implicated EGFR signalling in OAC.  
Using tissue microarrays, EGFR has been validated by IHC along with two other 
genes to aid in the determination of long term prognosis after resection of OAC715.  
EGFR has been demonstrated to be overexpressed in 15-50% of patients with OAC 
with amplification in 20%83,716.  Similarly ErbB2 is amplified in around 20% of 
patients with oesophageal or OGJ adenocarcinoma717. The monoclonal antibodies 
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designed to inhibit both EGFR and ErbB2; Lapatinib, or EGFR alone; Erlotinib, 
induce cell death in OAC cell lines showing high levels of target expression718.   
Despite the strong preclinical rationale for EGFR inhibition in OAC, a phase III 
clinical trial (REAL-3) of the monoclonal anti-EGFR antibody panitumumab 
recently reported a poorer prognosis with the addition of the EGFR inhibitor to the 
standard regimen or Epirubicin, Oxaliplatin and Capecitabine (EOX)719.  This may 
have been secondary to a synergistic effect of panitumumab on toxicity from EOX or 
the lack of patient stratification by EGFR expression.   
Resistance to EGFR inhibition despite EGFR amplification has also been 
demonstrated in KRAS mutant cancers720.  This is unlikely to explain the data in 
oesophageal cancer as KRAS mutations are generally infrequent in this cancer218 and 
in the subgroup of around 1/3 of patients assessed for KRAS allele genotype in the 
REAL-3 trail, mutations were detected in less than 6% of tumours719.   
The failure of this therapy in patients underscores the complexity of cellular 
signalling and the potential for secondary compensation when agents directed against 
a single receptor tyrosine kinase (RTK) are used.  Even in tumours with apparent 
clinical response to therapies targeted to RTKs, the later emergence of resistance is 
common and in some cases universal160,361,721,722.  This is likely due to selective 
pressure leading to the expansion of resistant clones, present initially in small 
numbers.     
A novel strategy embracing the complexity of cell signalling at the network level 
identified time-dependent changes in the response to EGFR inhibition that offered a 
window of opportunity for effective sequential therapy.  When applied to triple-
negative breast cancer cells, pre-treatment by inhibition of EGFR, either using a 
small molecule or siRNA, conditioned cells to a network state sensitive to the DNA 
damaging agent doxorubicin723.  Importantly co-treatment did not produce the same 
effect.  Similar approaches may be more successful in OAC than current strategies. 
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Oesophageal adenocarcinoma remains a highly lethal disease with a 5 year survival 
rate of less than 15%1,127.  The early dissemination of OAC mandates that effective 
systemic therapies are required to improve survival.  The majority of OACs have not 
been demonstrated to express a single dominant oncogene or kinase limiting the 
application of existing targeted therapies.  This thesis has therefore focused on 
strategies to identify therapeutic targets in this cancer.   
Mutation of TP53 has been demonstrated in over 75% of OACs generating a 
possibility for tumour-specific therapy if a synthetic lethal interactor can be 
identified550.  Published in vitro work proposed PLK-1 as a candidate220.   
8.1 Mutation of TP53 Suggests a Synthetic Lethal 
Strategy for OAC 
PLK-1 was confirmed to be over-expressed in verified OAC cells and tissue 
compared to primary squamous cells, non-transformed Barrett’s epithelial cells and 
Barrett’s and normal squamous oesophageal tissue.  Mutation of p53 was associated 
with over-expression of PLK-1 in OAC and ovarian cancer providing in vivo 
evidence of a possible synthetic lethal therapeutic strategy through targeting PLK-1 
(Chapter 3).    
The identification of cancer cell cytotoxicity compared to cytostasis or reduction in 
proliferation was deemed important to evaluate potential therapeutic efficacy.  The 
AlamarBlue viability assay was adapted for this purpose and was demonstrated to be 
sensitive, accurate and specific.   
Inhibition of PLK-1 expression by siRNA reduced viability in oesophageal cell lines 
with the magnitude of reduction related to the degree of PLK-1 suppression.  An 
established (BI2536) and a novel, short half-life, PLK-1 inhibitor (PLK-1A) reduced 
proliferation in short-term viability assays with constant drug exposure.  An 
enhanced effect was observed in oesophageal cancer cell lines compared to primary 
squamous cells and this relative selectivity appeared marginally greater with PLK-
1A.    
 Conclusions and Future Work Chapter 8:
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Assays using constant drug concentrations in vitro do not mimic in vivo cancer cell 
drug exposure and therefore a variety of intermittent exposure experiments were 
conducted.  Sensitivity to PLK-1A was enhanced by pulsed administration and this 
effect appeared to be specific to PLK-1A compared to BI2536.  The relative cancer 
cell specificity and the enhanced therapeutic effect with pulsed administration for 
PLK-1A provide a clear rationale for further development towards in vivo human 
studies.  Augmenting the therapeutic window by pulsed administration of a short 
half-life compound is a new strategy for PLK-1 inhibitors and if verified with other 
compounds may help to limit the toxicity which has plagued Phase I and II trials of 
BI2536 and other similar long half-life inhibitors.  The in vitro methods adopted for 
the assay of proliferation and cytotoxicity in this study and the use of a panel of both 
non-transformed and transformed oesophageal cells also provide a framework for the 
interrogation of other future candidate therapeutic targets.    
Evaluation of pulsed administration regimes in vivo would help to confirm these cell 
line derived data.  For oesophageal cancer this would likely rely on the use of nude 
mouse xenografts.  Tumour size measurements could be used to confirm efficacy, 
however, PLK-1 inhibitors are associated with significant hematological toxicity in 
human trials and immuno-competent models would be required to capture this and 
allow iteration of dosing schedules.  The recently described transgenic mouse model 
of Barrett’s carcinogenesis could, in contrast, be used to optimise the therapeutic 
index for PLK-1 inhibitors and other candidates in preclinical trials102. 
From this work it appears that oesophageal cancer offers a disease indication for this 
class of inhibitors.  This finding has driven the development of an oesophageal 
cancer focused Academic/Industry collaborative programme “First-In-Human 
directed pre-clinical development of anti-cancer agent CYC140”.  This was recently 
supported by Biomedical Catalyst Funding as an Early Stage Award from the MRC 
and the Technology Strategy Board.  This project will focus on further 
characterisation of in vitro resistance mechanisms, optimisation of drug dosing 
regimens including combination therapy and evaluation of large mammal toxicity 
with the PLK-1A drug and more potent derivatives.  It is hoped that this will result in 
the progression of this class of compounds into clinical trials in oesophageal cancer.   
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8.2 Using Quantitative Shotgun Proteomics to Identify 
OAC-specific Proteins  
Although highly expressed in OAC compared to surrounding tissues, PLK-1 is still 
expressed in non-transformed cells due to its central role in the cell cycle.  The 
highly conserved structure of the kinase domain also creates difficulties in generating 
truly kinase-specific inhibitors.  Both of these limitations increase the probability of 
off-target effects and toxicity.     
An alternative strategy for therapeutic target identification is comparative proteomic 
profiling to identify proteins specifically expressed in OAC cells.  These could form 
the basis for the development of targeted immunotherapeutics with the potential for 
high specificity and low toxicity.   
At the commencement of this project, no studies had been published using entirely 
shotgun proteomic methods on OAC tissue.  An oesophageal tissue resource was 
established and the feasibility and accuracy of a quantitative shotgun proteomic 
strategy using patient-matched OAC and normal squamous tissue assessed (Chapter 
4).  A relative quantitative approach was employed and many proteins previously 
published as dysregulated in OAC were identified, verifying the validity and 
potential power of this approach.  The quantitative accuracy was also confirmed from 
the expression pattern of six proteins (AGR2, GRP78, SAMHD1, D4GDI, HSP27 
and TGM3) determined by IHC using validated antibodies on the same tissues used 
for proteomic analysis.  The IHC expression pattern revealed insights into the 
cellular origin of dysregulated proteins and underscores the importance of IHC for 
validation of proteomic and transcriptomic studies of human tissue.       
The proteomic method was subsequently optimised to increase the number of protein 
identifications and improve the sensitivity to detect OAC-specific proteins.  The 
combination of the mFASP method and an increased number of OFF-GEL fractions 
significantly enhanced proteome coverage (Chapter 5).  A published label-free 
systematic sequencing method, PAcIFIC, had been proposed to increase protein 
identifications and dynamic range but in this investigation, the isobaric quantitative 
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strategy with sample fractionation by isoelectric point appeared to be superior to 
PAcIFIC (Chapter 5).   
Label-free proteomic methods are becoming increasingly common, however, and 
have the advantage of minimal sample preparation and applicability to low yield 
sample types.  In the label-free approach, each sample is analysed individually.  A 
fundamental limitation of proteomic studies on human tissues is the identification of 
only a subset of all proteins expressed in a sample.  This leads to the central problem 
of identifying which proteins have been missed but are present in the sample and 
which are truly not expressed and potentially tumour specific.       
To address this, a Bayesian statistical approach was developed in collaboration with 
Dr. Ian Overton (IGMM, Edinburgh University).  This allowed the prediction of a 
threshold of tumour protein abundance associated with a high probability of tumour-
specific expression when the protein was not detected in normal oesophageal tissue 
and vice versa (Chapter 5).  Several of the proposed candidate tumour specific 
proteins were independently demonstrated to be highly expressed in OAC compared 
to surrounding normal tissues (Chapter 4, 7) lending support for the validity of the 
method.   This approach was not, however, formally externally validated.  This could 
be performed by obtaining serial PAcIFIC proteomes from a sample of known 
protein composition.  A challenge would be in creating the necessary sample of 
known composition with several thousand different proteins.  
A list of all identified proteins with their relative tissue expression was generated 
from the PAcIFIC data using the Bayesian approach.  The quantitative methods of 
spectral counting and TMT reporter ion intensity were not comparable, potentially 
due to limitations in the spectral counting method.  The PAcIFIC and TMT data were 
therefore subsequently treated separately.   
A third strategy to identify therapeutic targets in OAC is to identify dysregulated 
targetable pathways specific to OAC tissue.  Using quantitative proteomic data has 
the advantage of potentially greater functional relevance but incomplete proteomic 
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datasets make the identification of dysregulated pathways a challenge.  This was 
addressed using network analysis methods.  
8.3 Identifying Dysregulated Biological Processes in OAC 
using Quantitative Proteomic Data 
Strategies originally developed for gene-set and gene-network enrichment analysis 
were adapted to identify functional pathways from incomplete proteomic data.  A 
genome-scale functional linkage network was clustered to generate biological 
functional clusters – verified by the significant enrichment of DAVID biological 
process ontologies.   
Multiple dysregulated functional clusters were identified by network analysis of the 
mFASP TMT and PAcIFIC proteomic data.  The identified clusters were highly 
enriched for biological processes including inflammatory signalling and oxidative 
phosphorylation which may represent evidence of targetable pathways.  The findings 
from the Linghu functional linkage network were replicated using an independent 
human network, providing support for their validity.  Although apparently robust, 
these data were obtained from only seven patients samples and can only be 
considered preliminary until validated in tissue from a larger cohort of patients with 
OAC.            
The PAcIFIC and pilot TMT data revealed significant variability in protein 
identification between patient’s samples.  High technical reproducibility from the 
TMT data suggested a large component of this was biological variation.  The 
optimised (mFASP) TMT method was therefore used on samples from a further five 
patients and all mFASP TMT data considered together (Chapter 7).  
This study of 7 patients’ tissues identified and quantified 6,339 unique protein 
groups, the most comprehensive proteomic study to date in oesophageal cancer.  The 
mFASP TMT method demonstrated high technical reproducibility but incomplete 
proteome coverage was still a factor.  Despite this, tumour-selective expression was 
proposed for a subset of proteins containing both novel and existing 
immunotherapeutic candidates.   
Identification of Novel Therapeutic Targets for Oesophageal Adenocarcinoma 
Conclusions and Future Work 345 
One of these, EpCAM, has been previously demonstrated to be highly expressed in 
OAC tissue compared to normal squamous and gastric epithelium724,725.  EpCAM-
directed immunotherapeutics have been licensed for the treatment of malignant 
ascites and are under investigation for several other malignancies726.  If EpCAM can 
be validated as specific for tumour cells in OAC, existing EpCAM therapies could 
enter clinical trials in this disease.          
A subsequent network analysis of the complete mFASP TMT dataset confirmed the 
prominent role of inflammatory signalling and RNA processing in these tumours and 
widespread changes in metabolic pathways consistent with the Warburg effect were 
identified.  This study illustrates the potential of network and proteomic methods to 
uncover dysregulated signalling pathways and candidate therapeutic targets.  
In conclusion, this thesis examines three strategies to identify therapeutic targets for 
OAC and reveals several novel findings.  The evaluation of PLK-1 as a therapeutic 
target in OAC will continue as part of an Academic-Industry collaborative 
programme.  Using comparative proteomics, several compelling immunotherapeutic 
candidates are proposed and require to be validated in a larger cohort of patient’s 
samples.  To achieve this, a tissue-microarray comprising of FFPE cores from OAC 
and patient-matched normal and metastatic tissues is being constructed to validate 
the relative specificity of expression of candidate targets by IHC.  Candidates will be 
taken forward for in vitro study using the approaches employed in the evaluation of 
PLK-1 as a therapeutic target.  Finally, network analysis of proteomic data proposed 
deranged glucose metabolism in OAC through changes consistent with the Warburg 
effect.  The role of PKM2 as a key mediator of this switch and potential target is 
being actively explored710.   Together these strategies reveal new areas for 
therapeutic innovation.  It is hoped they will inspire future efforts to develop 
effective therapeutics that will ultimately improve the survival from OAC.            
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